Please wait...
| ID | PMID | YEAR | Sequence | MAP | Name | C-ter MOD | N-ter MOD | Linear/Cyclic | Stereo-Chemistry | Modified | Length | Fuction | Activity | RBCs Source | Origin | Experimental structure | Non-Hemolytic |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 18942691 | 2008 | KVMAHMK{ct:Amid} | MEP-5 | Amidation | Free | Linear | L | None | 7 | Antimicrobial | LC50 >100μM | Rat | Melectin analog isolated from the venom of the cleptoparasitic bee Melecta albifrons | NA | NA | ||
| 18942691 | 2008 | PKVMAHMK{ct:Amid} | MEP-6 | Amidation | Free | Linear | L | None | 8 | Antimicrobial | LC50 >100μM | Rat | Melectin analog isolated from the venom of the cleptoparasitic bee Melecta albifrons | NA | NA | ||
| 18942691 | 2008 | LPKVMAHMK{ct:Amid} | MEP-7 | Amidation | Free | Linear | L | None | 9 | Antimicrobial | LC50 >100μM | Rat | Melectin analog isolated from the venom of the cleptoparasitic bee Melecta albifrons | NA | NA | ||
| 17145799 | 2007 | RW{ct:Amid} | RW | Amidation | Free | Linear | L | None | 2 | Antimicrobial | HD50 =8.9x103μM | Sheep | Synthetic peptide (Phage display libraries) | NA | NA | ||
| 17145799 | 2007 | RWRW{ct:Amid} | (RW)2 | Amidation | Free | Linear | L | None | 4 | Antimicrobial | HD50 =3.7x103μM | Sheep | Synthetic peptide (Phage display libraries) | NA | NA | ||
| 17145799 | 2007 | RWRWRW{ct:Amid} | (RW)3 | Amidation | Free | Linear | L | None | 6 | Antimicrobial | HD50 =2.1x102μM | Sheep | Synthetic peptide (Phage display libraries) | NA | NA | ||
| 17145799 | 2007 | RWRWRWRW{ct:Amid} | (RW)4 | Amidation | Free | Linear | L | None | 8 | Antimicrobial | HD50 =1.0x102μM | Sheep | Synthetic peptide (Phage display libraries) | NA | NA | ||
| 17307975 | 2007 | {nnr:alK}-{nnr:l}K-{nnr:l}K-{nnr:l}K | OAK 1 | Free | Free | Linear | Mix | a = amino, l = lauric acid, alK = aminolauryl-lysine | 4 | Antiplasmodial | 24.6± 1.2% hemolysis at 100 μM | Human | Oligoacyllysine analog (Synthetic peptide) | NA | NA | ||
| 17307975 | 2007 | {nnr:l}K-{nnr:l}K-{nnr:l}K-{nnr:l}K | OAK 2 | Free | Free | Linear | Mix | l = lauric acid, alK = aminolauryl-lysine | 4 | Antiplasmodial | 26.1±4.5% hemolysis at 100 μM | Human | Oligoacyllysine analog (Synthetic peptide) | NA | NA | ||
| 17307975 | 2007 | K-{nnr:l}K-{nnr:l}K-{nnr:l}K | OAK 3 | Free | Free | Linear | Mix | l = lauric acid, alK = aminolauryl-lysine | 4 | Antiplasmodial | 2.3±1.5% hemolysis at 100 μM | Human | Oligoacyllysine analog (Synthetic peptide) | NA | NA | ||
| 17307975 | 2007 | {nnr:a}{nnr:l}K-{nnr:l}K-{nnr:l}K | OAK 4 | Free | Free | Linear | Mix | a = amino, l = lauric acid | 3 | Antiplasmodial | 3.4±0.8% hemolysis at 100 μM | Human | Oligoacyllysine analog (Synthetic peptide) | NA | NA | ||
| 17307975 | 2007 | {nnr:l}K-{nnr:l}K-{nnr:l}K | OAK 5 | Free | Free | Linear | Mix | l = lauric acid, alK = aminolauryl-lysine | 3 | Antiplasmodial | 13.3±4.3% hemolysis at 100 μM | Human | Oligoacyllysine analog (Synthetic peptide) | NA | NA | ||
| 17307975 | 2007 | K-{nnr:l}K-{nnr:l}K | OAK 6 | Free | Free | Linear | Mix | l = lauric acid, alK = aminolauryl-lysine | 3 | Antiplasmodial | <0.1% hemolysis at 100 μM | Human | Oligoacyllysine analog (Synthetic peptide) | NA | NA | ||
| 17307975 | 2007 | {nnr:alK}-{nnr:l}K | OAK 7 | Free | Free | Linear | Mix | a = amino, l = lauric acid, alK = aminolauryl-lysine | 2 | Antiplasmodial | 0.14±0.3% hemolysis at 100 μM | Human | Oligoacyllysine analog (Synthetic peptide) | NA | NA | ||
| 17307975 | 2007 | {nnr:l}K-{nnr:l}K | OAK 8 | Free | Free | Linear | Mix | l = lauric acid | 2 | Antiplasmodial | 4.9±1.7% hemolysis at 100 μM | Human | Oligoacyllysine analog (Synthetic peptide) | NA | NA | ||
| 17307975 | 2007 | K-{nnr:l}K | OAK 9 | Free | Free | Linear | Mix | l = lauric acid | 2 | Antiplasmodial | <0.1% hemolysis at 100 μM | Human | Oligoacyllysine analog (Synthetic peptide) | NA | NA | ||
| 19399781 | 2009 | {nnr:Aib}-GGL-{nnr:Aib}-GIL{nt:Acet}{ct:Methoxy(Ome)} | Tric-8 | Methoxy (Ome) | Acetylated by lipol (n-octanoyl) | Linear | L | Aib = α-aminoisobutyric acid | 8 | Antifungal and Antibacterial | 0% hemolysis at 15 μM (non-hemolytic) | Human | Trichogin GA IV analogue (Trichoderma longibrachiatum) | mixed 310/α-helical | Non-hemolytic | ||
| 19399781 | 2009 | {nnr:Aib}-GIL{nt:Acet}{ct:Methoxy(Ome)} | Tric-4 | Methoxy (Ome) | Acetylated by lipol (n-octanoyl) | Linear | L | Aib = α-aminoisobutyric acid | 4 | Antifungal and Antibacterial | 0% hemolysis at 15 μM (non-hemolytic) | Human | Trichogin GA IV analogue (Trichoderma longibrachiatum) | mixed 310/α-helical | Non-hemolytic | ||
| 19445503 | 2009 | WALRLYLVY | ARYV | Free | Free | Linear | L | None | 9 | Antimicrobial | 0.0 fractions hemolysis at 0.5μM | Sheep | Synthetic peptide | β-sheet structure | NA | ||
| 19445503 | 2009 | WALRLYLVY | ARYV | Free | Free | Linear | L | None | 9 | Antimicrobial | 0.0 fractions hemolysis at 5.0μM | Sheep | Synthetic peptide | β-sheet structure | NA | ||
| 19445503 | 2009 | WALRLYLVY | ARYV | Free | Free | Linear | L | None | 9 | Antimicrobial | 0.05 fractions hemolysis at 15μM | Sheep | Synthetic peptide | β-sheet structure | NA | ||
| 19445503 | 2009 | WALRLYLVY | ARYV | Free | Free | Linear | L | None | 9 | Antimicrobial | 0.01 fractions hemolysis at 0.5μM | Human | Synthetic peptide | β-sheet structure | NA | ||
| 19445503 | 2009 | WALRLYLVY | ARYV | Free | Free | Linear | L | None | 9 | Antimicrobial | 0.07 fractions hemolysis at 5.0μM | Human | Synthetic peptide | β-sheet structure | NA | ||
| 19445503 | 2009 | WALRLYLVY | ARYV | Free | Free | Linear | L | None | 9 | Antimicrobial | 0.14 fractions hemolysis at 15μM | Human | Synthetic peptide | β-sheet structure | NA | ||
| 19445503 | 2009 | WVLVLRLGY | VVRG | Free | Free | Linear | L | None | 9 | Antimicrobial | 0.02 fractions hemolysis at 0.5μM | Sheep | Synthetic peptide | β-sheet structure | NA | ||
| 19445503 | 2009 | WVLVLRLGY | VVRG | Free | Free | Linear | L | None | 9 | Antimicrobial | 0.03 fractions hemolysis at 5.0μM | Sheep | Synthetic peptide | β-sheet structure | NA | ||
| 19445503 | 2009 | WVLVLRLGY | VVRG | Free | Free | Linear | L | None | 9 | Antimicrobial | 0.1 fractions hemolysis at 15μM | Sheep | Synthetic peptide | β-sheet structure | NA | ||
| 19445503 | 2009 | WVLVLRLGY | VVRG | Free | Free | Linear | L | None | 9 | Antimicrobial | 0.02 fractions hemolysis at 0.5μM | Human | Synthetic peptide | β-sheet structure | NA | ||
| 19445503 | 2009 | WVLVLRLGY | VVRG | Free | Free | Linear | L | None | 9 | Antimicrobial | 0.1 fractions hemolysis at 5.0μM | Human | Synthetic peptide | β-sheet structure | NA | ||
| 19445503 | 2009 | WVLVLRLGY | VVRG | Free | Free | Linear | L | None | 9 | Antimicrobial | 0.26 fractions hemolysis at 15μM | Human | Synthetic peptide | β-sheet structure | NA | ||
| 19445503 | 2009 | WVLVLRL{d}GY | dVVRG | Free | Free | Linear | Mix | None | 9 | Antimicrobial | 12±13 % hemolysis at 15μM | Human | Synthetic peptide | β-sheet | NA | ||
| 19445503 | 2009 | WVLVLRL{d}GY | dVVRG | Free | Free | Linear | Mix | None | 9 | Antimicrobial | 11±9% hemolysis at 15μM | Sheep | Synthetic peptide | β-sheet | NA | ||
| 19544481 | 2009 | LKKWLK{ct:Amid} | L2K3W4 | Amidation | Free | Linear | L | None | 6 | Antimicrobial | 4.84% hemolysis at 200μg/ml | Human | Synthetic peptide | helical | NA | ||
| 19544481 | 2009 | LKKWLK{ct:Amid} | L2K3W4 | Amidation | Free | Linear | L | None | 6 | Antimicrobial | 4.90% hemolysis at 100μg/ml | Human | Synthetic peptide | helical | NA | ||
| 19544481 | 2009 | LKKWLK{ct:Amid} | L2K3W4 | Amidation | Free | Linear | L | None | 6 | Antimicrobial | 4.73% hemolysis at 50μg/ml | Human | Synthetic peptide | helical | NA | ||
| 19544481 | 2009 | LKKWLK{ct:Amid} | L2K3W4 | Amidation | Free | Linear | L | None | 6 | Antimicrobial | 5.07% hemolysis at 25μg/ml | Human | Synthetic peptide | helical | NA | ||
| 19544481 | 2009 | LKKWLK{ct:Amid} | L2K3W4 | Amidation | Free | Linear | L | None | 6 | Antimicrobial | 5.13%hemolysis at 12.5μg/ml | Human | Synthetic peptide | helical | NA | ||
| 19544481 | 2009 | LKKWLK{ct:Amid} | L2K3W4 | Amidation | Free | Linear | L | None | 6 | Antimicrobial | 5.07% hemolysis at 6.3μg/ml | Human | Synthetic peptide | helical | NA | ||
| 19544481 | 2009 | LKKWLKK{ct:Amid} | L2K4W4 | Amidation | Free | Linear | L | None | 7 | Antimicrobial | 4.90% hemolysis at 200μg/ml | Human | Synthetic peptide | helical | NA | ||
| 19544481 | 2009 | LKKWLKK{ct:Amid} | L2K4W4 | Amidation | Free | Linear | L | None | 7 | Antimicrobial | 5.13% hemolysis at 100μg/ml | Human | Synthetic peptide | helical | NA | ||
| 19544481 | 2009 | LKKWLKK{ct:Amid} | L2K4W4 | Amidation | Free | Linear | L | None | 7 | Antimicrobial | 4.90% hemolysis at 50μg/ml | Human | Synthetic peptide | helical | NA | ||
| 19544481 | 2009 | LKKWLKK{ct:Amid} | L2K4W4 | Amidation | Free | Linear | L | None | 7 | Antimicrobial | 5.19% hemolysis at 25μg/ml | Human | Synthetic peptide | helical | NA | ||
| 19544481 | 2009 | LKKWLKK{ct:Amid} | L2K4W4 | Amidation | Free | Linear | L | None | 7 | Antimicrobial | 5.01% hemolysis at 12.5μg/ml | Human | Synthetic peptide | helical | NA | ||
| 19544481 | 2009 | LKKWLKK{ct:Amid} | L2K4W4 | Amidation | Free | Linear | L | None | 7 | Antimicrobial | 4.90% hemolysis at 6.3μg/ml | Human | Synthetic peptide | helical | NA | ||
| 19544481 | 2009 | LLKWLKK{ct:Amid} | L3K3W4 | Amidation | Free | Linear | L | None | 7 | Antimicrobial | 5.19% hemolysis at 200μg/ml | Human | Synthetic peptide | helical | NA | ||
| 19544481 | 2009 | LLKWLKK{ct:Amid} | L3K3W4 | Amidation | Free | Linear | L | None | 7 | Antimicrobial | 4.96% hemolysis at 100μg/ml | Human | Synthetic peptide | helical | NA | ||
| 19544481 | 2009 | LLKWLKK{ct:Amid} | L3K3W4 | Amidation | Free | Linear | L | None | 7 | Antimicrobial | 4.73% hemolysis at 50μg/ml | Human | Synthetic peptide | helical | NA | ||
| 19544481 | 2009 | LLKWLKK{ct:Amid} | L3K3W4 | Amidation | Free | Linear | L | None | 7 | Antimicrobial | 4.84% hemolysis at 25μg/ml | Human | Synthetic peptide | helical | NA | ||
| 19544481 | 2009 | LLKWLKK{ct:Amid} | L3K3W4 | Amidation | Free | Linear | L | None | 7 | Antimicrobial | 4.96% hemolysis at 12.5μg/ml | Human | Synthetic peptide | helical | NA | ||
| 19544481 | 2009 | LLKWLKK{ct:Amid} | L3K3W4 | Amidation | Free | Linear | L | None | 7 | Antimicrobial | 4.78% Hmolysis at 6.3μg/ml | Human | Synthetic peptide | helical | NA | ||
| 19544481 | 2009 | LLKWLLK{ct:Amid} | L4K2W4 | Amidation | Free | Linear | L | None | 7 | Antimicrobial | 4.61% hemolysis at 200μg/ml | Human | Synthetic peptide | helical | NA | ||
| 19544481 | 2009 | LLKWLLK{ct:Amid} | L4K2W4 | Amidation | Free | Linear | L | None | 7 | Antimicrobial | 6.05% hemolysis at 100μg/ml | Human | Synthetic peptide | helical | NA | ||
| 19544481 | 2009 | LLKWLLK{ct:Amid} | L4K2W4 | Amidation | Free | Linear | L | None | 7 | Antimicrobial | 4.73% hemolysis at 50μg/ml | Human | Synthetic peptide | helical | NA | ||
| 19544481 | 2009 | LLKWLLK{ct:Amid} | L4K2W4 | Amidation | Free | Linear | L | None | 7 | Antimicrobial | 4.44% hemolysis at 25μg/ml | Human | Synthetic peptide | helical | NA | ||
| 19544481 | 2009 | LLKWLLK{ct:Amid} | L4K2W4 | Amidation | Free | Linear | L | None | 7 | Antimicrobial | 4.78% hemolysis at12.5μg/ml | Human | Synthetic peptide | helical | NA | ||
| 19544481 | 2009 | LLKWLLK{ct:Amid} | L4K2W4 | Amidation | Free | Linear | L | None | 7 | Antimicrobial | 4.61% hemolysis at 6.3μg/ml | Human | Synthetic peptide | helical | NA | ||
| 19544481 | 2009 | LLKWLKKL{ct:Amid} | L4K3W4 | Amidation | Free | Linear | L | None | 8 | Antimicrobial | 5.01% hemolysis at 200μg/ml | Human | Synthetic peptide | helical | NA | ||
| 19544481 | 2009 | LLKWLKKL{ct:Amid} | L4K3W4 | Amidation | Free | Linear | L | None | 8 | Antimicrobial | 4.84% hemolysis at 100μg/ml | Human | Synthetic peptide | helical | NA | ||
| 19544481 | 2009 | LLKWLKKL{ct:Amid} | L4K3W4 | Amidation | Free | Linear | L | None | 8 | Antimicrobial | 4.84% hemolysis at 50μg/ml | Human | Synthetic peptide | helical | NA | ||
| 19544481 | 2009 | LLKWLKKL{ct:Amid} | L4K3W4 | Amidation | Free | Linear | L | None | 8 | Antimicrobial | 5.01% hemolysis at 25μg/ml | Human | Synthetic peptide | helical | NA | ||
| 19544481 | 2009 | LLKWLKKL{ct:Amid} | L4K3W4 | Amidation | Free | Linear | L | None | 8 | Antimicrobial | 4.44% hemolysis at 12.5μg/ml | Human | Synthetic peptide | helical | NA | ||
| 19544481 | 2009 | LLKWLKKL{ct:Amid} | L4K3W4 | Amidation | Free | Linear | L | None | 8 | Antimicrobial | 4.78% hemolysis at 6.3μg/ml | Human | Synthetic peptide | helical | NA | ||
| 19544481 | 2009 | KLLKWLLK{ct:Amid} | L4K3W4 | Amidation | Free | Linear | L | None | 8 | Antimicrobial | 5.42% hemolysis at 200μg/ml | Human | Synthetic peptide | helical | NA | ||
| 19544481 | 2009 | KLLKWLLK{ct:Amid} | L4K3W4 | Amidation | Free | Linear | L | None | 8 | Antimicrobial | 5.99% hemolysis at 100μg/ml | Human | Synthetic peptide | helical | NA | ||
| 19544481 | 2009 | KLLKWLLK{ct:Amid} | L4K3W4 | Amidation | Free | Linear | L | None | 8 | Antimicrobial | 5.13% hemolysis at 50μg/ml | Human | Synthetic peptide | helical | NA | ||
| 19544481 | 2009 | KLLKWLLK{ct:Amid} | L4K3W4 | Amidation | Free | Linear | L | None | 8 | Antimicrobial | 5.13% hemolysis at 25μg/ml | Human | Synthetic peptide | helical | NA | ||
| 19544481 | 2009 | KLLKWLLK{ct:Amid} | L4K3W4 | Amidation | Free | Linear | L | None | 8 | Antimicrobial | 4.73% hemolysis at 12.5μg/ml | Human | Synthetic peptide | helical | NA | ||
| 19544481 | 2009 | KLLKWLLK{ct:Amid} | L4K3W4 | Amidation | Free | Linear | L | None | 8 | Antimicrobial | 5.47% hemolysis at 63μg/ml | Human | Synthetic peptide | helical | NA | ||
| 19544481 | 2009 | KLLKWLLKL{ct:Amid} | L5K3W5 | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 7.09% hemolysis at 200μg/ml | Human | Synthetic peptide | helical | NA | ||
| 19544481 | 2009 | KLLKWLLKL{ct:Amid} | L5K3W5 | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 5.36% hemolysis at 100μg/ml | Human | Synthetic peptide | helical | NA | ||
| 19544481 | 2009 | KLLKWLLKL{ct:Amid} | L5K3W5 | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 4.73% hemolysis at 50μg/ml | Human | Synthetic peptide | helical | NA | ||
| 19544481 | 2009 | KLLKWLLKL{ct:Amid} | L5K3W5 | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 4.84% hemolysis at 25μg/ml | Human | Synthetic peptide | helical | NA | ||
| 19544481 | 2009 | KLLKWLLKL{ct:Amid} | L5K3W5 | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 5.19% hemolysis at 12.5μg/ml | Human | Synthetic peptide | helical | NA | ||
| 19544481 | 2009 | KLLKWLLKL{ct:Amid} | L5K3W5 | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 4.84% hemolysis at 6.3μg/ml | Human | Synthetic peptide | helical | NA | ||
| 20308076 | 2010 | FFFLSRIF{ct:Amid} | Temporin-SHf | Amidation | Free | Linear | L | None | 8 | Antimicrobial | LC50 = 200μM | Human | Skin of the frog Pelophylax saharica | α Helical | NA | ||
| 21184776 | 2011 | NGVQPKY | Leucrocin I | Free | Free | Linear | L | None | 7 | Antibacterial | 15.88% hemolysis upto 48.0μg | Human | Leucrocin (serum and plasma of Crocodylus siamensis) | 28.57% Extended strand 71.43% Random coil | NA | ||
| 16730857 | 2006 | KFKLKQ{cyc:N-C} | BPC6L | Free | Free | Cyclic | L | None | 6 | Hemolytic | 11±4.6% hemolysis at 360µM | Human | Synthetic peptide | NA | NA | ||
| 16730857 | 2006 | KLKFKLKQ{cyc:N-C} | BPC8L | Free | Free | Cyclic | L | None | 8 | Antibacterial | 68±7.5% hemolysis at 360µM | Human | Synthetic peptide | NA | NA | ||
| 16730857 | 2006 | KLKF{d}KLKQ{cyc:N-C} | BPC8D | Free | Free | Cyclic | Mix | None | 8 | Hemolytic | 37±5.2% hemolysis at 360µM | Human | Synthetic peptide | NA | NA | ||
| 16730857 | 2006 | KLKLKLKQ{cyc:N-C} | BPC8S1 | Free | Free | Cyclic | L | None | 8 | Hemolytic | 1±0.1% hemolysis at 360µM | Human | Synthetic peptide | NA | NA | ||
| 16730857 | 2006 | LKLKLKLQ{cyc:N-C} | BPC8S3 | Free | Free | Cyclic | L | None | 8 | Hemolytic | 5±0.1% hemolysis at 360µM | Human | Synthetic peptide | NA | NA | ||
| 17065623 | 2006 | RKKWFW{nt:Acet}{ct:Amid} | PAF26 | Amidation | Acetylation | Linear | L | None | 6 | Antifungal | <0.3% hemolysis at 100µM | Human | Synthetic peptide | NA | NA | ||
| 15003352 | 2004 | RLRLRIGRR{cyc:N-C}{ct:Amid} | 9-Fluorenylmethoxycarbonyl (F-moc) | Amidation | Free | Cyclic | L | None | 9 | Antimicrobial | 0% hemolysis at 100µg/ml (non-hemolytic) | Rabbit | Synthetic peptide | NA | Non-hemolytic | ||
| 15003352 | 2004 | RLRLRIGRR{cyc:N-C}{ct:Amid} | 9-Fluorenylmethoxycarbonyl (F-moc) | Amidation | Free | Cyclic | L | None | 9 | Antimicrobial | 0% hemolysis at 100µg/ml (non-hemolytic) | Rabbit | Synthetic peptide | NA | Non-hemolytic | ||
| 15003352 | 2004 | RLRLRIGRR{cyc:N-C}{ct:Amid} | 9-Fluorenylmethoxycarbonyl (F-moc) | Amidation | Free | Cyclic | L | None | 9 | Antimicrobial | 0% hemolysis at 100µg/ml (non-hemolytic) | Rabbit | Synthetic peptide | NA | Non-hemolytic | ||
| 15980334 | 2005 | KIRVRLSA | M5 | Free | Free | Linear | L | None | 8 | Antimicrobial | <1% hemolysis at 120μg/ml | Human | Synthetic peptide | NA | NA | ||
| 16730857 | 2006 | KFKQ{cyc:N-C} | BPC4L | Free | Free | Cyclic | L | None | 4 | Antibacterial | 0% hemolysis at 360µM (non-hemolytic) | Human | Synthetic peptide | NA | Non-hemolytic | ||
| 16730857 | 2006 | KF{d}KQ{cyc:N-C} | BPC4D | Free | Free | Cyclic | Mix | None | 4 | Antibacterial | 0% hemolysis at 360µM (non-hemolytic) | Human | Synthetic peptide | NA | Non-hemolytic | ||
| 16730857 | 2006 | KF{d}KLKQ{cyc:N-C} | BPC6D | Free | Free | Cyclic | Mix | None | 6 | Antibacterial | 0% hemolysis at 360µM (non-hemolytic) | Human | Synthetic peptide | NA | Non-hemolytic | ||
| 16730857 | 2006 | KLKLKLKE{cyc:N-C} | BPC8S2 | Free | Free | Cyclic | L | None | 8 | Antibacterial | 0% hemolysis at 360µM (non-hemolytic) | Human | Synthetic peptide | NA | Non-hemolytic | ||
| 16730859 | 2006 | TSKYR | α137–141 | Free | Free | Linear | L | None | 5 | Antibacterial | Non-hemolytic | Bovine | Bovine hemoglobin | NA | Non-hemolytic | ||
| 16730859 | 2006 | STVLTSKYR | α133–141 | Free | Free | Linear | L | None | 9 | Antibacterial | Non-hemolytic | Bovine | Bovine hemoglobin | NA | Non-hemolytic | ||
| 17553680 | 2007 | {nnr:O}{nnr:O}WW{ct:Amid} | MP-1 | Amidation | Free | Linear | L | O = L-Ornithine | 4 | Antimicrobial | No hemolysis at 1000µg/ml (non-hemolytic) | Human | Synthetic peptide | NA | Non-hemolytic | ||
| 17553680 | 2007 | {nnr:O}{nnr:O}WW{nt:Hydroxy cinnamic acid (pHCA)}{ct:Amid} | MP-2 | Amidation | Hydroxy cinnamic acid (pHCA) | Linear | L | O = L-Ornithine | 4 | Antimicrobial | No hemolysis at 1000µg/ml (non-hemolytic) | Human | Synthetic peptide | NA | Non-hemolytic | ||
| 17553680 | 2007 | {nnr:O}{nnr:O}WW{nt:Acet}{ct:Amid} | MP-3 | Amidation | Acetylation | Linear | L | O = L-Ornithine | 4 | Antimicrobial | No hemolysis at 1000µg/ml (non-hemolytic) | Human | Synthetic peptide | NA | Non-hemolytic | ||
| 17553680 | 2007 | {nnr:O}{nnr:O}WW{nt:pHCA= Hydroxy cinnamic acid} | MP-4 | Free | pHCA= Hydroxy cinnamic acid | Linear | L | O = L-Ornithine | 4 | Antimicrobial | No hemolysis at 1000µg/ml (non-hemolytic) | Human | Synthetic peptide | NA | Non-hemolytic | ||
| 17553680 | 2007 | {nnr:O}{nnr:O}WW{nt:CIN= Cinnamic acid}{ct:Amid} | MP-5 | Amidation | CIN= Cinnamic acid | Linear | L | O = L-Ornithine | 4 | Antimicrobial | No hemolysis at 1000µg/ml (non-hemolytic) | Human | Synthetic peptide | NA | Non-hemolytic | ||
| 17553680 | 2007 | {nnr:O}{nnr:O}WW{nt:HPPA= 3-(4-hydroxyphenyl) propionic acid}{ct:Amid} | MP-6 | Amidation | HPPA= 3-(4-hydroxyphenyl) propionic acid | Linear | L | O = L-Ornithine | 4 | Antimicrobial | No hemolysis at 1000µg/ml (non-hemolytic) | Human | Synthetic peptide | NA | Non-hemolytic | ||
| 17553680 | 2007 | {nnr:O}{nnr:O}FF{nt:pHCA= Hydroxy cinnamic acid}{ct:Amid} | MP-7 | Amidation | pHCA= Hydroxy cinnamic acid | Linear | L | O = L-Ornithine | 4 | Antimicrobial | No hemolysis at 1000µg/ml (non-hemolytic) | Human | Synthetic peptide | NA | Non-hemolytic | ||
| 17553680 | 2007 | WW{nt:pHCA= Hydroxy cinnamic acid}{ct:Amid} | MP-8 | Amidation | pHCA= Hydroxy cinnamic acid | Linear | L | O = L-Ornithine | 2 | Antimicrobial | No hemolysis at 1000µg/ml (non-hemolytic) | Human | Synthetic peptide | NA | Non-hemolytic | ||
| 17961502 | 2007 | FKRLEKLFSKIQNDK | HPN2C4(6–13) | Free | Free | Linear | L | None | 8 | Antimicrobial | 0% hemolysis at 100µM (non-hemolytic) | Human | HP(2-20) analog (Helicobacter pylori) | NA | Non-hemolytic | ||
| 10631295 | 2000 | KLKLKLKLK{nt:Dansylation}{ct:Amid} | (KL)4K | Amidation | Dansylation | Linear | L | None | 9 | Antimicrobial | >20% hemolysis at 10µM | Human | Synthetic peptide | NA | NA | ||
| 21168911 | 2011 | FFRRFFRR{ct:Amid} | (FFRR)2 | Amidation | Free | Linear | L | None | 8 | Antimicrobial | HC50 > 500 | Human | Synthetic peptide | NA | NA | ||
| 21168911 | 2011 | LLRRLLRR{ct:Amid} | (LLRR)2 | Amidation | Free | Linear | L | None | 8 | Antimicrobial | HC50 > 500 | Human | Synthetic peptide | NA | NA | ||
| 21168911 | 2011 | LLKKLLKK{ct:Amid} | (LLKK)2 | Amidation | Free | Linear | L | None | 8 | Antimicrobial | HC50 > 500 | Human | Synthetic peptide | NA | NA | ||
| 12569105 | 2003 | FFHLHFH-{nnr:dcΔDOPA}{cyc:N-C} | Plicatamide | Free | Free | Cyclic | L | dcΔDOPA = decarboxy-(E)α,β-dehydro3,4-dihydroxyphenylalanine | 8 | Antibacterial | 100% hemolysis at ~40 μM | Human | Plicatamide (Styela plicata) | NA | NA | ||
| 12569105 | 2003 | FFHLHFH-{nnr:dcΔDOPA}{cyc:N-C} | Plicatamide | Free | Free | Cyclic | L | dcΔDOPA = decarboxy-(E)α,β-dehydro3,4-dihydroxyphenylalanine | 8 | Antibacterial | ~10% hemolysis at 80μM | Sheep | Plicatamide (Styela plicata) | NA | NA | ||
| 12712499 | 2003 | Y{d}PY{d}P{cyc:N-C} | GS4 | Free | Free | Cyclic | Mix | None | 4 | Antibacterial and Antifungal | 100% hemolysis at >150µg/ml | Human | Gramicidin S analogs | NA | NA | ||
| 12712499 | 2003 | KY{d}PKY{d}P{cyc:N-C} | GS6 | Free | Free | Cyclic | Mix | None | 6 | Antibacterial and Antifungal | 100% hemolysis at >150µg/ml | Human | Gramicidin S analogs | NA | NA | ||
| 12712499 | 2003 | VKY{d}PKLY{d}P{cyc:N-C} | GS8 | Free | Free | Cyclic | Mix | None | 8 | Antibacterial and Antifungal | 100% hemolysis at >150µg/ml | Human | Gramicidin S analogs | NA | NA | ||
| 15345319 | 2004 | TFRRLKWK{cyc:N-C} | LALF-10 | Free | Free | Cyclic | L | None | 8 | Antimicrobial | ~5% hemolysis at 100µg/ml | Human | Limulus analogs (Limulus polyphemus) | NA | NA | ||
| 15345319 | 2004 | TFRRLKWK{cyc:N-C} | LALF-11 | Free | Free | Cyclic | L | None | 8 | Antimicrobial | ~5% hemolysis at 100µg/ml | Human | Limulus analogs (Limulus polyphemus) | NA | NA | ||
| 11846794 | 2002 | RLYR | RLYR | Free | Free | Linear | L | None | 4 | Antibacterial and Antifungal | EC50 = 5200µM | Human | Synthetic peptide | NA | NA | ||
| 11846794 | 2002 | RLYRRLYR | (RLYR)2 | Free | Free | Linear | L | None | 8 | Antibacterial and Antifungal | EC50 = 1950µM | Human | Synthetic peptide | NA | NA | ||
| 11846794 | 2002 | RLYRRLYRRLYRRLYRRLYRRLYRRLYRKKKKK | (RLYR)8-([K2K]2K) | Free | Free | Linear | L | None | 8 | Antibacterial and Antifungal | EC50 = 1514µM | Human | Synthetic peptide | NA | NA | ||
| 23570790 | 2013 | WKSYVRRWR | TSG-10 | Free | Free | Linear | L | None | 9 | Antimicrobial | 1.1 ±1.3% hemolytic at 100μM | Human | Derivative of Ixosin-B | NA | NA | ||
| 23570790 | 2013 | WKSYVRRW | TSG-11 | Free | Free | Linear | L | None | 8 | Antimicrobial | 2.0 ±0.3% hemolytic at 100μM | Human | Derivative of Ixosin-B | NA | NA | ||
| 22914980 | 2013 | KWKW{ct:Amid} | (KW)2 | Amidation | Free | Linear | L | None | 4 | Antimicrobial | 0% hemolytic at 200μM | Human | Synthetic KW peptides | NA | Non-hemolytic | ||
| 22914980 | 2013 | KWKWKW{ct:Amid} | (KW)3 | Amidation | Free | Linear | L | None | 6 | Antimicrobial | 0% hemolytic at 200μM | Human | Synthetic KW peptides | NA | Non-hemolytic | ||
| 22914980 | 2013 | KWKWKWKW{ct:Amid} | (KW)4 | Amidation | Free | Linear | L | None | 8 | Antimicrobial | 8% hemolytic at 200μM | Human | Synthetic KW peptides | NA | NA | ||
| 22699557 | 2012 | IWRIFR{ct:Amid} | HFU2 | Amidation | Free | Linear | L | None | 6 | Antimicrobial | MHC >256μM | Human | Synthetic peptides | NA | NA | ||
| 22699557 | 2012 | IWRIFRRIF{ct:Amid} | HFU3 | Amidation | Free | Linear | L | None | 9 | Antimicrobial | MHC =101.4μM | Human | Synthetic peptides | NA | NA | ||
| 21607695 | 2011 | RRWQWRMKK | LfcinB9 | Free | Free | Linear | L | None | 9 | Antimicrobial | <5% hemolytic at 256mg/ml | Pig | Synthetic peptide derived from bovine lactoferricin | NA | NA | ||
| 21820306 | 2011 | {nnr:tle}-K-{nnr:tle}-A-{nnr:tle}-A-{nnr:tle}-A{cyc:N-C} | A | Free | Free | Cyclic | Mix | tle = D-Tert-leucine | 8 | Antimicrobial | HC50 =17μM | Human | Synthetic peptides | NA | NA | ||
| 21820306 | 2011 | {nnr:Tle}-K{d}-{nnr:Tle}-A{d}-{nnr:Tle}-A{d}-{nnr:Tle}-A{d}{cyc:N-C} | B | Free | Free | Cyclic | Mix | Tle = Tert-leucine | 8 | Antimicrobial | HC50 =17μM | Human | Synthetic peptides | NA | NA | ||
| 21820306 | 2011 | {nnr:tle}-K{d}-{nnr:tle}-A-{nnr:tle}-A-{nnr:tle}-A{cyc:N-C} | C | Free | Free | Cyclic | Mix | tle = D-Tert-leucine | 8 | Antimicrobial | HC50 =316μM | Human | Synthetic peptides | NA | NA | ||
| 21820306 | 2011 | {nnr:Tle}-K-{nnr:Tle}-A{d}-{nnr:Tle}-A{d}-{nnr:Tle}-A{d}{cyc:N-C} | D | Free | Free | Cyclic | Mix | Tle = Tert-leucine | 8 | Antimicrobial | HC50 =316μM | Human | Synthetic peptides | NA | NA | ||
| 21955251 | 2011 | GIIKKI{ct:Amid} | G(IIKK)I | Amidation | Free | Linear | L | None | 6 | Antimicrobial and Antitumor | Non-hemolytic up to 250 μM | Human | Synthetic peptides | NA | Non-hemolytic | ||
| 21462284 | 2011 | WKWKWK | Normal-(WK)3 | Free | Free | Linear | L | None | 6 | Antimicrobial | 0% hemolytic upto 400μM | Human | Synthetic peptides | NA | NA | ||
| 21462284 | 2011 | WKWKWK | Normal-(WK)3 | Free | Free | Linear | L | None | 6 | Antimicrobial | ~10% hemolytic at 600μM | Human | Synthetic peptides | NA | NA | ||
| 21462284 | 2011 | KWKWKW | Reversed-(KW)3 | Free | Free | Linear | L | None | 6 | Antimicrobial | 0% hemolytic upto 400μM | Human | Synthetic peptides | NA | NA | ||
| 21462284 | 2011 | KWKWKW | Reversed-(KW)3 | Free | Free | Linear | L | None | 6 | Antimicrobial | ~10% hemolytic at 600μM | Human | Synthetic peptides | NA | NA | ||
| 20736034 | 2011 | WLKKW{ct:Amid} | LK2W2 | Amidation | Free | Linear | L | None | 5 | Antimicrobial | negligible hemolysis at 320μg/ml | Human | Synthetic peptide | NA | Non-hemolytic | ||
| 20736034 | 2011 | WLLKW{ct:Amid} | L2KW2 | Amidation | Free | Linear | L | None | 5 | Antimicrobial | negligible hemolysis at 320μg/ml | Human | Synthetic peptide | NA | Non-hemolytic | ||
| 20736034 | 2011 | KWLKKWL{ct:Amid} | L2K3W2 | Amidation | Free | Linear | L | None | 7 | Antimicrobial | negligible hemolysis at 320μg/ml | Human | Synthetic peptide | NA | Non-hemolytic | ||
| 20736034 | 2011 | KWLLKWL{ct:Amid} | L3K2W2 | Amidation | Free | Linear | L | None | 7 | Antimicrobial | 0-5% hemolysis at 160μg/ml | Human | Synthetic peptide | NA | NA | ||
| 20736034 | 2011 | KKWLKKWLK{ct:Amid} | L2K5W2 | Amidation | Free | Linear | L | None | 9 | Antimicrobial | negligible hemolysis at 320μg/ml | Human | Synthetic peptide | NA | Non-hemolytic | ||
| 20736034 | 2011 | LKWLKKWLK{ct:Amid} | L3K4W2 | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 0% hemolysis at 160μg/ml | Human | Synthetic peptide | NA | NA | ||
| 20736034 | 2011 | LKWLLKWLK{ct:Amid} | L4K3W2 | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 10% hemolysis at 40μg/ml | Human | Synthetic peptide | NA | NA | ||
| 20736034 | 2011 | LKWLLKWLL{ct:Amid} | L5K2W2 | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 60% hemolysis at 40μg/ml | Human | Synthetic peptide | NA | NA | ||
| 20736034 | 2011 | KWLLKWL{ct:Amid} | L3K2W2 | Amidation | Free | Linear | L | None | 7 | Antimicrobial | 10% hemolysis at 320μg/ml | Human | Synthetic peptide | NA | NA | ||
| 20736034 | 2011 | LKWLKKWLK{ct:Amid} | L3K4W2 | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 0-5% hemolysis at 320μg/ml | Human | Synthetic peptide | NA | NA | ||
| 20736034 | 2011 | LKWLLKWLK{ct:Amid} | L4K3W2 | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 25% hemolysis at 80μg/ml | Human | Synthetic peptide | NA | NA | ||
| 20736034 | 2011 | LKWLLKWLK{ct:Amid} | L4K3W2 | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 40-50% hemolysis at 160μg/ml | Human | Synthetic peptide | NA | NA | ||
| 20736034 | 2011 | LKWLLKWLL{ct:Amid} | L5K2W2 | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 65% hemolysis at 80μg/ml | Human | Synthetic peptide | NA | NA | ||
| 20736034 | 2011 | LKWLLKWLL{ct:Amid} | L5K2W2 | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 70% hemolysis at 160μg/ml | Human | Synthetic peptide | NA | NA | ||
| 21682682 | 2011 | VDIHVWDGV | PIP[59-67] | Free | Free | Linear | L | None | 9 | Cytotoxic | 3.2% hemolysis at 100μM | Human | synthetic peptide | NA | NA | ||
| 21682682 | 2011 | VDIHVW{nnr:D*}GV | β-Asp65-PIP[59-67] | Free | Free | Linear | L | D* = β-aspartic acid | 9 | Cytotoxic | 1% hemolysis at 100μM | Human | synthetic peptide | NA | NA | ||
| 21682682 | 2011 | VDIHVWA{d}GV | D65A-PIP[59-67] | Free | Free | Linear | Mix | None | 9 | Cytotoxic | 7.5% hemolysis at 100μM | Human | synthetic peptide | NA | NA | ||
| 21682682 | 2011 | VDIHVWS{d}GV | D65S-PIP[59-67] | Free | Free | Linear | Mix | None | 9 | Cytotoxic | 1.03% hemolysis at 100μM | Human | synthetic peptide | NA | NA | ||
| 21682682 | 2011 | VDIHVWE{d}GV | D65E-PIP[59-67] | Free | Free | Linear | Mix | None | 9 | Cytotoxic | 9.9% hemolysis at 100μM | Human | synthetic peptide | NA | NA | ||
| 21682682 | 2011 | VE{d}IHVWE{d}GV | D60,65E-PIP[59-67] | Free | Free | Linear | Mix | None | 9 | Cytotoxic | 2.24% hemolysis at 100μM | Human | synthetic peptide | NA | NA | ||
| 23026014 | 2013 | WFRKQLKW | L10 | Free | Free | Linear | L | None | 8 | Antibacterial and Antifungal | No hemolysis upto 800μg/ml | Human | Derived from modified N-terminal domain of bovine lactoferrin | NA | Non-hemolytic | ||
| 23415044 | 2013 | FLGFLKNLF | WT | Free | Free | Linear | L | None | 9 | Antiviral | HC50 =137.9μg/ml | Human | Synthetic peptide (Ctry2459) | α-helical | NA | ||
| 23415044 | 2013 | FLGFLHHLF | H2 | Free | Free | Linear | L | None | 9 | Antiviral | HC50 =203.3μg/ml | Human | Synthetic peptide (Ctry2459) | α-helical | NA | ||
| 23415044 | 2013 | FLHFLHHLF | H3 | Free | Free | Linear | L | None | 9 | Antiviral | HC50 =416.4μg/ml | Human | Synthetic peptide (Ctry2459) | α-helical | NA | ||
| 23776609 | 2013 | RKKRRQRRR | Tat (49–57) | Free | Free | Linear | L | None | 9 | CPP | Inactive | Human | buforin IIb | NA | Non-hemolytic | ||
| 10600529 | 1999 | RHARHD | Hannahpep | Free | Free | Linear | L | None | 6 | Plasma-anticlotting | No hemolysis (non hemolytic) | Human | Indian King Cobra (Ophiophagus hannah) Venom | NA | Non-hemolytic | ||
| 10600529 | 1999 | RHARHD | Hannahpep | Free | Free | Linear | L | None | 6 | Plasma-anticlotting | No hemolysis (non hemolytic) | Goat | Indian King Cobra (Ophiophagus hannah) Venom | NA | Non-hemolytic | ||
| 10600529 | 1999 | RHARHD | Hannahpep | Free | Free | Linear | L | None | 6 | Plasma-anticlotting | No hemolysis (non hemolytic) | Mouse | Indian King Cobra (Ophiophagus hannah) Venom | NA | Non-hemolytic | ||
| 18942691 | 2008 | KVMAHMK{ct:Amid} | MEP-5 | Amidation | Free | Linear | L | None | 7 | Antimicrobial | LC50 >100µM | Rat | Melectin analog (Melecta albifrons) | NA | NA | ||
| 18942691 | 2008 | PKVMAHMK{ct:Amid} | MEP-6 | Amidation | Free | Linear | L | None | 8 | Antimicrobial | LC50 >100µM | Rat | Melectin analog (Melecta albifrons) | NA | NA | ||
| 18942691 | 2008 | LPKVMAHMK{ct:Amid} | MEP-7 | Amidation | Free | Linear | L | None | 9 | Antimicrobial | LC50 >100µM | Rat | Melectin analog (Melecta albifrons) | NA | NA | ||
| 8843284 | 1996 | KFFKFFKFF | Synthetic peptide | Free | Free | Linear | L | None | 9 | Antibacterial | Strongly hemolytic at 40µg/ml | Human | Synthetic peptide | NA | NA | ||
| 8810288 | 1996 | Y{d}PY{d}P{cyc:N-C} | GS4 | Free | Free | Cyclic | Mix | None | 4 | Antibacterial | 100% hemolysis at >800µg/ml | Human | Gramicidin S analog (Bacillus brevis) | NA | NA | ||
| 8810288 | 1996 | Y{d}PKY{d}PK{cyc:N-C} | GS6 | Free | Free | Cyclic | Mix | None | 6 | Antibacterial | 100% hemolysis at >1600µg/ml | Human | Gramicidin S analog (Bacillus brevis) | NA | NA | ||
| 8810288 | 1996 | Y{d}PVKY{d}PKL{cyc:N-C} | GS8 | Free | Free | Cyclic | Mix | None | 8 | Antibacterial | 100% hemolysis at >1600µg/ml | Human | Gramicidin S analog (Bacillus brevis) | NA | NA | ||
| 9204560 | 1997 | F{d}R{d}L{d}K{d}F{d}H{d} | 66-10 | Free | Free | Linear | D | None | 6 | Antimicrobial | 0% hemolysis at 312 to 0μg/ml | Human | Synthetic Peptide | NA | Non-hemolytic | ||
| 9204560 | 1997 | F{d}R{d}L{d}K{d}F{d}H{d} | 66-10 | Free | Free | Linear | D | None | 6 | Antimicrobial | 0% hemolysis at 312 to 0μg/ml | Bovine | Synthetic Peptide | NA | Non-hemolytic | ||
| 9204560 | 1997 | F{d}R{d}L{d}K{d}F{d}H{d} | 66-10 | Free | Free | Linear | D | None | 6 | Antimicrobial | 0% hemolysis at 312 to 0μg/ml | Ovine | Synthetic Peptide | NA | Non-hemolytic | ||
| 9889358 | 1998 | KLLLK{nt:Dansylation}{ct:Amid} | DnsLK5NH2 | Amidation | Dansylation | Linear | L | None | 5 | Cytotoxin | LD50 =90μM | Human | Synthetic Peptide | α-Helix | NA | ||
| 9889358 | 1998 | KLLLKLLLK{nt:Dansylation} | DnsLK9 | Free | Dansylation | Linear | L | None | 9 | Cytotoxin | LD50 =4.5 μM | Human | Synthetic Peptide | α-Helix | NA | ||
| 9889358 | 1998 | KLLLKLLLK{nt:Dansylation}{ct:Amid} | DnsLK9 | Amidation | Dansylation | Linear | L | None | 9 | Cytotoxin | LD50 =2.5 μM | Human | Synthetic Peptide | α-Helix | NA | ||
| 11318033 | 2001 | QL{d}LVDL{d}I{cyc:N-C} | Lichenysin | Free | Free | Cyclic | Mix | None | 7 | Chelating agent | 100% hemolysis at 15μM | Human | Bacillus licheniformis | NA | NA | ||
| 24009675 | 2013 | NIVNVSLVK | NK9 | Free | Free | Linear | L | None | 9 | Cytotoxicity | <0.1 % Hemolysis at 25 µM | Human | Sars Corona Virus E-Protein | α-Helical | Non-hemolytic | ||
| 24009675 | 2013 | NIVNVSLVK | NK9 | Free | Free | Linear | L | None | 9 | Cytotoxicity | <0.1 % Hemolysis at 50 µM | Human | Sars Corona Virus E-Protein | α-Helical | Non-hemolytic | ||
| 24009675 | 2013 | NIVNVSLVK | NK9 | Free | Free | Linear | L | None | 9 | Cytotoxicity | <0.2 % Hemolysis at 100 µM | Human | Sars Corona Virus E-Protein | α-Helical | Non-hemolytic | ||
| 24009675 | 2013 | NIVNVSLVK | NK9 | Free | Free | Linear | L | None | 9 | Cytotoxicity | <0.2 % Hemolysis at 150 µM | Human | Sars Corona Virus E-Protein | α-Helical | Non-hemolytic | ||
| 24009675 | 2013 | NIVNVSLVK | NK9 | Free | Free | Linear | L | None | 9 | Cytotoxicity | <0.4 % Hemolysis at 200 µM | Human | Sars Corona Virus E-Protein | α-Helical | Non-hemolytic | ||
| 24009675 | 2013 | NIVNVSLVK | NK9 | Free | Free | Linear | L | None | 9 | Cytotoxicity | <0.5 % Hemolysis at 250 µM | Human | Sars Corona Virus E-Protein | α-Helical | Non-hemolytic | ||
| 23831136 | 2013 | NGVQPKY | Luecrocin I | Free | Free | Linear | L | None | 7 | Antibacterial | 0 % Hemolysis at 91 μg/mL | Human | White Blood Cells Of Crocodylus Siamensis | α-Helical | Non-hemolytic | ||
| 24147906 | 2013 | A{d}L{d}L{d}L | 0 | Free | Free | Linear | Mix | lowercase letters correspond to D-amino acids | 4 | Antibacterial | 15.6 ± 3.2 % Hemolysis at 142 µM | Human | Synthetic | α-Helical | NA | ||
| 24147906 | 2013 | LLLLL | 1 | Free | Free | Linear | L | None | 5 | Antibacterial | 6.9 ± 1.8 % Hemolysis at 142 µM | Human | Synthetic | α-Helical | NA | ||
| 24147906 | 2013 | LLLLD | 2 | Free | Free | Linear | L | None | 5 | Antibacterial | 6.0 ± 0.5 % Hemolysis at 142 µM | Human | Synthetic | α-Helical | NA | ||
| 24147906 | 2013 | LLLDL | 3 | Free | Free | Linear | L | None | 5 | Antibacterial | 2.7 ± 0.1 % Hemolysis at 142 µM | Human | Synthetic | α-Helical | NA | ||
| 24147906 | 2013 | LLDLL | 4 | Free | Free | Linear | L | None | 5 | Antibacterial | 2.7 ± 1.4 % Hemolysis at 142 µM | Human | Synthetic | α-Helical | NA | ||
| 24147906 | 2013 | LDLLL | 5 | Free | Free | Linear | L | None | 5 | Antibacterial | 4.2 ± 0.6 % Hemolysis at 142 µM | Human | Synthetic | α-Helical | NA | ||
| 24147906 | 2013 | DLLLL | 6 | Free | Free | Linear | L | None | 5 | Antibacterial | 4.2 ± 0.8 % Hemolysis at 142 µM | Human | Synthetic | α-Helical | NA | ||
| 24147906 | 2013 | LLLDD | 7 | Free | Free | Linear | L | None | 5 | Antibacterial | 5.1 ± 2.3 % Hemolysis at 142 µM | Human | Synthetic | α-Helical | NA | ||
| 24147906 | 2013 | LLDLD | 8 | Free | Free | Linear | L | None | 5 | Antibacterial | 1.3 ± 0.2 % Hemolysis at 142 µM | Human | Synthetic | α-Helical | NA | ||
| 24147906 | 2013 | LDLLD | 9 | Free | Free | Linear | L | None | 5 | Antibacterial | 1.4 ± 1.5 % Hemolysis at 142 µM | Human | Synthetic | α-Helical | NA | ||
| 24147906 | 2013 | DLLLD | 10 | Free | Free | Linear | L | None | 5 | Antibacterial | 2.4 ± 0.8 % Hemolysis at 142 µM | Human | Synthetic | α-Helical | NA | ||
| 24147906 | 2013 | LLDDL | 11 | Free | Free | Linear | L | None | 5 | Antibacterial | 3.7 ± 1.7 % Hemolysis at 142 µM | Human | Synthetic | α-Helical | NA | ||
| 24147906 | 2013 | LDLDL | 12 | Free | Free | Linear | L | None | 5 | Antibacterial | 1.9 ± 2.2 % Hemolysis at 142 µM | Human | Synthetic | α-Helical | NA | ||
| 24147906 | 2013 | DLLDL | 13 | Free | Free | Linear | L | None | 5 | Antibacterial | 3.7 ± 0.3 % Hemolysis at 142 µM | Human | Synthetic | α-Helical | NA | ||
| 24147906 | 2013 | LDDLL | 14 | Free | Free | Linear | L | None | 5 | Antibacterial | 0.5 ± 0.5 % Hemolysis at 142 µM | Human | Synthetic | α-Helical | NA | ||
| 24147906 | 2013 | DLDLL | 15 | Free | Free | Linear | L | None | 5 | Antibacterial | 1.6 ± 0.6 % Hemolysis at 142 µM | Human | Synthetic | α-Helical | NA | ||
| 24147906 | 2013 | DDLLL | 16 | Free | Free | Linear | L | None | 5 | Antibacterial | 4.1 ± 0.9 % Hemolysis at 142 µM | Human | Synthetic | α-Helical | NA | ||
| 24147906 | 2013 | LLDDD | 17 | Free | Free | Linear | L | None | 5 | Antibacterial | 6.2 ± 0.4 % Hemolysis at 142 µM | Human | Synthetic | α-Helical | NA | ||
| 24147906 | 2013 | LDLDD | 18 | Free | Free | Linear | L | None | 5 | Antibacterial | 0–0.9 % Hemolysis at 142 µM | Human | Synthetic | α-Helical | NA | ||
| 24147906 | 2013 | DLLDD | 19 | Free | Free | Linear | L | None | 5 | Antibacterial | 0.5 ± 0.5 % Hemolysis at 142 µM | Human | Synthetic | α-Helical | NA | ||
| 24147906 | 2013 | LDDLD | 20 | Free | Free | Linear | L | None | 5 | Antibacterial | 0.8 ± 0.1 % Hemolysis at 142 µM | Human | Synthetic | α-Helical | NA | ||
| 24147906 | 2013 | DLDLD | 21 | Free | Free | Linear | L | None | 5 | Antibacterial | 0–0.6 % Hemolysis at 142 µM | Human | Synthetic | α-Helical | NA | ||
| 24147906 | 2013 | DDLLD | 22 | Free | Free | Linear | L | None | 5 | Antibacterial | 8 % Hemolysis at 142 µM | Human | Synthetic | α-Helical | NA | ||
| 24147906 | 2013 | LDDDL | 23 | Free | Free | Linear | L | None | 5 | Antibacterial | 3.3 ± 0.3 % Hemolysis at 142 µM | Human | Synthetic | α-Helical | NA | ||
| 24147906 | 2013 | DLDDL | 24 | Free | Free | Linear | L | None | 5 | Antibacterial | 1.0 ± 0.7 % Hemolysis at 142 µM | Human | Synthetic | α-Helical | NA | ||
| 24147906 | 2013 | DDLDL | 25 | Free | Free | Linear | L | None | 5 | Antibacterial | 3.5 ± 1.2 % Hemolysis at 142 µM | Human | Synthetic | α-Helical | NA | ||
| 24147906 | 2013 | DDDLL | 26 | Free | Free | Linear | L | None | 5 | Antibacterial | 5.3 ± 0.3 % Hemolysis at 142 µM | Human | Synthetic | α-Helical | NA | ||
| 24147906 | 2013 | LDDDD | 27 | Free | Free | Linear | L | None | 5 | Antibacterial | 1.3 ± 0.2 % Hemolysis at 142 µM | Human | Synthetic | α-Helical | NA | ||
| 24147906 | 2013 | DLDDD | 28 | Free | Free | Linear | L | None | 5 | Antibacterial | 0–1.4 % Hemolysis at 142 µM | Human | Synthetic | α-Helical | NA | ||
| 24147906 | 2013 | DDLDD | 29 | Free | Free | Linear | L | None | 5 | Antibacterial | 3.1 ± 1.1 % Hemolysis at 142 µM | Human | Synthetic | α-Helical | NA | ||
| 24147906 | 2013 | DDDLD | 30 | Free | Free | Linear | L | None | 5 | Antibacterial | 0–3.1 % Hemolysis at 142 µM | Human | Synthetic | α-Helical | NA | ||
| 24147906 | 2013 | DDDDL | 31 | Free | Free | Linear | L | None | 5 | Antibacterial | 8.5 ± 3.8 % Hemolysis at 142 µM | Human | Synthetic | α-Helical | NA | ||
| 24147906 | 2013 | DDDDD | 32 | Free | Free | Linear | L | None | 5 | Antibacterial | 15 ± 2.2 % Hemolysis at 142 µM | Human | Synthetic | α-Helical | NA | ||
| 24041699 | 2013 | LLCIALRKK{ct:Amid} | L-CopA3 | Amidation | Free | Linear | L | None | 9 | Antifungal | 0 % Hemolysis at 1.3 µM | Human | Truncated Coprisin Analog Peptide | α-Helical | Non-hemolytic | ||
| 24041699 | 2013 | LLCIALRKK{ct:Amid} | L-CopA3 | Amidation | Free | Linear | L | None | 9 | Antifungal | 0 % Hemolysis at 2.5 µM | Human | Truncated Coprisin Analog Peptide | α-Helical | Non-hemolytic | ||
| 24041699 | 2013 | LLCIALRKK{ct:Amid} | L-CopA3 | Amidation | Free | Linear | L | None | 9 | Antifungal | 0 % Hemolysis at 5 µM | Human | Truncated Coprisin Analog Peptide | α-Helical | Non-hemolytic | ||
| 24041699 | 2013 | LLCIALRKK{ct:Amid} | L-CopA3 | Amidation | Free | Linear | L | None | 9 | Antifungal | 0 % Hemolysis at 10 µM | Human | Truncated Coprisin Analog Peptide | α-Helical | Non-hemolytic | ||
| 24041699 | 2013 | LLCIALRKK{ct:Amid} | L-CopA3 | Amidation | Free | Linear | L | None | 9 | Antifungal | 0 % Hemolysis at 20 µM | Human | Truncated Coprisin Analog Peptide | α-Helical | Non-hemolytic | ||
| 24041699 | 2013 | LLCIALRKK{ct:Amid} | L-CopA3 | Amidation | Free | Linear | L | None | 9 | Antifungal | 0 % Hemolysis at 40 µM | Human | Truncated Coprisin Analog Peptide | α-Helical | Non-hemolytic | ||
| 24041699 | 2013 | LLCIALRKK{ct:Amid} | L-CopA3 | Amidation | Free | Linear | L | None | 9 | Antifungal | 0 % Hemolysis at 80 µM | Human | Truncated Coprisin Analog Peptide | α-Helical | Non-hemolytic | ||
| 24041699 | 2013 | L{d}L{d}C{d}I{d}A{d}L{d}R{d}K{d}K{d}{ct:Amid} | D-CopA3 | Amidation | Free | Linear | D | lowercase letters correspond to D-amino acids | 9 | Antifungal | 0 % Hemolysis at 1.3 µM | Human | Truncated Coprisin Analog Peptide | α-Helical | Non-hemolytic | ||
| 24041699 | 2013 | L{d}L{d}C{d}I{d}A{d}L{d}R{d}K{d}K{d}{ct:Amid} | D-CopA3 | Amidation | Free | Linear | D | lowercase letters correspond to D-amino acids | 9 | Antifungal | 0 % Hemolysis at 2.5 µM | Human | Truncated Coprisin Analog Peptide | α-Helical | Non-hemolytic | ||
| 24041699 | 2013 | L{d}L{d}C{d}I{d}A{d}L{d}R{d}K{d}K{d}{ct:Amid} | D-CopA3 | Amidation | Free | Linear | D | lowercase letters correspond to D-amino acids | 9 | Antifungal | 0 % Hemolysis at 5 µM | Human | Truncated Coprisin Analog Peptide | α-Helical | Non-hemolytic | ||
| 24041699 | 2013 | L{d}L{d}C{d}I{d}A{d}L{d}R{d}K{d}K{d}{ct:Amid} | D-CopA3 | Amidation | Free | Linear | D | lowercase letters correspond to D-amino acids | 9 | Antifungal | 0 % Hemolysis at 10 µM | Human | Truncated Coprisin Analog Peptide | α-Helical | Non-hemolytic | ||
| 24041699 | 2013 | L{d}L{d}C{d}I{d}A{d}L{d}R{d}K{d}K{d}{ct:Amid} | D-CopA3 | Amidation | Free | Linear | D | lowercase letters correspond to D-amino acids | 9 | Antifungal | 0 % Hemolysis at 20 µM | Human | Truncated Coprisin Analog Peptide | α-Helical | Non-hemolytic | ||
| 24041699 | 2013 | L{d}L{d}C{d}I{d}A{d}L{d}R{d}K{d}K{d}{ct:Amid} | D-CopA3 | Amidation | Free | Linear | D | lowercase letters correspond to D-amino acids | 9 | Antifungal | 0 % Hemolysis at 40 µM | Human | Truncated Coprisin Analog Peptide | α-Helical | Non-hemolytic | ||
| 24041699 | 2013 | L{d}L{d}C{d}I{d}A{d}L{d}R{d}K{d}K{d}{ct:Amid} | D-CopA3 | Amidation | Free | Linear | D | lowercase letters correspond to D-amino acids | 9 | Antifungal | 0 % Hemolysis at 80 µM | Human | Truncated Coprisin Analog Peptide | α-Helical | Non-hemolytic | ||
| 23816372 | 2013 | WRWRWR{ct:Amid} | 1 | Amidation | Free | Linear | L | None | 6 | Antimicrobial | 10 % Hemolysis at >256 μg/mL | Human | Synthetic | α-Helical | Non-hemolytic | ||
| 23816372 | 2013 | WRWR{ct:Amid} | 2 | Amidation | Free | Linear | L | None | 4 | Antimicrobial | 10 % Hemolysis at >256 μg/mL | Human | Synthetic | α-Helical | Non-hemolytic | ||
| 23816372 | 2013 | RWR{ct:Amid} | 3 | Amidation | Free | Linear | L | None | 3 | Antimicrobial | 10 % Hemolysis at >256 μg/mL | Human | Synthetic | α-Helical | Non-hemolytic | ||
| 24211081 | 2014 | IRIKIRIK{ct:Amid} | IK8-all L | Amidation | Free | Linear | L | None | 8 | Antimicrobial | 10 % Hemolysis at 2000 mg/L | Rabbit | Synthetic | β-Sheet | NA | ||
| 24211081 | 2014 | I{d}R{d}I{d}K{d}I{d}R{d}I{d}K{d}{ct:Amid} | IK8-all D | Amidation | Free | Linear | D | None | 8 | Antimicrobial | 10 % Hemolysis at 1750 mg/L | Rabbit | Synthetic | β-Sheet | NA | ||
| 24211081 | 2014 | I{d}R{d}I{d}K{d}I{d}R{d}{ct:Amid} | IK6-all D | Amidation | Free | Linear | D | None | 6 | Antimicrobial | 10 % Hemolysis at >2000 mg/L | Rabbit | Synthetic | β-Sheet | NA | ||
| 24211081 | 2014 | I{d}R{d}I{d}K{d}{ct:Amid} | IK4-all D | Amidation | Free | Linear | D | None | 4 | Antimicrobial | 10 % Hemolysis at >2000 mg/L | Rabbit | Synthetic | β-Sheet | NA | ||
| 24211081 | 2014 | IR{d}IK{d}IR{d}IK{d}{ct:Amid} | IK8-4D | Amidation | Free | Linear | D | None | 8 | Antimicrobial | 10 % Hemolysis at >2000 mg/L | Rabbit | Synthetic | β-Sheet | NA | ||
| 24211081 | 2014 | IRIK{d}IR{d}IK{ct:Amid} | IK8-2D | Amidation | Free | Linear | Mix | lowercase letters correspond to D-amino acids | 8 | Antimicrobial | 10 % Hemolysis at 1600 mg/L | Rabbit | Synthetic | β-Sheet | NA | ||
| 24211081 | 2014 | IIRKIIRK{ct:Amid} | Control-all L | Amidation | Free | Linear | L | None | 8 | Antimicrobial | 10 % Hemolysis at >2000 mg/L | Rabbit | Synthetic | β-Sheet | NA | ||
| 24211081 | 2014 | I{d}I{d}R{d}K{d}I{d}I{d}R{d}K{d}{ct:Amid} | Control-all D | Amidation | Free | Linear | D | None | 8 | Antimicrobial | 10 % Hemolysis at >2000 mg/L | Rabbit | Synthetic | β-Sheet | NA | ||
| 24211081 | 2014 | II{d}R{d}KII{d}R{d}K{ct:Amid} | Control-4D | Amidation | Free | Linear | Mix | lowercase letters correspond to D-amino acids | 8 | Antimicrobial | 10 % Hemolysis at >2000 mg/L | Rabbit | Synthetic | β-Sheet | NA | ||
| 25003126 | 2014 | FLGLLGGLL{ct:Amid} | Feleucin-BV1 | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 100 % Hemolysis at >512 mg/L | Horse | Skin Secretion-Derived (Bombina Variegata) | α-Helix | NA | ||
| 25003126 | 2014 | FLGLIGSLL{ct:Amid} | Feleucin-BV2 | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 100 % Hemolysis at >512 mg/L | Horse | Skin Secretion-Derived(Bombina Variegata) | α-Helix | NA | ||
| 24321546 | 2014 | LL{nnr:SelenoCys}IALRKK{ct:Amid} | CopSe | Amidation | Free | Linear | L | selenocys = selenocysteine | 9 | Antimicrobial | 1.6 % Hemolysis at 200 µg/ml | Human | Coprisin Analogs, Dung Beetle, Copris Tripartitus | α-Helix | NA | ||
| 24321546 | 2014 | LL{nnr:MethylCys}IALRKK{ct:Amid} | CopMe | Amidation | Free | Linear | L | methylcys = methylcysteine | 9 | Antimicrobial | 1 % Hemolysis at 200 µg/ml | Human | Coprisin Analogs, Dung Beetle, Copris Tripartitus | α-Helix | NA | ||
| 24321546 | 2014 | LLRIALRKK{ct:Amid} | CopR | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 1 % Hemolysis at 200 µg/ml | Human | Coprisin Analogs, Dung Beetle, Copris Tripartitus | α-Helix | NA | ||
| 24321546 | 2014 | LLLIALRKK{ct:Amid} | CopL | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 30 % Hemolysis at 200 µg/ml | Human | Coprisin Analogs, Dung Beetle, Copris Tripartitus | α-Helix | NA | ||
| 24321546 | 2014 | LLWIALRKK{ct:Amid} | CopW | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 1.5 % Hemolysis at 200 µg/ml | Human | Coprisin Analogs, Dung Beetle, Copris Tripartitus | α-Helix | Non-hemolytic | ||
| 24321546 | 2014 | LLLIVLRKK{ct:Amid} | CopLV | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 13.6 % Hemolysis at 200 µg/ml | Human | Coprisin Analogs, Dung Beetle, Copris Tripartitus | α-Helix | NA | ||
| 24321546 | 2014 | LLCIALRKK{ct:Amid} | CopA3 (Mono) | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 2 % Hemolysis at 200 µg/ml | Human | Coprisin Analogs, Dung Beetle, Copris Tripartitus | α-Helix | NA | ||
| 24321546 | 2014 | LLCKALRKI{ct:Amid} | CopIK (Mono) | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 2 % Hemolysis at 200 µg/ml | Human | Coprisin Analogs, Dung Beetle, Copris Tripartitus | α-Helix | NA | ||
| 24411680 | 2014 | RKDVY{ct:Amid} | TP-5 | Amidation | Free | Linear | L | None | 5 | Anti-mycobacterial | 50 % Hemolysis at >2000 mg/L | Rat | Synthetic Immunomodulatory Pentapeptide Of Thymopentin | α-Helix | Non-hemolytic | ||
| 24411680 | 2014 | RRRRRR{ct:Amid} | RR-6 | Amidation | Free | Linear | L | None | 6 | Anti-mycobacterial | 50 % Hemolysis at >2000 mg/L | Rat | Synthetic Peptide | α-Helix | Non-hemolytic | ||
| 24945359 | 2014 | FRIRVRV{ct:Amid} | FV7 | Amidation | Free | Linear | L | None | 7 | Antimicrobial | 5 % Hemolysis at >256 µM | Human | Synthetic Peptide Embedded Anti-Biofilm Sequence | α-Helix | Low hemolytic | ||
| 24945359 | 2014 | RKKTRKR{ct:Amid} | RR7 | Amidation | Free | Linear | L | None | 7 | Antimicrobial | 5 % Hemolysis at >256 µM | Human | Synthetic Peptide | α-Helix | Low hemolytic | ||
| 24953028 | 2014 | W-{nnr:3-ABA}-R{ct:Amid} | 1a | Amidation | Free | Linear | L | 3-ABA = 3-amino benzoic acid | 3 | Antibacterial | 10 % Hemolysis at 400 μg/ml | Human | Synthetic | NA | NA | ||
| 24953028 | 2014 | W-{nnr:3-ABA}-R{ct:Amid} | 1a | Amidation | Free | Linear | L | 3-ABA = 3-amino benzoic acid | 3 | Antibacterial | 50 % Hemolysis at >500 μg/ml | Human | Synthetic | NA | NA | ||
| 24953028 | 2014 | WW-{nnr:3-ABA}-R{ct:Amid} | 2a | Amidation | Free | Linear | L | 3-ABA = 3-amino benzoic acid | 4 | Antibacterial | 10 % Hemolysis at 100 μg/ml | Human | Synthetic | NA | NA | ||
| 24953028 | 2014 | WW-{nnr:3-ABA}-R{ct:Amid} | 2a | Amidation | Free | Linear | L | 3-ABA = 3-amino benzoic acid | 4 | Antibacterial | 50 % Hemolysis at 240 μg/ml | Human | Synthetic | NA | NA | ||
| 24953028 | 2014 | RW-{nnr:3-ABA}-R{ct:Amid} | 2b | Amidation | Free | Linear | L | 3-ABA = 3-amino benzoic acid | 4 | Antibacterial | 10 % Hemolysis at 205 μg/ml | Human | Synthetic | NA | NA | ||
| 24953028 | 2014 | RW-{nnr:3-ABA}-R{ct:Amid} | 2b | Amidation | Free | Linear | L | 3-ABA = 3-amino benzoic acid | 4 | Antibacterial | 50 % Hemolysis at 500 μg/ml | Human | Synthetic | NA | NA | ||
| 24953028 | 2014 | WR-{nnr:3-ABA}-R{ct:Amid} | 2c | Amidation | Free | Linear | L | 3-ABA = 3-amino benzoic acid | 4 | Antibacterial | 10 % Hemolysis at 300 μg/ml | Human | Synthetic | NA | NA | ||
| 24953028 | 2014 | WR-{nnr:3-ABA}-R{ct:Amid} | 2c | Amidation | Free | Linear | L | 3-ABA = 3-amino benzoic acid | 4 | Antibacterial | 50 % Hemolysis at >500 μg/ml | Human | Synthetic | NA | NA | ||
| 24953028 | 2014 | WW-{nnr:3-ABA}-RR{ct:Amid} | 3a | Amidation | Free | Linear | L | 3-ABA = 3-amino benzoic acid | 5 | Antibacterial | 10 % Hemolysis at 150 μg/ml | Human | Synthetic | NA | NA | ||
| 24953028 | 2014 | WW-{nnr:3-ABA}-RR{ct:Amid} | 3a | Amidation | Free | Linear | L | 3-ABA = 3-amino benzoic acid | 5 | Antibacterial | 50 % Hemolysis at 400 μg/ml | Human | Synthetic | NA | NA | ||
| 24953028 | 2014 | RW-{nnr:3-ABA}-RR{ct:Amid} | 3b | Amidation | Free | Linear | L | 3-ABA = 3-amino benzoic acid | 5 | Antibacterial | 10 % Hemolysis at 350 μg/ml | Human | Synthetic | NA | NA | ||
| 24953028 | 2014 | RW-{nnr:3-ABA}-RR{ct:Amid} | 3b | Amidation | Free | Linear | L | 3-ABA = 3-amino benzoic acid | 5 | Antibacterial | 50 % Hemolysis at >500 μg/ml | Human | Synthetic | NA | NA | ||
| 24953028 | 2014 | WR-{nnr:3-ABA}-RR{ct:Amid} | 3c | Amidation | Free | Linear | L | 3-ABA = 3-amino benzoic acid | 5 | Antibacterial | 10 % Hemolysis at 325 μg/ml | Human | Synthetic | NA | NA | ||
| 24953028 | 2014 | WR-{nnr:3-ABA}-RR{ct:Amid} | 3c | Amidation | Free | Linear | L | 3-ABA = 3-amino benzoic acid | 5 | Antibacterial | 50 % Hemolysis at >500 μg/ml | Human | Synthetic | NA | NA | ||
| 24953028 | 2014 | WR-{nnr:3-ABA}-WR{ct:Amid} | 3d | Amidation | Free | Linear | L | 3-ABA = 3-amino benzoic acid | 5 | Antibacterial | 10 % Hemolysis at 220 μg/ml | Human | Synthetic | NA | NA | ||
| 24953028 | 2014 | WR-{nnr:3-ABA}-WR{ct:Amid} | 3d | Amidation | Free | Linear | L | 3-ABA = 3-amino benzoic acid | 5 | Antibacterial | 50 % Hemolysis at 400 μg/ml | Human | Synthetic | NA | NA | ||
| 24953028 | 2014 | RW-{nnr:3-ABA}-WR{ct:Amid} | 3e | Amidation | Free | Linear | L | 3-ABA = 3-amino benzoic acid | 5 | Antibacterial | 10 % Hemolysis at 250 μg/ml | Human | Synthetic | NA | NA | ||
| 24953028 | 2014 | RW-{nnr:3-ABA}-WR{ct:Amid} | 3e | Amidation | Free | Linear | L | 3-ABA = 3-amino benzoic acid | 5 | Antibacterial | 50 % Hemolysis at 410 μg/ml | Human | Synthetic | NA | NA | ||
| 24953028 | 2014 | WWR-{nnr:3-ABA}-RR{ct:Amid} | 4a | Amidation | Free | Linear | L | 3-ABA = 3-amino benzoic acid | 6 | Antibacterial | 10 % Hemolysis at 200 μg/ml | Human | Synthetic | NA | NA | ||
| 24953028 | 2014 | WWR-{nnr:3-ABA}-RR{ct:Amid} | 4a | Amidation | Free | Linear | L | 3-ABA = 3-amino benzoic acid | 6 | Antibacterial | 50 % Hemolysis at 380 μg/ml | Human | Synthetic | NA | NA | ||
| 24953028 | 2014 | RWR-{nnr:3-ABA}-WR{ct:Amid} | 4b | Amidation | Free | Linear | L | 3-ABA = 3-amino benzoic acid | 6 | Antibacterial | 10 % Hemolysis at 210 μg/ml | Human | Synthetic | NA | NA | ||
| 24953028 | 2014 | RWR-{nnr:3-ABA}-WR{ct:Amid} | 4b | Amidation | Free | Linear | L | 3-ABA = 3-amino benzoic acid | 6 | Antibacterial | 50 % Hemolysis at 400 μg/ml | Human | Synthetic | NA | NA | ||
| 24953028 | 2014 | RWW-{nnr:3-ABA}-RR{ct:Amid} | 4c | Amidation | Free | Linear | L | 3-ABA = 3-amino benzoic acid | 6 | Antibacterial | 10 % Hemolysis at 255 μg/ml | Human | Synthetic | NA | NA | ||
| 24953028 | 2014 | RWW-{nnr:3-ABA}-RR{ct:Amid} | 4c | Amidation | Free | Linear | L | 3-ABA = 3-amino benzoic acid | 6 | Antibacterial | 50 % Hemolysis at 420 μg/ml | Human | Synthetic | NA | NA | ||
| 24953028 | 2014 | WRR-{nnr:3-ABA}-WR{ct:Amid} | 4d | Amidation | Free | Linear | L | 3-ABA = 3-amino benzoic acid | 6 | Antibacterial | 10 % Hemolysis at 190 μg/ml | Human | Synthetic | NA | NA | ||
| 24953028 | 2014 | WRR-{nnr:3-ABA}-WR{ct:Amid} | 4d | Amidation | Free | Linear | L | 3-ABA = 3-amino benzoic acid | 6 | Antibacterial | 50 % Hemolysis at 380 μg/ml | Human | Synthetic | NA | NA | ||
| 24953028 | 2014 | WRW-{nnr:3-ABA}-RR{ct:Amid} | 4e | Amidation | Free | Linear | L | 3-ABA = 3-amino benzoic acid | 6 | Antibacterial | 10 % Hemolysis at 140 μg/ml | Human | Synthetic | NA | NA | ||
| 24953028 | 2014 | WRW-{nnr:3-ABA}-RR{ct:Amid} | 4e | Amidation | Free | Linear | L | 3-ABA = 3-amino benzoic acid | 6 | Antibacterial | 50 % Hemolysis at 370 μg/ml | Human | Synthetic | NA | NA | ||
| 24953028 | 2014 | RRW-{nnr:3-ABA}-WR{ct:Amid} | 4f | Amidation | Free | Linear | L | 3-ABA = 3-amino benzoic acid | 6 | Antibacterial | 10 % Hemolysis at 100 μg/ml | Human | Synthetic | NA | NA | ||
| 24953028 | 2014 | RRW-{nnr:3-ABA}-WR{ct:Amid} | 4f | Amidation | Free | Linear | L | 3-ABA = 3-amino benzoic acid | 6 | Antibacterial | 50 % Hemolysis at 355 μg/ml | Human | Synthetic | NA | NA | ||
| 24953028 | 2014 | WRW-{nnr:3-ABA}-WR{ct:Amid} | 4g | Amidation | Free | Linear | L | 3-ABA = 3-amino benzoic acid | 6 | Antibacterial | 10 % Hemolysis at 80 μg/ml | Human | Synthetic | NA | NA | ||
| 24953028 | 2014 | WRW-{nnr:3-ABA}-WR{ct:Amid} | 4g | Amidation | Free | Linear | L | 3-ABA = 3-amino benzoic acid | 6 | Antibacterial | 50 % Hemolysis at 310 μg/ml | Human | Synthetic | NA | NA | ||
| 24953028 | 2014 | OW-{nnr:3-ABA}-WO{ct:Amid} | 3f | Amidation | Free | Linear | L | 3-ABA = 3-amino benzoic acid | 5 | Antibacterial | 10 % Hemolysis at 190 μg/ml | Human | Synthetic | NA | NA | ||
| 24953028 | 2014 | OW-{nnr:3-ABA}-WO{ct:Amid} | 3f | Amidation | Free | Linear | L | 3-ABA = 3-amino benzoic acid | 5 | Antibacterial | 50 % Hemolysis at >500 μg/ml | Human | Synthetic | NA | NA | ||
| 24953028 | 2014 | OWW-{nnr:3-ABA}-OO{ct:Amid} | 4h | Amidation | Free | Linear | L | 3-ABA = 3-amino benzoic acid | 6 | Antibacterial | 10 % Hemolysis at 150 μg/ml | Human | Synthetic | NA | NA | ||
| 24953028 | 2014 | OWW-{nnr:3-ABA}-OO{ct:Amid} | 4h | Amidation | Free | Linear | L | 3-ABA = 3-amino benzoic acid | 6 | Antibacterial | 50 % Hemolysis at 440 μg/ml | Human | Synthetic | NA | NA | ||
| 24953028 | 2014 | WOO-{nnr:3-ABA}-WO{ct:Amid} | 4i | Amidation | Free | Linear | L | 3-ABA = 3-amino benzoic acid | 6 | Antibacterial | 10 % Hemolysis at 170 μg/ml | Human | Synthetic | NA | NA | ||
| 24953028 | 2014 | WOO-{nnr:3-ABA}-WO{ct:Amid} | 4i | Amidation | Free | Linear | L | 3-ABA = 3-amino benzoic acid | 6 | Antibacterial | 50 % Hemolysis at 500 μg/ml | Human | Synthetic | NA | NA | ||
| 24953028 | 2014 | WOW-{nnr:3-ABA}-OO{ct:Amid} | 4j | Amidation | Free | Linear | L | 3-ABA = 3-amino benzoic acid | 6 | Antibacterial | 10 % Hemolysis at 175 μg/ml | Human | Synthetic | NA | NA | ||
| 24953028 | 2014 | WOW-{nnr:3-ABA}-OO{ct:Amid} | 4j | Amidation | Free | Linear | L | 3-ABA = 3-amino benzoic acid | 6 | Antibacterial | 50 % Hemolysis at 450 μg/ml | Human | Synthetic | NA | NA | ||
| 24953028 | 2014 | OOW-{nnr:3-ABA}-WO{ct:Amid} | 4k | Amidation | Free | Linear | L | 3-ABA = 3-amino benzoic acid | 6 | Antibacterial | 10 % Hemolysis at 120 μg/ml | Human | Synthetic | NA | NA | ||
| 24953028 | 2014 | OOW-{nnr:3-ABA}-WO{ct:Amid} | 4k | Amidation | Free | Linear | L | 3-ABA = 3-amino benzoic acid | 6 | Antibacterial | 50 % Hemolysis at 450 μg/ml | Human | Synthetic | NA | NA | ||
| 24953028 | 2014 | WOW-{nnr:3-ABA}-WO{ct:Amid} | 4l | Amidation | Free | Linear | L | 3-ABA = 3-amino benzoic acid | 6 | Antibacterial | 10 % Hemolysis at 100 μg/ml | Human | Synthetic | NA | NA | ||
| 24953028 | 2014 | WOW-{nnr:3-ABA}-WO{ct:Amid} | 4l | Amidation | Free | Linear | L | 3-ABA = 3-amino benzoic acid | 6 | Antibacterial | 50 % Hemolysis at 390 μg/ml | Human | Synthetic | NA | NA | ||
| 24953028 | 2014 | RRF-{nnr:3-ABA}-FR{ct:Amid} | 4m | Amidation | Free | Linear | L | 3-ABA = 3-amino benzoic acid | 6 | Antibacterial | 10 % Hemolysis at 130 μg/ml | Human | Synthetic | NA | NA | ||
| 24953028 | 2014 | RRF-{nnr:3-ABA}-FR{ct:Amid} | 4m | Amidation | Free | Linear | L | 3-ABA = 3-amino benzoic acid | 6 | Antibacterial | 50 % Hemolysis at 375 μg/ml | Human | Synthetic | NA | NA | ||
| 24953028 | 2014 | FRF-{nnr:3-ABA}-FR{ct:Amid} | 4n | Amidation | Free | Linear | L | 3-ABA = 3-amino benzoic acid | 6 | Antibacterial | 10 % Hemolysis at 125 μg/ml | Human | Synthetic | NA | NA | ||
| 24953028 | 2014 | FRF-{nnr:3-ABA}-FR{ct:Amid} | 4n | Amidation | Free | Linear | L | 3-ABA = 3-amino benzoic acid | 6 | Antibacterial | 50 % Hemolysis at 310 μg/ml | Human | Synthetic | NA | NA | ||
| 24953028 | 2014 | OOF-{nnr:3-ABA}-FO{ct:Amid} | 4o | Amidation | Free | Linear | L | 3-ABA = 3-amino benzoic acid | 6 | Antibacterial | 10 % Hemolysis at 210 μg/ml | Human | Synthetic | NA | NA | ||
| 24953028 | 2014 | OOF-{nnr:3-ABA}-FO{ct:Amid} | 4o | Amidation | Free | Linear | L | 3-ABA = 3-amino benzoic acid | 6 | Antibacterial | 50 % Hemolysis at 490 μg/ml | Human | Synthetic | NA | NA | ||
| 24953028 | 2014 | FOF-{nnr:3-ABA}-FO{ct:Amid} | 4p | Amidation | Free | Linear | L | 3-ABA = 3-amino benzoic acid | 6 | Antibacterial | 10 % Hemolysis at 180 μg/ml | Human | Synthetic | NA | NA | ||
| 24953028 | 2014 | FOF-{nnr:3-ABA}-FO{ct:Amid} | 4p | Amidation | Free | Linear | L | 3-ABA = 3-amino benzoic acid | 6 | Antibacterial | 50 % Hemolysis at 400 μg/ml | Human | Synthetic | NA | NA | ||
| 24953028 | 2014 | RRWWR{ct:Amid} | 5a | Amidation | Free | Linear | L | None | 5 | Antibacterial | 10 % Hemolysis at 90 μg/ml | Human | Synthetic | NA | NA | ||
| 24953028 | 2014 | RRWWR{ct:Amid} | 5a | Amidation | Free | Linear | L | None | 5 | Antibacterial | 50 % Hemolysis at 240 μg/ml | Human | Synthetic | NA | NA | ||
| 24953028 | 2014 | WRWWR{ct:Amid} | 5b | Amidation | Free | Linear | L | None | 5 | Antibacterial | 10 % Hemolysis at 60 μg/ml | Human | Synthetic | NA | NA | ||
| 24953028 | 2014 | WRWWR{ct:Amid} | 5b | Amidation | Free | Linear | L | None | 5 | Antibacterial | 50 % Hemolysis at 200 μg/ml | Human | Synthetic | NA | NA | ||
| 24953028 | 2014 | OOWWO{ct:Amid} | 5c | Amidation | Free | Linear | L | None | 5 | Antibacterial | 10 % Hemolysis at 100 μg/ml | Human | Synthetic | NA | NA | ||
| 24953028 | 2014 | OOWWO{ct:Amid} | 5c | Amidation | Free | Linear | L | None | 5 | Antibacterial | 50 % Hemolysis at 310 μg/ml | Human | Synthetic | NA | NA | ||
| 24953028 | 2014 | WOWWO{ct:Amid} | 5d | Amidation | Free | Linear | L | None | 5 | Antibacterial | 10 % Hemolysis at 65 μg/ml | Human | Synthetic | NA | NA | ||
| 24953028 | 2014 | WOWWO{ct:Amid} | 5d | Amidation | Free | Linear | L | None | 5 | Antibacterial | 50 % Hemolysis at 220 μg/ml | Human | Synthetic | NA | NA | ||
| 25055061 | 2014 | FEFQFNFK{nt:Acet}{ct:Amid} | AC8 | Amidation | Acetylation | Linear | L | None | 8 | cytotoxic | 0 % Hemolysis at 3 µM | Human | Self/Coassembling Peptide | β-Sheet | Non-hemolytic | ||
| 25055061 | 2014 | FEFQFNFK{nt:Acet}{ct:Amid} | AC8 | Amidation | Acetylation | Linear | L | None | 8 | cytotoxic | 0 % Hemolysis at 6 µM | Human | Self/Coassembling Peptide | β-Sheet | Non-hemolytic | ||
| 25055061 | 2014 | FEFQFNFK{nt:Acet}{ct:Amid} | AC8 | Amidation | Acetylation | Linear | L | None | 8 | cytotoxic | 0 % Hemolysis at 12 µM | Human | Self/Coassembling Peptide | β-Sheet | Non-hemolytic | ||
| 25055061 | 2014 | FEFQFNFK{nt:Acet}{ct:Amid} | AC8 | Amidation | Acetylation | Linear | L | None | 8 | cytotoxic | 0 % Hemolysis at 18 µM | Human | Self/Coassembling Peptide | β-Sheet | Non-hemolytic | ||
| 25055061 | 2014 | FEFQFNFK{nt:Acet}{ct:Amid} | AC8 | Amidation | Acetylation | Linear | L | None | 8 | cytotoxic | 0 % Hemolysis at 30 µM | Human | Self/Coassembling Peptide | β-Sheet | Non-hemolytic | ||
| 25055061 | 2014 | FEFQFNFK{nt:Acet}{ct:Amid} | AC8 | Amidation | Acetylation | Linear | L | None | 8 | cytotoxic | 5 % Hemolysis at 60 µM | Human | Self/Coassembling Peptide | β-Sheet | NA | ||
| 24965354 | 2014 | WQWRMKKLG | LfcinB9 | Free | Free | Linear | L | None | 9 | Anti-ovarian cancer | ~7 % Hemolysis at 640 μg/ml | Sheep | Bovine Lactoferricin B | NA | Low hemolytic | ||
| 25025626 | 2014 | KGD | vasotab TY | Free | Free | Linear | L | None | 3 | Anti-thrombosis, vasodilator activity | 0 % Hemolysis at 5 μg/ml | Human | Horsefly Of Tabanus Yao | NA | Non-hemolytic | ||
| 25025626 | 2014 | KGD | vasotab TY | Free | Free | Linear | L | None | 3 | Anti-thrombosis, vasodilator activity | 0 % Hemolysis at 320 μg/ml | Human | Horsefly Of Tabanus Yao | NA | Non-hemolytic | ||
| 24946217 | 2014 | KWK{nt:C10}{ct:Amid} | AMP-C10-12 | Amidation | C10 | Linear | L | None | 3 | Antimicrobial | <10 % Hemolysis at 250 µM | Human | Synthetic | NA | Non-hemolytic | ||
| 24946217 | 2014 | RKWWK{nt:C10}{ct:Amid} | AMP-C10-3 | Amidation | C10 | Linear | L | None | 5 | Antimicrobial | <10 % Hemolysis at 125 µM | Human | Synthetic | NA | NA | ||
| 24946217 | 2014 | RIKWK{nt:C10}{ct:Amid} | AMP-C10-14 | Amidation | C10 | Linear | L | None | 5 | Antimicrobial | <10 % Hemolysis at 250 µM | Human | Synthetic | NA | NA | ||
| 24946217 | 2014 | KWK{nt:C14}{ct:Amid} | AMP-C14-12 | Amidation | C14 | Linear | L | None | 3 | Antimicrobial | 11 % Hemolysis at 125 µM | Human | Synthetic | NA | NA | ||
| 24946217 | 2014 | KWK{nt:C14}{ct:Amid} | AMP-C14-12 | Amidation | C14 | Linear | L | None | 3 | Antimicrobial | 19 % Hemolysis at 250 µM | Human | Synthetic | NA | NA | ||
| 24946217 | 2014 | KWKW{nt:C14}{ct:Amid} | AMP-C14-16 | Amidation | C14 | Linear | L | None | 4 | Antimicrobial | 17 % Hemolysis at 125 µM | Human | Synthetic | NA | NA | ||
| 24946217 | 2014 | KWKW{nt:C14}{ct:Amid} | AMP-C14-16 | Amidation | C14 | Linear | L | None | 4 | Antimicrobial | <60 % Hemolysis at 250 µM | Human | Synthetic | NA | NA | ||
| 24946217 | 2014 | KWWK{nt:C14}{ct:Amid} | AMP-C14-1 | Amidation | C14 | Linear | L | None | 4 | Antimicrobial | 56 % Hemolysis at 125 µM | Human | Synthetic | NA | NA | ||
| 24946217 | 2014 | RWWR{nt:C14}{ct:Amid} | AMP-C14-5 | Amidation | C14 | Linear | L | None | 4 | Antimicrobial | 90 % Hemolysis at 250 µM | Human | Synthetic | NA | NA | ||
| 24946217 | 2014 | RIKWK{nt:C14}{ct:Amid} | AMP-C14-14 | Amidation | C14 | Linear | L | None | 5 | Antimicrobial | 20 % Hemolysis at 250 µM | Human | Synthetic | NA | NA | ||
| 24946217 | 2014 | RIKWWK{nt:C14}{ct:Amid} | AMP-C14-4 | Amidation | C14 | Linear | L | None | 6 | Antimicrobial | 60 % Hemolysis at 250 µM | Human | Synthetic | NA | NA | ||
| 25056849 | 2015 | FLGLLGSLL{ct:Amid} | Feleucin-BO1 | Amidation | Free | Linear | L | None | 9 | Antibaterial | 100 % Hemolysis at 80 µM | Horse | Synthetic,Skin Secretion Of Bombina Orientalis | Random coil | NA | ||
| 25056849 | 2015 | FLKLLKKLL{ct:Amid} | Feleucin-K3 | Amidation | Free | Linear | L | None | 9 | Antibaterial, Antifungal | 100 % Hemolysis at >250 µM | Horse | Analogue Of Fpa-Bombinin-Bo, Skin Secretion Of Bombina Orientalis | α-Helix | NA | ||
| 25807936 | 2015 | {nnr:6#}IK{ct:Amid} | P1 | Amidation | Free | Linear | L | 6# = BDZ,benzodiazepine scaffold | 2 | Antibacterial | 50 % Hemolysis at >1000 μg/ml | Human | Bdz Peptidomimetic Compounds | α-Helix | NA | ||
| 25807936 | 2015 | K{nnr:6#}CK{ct:Amid} | P2 | Amidation | Free | Linear | L | 6# = BDZ,benzodiazepine scaffold | 3 | Antibacterial | 50 % Hemolysis at >1000 μg/ml | Human | Bdz Peptidomimetic Compounds | α-Helix | NA | ||
| 25807936 | 2015 | K{d}{nnr:6#}K{d}{ct:Amid} | P3 | Amidation | Free | Linear | D | 6# = BDZ,benzodiazepine scaffold | 2 | Antibacterial | 50 % Hemolysis at >1000 μg/ml | Human | Bdz Peptidomimetic Compounds | α-Helix | NA | ||
| 25807936 | 2015 | K{nnr:6#}VH{ct:Amid} | P4 | Amidation | Free | Linear | L | 6# = BDZ,benzodiazepine scaffold | 3 | Antibacterial | 50 % Hemolysis at >1000 μg/ml | Human | Bdz Peptidomimetic Compounds | α-Helix | NA | ||
| 25807936 | 2015 | K{nnr:6#}K{ct:Amid} | P5 | Amidation | Free | Linear | L | 6# = BDZ,benzodiazepine scaffold | 2 | Antibacterial | 50 % Hemolysis at >1000 μg/ml | Human | Bdz Peptidomimetic Compounds | α-Helix | NA | ||
| 25807936 | 2015 | K{nnr:6#}KC{ct:Amid} | P6 | Amidation | Free | Linear | L | 6# = BDZ,benzodiazepine scaffold | 3 | Antibacterial | 50 % Hemolysis at >1000 μg/ml | Human | Bdz Peptidomimetic Compounds | α-Helix | NA | ||
| 25807936 | 2015 | K{nnr:6#}FK{ct:Amid} | P7 | Amidation | Free | Linear | L | 6# = BDZ,benzodiazepine scaffold | 3 | Antibacterial | 50 % Hemolysis at >1000 μg/ml | Human | Bdz Peptidomimetic Compounds | α-Helix | NA | ||
| 25807936 | 2015 | K{d}{nnr:6#}F{d}K{d}{ct:Amid} | P8 | Amidation | Free | Linear | D | 6# = BDZ,benzodiazepine scaffold | 3 | Antibacterial | 50 % Hemolysis at >1000 μg/ml | Human | Bdz Peptidomimetic Compounds | α-Helix | NA | ||
| 25807936 | 2015 | K{nnr:6#}LK{ct:Amid} | P9 | Amidation | Free | Linear | L | 6# = BDZ,benzodiazepine scaffold | 3 | Antibacterial | 50 % Hemolysis at >1000 μg/ml | Human | Bdz Peptidomimetic Compounds | α-Helix | NA | ||
| 25966444 | 2015 | Q(L)R{nt:C18-aliphatic chain}{ct:Amid} | LP1 | Amidation | C18-aliphatic chain | Linear | L | C18 = aliphatic chain | 3 | Antibacterial | 50 % Hemolysis at >100 µM | Human | Host Defence Peptides | α-Helix | NA | ||
| 25966444 | 2015 | QLR{nt:C18-aliphatic chain}{ct:Amid} | LP2 | Amidation | C18-aliphatic chain | Linear | L | C18 = aliphatic chain | 3 | Antibacterial | 50 % Hemolysis at >100 µM | Human | Host Defence Peptides | α-Helix | NA | ||
| 25966444 | 2015 | CGCQ(L)R{nt:C18-aliphatic chain}{ct:Amid} | LP3 | Amidation | C18-aliphatic chain | Linear | L | C18 = aliphatic chain | 6 | Antibacterial | 50 % Hemolysis at >100 µM | Human | Host Defence Peptides | α-Helix | NA | ||
| 25966444 | 2015 | CGCQLR{nt:C18-aliphatic chain}{ct:Amid} | LP4 | Amidation | C18-aliphatic chain | Linear | L | C18 = aliphatic chain | 6 | Antibacterial | 50 % Hemolysis at >100 µM | Human | Host Defence Peptides | α-Helix | NA | ||
| 25966444 | 2015 | Q(L)R{nt:C18-aliphatic chain}{ct:Amid} | LP1 | Amidation | C18-aliphatic chain | Linear | L | C18 = aliphatic chain | 3 | Antibacterial | 50 % Hemolysis at >100 µM | Bovine | Host Defence Peptides | α-Helix | NA | ||
| 25966444 | 2015 | QLR{nt:C18-aliphatic chain}{ct:Amid} | LP2 | Amidation | C18-aliphatic chain | Linear | L | C18 = aliphatic chain | 3 | Antibacterial | 50 % Hemolysis at >100 µM | Bovine | Host Defence Peptides | α-Helix | NA | ||
| 25966444 | 2015 | CGCQ(L)R{nt:C18-aliphatic chain}{ct:Amid} | LP3 | Amidation | C18-aliphatic chain | Linear | L | C18 = aliphatic chain | 6 | Antibacterial | 50 % Hemolysis at >100 µM | Bovine | Host Defence Peptides | α-Helix | NA | ||
| 25966444 | 2015 | CGCQLR{nt:C18-aliphatic chain}{ct:Amid} | LP4 | Amidation | C18-aliphatic chain | Linear | L | C18 = aliphatic chain | 6 | Antibacterial | 50 % Hemolysis at >100 µM | Bovine | Host Defence Peptides | α-Helix | NA | ||
| 25941221 | 2015 | RIWVIWRR{ct:Amid} | Bac8c | Amidation | Free | Linear | L | None | 8 | Antimicrobial | 10 % Hemolysis at 128 μg/ml | Human | Synthetic Peptide | α-Helix | NA | ||
| 25941221 | 2015 | RWKRWWRWI{ct:Amid} | GN-2 peptide | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 10 % Hemolysis at 100 μg/ml | Human | Synthetic Peptide | α-Helix | NA | ||
| 25941221 | 2015 | RWKKWWRWL{ct:Amid} | GN-4 peptide | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 10 % Hemolysis at 100 μg/ml | Human | Synthetic Peptide | α-Helix | NA | ||
| 25941221 | 2015 | RKRWWWWFR{ct:Amid} | GN-6 peptide | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 10 % Hemolysis at 100 μg/ml | Human | Synthetic Peptide | α-Helix | NA | ||
| 26149664 | 2015 | RWK({nnr:N3}){nt:H}{ct:Amid} | 3 a | Amidation | H | Linear | L | N3 = 1,2,3-triazol-4-methoxy | 3 | Antibacterial | <1 % Hemolysis at <100 µM | Human | Arg-Trp-Based Peptides | α-Helix | Non-hemolytic | ||
| 26149664 | 2015 | RWK({nnr:N3}){nt:H}{ct:Amid} | 3 b | Amidation | H | Linear | L | N3 = 1,2,3-triazol-4-methoxy | 3 | Antibacterial | <1 % Hemolysis at <100 µM | Human | Arg-Trp-Based Peptides | α-Helix | Non-hemolytic | ||
| 26149664 | 2015 | RWK({nnr:N3}){nt:H}{ct:Amid} | 3 c | Amidation | H | Linear | L | N3 = 1,2,3-triazol-4-methoxy | 3 | Antibacterial | <1 % Hemolysis at <100 µM | Human | Arg-Trp-Based Peptides | α-Helix | Non-hemolytic | ||
| 26149664 | 2015 | WRK({nnr:N3}){nt:H}{ct:Amid} | 4 a | Amidation | H | Linear | L | N3 = 1,2,3-triazol-4-methoxy | 3 | Antibacterial | <1 % Hemolysis at <100 µM | Human | Arg-Trp-Based Peptides | α-Helix | Non-hemolytic | ||
| 26149664 | 2015 | WRK({nnr:N3}){nt:H}{ct:Amid} | 4b | Amidation | H | Linear | L | N3 = 1,2,3-triazol-4-methoxy | 3 | Antibacterial | <1 % Hemolysis at <100 µM | Human | Arg-Trp-Based Peptides | α-Helix | Non-hemolytic | ||
| 26149664 | 2015 | WRK({nnr:N3}){nt:H}{ct:Amid} | 4c | Amidation | H | Linear | L | N3 = 1,2,3-triazol-4-methoxy | 3 | Antibacterial | <1 % Hemolysis at <100 µM | Human | Arg-Trp-Based Peptides | α-Helix | Non-hemolytic | ||
| 26149664 | 2015 | RWRK({nnr:N3}){nt:H}{ct:Amid} | 5a | Amidation | H | Linear | L | N3 = 1,2,3-triazol-4-methoxy | 4 | Antibacterial | <1 % Hemolysis at <100 µM | Human | Arg-Trp-Based Peptides | α-Helix | Non-hemolytic | ||
| 26149664 | 2015 | RWRK({nnr:N3}){nt:H}{ct:Amid} | 5b | Amidation | H | Linear | L | N3 = 1,2,3-triazol-4-methoxy | 4 | Antibacterial | <1 % Hemolysis at <100 µM | Human | Arg-Trp-Based Peptides | α-Helix | Non-hemolytic | ||
| 26149664 | 2015 | RWRK({nnr:N3}){nt:H}{ct:Amid} | 5c | Amidation | H | Linear | L | N3 = 1,2,3-triazol-4-methoxy | 4 | Antibacterial | <1 % Hemolysis at <100 µM | Human | Arg-Trp-Based Peptides | α-Helix | Non-hemolytic | ||
| 26149664 | 2015 | WRWK({nnr:N3}){nt:H}{ct:Amid} | 6a | Amidation | H | Linear | L | N3 = 1,2,3-triazol-4-methoxy | 4 | Antibacterial | <1 % Hemolysis at <100 µM | Human | Arg-Trp-Based Peptides | α-Helix | Non-hemolytic | ||
| 26149664 | 2015 | WRWK({nnr:N3}){nt:H}{ct:Amid} | 6b | Amidation | H | Linear | L | N3 = 1,2,3-triazol-4-methoxy | 4 | Antibacterial | <1 % Hemolysis at <100 µM | Human | Arg-Trp-Based Peptides | α-Helix | Non-hemolytic | ||
| 26149664 | 2015 | WRWK({nnr:N3}){nt:H}{ct:Amid} | 6c | Amidation | H | Linear | L | N3 = 1,2,3-triazol-4-methoxy | 4 | Antibacterial | <1 % Hemolysis at <100 µM | Human | Arg-Trp-Based Peptides | α-Helix | Non-hemolytic | ||
| 26149664 | 2015 | RWRWRWK({nnr:N3}){nt:H}{ct:Amid} | 7a | Amidation | H | Linear | L | N3 = 1,2,3-triazol-4-methoxy | 7 | Antibacterial | <1 % Hemolysis at <100 µM | Human | Arg-Trp-Based Peptides | α-Helix | Non-hemolytic | ||
| 26149664 | 2015 | RWRWRWK({nnr:N3}){nt:H}{ct:Amid} | 7b | Amidation | H | Linear | L | N3 = 1,2,3-triazol-4-methoxy | 7 | Antibacterial | <1 % Hemolysis at <100 µM | Human | Arg-Trp-Based Peptides | α-Helix | Non-hemolytic | ||
| 26149664 | 2015 | RWRWRWK({nnr:N3}){nt:H}{ct:Amid} | 7c | Amidation | H | Linear | L | N3 = 1,2,3-triazol-4-methoxy | 7 | Antibacterial | <1 % Hemolysis at <100 µM | Human | Arg-Trp-Based Peptides | α-Helix | Non-hemolytic | ||
| 26318064 | 2015 | LR{nnr:2-Nal}LR{nnr:2-Nal}G{cyc:N-C} | 1 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine | 5 | Antimicrobial | 50 % Hemolysis at 215 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LRWLRWG{cyc:N-C} | 2 | Free | Free | Cyclic | L | None | 7 | Antimicrobial | 50 % Hemolysis at >150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LK{nnr:2-Nal}LR{nnr:2-Nal}G{cyc:N-C} | 3 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine | 5 | Antimicrobial | 50 % Hemolysis at >150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LR{nnr:2-Nal}LK{nnr:2-Nal}G{cyc:N-C} | 4 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine | 5 | Antimicrobial | 50 % Hemolysis at >150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LK{nnr:2-Nal}LK{nnr:2-Nal}G{cyc:N-C} | 5 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine | 5 | Antimicrobial | 50 % Hemolysis at >150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LKWLKWG{cyc:N-C} | 6 | Free | Free | Cyclic | L | None | 7 | Antimicrobial | 50 % Hemolysis at >150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LKFLKFG{cyc:N-C} | 7 | Free | Free | Cyclic | L | None | 7 | Antimicrobial | 50 % Hemolysis at >150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LR{nnr:2-Nal}LR{nnr:2-Nal}({nnr:Abu}){cyc:N-C} | 8 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine, Abu = 4-aminobutyric acid | 4 | Antimicrobial | 50 % Hemolysis at 230 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LR{nnr:2-Nal}LR{nnr:2-Nal}{nnr:6-Ahx}{cyc:N-C} | 9 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine, 6-Ahx = 6-aminohexanoic acid | 4 | Antimicrobial | 50 % Hemolysis at 115 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LR{nnr:2-Nal}LR{nnr:2-Nal}{nnr:8-Aoc}{cyc:N-C} | 10 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine, 8-Aoc = 8-aminooctanoic acid | 4 | Antimicrobial | 50 % Hemolysis at 22 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LR{nnr:2-Nal}LR{nnr:2-Nal}{nnr:10-Adc}{cyc:N-C} | 11 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine, 10-Adc = 10-aminodecanoic acid | 4 | Antimicrobial | 50 % Hemolysis at 15 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LR{nnr:2-Nal}LR{nnr:2-Nal}({nnr:Dab}){cyc:N-C} | 12 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine, Dab = 2,4-diaminobutyric acid | 4 | Antimicrobial | 50 % Hemolysis at 265 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LR{nnr:2-Nal}LR{nnr:2-Nal}({nnr:εK}){cyc:N-C} | 13 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine, εK = coupling of 2-Nal6 has occurred on lysine’s ε-amino functionality | 4 | Antimicrobial | 50 % Hemolysis at 150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LR{nnr:2-Nal}LR{nnr:2-Nal}({nnr:Dab}{nnr:Dab}){cyc:N-C} | 14 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine, Dab = 2,4-diaminobutyric acid | 4 | Antimicrobial | 50 % Hemolysis at >450 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LR{nnr:2-Nal}LR{nnr:2-Nal}({nnr:Abu})({nnr:Dab}){cyc:N-C} | 15 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine, Dab = 2,4-diaminobutyric acid, Abu = 4-aminobutyric acid | 4 | Antimicrobial | 50 % Hemolysis at 420 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LR{nnr:2-Nal}LR{nnr:2-Nal}({nnr:Dab})({nnr:Abu}){cyc:N-C} | 16 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine, Dab = 2,4-diaminobutyric acid, Abu = 4-aminobutyric acid | 4 | Antimicrobial | 50 % Hemolysis at 255 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LR({nnr:Bip})LR({nnr:Bip})G{cyc:N-C} | 17 | Free | Free | Cyclic | Mix | Bip = 4,4’-biphenyl-L-alanine | 4 | Antimicrobial | 50 % Hemolysis at 16 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LR({nnr:Dip})LR({nnr:Dip})G{cyc:N-C} | 18 | Free | Free | Cyclic | Mix | Dip = 3,3-diphenyl-L-alanine | 4 | Antimicrobial | 50 % Hemolysis at 145 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | {nnr:2-Aoc}R{nnr:2-Nal}LR{nnr:2-Nal}G{cyc:N-C} | 19 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine, 2-Aoc = 2-aminooctanoic acid | 4 | Antimicrobial | 50 % Hemolysis at 55 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LR{nnr:2-Nal}{nnr:2-Aoc}R{nnr:2-Nal}G{cyc:N-C} | 20 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine, 2-Aoc = 2-aminooctanoic acid | 4 | Antimicrobial | 50 % Hemolysis at 33 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | ({nnr:Cha})R{nnr:2-Nal}LR{nnr:2-Nal}G{cyc:N-C} | 21 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine, Cha = 3-cyclohexyl-L-alanine | 4 | Antimicrobial | 50 % Hemolysis at 28 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LR{nnr:2-Nal}({nnr:Cha})R{nnr:2-Nal}G{cyc:N-C} | 22 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine, Cha = 3-cyclohexyl-L-alanine | 4 | Antimicrobial | 50 % Hemolysis at 60 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LR{nnr:2-Nal}({nnr:Nle})R{nnr:2-Nal}G{cyc:N-C} | 23 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine, Nle = norleucine | 4 | Antimicrobial | 50 % Hemolysis at >150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | PR{nnr:2-Nal}LR{nnr:2-Nal}G{cyc:N-C} | 24 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine | 4 | Antimicrobial | 50 % Hemolysis at >150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LR{nnr:2-Nal}PR{nnr:2-Nal}G{cyc:N-C} | 25 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine | 5 | Antimicrobial | 50 % Hemolysis at >150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LR{nnr:2-Nal}LRYG{cyc:N-C} | 26 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine | 6 | Antimicrobial | 50 % Hemolysis at >150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | TR{nnr:2-Nal}LR{nnr:2-Nal}G{cyc:N-C} | 27 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine | 5 | Antimicrobial | 50 % Hemolysis at >150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LR{nnr:2-Nal}TR{nnr:2-Nal}G{cyc:N-C} | 28 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine | 5 | Antimicrobial | 50 % Hemolysis at >150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | QR{nnr:2-Nal}LR{nnr:2-Nal}G{cyc:N-C} | 29 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine | 5 | Antimicrobial | 50 % Hemolysis at >150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LR{nnr:D-2-Nal}{nnr:2-Aoc}R{nnr:2-Nal}G{cyc:N-C} | 30 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine, 2-Aoc = 2-aminooctanoic acid | 4 | Antimicrobial | 50 % Hemolysis at 55 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LR{nnr:2-Nal}(D-2-Aoc)R{nnr:2-Nal}G{cyc:N-C} | 31 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine, 2-Aoc = 2-aminooctanoic acid | 4 | Antimicrobial | 50 % Hemolysis at 55 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LR(2NalNal)LR{nnr:D-2-Nal}G{cyc:N-C} | 32 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine, 8-Aoc = 8-aminooctanoic acid | 5 | Antimicrobial | 50 % Hemolysis at >150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | TR{nnr:2-Nal}IR{nnr:2-Nal}{nnr:8-Aoc}{cyc:N-C} | 33 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine, 8-Aoc = 8-aminooctanoic acid | 4 | Antimicrobial | 50 % Hemolysis at >150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LR{nnr:2-Nal}{nnr:2-Aoc}R{nnr:2-Nal}{nnr:Dab}{nnr:Dab}{cyc:N-C} | 34 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine | 3 | Antimicrobial | 50 % Hemolysis at 55 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LR{nnr:2-Nal}LR{nnr:2-Nal}G{cyc:N-C} | 1 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine | 5 | Antimicrobial | 27 % Hemolysis at 150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LRWLRWG{cyc:N-C} | 2 | Free | Free | Cyclic | L | None | 7 | Antimicrobial | <8 % Hemolysis at 150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LK{nnr:2-Nal}LR{nnr:2-Nal}G{cyc:N-C} | 3 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine | 5 | Antimicrobial | 14 % Hemolysis at 150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LR(NalNaI)LK{nnr:2-Nal}G{cyc:N-C} | 4 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine | 5 | Antimicrobial | 19 % Hemolysis at 150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LK{nnr:2-Nal}LK{nnr:2-Nal}G{cyc:N-C} | 5 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine | 5 | Antimicrobial | 13 % Hemolysis at 150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LKWLKWG{cyc:N-C} | 6 | Free | Free | Cyclic | L | None | 7 | Antimicrobial | <8 % Hemolysis at 150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LKFLKFG{cyc:N-C} | 7 | Free | Free | Cyclic | L | None | 7 | Antimicrobial | <8 % Hemolysis at 150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LR{nnr:2-Nal}LR{nnr:2-Nal}({nnr:Abu}){cyc:N-C} | 8 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine, Abu = 4-aminobutyric acid | 4 | Antimicrobial | 22 % Hemolysis at 150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LR{nnr:2-Nal}LR{nnr:2-Nal}{nnr:6-Ahx}{cyc:N-C} | 9 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine, 6-Ahx = 6-aminohexanoic acid | 4 | Antimicrobial | 75 % Hemolysis at 150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LR{nnr:2-Nal}LR{nnr:2-Nal}{nnr:8-Aoc}{cyc:N-C} | 10 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine, 8-Aoc = 8-aminooctanoic acid | 4 | Antimicrobial | 100 % Hemolysis at 150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LR{nnr:2-Nal}LR{nnr:2-Nal}{nnr:10-Adc}{cyc:N-C} | 11 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine, 10-Adc = 10-aminodecanoic acid | 4 | Antimicrobial | 100 % Hemolysis at 150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LR{nnr:2-Nal}LR{nnr:2-Nal}({nnr:Dab}){cyc:N-C} | 12 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine, Dab = 2,4-diaminobutyric acid | 4 | Antimicrobial | <8 % Hemolysis at 150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LR{nnr:2-Nal}LR{nnr:2-Nal}({nnr:εK}){cyc:N-C} | 13 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine, εK = coupling of 2-Nal6 has occurred on lysine’s ε-amino functionality | 4 | Antimicrobial | 51 % Hemolysis at 150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LR{nnr:2-Nal}LR{nnr:2-Nal}{nnr:Dab}{nnr:Dab}{cyc:N-C} | 14 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine, Dab = 2,4-diaminobutyric acid | 4 | Antimicrobial | <8 % Hemolysis at 150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LR{nnr:2-Nal}LR{nnr:2-Nal}({nnr:Abu})({nnr:Dab}){cyc:N-C} | 15 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine, Dab = 2,4-diaminobutyric acid, Abu = 4-aminobutyric acid | 4 | Antimicrobial | <8 % Hemolysis at 150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LR{nnr:2-Nal}LR{nnr:2-Nal}({nnr:Dab})({nnr:Abu}){cyc:N-C} | 16 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine, Dab = 2,4-diaminobutyric acid, Abu = 4-aminobutyric acid | 4 | Antimicrobial | 12 % Hemolysis at 150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LR({nnr:Bip})LR({nnr:Bip})G{cyc:N-C} | 17 | Free | Free | Cyclic | Mix | Bip = 4,4’-biphenyl-L-alanine | 5 | Antimicrobial | 96 % Hemolysis at 150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LR({nnr:Dip})LR({nnr:Dip})G{cyc:N-C} | 18 | Free | Free | Cyclic | Mix | Dip = 3,3-diphenyl-L-alanine | 5 | Antimicrobial | 54 % Hemolysis at 150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | {nnr:2-Aoc}R{nnr:2-Nal}LR{nnr:2-Nal}G{cyc:N-C} | 19 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine, 2-Aoc = 2-aminooctanoic acid | 4 | Antimicrobial | 100 % Hemolysis at 150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LR{nnr:2-Nal}{nnr:2-Aoc}R{nnr:2-Nal}G{cyc:N-C} | 20 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine, 2-Aoc = 2-aminooctanoic acid | 4 | Antimicrobial | 100 % Hemolysis at 150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | ({nnr:Cha})R{nnr:2-Nal}LR{nnr:2-Nal}G{cyc:N-C} | 21 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine, Cha = 3-cyclohexyl-L-alanine | 4 | Antimicrobial | 99 % Hemolysis at 150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LR{nnr:2-Nal}({nnr:Cha})R{nnr:2-Nal}G{cyc:N-C} | 22 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine, Cha = 3-cyclohexyl-L-alanine | 4 | Antimicrobial | 96 % Hemolysis at 150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LR{nnr:2-Nal}({nnr:Nle})R{nnr:2-Nal}G{cyc:N-C} | 23 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine, Nle = norleucine | 4 | Antimicrobial | 35 % Hemolysis at 150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | PR{nnr:2-Nal}LR{nnr:2-Nal}G{cyc:N-C} | 24 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine | 5 | Antimicrobial | <8 % Hemolysis at 150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LR{nnr:2-Nal}PR{nnr:2-Nal}G{cyc:N-C} | 25 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine | 5 | Antimicrobial | <8 % Hemolysis at 150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LR{nnr:2-Nal}LRYG{cyc:N-C} | 26 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine | 6 | Antimicrobial | 19 % Hemolysis at 150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | TR{nnr:2-Nal}LR{nnr:2-Nal}G{cyc:N-C} | 27 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine | 5 | Antimicrobial | <8 % Hemolysis at 150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LR{nnr:2-Nal}TR{nnr:2-Nal}G{cyc:N-C} | 28 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine | 5 | Antimicrobial | <8 % Hemolysis at 150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | QR{nnr:2-Nal}LR{nnr:2-Nal}G{cyc:N-C} | 29 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine | 5 | Antimicrobial | <8 % Hemolysis at 150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LR{nnr:D-2-Nal}{nnr:2-Aoc}R{nnr:2-Nal}G{cyc:N-C} | 30 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine, 2-Aoc = 2-aminooctanoic acid | 4 | Antimicrobial | 92 % Hemolysis at 150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LR{nnr:2-Nal}(D-2-Aoc)R{nnr:2-Nal}G{cyc:N-C} | 31 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine, 2-Aoc = 2-aminooctanoic acid | 4 | Antimicrobial | 100 % Hemolysis at 150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LR{nnr:2-Nal}LR{nnr:D-2-Nal}G{cyc:N-C} | 32 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine, 8-Aoc = 8-aminooctanoic acid | 4 | Antimicrobial | <8 % Hemolysis at 150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | TR{nnr:2-Nal}IR{nnr:2-Nal}{nnr:8-Aoc}{cyc:N-C} | 33 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine, 8-Aoc = 8-aminooctanoic acid | 4 | Antimicrobial | 10 % Hemolysis at 150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LR{nnr:2-Nal}{nnr:2-Aoc}R{nnr:2-Nal}{nnr:Dab}{nnr:Dab}{cyc:N-C} | 34 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine | 3 | Antimicrobial | 100 % Hemolysis at 150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26291880 | 2015 | RRRRRRRRR{ct:Amid} | R9 | Amidation | Free | Linear | L | None | 9 | Antimicrobial | NA | Human | Cpp | α-Helix | Non-hemolytic | ||
| 26088720 | 2015 | WKPGKW{ct:Amid} | WK1 | Amidation | Free | Linear | L | None | 6 | Antimicrobial | 5 % Hemolysis at 512 µM | Human | Tryptophan Zipper | β-Hairpin | NA | ||
| 26530005 | 2015 | GKLWLKG{ct:Amid} | GG1 | Amidation | Free | Linear | L | None | 7 | Antimicrobial | 5 % Hemolysis at >128 µM | Human | Centrosymmetric | α-Helix | NA | ||
| 26530005 | 2015 | AKLWLKA{ct:Amid} | AA1 | Amidation | Free | Linear | L | None | 7 | Antimicrobial | 5 % Hemolysis at >128 µM | Human | Centrosymmetric | α-Helix | NA | ||
| 26489599 | 2015 | BRBR{ct:Amid} | 23 | Amidation | Free | Linear | L | None | 4 | Antibacterial | <1 % Hemolysis at 100 µM | Human | Tetrapeptide | NA | Low hemolytic | ||
| 26380930 | 2015 | LLKKLLKK{ct:Amid} | LK | Amidation | Free | Linear | L | None | 8 | Anti-mycobacterial | 50 % Hemolysis at >500 μg/ml | Rat | Synthetic Peptide | α-Helix | Low hemolytic | ||
| 25728268 | 2015 | FFWLSRRTK{ct:Amid} | Pep4 | Amidation | Free | Linear | L | None | 9 | Antibacterial | 50 % Hemolysis at 300-900 µM | Human | Derived From Pepa6 | NA | NA | ||
| 25728268 | 2015 | FFWLSRTK{ct:Amid} | Pep5 | Amidation | Free | Linear | L | None | 8 | Antibacterial | 50 % Hemolysis at 300-900 µM | Human | Derived From Pepa7 | NA | NA | ||
| 25728268 | 2015 | FFWLSRRTK{cyc:N-C} | Pep6 | Free | Free | Cyclic | L | None | 9 | Antibacterial | 50 % Hemolysis at 5 µM | Human | Derived From Pepa8 | NA | NA | ||
| 25728268 | 2015 | FFWSRRTK{cyc:N-C} | Pep7 | Free | Free | Cyclic | L | None | 8 | Antibacterial | 50 % Hemolysis at 14 µM | Human | Derived From Pepa9 | NA | NA | ||
| 25728268 | 2015 | FFWRRTK{cyc:N-C} | Pep8 | Free | Free | Cyclic | L | None | 7 | Antibacterial | 50 % Hemolysis at 160 µM | Human | Derived From Pepa10 | NA | NA | ||
| 25728268 | 2015 | FFWLRR{nnr:aza-β3Hyt}K{ct:Amid} | Pep9 | Amidation | Free | Linear | L | aza-β3Hyt = aza-b3 -homohydroxythreonine | 8 | Antibacterial | 50 % Hemolysis at 300-900 µM | Human | Derived From Pepa11 | NA | NA | ||
| 25728268 | 2015 | FFWLRR{nnr:aza-β3Hyt}K{cyc:N-C} | Pep10 | Free | Free | Cyclic | L | aza-b3 = homohydroxythreonine | 8 | Antibacterial | 50 % Hemolysis at 150 µM | Human | Derived From Pepa12 | NA | NA | ||
| 25728268 | 2015 | FFWRR{nnr:aza-β3Hyt}K{cyc:N-C} | Pep11 | Free | Free | Cyclic | L | aza-b3 = homohydroxythreonine | 7 | Antibacterial | 50 % Hemolysis at 840 µM | Human | Derived From Pepa13 | NA | NA | ||
| 25495219 | 2015 | {nnr:dab}-{nnr:Dab}-{nnr:Dab}-L-F{d}-{nnr:Dab}-{nnr:Dab}-L{ct:Amid} | 29 | Amidation | Free | Linear | Mix | Dab = diaminobutyric acid | 3 | Antimicrobial | <2 % Hemolysis at 100 µM | Mouse | Synthetic Analogues Of Battacin | NA | NA | ||
| 25495219 | 2015 | {nnr:F{d}A}-{nnr:dab}-{nnr:Dab}-{nnr:Dab}-L-F{d}-{nnr:Dab}-{nnr:Dab}-L{ct:Amid} | 17 | Amidation | Free | Linear | Mix | FA = fatty acid, Dab = diaminobutyric acid | 3 | Antimicrobial | 1.79 % Hemolysis at 100 µM | Mouse | Synthetic Analogues Of Battacin | Random coil | NA | ||
| 25495219 | 2015 | {nnr:R1}-{nnr:dab}-[{nnr:Dab}-{nnr:Dab}-L-F{d}-{nnr:Dab}-{nnr:Dab}-L] | 13 | Free | Free | Cyclic | Mix | R1 = 4-methylhexanoyl, Dab = diaminobutyric acid | 3 | Antimicrobial | 2.02 % Hemolysis at 100 µM | Mouse | Synthetic Analogues Of Battacin | NA | NA | ||
| 25495219 | 2015 | {nnr:F{d}moc}-{nnr:dab}-[{nnr:Dab}-{nnr:Dab}-L-F{d}-{nnr:Dab}-{nnr:Dab}-L] | 12 | Free | Free | Cyclic | Mix | Dab = diaminobutyric acid, Fmoc = fluorenylmethyloxycarbonyl | 3 | Antimicrobial | 41 % Hemolysis at 100 µM | Mouse | Synthetic Analogues Of Battacin | NA | NA | ||
| 25495219 | 2015 | {nnr:R3}-{nnr:dab}-{nnr:Dab}-{nnr:Dab}-L-F{d}-{nnr:Dab}-{nnr:Dab}-L{ct:Amid} | 19 | Amidation | Free | Linear | Mix | R3 = myristyl, Dab = diaminobutyric acid | 3 | Antimicrobial | 76.9 % Hemolysis at 100 µM | Mouse | Synthetic Analogues Of Battacin | NA | NA | ||
| 25583073 | 2015 | VEIHVWEGV | D60,65E-PIP[59-67] | Free | Free | Linear | L | None | 9 | Antibacterial | <30 % Hemolysis at 100 μg/mL | Human | Python Reticulatus Serum Protein | α-Helical | NA | ||
| 25583073 | 2015 | VDIHVWDGV | β-Asp65-PIP[59-67] | Free | Free | Linear | L | None | 9 | Antibacterial, Wound healing activity | <20 % Hemolysis at 100 μg/mL | Human | Python Reticulatus Serum Protein | α-Helical | Low hemolytic | ||
| 25425644 | 2015 | {nnr:T1}-GLALIVAGV-{nnr:T2} | TM4(90–98) | Free | Free | Linear | L | T1 = CH3CO-Ala-Sar3-(N-methyl-Gly), T2 = -Lys3-NH3 | 9 | Antimicrobial | 10 % Hemolysis at >200 µM | Human | Synthetic | α-Helical | NA | ||
| 26700464 | 2016 | RTLAFVRFK | RTL-PA | Free | Free | Linear | L | None | 9 | Antimicrobial | 100 % Hemolysis at 1.4 ± 0.1 µM | Rat | Tissue-Factor Targeted Found In The Heavy Chain Of Factor Vii | α-Helix | NA | ||
| 26700464 | 2016 | RTLAFVRFK | RTL-PA | Free | Free | Linear | L | None | 9 | Antimicrobial | 400 % Hemolysis at 2.0 ± 0.1 µM | Rat | Tissue-Factor Targeted Found In The Heavy Chain Of Factor Vii | α-Helix | NA | ||
| 26902768 | 2016 | LYKAIRRK{ct:Amid} | Fow-3(20-27) | Amidation | Free | Linear | L | None | 8 | Antibacterial | <5 % Hemolysis at 256 µM | Human | Truncated Peptides Of Fowlicidin-3 | α-Helix | NA | ||
| 27129462 | 2016 | RGSALTHLP | RP9 | Free | Free | Linear | L | None | 9 | Antibacterial, Anticancer | 3.3 ± 0.5 % Hemolysis at 61.2 µM | Human | Crocodile Leukocyte Extract | α-Helix | NA | ||
| 27129462 | 2016 | RGSALTHLP | RP9 | Free | Free | Linear | L | None | 9 | Antibacterial, Anticancer | 5.7 ± 0.2 % Hemolysis at 122.4 µM | Human | Crocodile Leukocyte Extract | α-Helix | NA | ||
| 27617260 | 2016 | RWRWRW{ct:Amid} | MP196 | Amidation | Free | Linear | L | None | 6 | Antibacterial | 14 % Hemolysis at 250 µg/mL | Mouse | Synthetic | α-Helix | NA | ||
| 27617260 | 2016 | RWRWRW{ct:Amid} | MP196 | Amidation | Free | Linear | L | None | 6 | Antibacterial | 23 % Hemolysis at 500 µg/mL | Mouse | Synthetic | α-Helix | NA | ||
| 27165480 | 2016 | GAKERAHQ{nt:Amid}{ct:carboxylic acid} | CGA-N8 | carboxylic acid | Amidation | Linear | L | None | 8 | Antifungal | 5 % Hemolysis at 0.27 mmol/L | Human | Derivative Of Cga-N46 | α-Helix | NA | ||
| 27723187 | 2016 | RRRRRRRR{nt:CH3(CH2)16CO}{ct:Amid} | Str–R8 | Amidation | CH3(CH2)16CO | Linear | L | R8 = Octa-arginine | 8 | Cytotoxic | 55.68 % Hemolysis at 100 µg/mL | Rat | Cpp | α-Helix | NA | ||
| 26949161 | 2016 | AEAEARAR{nt:Acet}{ct:Amid} | EAR8-II | Amidation | Acetylation | Linear | L | None | 8 | Anticancer | <5 % Hemolysis at 1.25-125 µg/mL | Rabbit | Complementary Peptide Eak16-Ii | α-Helix; Random coil | Non-hemolytic | ||
| 26949161 | 2016 | AAEEAARR{nt:Acet}{ct:Amid} | EAR8-IIa | Amidation | Acetylation | Linear | L | None | 8 | Anticancer | <5 % Hemolysis at 1.25-125 µg/mL | Rabbit | Complementary Peptide Eak16-Ii | α-Helix; Random coil | Non-hemolytic | ||
| 26949161 | 2016 | LLEELLRR{nt:Acet}{ct:Amid} | ELR8-IIa | Amidation | Acetylation | Linear | L | None | 8 | Anticancer | <5 % Hemolysis at 1.25-125 µg/mL | Rabbit | Complementary Peptide Eak16-Ii | α-Helix; Random coil | Non-hemolytic | ||
| 27606830 | 2016 | KGGK{nt:16C- palmitate}{ct:Amid} | C16-KGGK | Amidation | 16C- palmitate | Linear | L | 16C = palmitate | 4 | Antibacterial and Antibiofilm | <20 % Hemolysis at 5 µg/mL | Sheep | Lipopeptides | NA | NA | ||
| 27606830 | 2016 | KGGK{nt:16C- palmitate}{ct:Amid} | C16-KGGK | Amidation | 16C- palmitate | Linear | L | 16C = palmitate | 4 | Antibacterial and Antibiofilm | <20 % Hemolysis at 10 µg/mL | Sheep | Lipopeptides | NA | NA | ||
| 27606830 | 2016 | KGGK{nt:16C- palmitate}{ct:Amid} | C16-KGGK | Amidation | 16C- palmitate | Linear | L | 16C = palmitate | 4 | Antibacterial and Antibiofilm | 20 % Hemolysis at 20 µg/mL | Sheep | Lipopeptides | NA | NA | ||
| 27606830 | 2016 | KGGK{nt:16C- palmitate}{ct:Amid} | C16-KGGK | Amidation | 16C- palmitate | Linear | L | 16C = palmitate | 4 | Antibacterial and Antibiofilm | >40 % Hemolysis at 50 µg/mL | Sheep | Lipopeptides | NA | NA | ||
| 27606830 | 2016 | KGGK{nt:16C- palmitate}{ct:Amid} | C16-KGGK | Amidation | 16C- palmitate | Linear | L | 16C = palmitate | 4 | Antibacterial and Antibiofilm | <80 % Hemolysis at 100 µg/mL | Sheep | Lipopeptides | NA | NA | ||
| 27606830 | 2016 | KkK{nt:16C- palmitate}{ct:Amid} | C16-KKK | Amidation | 16C- palmitate | Linear | L | 16C = palmitate | 3 | Antibacterial and Antibiofilm | <20 % Hemolysis at 5 µg/mL | Sheep | Lipopeptides | NA | NA | ||
| 27606830 | 2016 | KkK{nt:16C- palmitate}{ct:Amid} | C16-KKK | Amidation | 16C- palmitate | Linear | L | 16C = palmitate | 3 | Antibacterial and Antibiofilm | 20 % Hemolysis at 10 µg/mL | Sheep | Lipopeptides | NA | NA | ||
| 27606830 | 2016 | KkK{nt:16C- palmitate}{ct:Amid} | C16-KKK | Amidation | 16C- palmitate | Linear | L | 16C = palmitate | 3 | Antibacterial and Antibiofilm | >20 % Hemolysis at 20 µg/mL | Sheep | Lipopeptides | NA | NA | ||
| 27606830 | 2016 | KkK{nt:16C- palmitate}{ct:Amid} | C16-KKK | Amidation | 16C- palmitate | Linear | L | 16C = palmitate | 3 | Antibacterial and Antibiofilm | 40 % Hemolysis at 50 µg/mL | Sheep | Lipopeptides | NA | NA | ||
| 27606830 | 2016 | KkK{nt:16C- palmitate}{ct:Amid} | C16-KKK | Amidation | 16C- palmitate | Linear | L | 16C = palmitate | 3 | Antibacterial and Antibiofilm | <60 % Hemolysis at 100 µg/mL | Sheep | Lipopeptides | NA | NA | ||
| 27606830 | 2016 | KAaK{nt:16C- palmitate}{ct:Amid} | C16-KAAK | Amidation | 16C- palmitate | Linear | L | 16C = palmitate | 4 | Antibacterial and Antibiofilm | <20 % Hemolysis at 5 µg/mL | Sheep | Lipopeptides | NA | NA | ||
| 27606830 | 2016 | KAaK{nt:16C- palmitate}{ct:Amid} | C16-KAAK | Amidation | 16C- palmitate | Linear | L | 16C = palmitate | 4 | Antibacterial and Antibiofilm | <20 % Hemolysis at 10 µg/mL | Sheep | Lipopeptides | NA | NA | ||
| 27606830 | 2016 | KAaK{nt:16C- palmitate}{ct:Amid} | C16-KAAK | Amidation | 16C- palmitate | Linear | L | 16C = palmitate | 4 | Antibacterial and Antibiofilm | <20 % Hemolysis at 20 µg/mL | Sheep | Lipopeptides | NA | NA | ||
| 27606830 | 2016 | KAaK{nt:16C- palmitate}{ct:Amid} | C16-KAAK | Amidation | 16C- palmitate | Linear | L | 16C = palmitate | 4 | Antibacterial and Antibiofilm | 20 % Hemolysis at 50 µg/mL | Sheep | Lipopeptides | NA | NA | ||
| 27606830 | 2016 | KAaK{nt:16C- palmitate}{ct:Amid} | C16-KAAK | Amidation | 16C- palmitate | Linear | L | 16C = palmitate | 4 | Antibacterial and Antibiofilm | <40 % Hemolysis at 100 µg/mL | Sheep | Lipopeptides | NA | NA | ||
| 27606830 | 2016 | KLlK{nt:16C- palmitate}{ct:Amid} | C16-KLLK | Amidation | 16C- palmitate | Linear | L | 16C = palmitate | 4 | Antibacterial and Antibiofilm | <20 % Hemolysis at 5 µg/mL | Sheep | Lipopeptides | NA | NA | ||
| 27606830 | 2016 | KLlK{nt:16C- palmitate}{ct:Amid} | C16-KLLK | Amidation | 16C- palmitate | Linear | L | 16C = palmitate | 4 | Antibacterial and Antibiofilm | <20 % Hemolysis at 10 µg/mL | Sheep | Lipopeptides | NA | NA | ||
| 27606830 | 2016 | KLlK{nt:16C- palmitate}{ct:Amid} | C16-KLLK | Amidation | 16C- palmitate | Linear | L | 16C = palmitate | 4 | Antibacterial and Antibiofilm | 20 % Hemolysis at 20 µg/mL | Sheep | Lipopeptides | NA | NA | ||
| 27606830 | 2016 | KLlK{nt:16C- palmitate}{ct:Amid} | C16-KLLK | Amidation | 16C- palmitate | Linear | L | 16C = palmitate | 4 | Antibacterial and Antibiofilm | <40 % Hemolysis at 50 µg/mL | Sheep | Lipopeptides | NA | NA | ||
| 27606830 | 2016 | KLlK{nt:16C- palmitate}{ct:Amid} | C16-KLLK | Amidation | 16C- palmitate | Linear | L | 16C = palmitate | 4 | Antibacterial and Antibiofilm | <50 % Hemolysis at 100 µg/mL | Sheep | Lipopeptides | NA | NA | ||
| 25546564 | 2016 | FLKMN | 3 | Free | Free | Linear | L | None | 5 | Antioxidant | 35 % Hemolysis at 1 mg/mL | Rat | Synthetic | NA | NA | ||
| 25546564 | 2016 | GKFNV | 4 | Free | Free | Linear | L | None | 5 | Antioxidant | <35 % Hemolysis at 1 mg/mL | Rat | Synthetic | NA | NA | ||
| 25546564 | 2016 | LPGGGT | 5 | Free | Free | Linear | L | None | 6 | Antioxidant | <45 % Hemolysis at 1 mg/mL | Rat | Synthetic | NA | NA | ||
| 25546564 | 2016 | HA | 6 | Free | Free | Linear | L | None | 2 | Antioxidant | 45 % Hemolysis at 1 mg/mL | Rat | Synthetic | NA | NA | ||
| 25546564 | 2016 | KEER | 7 | Free | Free | Linear | L | None | 4 | Antioxidant | <40 % Hemolysis at 1 mg/mL | Rat | Synthetic | NA | NA | ||
| 26860588 | 2016 | PFWRIRIRR{ct:Amid} | PFR | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 0 % Hemolysis at 10 µM | Human | Derivatives Of Lactoferrin | α-Helical | Non-hemolytic | ||
| 26860588 | 2016 | PFWRIRIRR{ct:Amid} | PFR | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 0 % Hemolysis at 30 µM | Human | Derivatives Of Lactoferrin | α-Helical | Non-hemolytic | ||
| 26860588 | 2016 | PFWRIRIRR{ct:Amid} | PFR | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 0 % Hemolysis at 50 µM | Human | Derivatives Of Lactoferrin | α-Helical | Non-hemolytic | ||
| 26860588 | 2016 | PFWRIRIRR{ct:Amid} | PFR | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 0 % Hemolysis at 100 µM | Human | Derivatives Of Lactoferrin | α-Helical | Non-hemolytic | ||
| 26860588 | 2016 | PFWRIRIRR{ct:Amid} | PFR | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 0 % Hemolysis at 150 µM | Human | Derivatives Of Lactoferrin | α-Helical | Non-hemolytic | ||
| 26860588 | 2016 | PFWRIRIRR{ct:Amid} | PFR | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 0 % Hemolysis at 225 µM | Human | Derivatives Of Lactoferrin | α-Helical | Non-hemolytic | ||
| 26860588 | 2016 | PFWRIRIRR{ct:Amid} | PFR | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 0 % Hemolysis at 300 µM | Human | Derivatives Of Lactoferrin | α-Helical | Non-hemolytic | ||
| 27992168 | 2017 | {nnr:dab}{nnr:Dab}{nnr:Dab}LF{d}{nnr:Dab}{nnr:Dab}L{nt:R1 = 4-methylhexanoyl}{ct:Amid} | GZ3.27 | Amidation | R1 = 4-methylhexanoyl | Linear | Mix | R1 = 4-methylhexanoyl, Dab = 2,4-diaminobutyric acid, dab = D-2,4-diaminobutyric acid | 3 | Antimicrobial | 1.8 ± 0.45 % Hemolysis at 100 µM | Mouse | Lipopeptide | NA | NA | ||
| 27992168 | 2017 | C{nnr:dab}{nnr:Dab}{nnr:Dab}LF{d}{nnr:Dab}{nnr:Dab}L{nt:R1 = 4-methylhexanoyl}{ct:Amid} | GZ3.163 | Amidation | R1 = 4-methylhexanoyl | Linear | Mix | R1 = 4-methylhexanoyl, Dab = 2,4-diaminobutyric acid, dab = D-2,4-diaminobutyric acid | 4 | Antimicrobial | 4.3 ± 0.42 % Hemolysis at 100 µM | Mouse | Battacin Lipopeptide Analogue | NA | NA | ||
| 27992168 | 2017 | {nnr:dab}{nnr:Dab}{nnr:Dab}LF{d}{nnr:Dab}{nnr:Dab}LC{nt:R1 = 4-methylhexanoyl}{ct:Amid} | GZ3.160 | Amidation | R1 = 4-methylhexanoyl | Linear | Mix | R1 = 4-methylhexanoyl, Dab = 2,4-diaminobutyric acid, dab = D-2,4-diaminobutyric acid | 4 | Antimicrobial | 2.8 ± 0.30 % Hemolysis at 100 µM | Mouse | Battacin Lipopeptide Analogue | NA | NA | ||
| 27992168 | 2017 | {nnr:dab}{nnr:Dab}(C){nnr:Dab}LF{d}{nnr:Dab}{nnr:Dab}L{nt:R1 = 4-methylhexanoyl}{ct:Amid} | GZ3.155 | Amidation | R1 = 4-methylhexanoyl | Linear | Mix | R1 = 4-methylhexanoyl, Dab = 2,4-diaminobutyric acid, dab = D-2,4-diaminobutyric acid | 4 | Antimicrobial | 2.2 ± 0.93 % Hemolysis at 100 µM | Mouse | Battacin Lipopeptide Analogue | NA | NA | ||
| 28165293 | 2017 | RRWQWR{nt:Acet}{ct:Amid} | LFcinB1 | Amidation | Acetylation | Linear | L | None | 6 | Anticancer | <2 % Hemolysis at 10 µM | Human | Lf-Derived | β-Hairpin | NA | ||
| 28178190 | 2017 | FRIRVRV{ct:Amid} | FV7 | Amidation | Free | Linear | L | None | 7 | Antimicrobial | 5 % Hemolysis at 4 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 28178190 | 2017 | FRIRVRV{ct:Amid} | FV7 | Amidation | Free | Linear | L | None | 7 | Antimicrobial | 15 % Hemolysis at 128 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 28230084 | 2017 | MLKKFRGMF{ct:Amid} | MreB1–9 | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 0 % Hemolysis at 50 µM | Human | Membrane-Binding Region Of E. Coli Mreb | α-Helix | Non-hemolytic | ||
| 28230084 | 2017 | MLKKFRGMF{nt:Acet}{ct:Amid} | Ac-MreB1–9 | Amidation | Acetylation | Linear | L | None | 9 | Antimicrobial | 0 % Hemolysis at 50 µM | Human | Membrane-Binding Region Of E. Coli Mreb | α-Helix | Non-hemolytic | ||
| 28230084 | 2017 | WMLKKFRGMF{ct:Amid} | W-MreB1–9 | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 0 % Hemolysis at 50 µM | Human | Membrane-Binding Region Of E. Coli Mreb | α-Helix | NA | ||
| 28230084 | 2017 | WMLKKFRGMF{nt:Acet}{ct:Amid} | Ac-W-MreB1–9 | Amidation | Acetylation | Linear | L | None | 9 | Antimicrobial | 4.15±0.96 % Hemolysis at 50 µM | Human | Membrane-Binding Region Of E. Coli Mreb | α-Helix | NA | ||
| 28230084 | 2017 | MLKKFRGMF{ct:Amid} | MreB1–9 | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 0 % Hemolysis at 100 µM | Human | Membrane-Binding Region Of E. Coli Mreb | α-Helix | Non-hemolytic | ||
| 28230084 | 2017 | MLKKFRGMF{nt:Acet}{ct:Amid} | Ac-MreB1–9 | Amidation | Acetylation | Linear | L | None | 9 | Antimicrobial | 0 % Hemolysis at 100 µM | Human | Membrane-Binding Region Of E. Coli Mreb | α-Helix | Non-hemolytic | ||
| 28230084 | 2017 | WMLKKFRGMF{ct:Amid} | W-MreB1–9 | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 1.62±0.08 % Hemolysis at 100 µM | Human | Membrane-Binding Region Of E. Coli Mreb | α-Helix | NA | ||
| 28230084 | 2017 | WMLKKFRGMF{nt:Acet}{ct:Amid} | Ac-W-MreB1–9 | Amidation | Acetylation | Linear | L | None | 9 | Antimicrobial | 11.88±2.44 % Hemolysis at 100 µM | Human | Membrane-Binding Region Of E. Coli Mreb | α-Helix | NA | ||
| 28453851 | 2017 | R{d}L{d}W{d}V{d}L{d}W{d}R{d}R{d} | D-Bac8c2,5Leu | Free | Free | Linear | D | None | 8 | Antimicrobial | 50 % Hemolysis at 414 μg/ml | Human | Synthetic | NA | NA | ||
| 28533236 | 2017 | {nnr:Dap}L{d}WK{d}N{d}R{d}{cyc:N-C} | CLP-4 | Free | Free | Cyclic | Mix | Dap = 2,3-diaminopropionic acid, l = D-leucine, k = D-lysine, n = D-asparagine, r = D-arginine | 5 | Antibacterial, Antibiofilm | 0 % Hemolysis at 8 μg/ml | Human | Fusaricidin | NA | Non-hemolytic | ||
| 28533236 | 2017 | {nnr:Dap}L{d}WK{d}N{d}R{d}{cyc:N-C} | CLP-4 | Free | Free | Cyclic | Mix | Dap = 2,3-diaminopropionic acid, l = D-leucine, k = D-lysine, n = D-asparagine, r = D-arginine | 5 | Antibacterial, Antibiofilm | 0 % Hemolysis at 15.6 μg/ml | Human | Fusaricidin | NA | Non-hemolytic | ||
| 28533236 | 2017 | {nnr:Dap}L{d}WK{d}N{d}R{d}{cyc:N-C} | CLP-4 | Free | Free | Cyclic | Mix | Dap = 2,3-diaminopropionic acid, l = D-leucine, k = D-lysine, n = D-asparagine, r = D-arginine | 5 | Antibacterial, Antibiofilm | 0 % Hemolysis at 31.2 μg/ml | Human | Fusaricidin | NA | Non-hemolytic | ||
| 28533236 | 2017 | {nnr:Dap}L{d}WK{d}N{d}R{d}{cyc:N-C} | CLP-4 | Free | Free | Cyclic | Mix | Dap = 2,3-diaminopropionic acid, l = D-leucine, k = D-lysine, n = D-asparagine, r = D-arginine | 5 | Antibacterial, Antibiofilm | 0 % Hemolysis at 62.5 μg/ml | Human | Fusaricidin | NA | Non-hemolytic | ||
| 28533236 | 2017 | {nnr:Dap}L{d}WK{d}N{d}R{d}{cyc:N-C} | CLP-4 | Free | Free | Cyclic | Mix | Dap = 2,3-diaminopropionic acid, l = D-leucine, k = D-lysine, n = D-asparagine, r = D-arginine | 5 | Antibacterial, Antibiofilm | 0 % Hemolysis at 125 μg/ml | Human | Fusaricidin | NA | Non-hemolytic | ||
| 28533236 | 2017 | {nnr:Dap}L{d}WK{d}N{d}R{d}{cyc:N-C} | CLP-4 | Free | Free | Cyclic | Mix | Dap = 2,3-diaminopropionic acid, l = D-leucine, k = D-lysine, n = D-asparagine, r = D-arginine | 5 | Antibacterial, Antibiofilm | 0 % Hemolysis at 250 μg/ml | Human | Fusaricidin | NA | Non-hemolytic | ||
| 28533236 | 2017 | {nnr:Dap}L{d}WK{d}N{d}R{d}{cyc:N-C} | CLP-4 | Free | Free | Cyclic | Mix | Dap = 2,3-diaminopropionic acid, l = D-leucine, k = D-lysine, n = D-asparagine, r = D-arginine | 5 | Antibacterial, Antibiofilm | 0 % Hemolysis at 500 μg/ml | Human | Fusaricidin | NA | Non-hemolytic | ||
| 28533236 | 2017 | {nnr:Dap}L{d}WK{d}N{d}R{d}{cyc:N-C} | CLP-4 | Free | Free | Cyclic | Mix | Dap = 2,3-diaminopropionic acid, l = D-leucine, k = D-lysine, n = D-asparagine, r = D-arginine | 5 | Antibacterial, Antibiofilm | <10 % Hemolysis at 1000 μg/ml | Human | Fusaricidin | NA | Non-hemolytic | ||
| 28346717 | 2017 | VGVGGGFGR{ct:Amid} | Crinicepsin-1 | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 0 % Hemolysis at 100 μg/ml | Human | Ant Trichomyrmex Criniceps(Mayr) | α-Helix | NA | ||
| 28346717 | 2017 | VGVGGGFGR{ct:Amid} | Crinicepsin-1 | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 0 % Hemolysis at 150 μg/ml | Human | Ant Trichomyrmex Criniceps(Mayr) | α-Helix | NA | ||
| 28346717 | 2017 | VGVGGGFGR{ct:Amid} | Crinicepsin-1 | Amidation | Free | Linear | L | None | 9 | Antimicrobial | <5 % Hemolysis at 200 μg/ml | Human | Ant Trichomyrmex Criniceps(Mayr) | α-Helix | NA | ||
| 28346717 | 2017 | VGVGGGFGR{ct:Amid} | Crinicepsin-1 | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 5 % Hemolysis at 250 μg/ml | Human | Ant Trichomyrmex Criniceps(Mayr) | α-Helix | NA | ||
| 28346717 | 2017 | VGVGGGFGR{ct:Amid} | Crinicepsin-1 | Amidation | Free | Linear | L | None | 9 | Antimicrobial | <10 % Hemolysis at 300 μg/ml | Human | Ant Trichomyrmex Criniceps(Mayr) | α-Helix | NA | ||
| 28346717 | 2017 | VGVGGGFGR{ct:Amid} | Crinicepsin-1 | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 18 % Hemolysis at 500 μg/ml | Human | Ant Trichomyrmex Criniceps(Mayr) | α-Helix | NA | ||
| 28299865 | 2017 | ASKAGAIAG | XLAsp-P2 | Free | Free | Linear | L | None | 9 | Antibacterial | 0 % Hemolysis at 8 μg/ml | Rabbit | Xenopus Laevis Skin | Double Helix | Non-hemolytic | ||
| 28299865 | 2017 | ASKAGAIAG | XLAsp-P2 | Free | Free | Linear | L | None | 9 | Antibacterial | <10 % Hemolysis at 16 μg/ml | Rabbit | Xenopus Laevis Skin | Double Helix | NA | ||
| 28299865 | 2017 | ASKAGAIAG | XLAsp-P2 | Free | Free | Linear | L | None | 9 | Antibacterial | <10 % Hemolysis at 32 μg/ml | Rabbit | Xenopus Laevis Skin | Double Helix | NA | ||
| 28299865 | 2017 | ASKAGAIAG | XLAsp-P2 | Free | Free | Linear | L | None | 9 | Antibacterial | <10 % Hemolysis at 64 μg/ml | Rabbit | Xenopus Laevis Skin | Double Helix | NA | ||
| 28299865 | 2017 | ASKAGAIAG | XLAsp-P2 | Free | Free | Linear | L | None | 9 | Antibacterial | <40 % Hemolysis at 128 μg/ml | Rabbit | Xenopus Laevis Skin | Double Helix | NA | ||
| 28547390 | 2017 | K{nnr:*}WK{nnr:X}{nnr:*}K{ct:Amid} | ALA | Amidation | Free | Linear | L | * = cross-linked residues, X = Ala | 7 | Antimicrobial | <1 % Hemolysis at 50 µM | Human | Stapled Heptapeptide Helices | α-Helix | NA | ||
| 28547390 | 2017 | K{nnr:*}WK{nnr:X}{nnr:*}K{ct:Amid} | LEU | Amidation | Free | Linear | L | * = cross-linked residues, X = Leu | 7 | Antimicrobial | <1 % Hemolysis at 50 µM | Human | Stapled Heptapeptide Helices | α-Helix | NA | ||
| 28547390 | 2017 | K{nnr:*}WK{nnr:X}{nnr:*}K{ct:Amid} | VAL | Amidation | Free | Linear | L | * = cross-linked residues, X = Leu | 7 | Antimicrobial | 2.5 % Hemolysis at 50 µM | Human | Stapled Heptapeptide Helices | α-Helix | NA | ||
| 28547390 | 2017 | K{nnr:*}WK{nnr:X}{nnr:*}K{ct:Amid} | ILE | Amidation | Free | Linear | L | * = cross-linked residues, X = Leu | 7 | Antimicrobial | 3 % Hemolysis at 50 µM | Human | Stapled Heptapeptide Helices | α-Helix | NA | ||
| 28547390 | 2017 | K{nnr:*}WK{nnr:X}{nnr:*}K{ct:Amid} | NLE | Amidation | Free | Linear | L | * = cross-linked residues, X = Nle | 7 | Antimicrobial | 7.9 % Hemolysis at 50 µM | Human | Stapled Heptapeptide Helices | α-Helix | NA | ||
| 28547390 | 2017 | K{nnr:*}WK{nnr:X}{nnr:*}K{ct:Amid} | PHE | Amidation | Free | Linear | L | * = cross-linked residues, X = Phe | 7 | Antimicrobial | 4.4 % Hemolysis at 50 µM | Human | Stapled Heptapeptide Helices | α-Helix | NA | ||
| 28547390 | 2017 | K{nnr:*}WK{nnr:X}{nnr:*}K{ct:Amid} | TRP | Amidation | Free | Linear | L | * = cross-linked residues, X = Trp | 7 | Antimicrobial | 5.9 % Hemolysis at 50 µM | Human | Stapled Heptapeptide Helices | α-Helix | NA | ||
| 28547390 | 2017 | K{nnr:*}WK{nnr:X}{nnr:*}K{ct:Amid} | GLU | Amidation | Free | Linear | L | * = cross-linked residues, X = Glu | 7 | Antimicrobial | <1 % Hemolysis at 50 µM | Human | Stapled Heptapeptide Helices | α-Helix | NA | ||
| 28547390 | 2017 | K{nnr:*}WK{nnr:X}{nnr:*}K{ct:Amid} | LYS | Amidation | Free | Linear | L | * = cross-linked residues, X = Lys | 7 | Antimicrobial | <1 % Hemolysis at 50 µM | Human | Stapled Heptapeptide Helices | α-Helix | NA | ||
| 28547390 | 2017 | K{nnr:*}WK{nnr:X}{nnr:*}K{ct:Amid} | ALA | Amidation | Free | Linear | L | * = cross-linked residues, X = Ala | 7 | Antimicrobial | <1 % Hemolysis at 25 µM | Human | Stapled Heptapeptide Helices | α-Helix | NA | ||
| 28547390 | 2017 | K{nnr:*}WK{nnr:X}{nnr:*}K{ct:Amid} | LEU | Amidation | Free | Linear | L | * = cross-linked residues, X = Leu | 7 | Antimicrobial | <1 % Hemolysis at 25 µM | Human | Stapled Heptapeptide Helices | α-Helix | NA | ||
| 28547390 | 2017 | K{nnr:*}WK{nnr:X}{nnr:*}K{ct:Amid} | VAL | Amidation | Free | Linear | L | * = cross-linked residues, X = Leu | 7 | Antimicrobial | 1.3 % Hemolysis at 25 µM | Human | Stapled Heptapeptide Helices | α-Helix | NA | ||
| 28547390 | 2017 | K{nnr:*}WK{nnr:X}{nnr:*}K{ct:Amid} | ILE | Amidation | Free | Linear | L | * = cross-linked residues, X = Leu | 7 | Antimicrobial | 1.5 % Hemolysis at 25 µM | Human | Stapled Heptapeptide Helices | α-Helix | NA | ||
| 28547390 | 2017 | K{nnr:*}WK{nnr:X}{nnr:*}K{ct:Amid} | NLE | Amidation | Free | Linear | L | * = cross-linked residues, X = Nle | 7 | Antimicrobial | 3.3 % Hemolysis at 25 µM | Human | Stapled Heptapeptide Helices | α-Helix | NA | ||
| 28547390 | 2017 | K{nnr:*}WK{nnr:X}{nnr:*}K{ct:Amid} | PHE | Amidation | Free | Linear | L | * = cross-linked residues, X = Phe | 7 | Antimicrobial | 1.9 % Hemolysis at 25 µM | Human | Stapled Heptapeptide Helices | α-Helix | NA | ||
| 28547390 | 2017 | K{nnr:*}WK{nnr:X}{nnr:*}K{ct:Amid} | TRP | Amidation | Free | Linear | L | * = cross-linked residues, X = Trp | 7 | Antimicrobial | 3.2 % Hemolysis at 25 µM | Human | Stapled Heptapeptide Helices | α-Helix | NA | ||
| 28547390 | 2017 | K{nnr:*}WK{nnr:X}{nnr:*}K{ct:Amid} | GLU | Amidation | Free | Linear | L | * = cross-linked residues, X = Glu | 7 | Antimicrobial | <1 % Hemolysis at 25 µM | Human | Stapled Heptapeptide Helices | α-Helix | NA | ||
| 28547390 | 2017 | K{nnr:*}WK{nnr:X}{nnr:*}K{ct:Amid} | LYS | Amidation | Free | Linear | L | * = cross-linked residues, X = Lys | 7 | Antimicrobial | <1 % Hemolysis at 25 µM | Human | Stapled Heptapeptide Helices | α-Helix | NA | ||
| 28372989 | 2017 | RRWWRHWRR{ct:Amid} | P1 | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 5 % Hemolysis at > 86.67 µM | Human | Synthetic | α-Helix | NA | ||
| 28372989 | 2017 | RRWHRWWRR{ct:Amid} | P2 | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 5 % Hemolysis at > 86.67 µM | Human | Synthetic | α-Helix | NA | ||
| 28372989 | 2017 | RRHWRWWRR{ct:Amid} | P3 | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 5 % Hemolysis at > 86.67 µM | Human | Synthetic | α-Helix | NA | ||
| 28372989 | 2017 | RRWHRHWRR{ct:Amid} | P4 | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 5 % Hemolysis at > 86.67 µM | Human | Synthetic | α-Helix | NA | ||
| 28372989 | 2017 | RRWWRWWRR{ct:Amid} | P5 | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 5 % Hemolysis at 33.33 µM | Human | Synthetic | α-Helix | NA | ||
| 28372989 | 2017 | HRWWRWWRR{ct:Amid} | P6 | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 5 % Hemolysis at 86.67 µM | Human | Synthetic | α-Helix | NA | ||
| 28372989 | 2017 | RRWWHWWRR{ct:Amid} | P7 | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 5 % Hemolysis at 86.67 µM | Human | Synthetic | α-Helix | NA | ||
| 28372989 | 2017 | HRWWRWWRH{ct:Amid} | P8 | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 5 % Hemolysis at 86.67 µM | Human | Synthetic | α-Helix | NA | ||
| 28731688 | 2017 | WWWLRRIW{ct:Amid} | WT | Amidation | Free | Linear | L | None | 8 | Antibacterial | 50 % Hemolysis at 35 µM | Human | Motif Of A Short Trp-Rich | α-Helix | NA | ||
| 28731688 | 2017 | RWWLRRIW{ct:Amid} | W1R | Amidation | Free | Linear | L | None | 8 | Antibacterial | 50 % Hemolysis at >200 µM | Human | Motif Of A Short Trp-Rich | α-Helix | NA | ||
| 28731688 | 2017 | WRWLRRIW{ct:Amid} | W2R | Amidation | Free | Linear | L | None | 8 | Antibacterial | 50 % Hemolysis at 100 µM | Human | Motif Of A Short Trp-Rich | α-Helix | NA | ||
| 28731688 | 2017 | WWRLRRIW{ct:Amid} | W3R | Amidation | Free | Linear | L | None | 8 | Antibacterial | 50 % Hemolysis at >200 µM | Human | Motif Of A Short Trp-Rich | α-Helix | NA | ||
| 28731688 | 2017 | WWWRRRIW{ct:Amid} | L4R | Amidation | Free | Linear | L | None | 8 | Antibacterial | 50 % Hemolysis at >200 µM | Human | Motif Of A Short Trp-Rich | α-Helix | NA | ||
| 28731688 | 2017 | WWWLRRRW{ct:Amid} | I7R | Amidation | Free | Linear | L | None | 8 | Antibacterial | 50 % Hemolysis at 150 µM | Human | Motif Of A Short Trp-Rich | α-Helix | NA | ||
| 28731688 | 2017 | WWWLRRIR{ct:Amid} | W8R | Amidation | Free | Linear | L | None | 8 | Antibacterial | 50 % Hemolysis at >200 µM | Human | Motif Of A Short Trp-Rich | α-Helix | NA | ||
| 28834399 | 2017 | YA{d}F{nnr:Cyn} | 1 | Free | Free | Linear | Mix | Cyn = trans-1-cinnamilpiperazine, a = D-Ala | 3 | Antitumour | 0.8±0.1 % Hemolysis at 0 µM | Human | Synthetic Peptidomimetics | NA | NA | ||
| 28834399 | 2017 | YA{d}F{nnr:Cyn} | 1 | Free | Free | Linear | Mix | Cyn = trans-1-cinnamilpiperazine, a = D-Ala | 3 | Antitumour | 2.2±0.0 % Hemolysis at 100 µM | Human | Synthetic Peptidomimetics | NA | NA | ||
| 28834399 | 2017 | YA{d}F{nnr:Cyn} | 1 | Free | Free | Linear | Mix | Cyn = trans-1-cinnamilpiperazine, a = D-Ala | 3 | Antitumour | 2.4±0.1 % Hemolysis at 250 µM | Human | Synthetic Peptidomimetics | NA | NA | ||
| 28834399 | 2017 | YA{d}W{cyn} | 2 | Free | Free | Linear | Mix | Cyn = trans-1-cinnamilpiperazine, a = D-Ala | 3 | Antitumour | 1.1±0.0 % Hemolysis at 0 µM | Human | Synthetic Peptidomimetics | NA | NA | ||
| 28834399 | 2017 | YA{d}W{cyn} | 2 | Free | Free | Linear | Mix | Cyn = trans-1-cinnamilpiperazine, a = D-Ala | 3 | Antitumour | 1.7±0.0 % Hemolysis at 100 µM | Human | Synthetic Peptidomimetics | NA | NA | ||
| 28834399 | 2017 | YA{d}W{cyn} | 2 | Free | Free | Linear | Mix | Cyn = trans-1-cinnamilpiperazine, a = D-Ala | 3 | Antitumour | 2.4±0.0 % Hemolysis at 250 µM | Human | Synthetic Peptidomimetics | NA | NA | ||
| 28834399 | 2017 | YT{d}F{nnr:Cyn} | 3 | Free | Free | Linear | Mix | Cyn = trans-1-cinnamilpiperazine, t = D-Thr | 3 | Antitumour | 1.2±0.1 % Hemolysis at 0 µM | Human | Synthetic Peptidomimetics | NA | NA | ||
| 28834399 | 2017 | YT{d}F{nnr:Cyn} | 3 | Free | Free | Linear | Mix | Cyn = trans-1-cinnamilpiperazine, t = D-Thr | 3 | Antitumour | 1.8±0.1 % Hemolysis at 100 µM | Human | Synthetic Peptidomimetics | NA | NA | ||
| 28834399 | 2017 | YT{d}F{nnr:Cyn} | 3 | Free | Free | Linear | Mix | Cyn = trans-1-cinnamilpiperazine, t = D-Thr | 3 | Antitumour | 1.8±0.1 % Hemolysis at 250 µM | Human | Synthetic Peptidomimetics | NA | NA | ||
| 28834399 | 2017 | YT{d}W{nnr:Cyn} | 4 | Free | Free | Linear | Mix | Cyn = trans-1-cinnamilpiperazine, t = D-Thr | 3 | Antitumour | 0.8±0.1 % Hemolysis at 0 µM | Human | Synthetic Peptidomimetics | NA | NA | ||
| 28834399 | 2017 | YT{d}W{nnr:Cyn} | 4 | Free | Free | Linear | Mix | Cyn = trans-1-cinnamilpiperazine, t = D-Thr | 3 | Antitumour | 1.0±0.1 % Hemolysis at 100 µM | Human | Synthetic Peptidomimetics | NA | NA | ||
| 28834399 | 2017 | YT{d}W{nnr:Cyn} | 4 | Free | Free | Linear | Mix | Cyn = trans-1-cinnamilpiperazine, t = D-Thr | 3 | Antitumour | 0.9±0.0 % Hemolysis at 250 µM | Human | Synthetic Peptidomimetics | NA | NA | ||
| 27937055 | 2017 | GHHNGR | oleylpeptide | Free | Free | Linear | L | None | 6 | Anticancer | 1.3 ± 0.04 % Hemolysis at 2 mM | Human | Resin | β-Turns and Bent | Non-hemolytic | ||
| 29163899 | 2017 | C{d}WK{d}KK{d}C{cyc:N-C}{ct:Amid} | RH1 | Amidation | Free | Cyclic | Mix | None | 6 | Antimicrobial | MHC at 1000 µg/mL | Human | Camp | β-Sheet | NA | ||
| 29163899 | 2017 | CW{d}WK{d}KK{d}C{cyc:N-C}{ct:Amid} | RH2 | Amidation | Free | Cyclic | Mix | None | 7 | Antimicrobial | MHC at 125 µg/mL | Human | Camp | β-Sheet | NA | ||
| 29163899 | 2017 | C{d}WW{d}KK{d}KK{d}C{cyc:N-C}{ct:Amid} | RH3 | Amidation | Free | Cyclic | Mix | None | 8 | Antimicrobial | MHC at 500 µg/mL | Human | Camp | β-Sheet | NA | ||
| 29163899 | 2017 | CW{d}WW{d}KK{d}KK{d}C{cyc:N-C}{ct:Amid} | RH4 | Amidation | Free | Cyclic | Mix | None | 9 | Antimicrobial | MHC at 125 µg/mL | Human | Camp | β-Sheet | NA | ||
| 28987278 | 2017 | RSVSKSR | REPRSV | Free | Free | Linear | L | None | 7 | LPS-neutralizing, angiogenic activities | 4.6 % Hemolysis at 500 µM | Sheep | Peptic Hydrolysates Of Rice Endosperm Protein | NA | Non-hemolytic | ||
| 28987278 | 2017 | RRVIEPR | REP-RRV | Free | Free | Linear | L | None | 7 | LPS-neutralizing, angiogenic activities | 2.5 % Hemolysis at 500 µM | Sheep | Peptic Hydrolysates Of Rice Endosperm Protein | NA | Non-hemolytic | ||
| 28203232 | 2017 | K{nt:X = C16 = Heksadecanoic fatty acid chain}{ct:Amid} | 1 | Amidation | X = C16 = Heksadecanoic fatty acid chain | Linear | L | C16 = Heksadecanoic fatty acid chain | 1 | Antimicrobial | 10 % Hemolysis at 512 µg/mL | Human | Synthetic Cationic Lipopeptides | NA | NA | ||
| 28203232 | 2017 | KK{nt:X = C16 = Heksadecanoic fatty acid chain}{ct:Amid} | 2 | Amidation | X = C16 = Heksadecanoic fatty acid chain | Linear | L | C16 = Heksadecanoic fatty acid chain | 2 | Antimicrobial | 10 % Hemolysis at 16 µg/mL | Human | Synthetic Cationic Lipopeptides | NA | NA | ||
| 28203232 | 2017 | KKK{nt:X = C16 = Heksadecanoic fatty acid chain}{ct:Amid} | 3 | Amidation | X = C16 = Heksadecanoic fatty acid chain | Linear | L | C16 = Heksadecanoic fatty acid chain | 3 | Antimicrobial | 10 % Hemolysis at 32 µg/mL | Human | Synthetic Cationic Lipopeptides | NA | NA | ||
| 28203232 | 2017 | KKKK{nt:X = C16 = Heksadecanoic fatty acid chain}{ct:Amid} | 4 | Amidation | X = C16 = Heksadecanoic fatty acid chain | Linear | L | C16 = Heksadecanoic fatty acid chain | 4 | Antimicrobial | 10 % Hemolysis at 16 µg/mL | Human | Synthetic Cationic Lipopeptides | NA | NA | ||
| 28203232 | 2017 | KG{nt:X = C16 = Heksadecanoic fatty acid chain}{ct:Amid} | 5 | Amidation | X = C16 = Heksadecanoic fatty acid chain | Linear | L | C16 = Heksadecanoic fatty acid chain | 2 | Antimicrobial | 10 % Hemolysis at 256 µg/mL | Human | Synthetic Cationic Lipopeptides | NA | NA | ||
| 28203232 | 2017 | KGK{nt:X = C16 = Heksadecanoic fatty acid chain}{ct:Amid} | 6 | Amidation | X = C16 = Heksadecanoic fatty acid chain | Linear | L | C16 = Heksadecanoic fatty acid chain | 3 | Antimicrobial | 10 % Hemolysis at 64 µg/mL | Human | Synthetic Cationic Lipopeptides | NA | NA | ||
| 28203232 | 2017 | KGKG{nt:X = C16 = Heksadecanoic fatty acid chain}{ct:Amid} | 7 | Amidation | X = C16 = Heksadecanoic fatty acid chain | Linear | L | C16 = Heksadecanoic fatty acid chain | 4 | Antimicrobial | 10 % Hemolysis at 64 µg/mL | Human | Synthetic Cationic Lipopeptides | NA | NA | ||
| 28203232 | 2017 | K{nt:X = C14 = Tetradecanoic fatty acid chain}{ct:Amid} | 8 | Amidation | X = C14 = Tetradecanoic fatty acid chain | Linear | L | C14 = Tetradecanoic fatty acid chain | 1 | Antimicrobial | 10 % Hemolysis at 512 µg/mL | Human | Synthetic Cationic Lipopeptides | NA | NA | ||
| 28203232 | 2017 | KK{nt:X = C14 = Tetradecanoic fatty acid chain}{ct:Amid} | 9 | Amidation | X = C14 = Tetradecanoic fatty acid chain | Linear | L | C14 = Tetradecanoic fatty acid chain | 2 | Antimicrobial | 10 % Hemolysis at 128 µg/mL | Human | Synthetic Cationic Lipopeptides | NA | NA | ||
| 28203232 | 2017 | KKK{nt:X = C14 = Tetradecanoic fatty acid chain}{ct:Amid} | 10 | Amidation | X = C14 = Tetradecanoic fatty acid chain | Linear | L | C14 = Tetradecanoic fatty acid chain | 3 | Antimicrobial | 10 % Hemolysis at 256 µg/mL | Human | Synthetic Cationic Lipopeptides | NA | NA | ||
| 28203232 | 2017 | KKKK{nt:X = C14 = Tetradecanoic fatty acid chain}{ct:Amid} | 11 | Amidation | X = C14 = Tetradecanoic fatty acid chain | Linear | L | C14 = Tetradecanoic fatty acid chain | 4 | Antimicrobial | 10 % Hemolysis at 256 µg/mL | Human | Synthetic Cationic Lipopeptides | NA | NA | ||
| 28203232 | 2017 | KG{nt:X = C14 = Tetradecanoic fatty acid chain}{ct:Amid} | 12 | Amidation | X = C14 = Tetradecanoic fatty acid chain | Linear | L | C14 = Tetradecanoic fatty acid chain | 2 | Antimicrobial | 10 % Hemolysis at >1000 µg/mL | Human | Synthetic Cationic Lipopeptides | NA | NA | ||
| 28203232 | 2017 | KGK{nt:X = C14 = Tetradecanoic fatty acid chain}{ct:Amid} | 13 | Amidation | X = C14 = Tetradecanoic fatty acid chain | Linear | L | C14 = Tetradecanoic fatty acid chain | 3 | Antimicrobial | 10 % Hemolysis at 128 µg/mL | Human | Synthetic Cationic Lipopeptides | NA | NA | ||
| 28203232 | 2017 | KGKG{nt:X = C14 = Tetradecanoic fatty acid chain}{ct:Amid} | 14 | Amidation | X = C14 = Tetradecanoic fatty acid chain | Linear | L | C14 = Tetradecanoic fatty acid chain | 4 | Antimicrobial | 10 % Hemolysis at 512 µg/mL | Human | Synthetic Cationic Lipopeptides | NA | NA | ||
| 28203232 | 2017 | K{nt:X = C12 = Dodecanoic fatty acid chain}{ct:Amid} | 15 | Amidation | X = C12 = Dodecanoic fatty acid chain | Linear | L | C12 = Dodecanoic fatty acid chain | 1 | Antimicrobial | 10 % Hemolysis at 1000 µg/mL | Human | Synthetic Cationic Lipopeptides | NA | NA | ||
| 28203232 | 2017 | KK{nt:X = C12 = Dodecanoic fatty acid chain}{ct:Amid} | 16 | Amidation | X = C12 = Dodecanoic fatty acid chain | Linear | L | C12 = Dodecanoic fatty acid chain | 2 | Antimicrobial | 10 % Hemolysis at >4000 µg/mL | Human | Synthetic Cationic Lipopeptides | NA | NA | ||
| 28203232 | 2017 | KKK{nt:X = C12 = Dodecanoic fatty acid chain}{ct:Amid} | 17 | Amidation | X = C12 = Dodecanoic fatty acid chain | Linear | L | C12 = Dodecanoic fatty acid chain | 3 | Antimicrobial | 10 % Hemolysis at 512 µg/mL | Human | Synthetic Cationic Lipopeptides | NA | NA | ||
| 28203232 | 2017 | KKKK{nt:X = C12 = Dodecanoic fatty acid chain}{ct:Amid} | 18 | Amidation | X = C12 = Dodecanoic fatty acid chain | Linear | L | C12 = Dodecanoic fatty acid chain | 4 | Antimicrobial | 10 % Hemolysis at 1000 µg/mL | Human | Synthetic Cationic Lipopeptides | NA | NA | ||
| 28203232 | 2017 | KG{nt:X = C12 = Dodecanoic fatty acid chain}{ct:Amid} | 19 | Amidation | X = C12 = Dodecanoic fatty acid chain | Linear | L | C12 = Dodecanoic fatty acid chain | 2 | Antimicrobial | 10 % Hemolysis at 1000 µg/mL | Human | Synthetic Cationic Lipopeptides | NA | NA | ||
| 28203232 | 2017 | KGK{nt:X = C12 = Dodecanoic fatty acid chain}{ct:Amid} | 20 | Amidation | X = C12 = Dodecanoic fatty acid chain | Linear | L | C12 = Dodecanoic fatty acid chain | 3 | Antimicrobial | 10 % Hemolysis at 1000 µg/mL | Human | Synthetic Cationic Lipopeptides | NA | NA | ||
| 28203232 | 2017 | KGKG{nt:X = C12 = Dodecanoic fatty acid chain}{ct:Amid} | 21 | Amidation | X = C12 = Dodecanoic fatty acid chain | Linear | L | C12 = Dodecanoic fatty acid chain | 4 | Antimicrobial | 10 % Hemolysis at 256 µg/mL | Human | Synthetic Cationic Lipopeptides | NA | NA | ||
| 28203232 | 2017 | K{nt:X = C10 = Decanoic fatty acid chain}{ct:Amid} | 22 | Amidation | X = C10 = Decanoic fatty acid chain | Linear | L | C10 = Decanoic fatty acid chain | 1 | Antimicrobial | 10 % Hemolysis at >4000 µg/mL | Human | Synthetic Cationic Lipopeptides | NA | NA | ||
| 28203232 | 2017 | KK{nt:X = C10 = Decanoic fatty acid chain}{ct:Amid} | 23 | Amidation | X = C10 = Decanoic fatty acid chain | Linear | L | C10 = Decanoic fatty acid chain | 2 | Antimicrobial | 10 % Hemolysis at 4000 µg/mL | Human | Synthetic Cationic Lipopeptides | NA | NA | ||
| 28203232 | 2017 | KKK{nt:X = C10 = Decanoic fatty acid chain}{ct:Amid} | 24 | Amidation | X = C10 = Decanoic fatty acid chain | Linear | L | C10 = Decanoic fatty acid chain | 3 | Antimicrobial | 10 % Hemolysis at >4000 µg/mL | Human | Synthetic Cationic Lipopeptides | NA | NA | ||
| 28203232 | 2017 | KKKK{nt:X = C10 = Decanoic fatty acid chain}{ct:Amid} | 25 | Amidation | X = C10 = Decanoic fatty acid chain | Linear | L | C10 = Decanoic fatty acid chain | 4 | Antimicrobial | 10 % Hemolysis at >4000 µg/mL | Human | Synthetic Cationic Lipopeptides | NA | NA | ||
| 28203232 | 2017 | KG{nt:X = C10 = Decanoic fatty acid chain}{ct:Amid} | 26 | Amidation | X = C10 = Decanoic fatty acid chain | Linear | L | C10 = Decanoic fatty acid chain | 2 | Antimicrobial | 10 % Hemolysis at >4000 µg/mL | Human | Synthetic Cationic Lipopeptides | NA | NA | ||
| 28203232 | 2017 | KGK{nt:X = C10 = Decanoic fatty acid chain}{ct:Amid} | 27 | Amidation | X = C10 = Decanoic fatty acid chain | Linear | L | C10 = Decanoic fatty acid chain | 3 | Antimicrobial | 10 % Hemolysis at >4000 µg/mL | Human | Synthetic Cationic Lipopeptides | NA | NA | ||
| 28203232 | 2017 | KGKG{nt:X = C10 = Decanoic fatty acid chain}{ct:Amid} | 28 | Amidation | X = C10 = Decanoic fatty acid chain | Linear | L | C10 = Decanoic fatty acid chain | 4 | Antimicrobial | 10 % Hemolysis at >4000 µg/mL | Human | Synthetic Cationic Lipopeptides | NA | NA | ||
| 28203232 | 2017 | K{nt:X = C8 = Octanoic fatty acid chain}{ct:Amid} | 29 | Amidation | X = C8 = Octanoic fatty acid chain | Linear | L | C8 = Octanoic fatty acid chain | 1 | Antimicrobial | 10 % Hemolysis at >4000 µg/mL | Human | Synthetic Cationic Lipopeptides | NA | NA | ||
| 28203232 | 2017 | KK{nt:X = C8 = Octanoic fatty acid chain}{ct:Amid} | 30 | Amidation | X = C8 = Octanoic fatty acid chain | Linear | L | C8 = Octanoic fatty acid chain | 2 | Antimicrobial | 10 % Hemolysis at >4000 µg/mL | Human | Synthetic Cationic Lipopeptides | NA | NA | ||
| 28203232 | 2017 | KKK{nt:X = C8 = Octanoic fatty acid chain}{ct:Amid} | 31 | Amidation | X = C8 = Octanoic fatty acid chain | Linear | L | C8 = Octanoic fatty acid chain | 3 | Antimicrobial | 10 % Hemolysis at >4000 µg/mL | Human | Synthetic Cationic Lipopeptides | NA | NA | ||
| 28203232 | 2017 | KKKK{nt:X = C8 = Octanoic fatty acid chain}{ct:Amid} | 32 | Amidation | X = C8 = Octanoic fatty acid chain | Linear | L | C8 = Octanoic fatty acid chain | 4 | Antimicrobial | 10 % Hemolysis at >4000 µg/mL | Human | Synthetic Cationic Lipopeptides | NA | NA | ||
| 28203232 | 2017 | KG{nt:X = C8 = Octanoic fatty acid chain}{ct:Amid} | 33 | Amidation | X = C8 = Octanoic fatty acid chain | Linear | L | C8 = Octanoic fatty acid chain | 2 | Antimicrobial | 10 % Hemolysis at >4000 µg/mL | Human | Synthetic Cationic Lipopeptides | NA | NA | ||
| 28203232 | 2017 | KGK{nt:X = C8 = Octanoic fatty acid chain}{ct:Amid} | 34 | Amidation | X = C8 = Octanoic fatty acid chain | Linear | L | C8 = Octanoic fatty acid chain | 3 | Antimicrobial | 10 % Hemolysis at >4000 µg/mL | Human | Synthetic Cationic Lipopeptides | NA | NA | ||
| 28203232 | 2017 | KGKG{nt:X = C8 = Octanoic fatty acid chain}{ct:Amid} | 35 | Amidation | X = C8 = Octanoic fatty acid chain | Linear | L | C8 = Octanoic fatty acid chain | 4 | Antimicrobial | 10 % Hemolysis at >4000 µg/mL | Human | Synthetic Cationic Lipopeptides | NA | NA | ||
| 28026016 | 2017 | AAA{nnr:Tr-Bn}{cyc:N-C} | BPC458 | Free | Free | Cyclic | L | Tr-Bn = triazole bearing a benzyl group | 3 | Antimicrobial | 2 ± 0.3 % Hemolysis at 150 µM | Horse | Bpc194 Analog | NA | NA | ||
| 28026016 | 2017 | AAA{nnr:Tr-Bn}{cyc:N-C} | BPC458 | Free | Free | Cyclic | L | Tr-Bn = triazole bearing a benzyl group | 3 | Antimicrobial | 3 ± 0.5 % Hemolysis at 250 µM | Horse | Bpc194 Analog | NA | NA | ||
| 28026016 | 2017 | AAA{nnr:Tr-Bn}{cyc:N-C} | BPC458 | Free | Free | Cyclic | L | Tr-Bn = triazole bearing a benzyl group | 3 | Antimicrobial | 5 ± 0.2 % Hemolysis at 375 µM | Horse | Bpc194 Analog | NA | NA | ||
| 28026016 | 2017 | AAA{nnr:Tr-Nle}{cyc:N-C} | BPC460 | Free | Free | Cyclic | L | Tr = unsubsituted triazole, Tr-Nle = triazole bearing a 2-aminohexanoic acid | 3 | Antimicrobial | 0 ± 0.3 % Hemolysis at 150 µM | Horse | Bpc194 Analog | NA | NA | ||
| 28026016 | 2017 | AAA{nnr:Tr-Nle}{cyc:N-C} | BPC460 | Free | Free | Cyclic | L | Tr = unsubsituted triazole, Tr-Nle = triazole bearing a 2-aminohexanoic acid | 3 | Antimicrobial | 0 ± 0.3 % Hemolysis at 250 µM | Horse | Bpc194 Analog | NA | NA | ||
| 28026016 | 2017 | AAA{nnr:Tr-Nle}{cyc:N-C} | BPC460 | Free | Free | Cyclic | L | Tr = unsubsituted triazole, Tr-Nle = triazole bearing a 2-aminohexanoic acid | 3 | Antimicrobial | 0 ± 0.1 % Hemolysis at 375 µM | Horse | Bpc194 Analog | NA | NA | ||
| 28026016 | 2017 | AAA{nnr:TrPhNH2}{cyc:N-C} | BPC518 | Free | Free | Cyclic | L | Tr = unsubsituted triazole, Tr-Ph-NH2 = triazole bearing an aniline moiety | 3 | Antimicrobial | 1 ± 0.1 % Hemolysis at 150 µM | Horse | Bpc194 Analog | NA | NA | ||
| 28026016 | 2017 | AAA{nnr:TrPhNH2}{cyc:N-C} | BPC518 | Free | Free | Cyclic | L | Tr = unsubsituted triazole, Tr-Ph-NH2 = triazole bearing an aniline moiety | 3 | Antimicrobial | 1 ± 0.1 % Hemolysis at 250 µM | Horse | Bpc194 Analog | NA | NA | ||
| 28026016 | 2017 | AAA{nnr:TrPhNH2}{cyc:N-C} | BPC518 | Free | Free | Cyclic | L | Tr = unsubsituted triazole, Tr-Ph-NH2 = triazole bearing an aniline moiety | 3 | Antimicrobial | 1 ± 0.1 % Hemolysis at 375 µM | Horse | Bpc194 Analog | NA | NA | ||
| 28026016 | 2017 | AAA{nnr:TrPhMe}{cyc:N-C} | BPC540 | Free | Free | Cyclic | L | Tr = unsubsituted triazole, Tr-Ph-Me = triazole bearing a tolyl group | 3 | Antimicrobial | 2 ± 0.5 % Hemolysis at 150 µM | Horse | Bpc194 Analog | NA | NA | ||
| 28026016 | 2017 | AAA{nnr:TrPhMe}{cyc:N-C} | BPC540 | Free | Free | Cyclic | L | Tr = unsubsituted triazole, Tr-Ph-Me = triazole bearing a tolyl group | 3 | Antimicrobial | 4 ± 0.4 % Hemolysis at 250 µM | Horse | Bpc194 Analog | NA | NA | ||
| 28026016 | 2017 | AAA{nnr:TrPhMe}{cyc:N-C} | BPC540 | Free | Free | Cyclic | L | Tr = unsubsituted triazole, Tr-Ph-Me = triazole bearing a tolyl group | 3 | Antimicrobial | 6 ± 1 % Hemolysis at 375 µM | Horse | Bpc194 Analog | NA | NA | ||
| 28026016 | 2017 | AAA{nnr:TrPhOMe}{cyc:N-C} | BPC542 | Free | Free | Cyclic | L | Tr = unsubsituted triazole, Tr-PhOMe = triazole bearing an anisole moiety | 3 | Antimicrobial | 1 ± 0.6 % Hemolysis at 150 µM | Horse | Bpc194 Analog | NA | NA | ||
| 28026016 | 2017 | AAA{nnr:TrPhOMe}{cyc:N-C} | BPC542 | Free | Free | Cyclic | L | Tr = unsubsituted triazole, Tr-PhOMe = triazole bearing an anisole moiety | 3 | Antimicrobial | 2 ± 0.2 % Hemolysis at 250 µM | Horse | Bpc194 Analog | NA | NA | ||
| 28026016 | 2017 | AAA{nnr:TrPhOMe}{cyc:N-C} | BPC542 | Free | Free | Cyclic | L | Tr = unsubsituted triazole, Tr-PhOMe = triazole bearing an anisole moiety | 3 | Antimicrobial | 4 ± 0.4 % Hemolysis at 375 µM | Horse | Bpc194 Analog | NA | NA | ||
| 28026016 | 2017 | AAA{nnr:TrPh}{cyc:N-C} | BPC544 | Free | Free | Cyclic | L | Tr = unsubsituted triazole, Tr-Ph = triazole bearing a phenyl group | 3 | Antimicrobial | 1 ± 0.4 % Hemolysis at 150 µM | Horse | Bpc194 Analog | NA | NA | ||
| 28026016 | 2017 | AAA{nnr:TrPh}{cyc:N-C} | BPC544 | Free | Free | Cyclic | L | Tr = unsubsituted triazole, Tr-Ph = triazole bearing a phenyl group | 3 | Antimicrobial | 1 ± 0.3 % Hemolysis at 250 µM | Horse | Bpc194 Analog | NA | NA | ||
| 28026016 | 2017 | AAA{nnr:TrPh}{cyc:N-C} | BPC544 | Free | Free | Cyclic | L | Tr = unsubsituted triazole, Tr-Ph = triazole bearing a phenyl group | 3 | Antimicrobial | 2 ± 0.4 % Hemolysis at 375 µM | Horse | Bpc194 Analog | NA | NA | ||
| 28026016 | 2017 | {nnr:Nle}{nnr:Nle}{nnr:Nle}{nnr:TrPh}{cyc:N-C} | BPC516 | Free | Free | Cyclic | L | Tr = unsubsituted triazole, Tr-Ph = triazole bearing a phenyl group | 3 | Antimicrobial | 5 ± 0.2 % Hemolysis at 150 µM | Horse | Bpc194 Analog | NA | NA | ||
| 28026016 | 2017 | {nnr:Nle}{nnr:Nle}{nnr:Nle}{nnr:TrPh}{cyc:N-C} | BPC516 | Free | Free | Cyclic | L | Tr = unsubsituted triazole, Tr-Ph = triazole bearing a phenyl group | 3 | Antimicrobial | 6 ± 0.4 % Hemolysis at 250 µM | Horse | Bpc194 Analog | NA | NA | ||
| 28026016 | 2017 | {nnr:Nle}{nnr:Nle}{nnr:Nle}{nnr:TrPh}{cyc:N-C} | BPC516 | Free | Free | Cyclic | L | Tr = unsubsituted triazole, Tr-Ph = triazole bearing a phenyl group | 3 | Antimicrobial | 8 ± 0.1 % Hemolysis at 375 µM | Horse | Bpc194 Analog | NA | NA | ||
| 28026016 | 2017 | {nnr:Nle}{nnr:Nle}{nnr:Nle}{nnr:TrPhNH2}{cyc:N-C} | BPC538 | Free | Free | Cyclic | L | Tr = unsubsituted triazole, Tr-Ph-NH2 = triazole bearing an aniline moiety | 3 | Antimicrobial | 1 ± 0.8 % Hemolysis at 150 µM | Horse | Bpc194 Analog | NA | NA | ||
| 28026016 | 2017 | {nnr:Nle}{nnr:Nle}{nnr:Nle}{nnr:TrPhNH2}{cyc:N-C} | BPC538 | Free | Free | Cyclic | L | Tr = unsubsituted triazole, Tr-Ph-NH2 = triazole bearing an aniline moiety | 3 | Antimicrobial | 1 ± 0.4 % Hemolysis at 250 µM | Horse | Bpc194 Analog | NA | NA | ||
| 28026016 | 2017 | {nnr:Nle}{nnr:Nle}{nnr:Nle}{nnr:TrPhNH2}{cyc:N-C} | BPC538 | Free | Free | Cyclic | L | Tr = unsubsituted triazole, Tr-Ph-NH2 = triazole bearing an aniline moiety | 3 | Antimicrobial | 2 ± 0.4 % Hemolysis at 375 µM | Horse | Bpc194 Analog | NA | NA | ||
| 28026016 | 2017 | {nnr:Nle}{nnr:Nle}{nnr:Nle}{nnr:TrPhMe}{cyc:N-C} | BPC548 | Free | Free | Cyclic | L | Tr = unsubsituted triazole, Tr-Ph-Me = triazole bearing a tolyl group | 3 | Antimicrobial | 12 ± 0.3 % Hemolysis at 150 µM | Horse | Bpc194 Analog | NA | NA | ||
| 28026016 | 2017 | {nnr:Nle}{nnr:Nle}{nnr:Nle}{nnr:TrPhMe}{cyc:N-C} | BPC548 | Free | Free | Cyclic | L | Tr = unsubsituted triazole, Tr-Ph-Me = triazole bearing a tolyl group | 3 | Antimicrobial | 24 ± 1 % Hemolysis at 250 µM | Horse | Bpc194 Analog | NA | NA | ||
| 28026016 | 2017 | {nnr:Nle}{nnr:Nle}{nnr:Nle}{nnr:TrPhMe}{cyc:N-C} | BPC548 | Free | Free | Cyclic | L | Tr = unsubsituted triazole, Tr-Ph-Me = triazole bearing a tolyl group | 3 | Antimicrobial | 26 ± 4 % Hemolysis at 375 µM | Horse | Bpc194 Analog | NA | NA | ||
| 28026016 | 2017 | {nnr:Nle}{nnr:Nle}{nnr:Nle}{nnr:TrPhOMe}{cyc:N-C} | BPC550 | Free | Free | Cyclic | L | Tr = unsubsituted triazole, Tr-PhOMe = triazole bearing an anisole moiety | 3 | Antimicrobial | 7 ± 0.8 % Hemolysis at 150 µM | Horse | Bpc194 Analog | NA | NA | ||
| 28026016 | 2017 | {nnr:Nle}{nnr:Nle}{nnr:Nle}{nnr:TrPhOMe}{cyc:N-C} | BPC550 | Free | Free | Cyclic | L | Tr = unsubsituted triazole, Tr-PhOMe = triazole bearing an anisole moiety | 3 | Antimicrobial | 10 ± 0.8 % Hemolysis at 250 µM | Horse | Bpc194 Analog | NA | NA | ||
| 28026016 | 2017 | {nnr:Nle}{nnr:Nle}{nnr:Nle}{nnr:TrPhOMe}{cyc:N-C} | BPC550 | Free | Free | Cyclic | L | Tr = unsubsituted triazole, Tr-PhOMe = triazole bearing an anisole moiety | 3 | Antimicrobial | 19 ± 5 % Hemolysis at 375 µM | Horse | Bpc194 Analog | NA | NA | ||
| 28026016 | 2017 | KKK{nnr:COTr}{cyc:N-C} | BPC692 | Free | Free | Cyclic | L | Tr = unsubsituted triazole | 3 | Antimicrobial | 5 ± 0.7 % Hemolysis at 150 µM | Horse | Bpc194 Analog | NA | NA | ||
| 28026016 | 2017 | KKK{nnr:COTr}{cyc:N-C} | BPC692 | Free | Free | Cyclic | L | Tr = unsubsituted triazole | 3 | Antimicrobial | 5 ± 0.8 % Hemolysis at 250 µM | Horse | Bpc194 Analog | NA | NA | ||
| 28026016 | 2017 | KKK{nnr:COTr}{cyc:N-C} | BPC692 | Free | Free | Cyclic | L | Tr = unsubsituted triazole | 3 | Antimicrobial | 7 ± 0.2 % Hemolysis at 375 µM | Horse | Bpc194 Analog | NA | NA | ||
| 28026016 | 2017 | KKK{nnr:COTrBn}{cyc:N-C} | BPC696 | Free | Free | Cyclic | L | Tr = unsubsituted triazole, Tr-Bn = triazole bearing a benzyl group | 3 | Antimicrobial | 19 ± 4 % Hemolysis at 150 µM | Horse | Bpc194 Analog | NA | NA | ||
| 28026016 | 2017 | KKK{nnr:COTrBn}{cyc:N-C} | BPC696 | Free | Free | Cyclic | L | Tr = unsubsituted triazole, Tr-Bn = triazole bearing a benzyl group | 3 | Antimicrobial | 20 ± 5 % Hemolysis at 250 µM | Horse | Bpc194 Analog | NA | NA | ||
| 28026016 | 2017 | KKK{nnr:COTrBn}{cyc:N-C} | BPC696 | Free | Free | Cyclic | L | Tr = unsubsituted triazole, Tr-Bn = triazole bearing a benzyl group | 3 | Antimicrobial | 30 ± 4 % Hemolysis at 375 µM | Horse | Bpc194 Analog | NA | NA | ||
| 28026016 | 2017 | KKK{nnr:COTrNle}{cyc:N-C} | BPC700 | Free | Free | Cyclic | L | Tr = unsubsituted triazole, Tr-Nle = triazole bearing a 2-aminohexanoic acid | 3 | Antimicrobial | 0 ± 2 % Hemolysis at 150 µM | Horse | Bpc194 Analog | NA | NA | ||
| 28026016 | 2017 | KKK{nnr:COTrNle}{cyc:N-C} | BPC700 | Free | Free | Cyclic | L | Tr = unsubsituted triazole, Tr-Nle = triazole bearing a 2-aminohexanoic acid | 3 | Antimicrobial | 0 ± 0.4 % Hemolysis at 250 µM | Horse | Bpc194 Analog | NA | NA | ||
| 28026016 | 2017 | KKK{nnr:COTrNle}{cyc:N-C} | BPC700 | Free | Free | Cyclic | L | Tr = unsubsituted triazole, Tr-Nle = triazole bearing a 2-aminohexanoic acid | 3 | Antimicrobial | 0 ± 0.1 % Hemolysis at 375 µM | Horse | Bpc194 Analog | NA | NA | ||
| 28026016 | 2017 | AAAAA({nnr:TrBn}{cyc:N-C} | BPC510 | Free | Free | Cyclic | L | Tr = unsubsituted triazole, Tr-Bn = triazole bearing a benzyl group | 5 | Antimicrobial | 32 ± 2 % Hemolysis at 150 µM | Horse | Bpc194 Analog | NA | NA | ||
| 28026016 | 2017 | AAAAA({nnr:TrBn}{cyc:N-C} | BPC510 | Free | Free | Cyclic | L | Tr = unsubsituted triazole, Tr-Bn = triazole bearing a benzyl group | 5 | Antimicrobial | 35 ± 3 % Hemolysis at 250 µM | Horse | Bpc194 Analog | NA | NA | ||
| 28026016 | 2017 | AAAAA({nnr:TrBn}{cyc:N-C} | BPC510 | Free | Free | Cyclic | L | Tr = unsubsituted triazole, Tr-Bn = triazole bearing a benzyl group | 5 | Antimicrobial | 40 ± 4 % Hemolysis at 375 µM | Horse | Bpc194 Analog | NA | NA | ||
| 28026016 | 2017 | AAAAA{nnr:Tr-Nle}{cyc:N-C} | BPC512 | Free | Free | Cyclic | L | Tr = unsubsituted triazole, Tr-Nle = triazole bearing a 2-aminohexanoic acid | 5 | Antimicrobial | 2 ± 0.1 % Hemolysis at 150 µM | Horse | Bpc194 Analog | NA | NA | ||
| 28026016 | 2017 | AAAAA{nnr:Tr-Nle}{cyc:N-C} | BPC512 | Free | Free | Cyclic | L | Tr = unsubsituted triazole, Tr-Nle = triazole bearing a 2-aminohexanoic acid | 5 | Antimicrobial | 2 ± 0.2 % Hemolysis at 250 µM | Horse | Bpc194 Analog | NA | NA | ||
| 28026016 | 2017 | AAAAA{nnr:Tr-Nle}{cyc:N-C} | BPC512 | Free | Free | Cyclic | L | Tr = unsubsituted triazole, Tr-Nle = triazole bearing a 2-aminohexanoic acid | 5 | Antimicrobial | 3 ± 0.4 % Hemolysis at 375 µM | Horse | Bpc194 Analog | NA | NA | ||
| 28026016 | 2017 | AAAAA{nnr:TrPhNH2}{cyc:N-C} | BPC514 | Free | Free | Cyclic | L | Tr = unsubsituted triazole, Tr-Ph-NH2 = triazole bearing an aniline moiety | 5 | Antimicrobial | 16 ± 0.9 % Hemolysis at 150 µM | Horse | Bpc194 Analog | NA | NA | ||
| 28026016 | 2017 | AAAAA{nnr:TrPhNH2}{cyc:N-C} | BPC514 | Free | Free | Cyclic | L | Tr = unsubsituted triazole, Tr-Ph-NH2 = triazole bearing an aniline moiety | 5 | Antimicrobial | 19 ± 0.8 % Hemolysis at 250 µM | Horse | Bpc194 Analog | NA | NA | ||
| 28026016 | 2017 | AAAAA{nnr:TrPhNH2}{cyc:N-C} | BPC514 | Free | Free | Cyclic | L | Tr = unsubsituted triazole, Tr-Ph-NH2 = triazole bearing an aniline moiety | 5 | Antimicrobial | 23 ± 2 % Hemolysis at 375 µM | Horse | Bpc194 Analog | NA | NA | ||
| 28026016 | 2017 | {nnr:Nle}{nnr:Nle}{nnr:Nle}{nnr:Nle}{nnr:Nle}{nnr:TrPh}{cyc:N-C} | BPC562 | Free | Free | Cyclic | L | Tr-Ph = triazole bearing a phenyl group | 5 | Antimicrobial | 42 ± 5 % Hemolysis at 150 µM | Horse | Bpc194 Analog | NA | NA | ||
| 28026016 | 2017 | {nnr:Nle}{nnr:Nle}{nnr:Nle}{nnr:Nle}{nnr:Nle}{nnr:TrPh}{cyc:N-C} | BPC562 | Free | Free | Cyclic | L | Tr-Ph = triazole bearing a phenyl group | 5 | Antimicrobial | 51 ± 3 % Hemolysis at 250 µM | Horse | Bpc194 Analog | NA | NA | ||
| 28026016 | 2017 | {nnr:Nle}{nnr:Nle}{nnr:Nle}{nnr:Nle}{nnr:Nle}{nnr:TrPh}{cyc:N-C} | BPC562 | Free | Free | Cyclic | L | Tr-Ph = triazole bearing a phenyl group | 5 | Antimicrobial | 58 ± 1 % Hemolysis at 375 µM | Horse | Bpc194 Analog | NA | NA | ||
| 28026016 | 2017 | {nnr:Nle}{nnr:Nle}{nnr:Nle}{nnr:Nle}{nnr:Nle}{nnr:TrPhNH2}{cyc:N-C} | BPC572 | Free | Free | Cyclic | L | Tr-Ph-NH2 = triazole bearing an aniline moiety | 5 | Antimicrobial | 8 ± 0.2 % Hemolysis at 150 µM | Horse | Bpc194 Analog | NA | NA | ||
| 28026016 | 2017 | {nnr:Nle}{nnr:Nle}{nnr:Nle}{nnr:Nle}{nnr:Nle}{nnr:TrPhNH2}{cyc:N-C} | BPC572 | Free | Free | Cyclic | L | Tr-Ph-NH2 = triazole bearing an aniline moiety | 5 | Antimicrobial | 13 ± 0.2 % Hemolysis at 250 µM | Horse | Bpc194 Analog | NA | NA | ||
| 28026016 | 2017 | {nnr:Nle}{nnr:Nle}{nnr:Nle}{nnr:Nle}{nnr:Nle}{nnr:TrPhNH2}{cyc:N-C} | BPC572 | Free | Free | Cyclic | L | Tr-Ph-NH2 = triazole bearing an aniline moiety | 5 | Antimicrobial | 25 ± 5 % Hemolysis at 375 µM | Horse | Bpc194 Analog | NA | NA | ||
| 28026016 | 2017 | {nnr:Nle}{nnr:Nle}{nnr:Nle}{nnr:Nle}{nnr:Nle}{nnr:TrPhOMe}{cyc:N-C} | BPC558 | Free | Free | Cyclic | L | Tr-PhOMe = triazole bearing an anisole moiety | 5 | Antimicrobial | 54 ± 4 % Hemolysis at 150 µM | Horse | Bpc194 Analog | NA | NA | ||
| 28026016 | 2017 | {nnr:Nle}{nnr:Nle}{nnr:Nle}{nnr:Nle}{nnr:Nle}{nnr:TrPhOMe}{cyc:N-C} | BPC558 | Free | Free | Cyclic | L | Tr-PhOMe = triazole bearing an anisole moiety | 5 | Antimicrobial | 76 ± 8 % Hemolysis at 250 µM | Horse | Bpc194 Analog | NA | NA | ||
| 28026016 | 2017 | {nnr:Nle}{nnr:Nle}{nnr:Nle}{nnr:Nle}{nnr:Nle}{nnr:TrPhOMe}{cyc:N-C} | BPC558 | Free | Free | Cyclic | L | Tr-PhOMe = triazole bearing an anisole moiety | 5 | Antimicrobial | 90 ± 8 % Hemolysis at 375 µM | Horse | Bpc194 Analog | NA | NA | ||
| 28026016 | 2017 | KKKKK{nnr:COTr}){cyc:N-C} | BPC690 | Free | Free | Cyclic | L | Tr = unsubsituted triazole | 5 | Antimicrobial | 47 ± 7 % Hemolysis at 150 µM | Horse | Bpc194 Analog | NA | NA | ||
| 28026016 | 2017 | KKKKK{nnr:COTr}){cyc:N-C} | BPC690 | Free | Free | Cyclic | L | Tr = unsubsituted triazole | 5 | Antimicrobial | 67 ± 8 % Hemolysis at 250 µM | Horse | Bpc194 Analog | NA | NA | ||
| 28026016 | 2017 | KKKKK{nnr:COTr}){cyc:N-C} | BPC690 | Free | Free | Cyclic | L | Tr = unsubsituted triazole | 5 | Antimicrobial | 75 ± 7 % Hemolysis at 375 µM | Horse | Bpc194 Analog | NA | NA | ||
| 28026016 | 2017 | KKKKK{nnr:COTrBn}{cyc:N-C} | BPC694 | Free | Free | Cyclic | L | Tr-Bn = triazole bearing a benzyl group | 5 | Antimicrobial | 57 ± 5 % Hemolysis at 150 µM | Horse | Bpc194 Analog | NA | NA | ||
| 28026016 | 2017 | KKKKK{nnr:COTrBn}{cyc:N-C} | BPC694 | Free | Free | Cyclic | L | Tr-Bn = triazole bearing a benzyl group | 5 | Antimicrobial | 74 ± 15 % Hemolysis at 250 µM | Horse | Bpc194 Analog | NA | NA | ||
| 28026016 | 2017 | KKKKK{nnr:COTrBn}{cyc:N-C} | BPC694 | Free | Free | Cyclic | L | Tr-Bn = triazole bearing a benzyl group | 5 | Antimicrobial | 93 ± 15 % Hemolysis at 375 µM | Horse | Bpc194 Analog | NA | NA | ||
| 28026016 | 2017 | KKKKK{nnr:COTrNle}{cyc:N-C} | BPC698 | Free | Free | Cyclic | L | Tr-Bn = triazole bearing a benzyl group | 5 | Antimicrobial | 3 ± 0.5 % Hemolysis at 150 µM | Horse | Bpc194 Analog | NA | NA | ||
| 28026016 | 2017 | KKKKK{nnr:COTrNle}{cyc:N-C} | BPC698 | Free | Free | Cyclic | L | Tr-Bn = triazole bearing a benzyl group | 5 | Antimicrobial | 4 ± 1 % Hemolysis at 250 µM | Horse | Bpc194 Analog | NA | NA | ||
| 28026016 | 2017 | KKKKK{nnr:COTrNle}{cyc:N-C} | BPC698 | Free | Free | Cyclic | L | Tr-Bn = triazole bearing a benzyl group | 5 | Antimicrobial | 5 ± 0.7 % Hemolysis at 375 µM | Horse | Bpc194 Analog | NA | NA | ||
| 37867694 | 2023 | RWQWRWQWR | [Pal] | Free | Free | Linear | L | None | 9 | Anticancer | 13.2 % Hemolysis at 200 μg/mL | Human | Bovine Lactoferricin | α-Helical | NA | ||
| 37867694 | 2023 | {nnr:Ahx}RWQWRWQWR | Ahx-[Pal] | Free | Free | Linear | L | Ahx = amino hexanoic acid | 9 | Anticancer | 7.7 % Hemolysis at 200 μg/mL | Human | Synthetic | α-Helical | NA | ||
| 37867694 | 2023 | RWQWRWQW{nnr:O} | 9[Orn] [Pal] | Free | Free | Linear | L | O = L-Ornithine | 8 | Anticancer | 6.6 % Hemolysis at 200 μg/mL | Human | Synthetic | α-Helical | NA | ||
| 37770629 | 2023 | K{nt:myristic — C14}{ct:Amid} | 1M | Amidation | myristic — C14 | Linear | L | C14 = myristic, Me3 = trimethyl | 1 | Antimicrobial | 50 % Hemolysis at 477.61 ± 28.02 μg/mL | Human | Ultrashort Cationic Lipopeptides (Uscls) | NA | NA | ||
| 37770629 | 2023 | KK{nt:myristic — C14}{ct:Amid} | 2M | Amidation | myristic — C14 | Linear | L | C14 = myristic | 2 | Antimicrobial | 50 % Hemolysis at 345.21 ± 12.80 μg/mL | Human | Ultrashort Cationic Lipopeptides (Uscls) | NA | NA | ||
| 37770629 | 2023 | KKK{nt:myristic — C14}{ct:Amid} | 3M | Amidation | myristic — C14 | Linear | L | C14 = myristic | 3 | Antimicrobial | 50 % Hemolysis at >512 μg/mL | Human | Ultrashort Cationic Lipopeptides (Uscls) | NA | NA | ||
| 37770629 | 2023 | KKKK{nt:myristic — C14}{ct:Amid} | 4M | Amidation | myristic — C14 | Linear | L | C14 = myristic | 4 | Antimicrobial | 50 % Hemolysis at >512 μg/mL | Human | Ultrashort Cationic Lipopeptides (Uscls) | NA | NA | ||
| 37770629 | 2023 | K{nt:palmitic — C16}{ct:Amid} | 1P | Amidation | palmitic — C16 | Linear | L | C16 = palmitic | 1 | Antimicrobial | 50 % Hemolysis at >512 μg/mL | Human | Ultrashort Cationic Lipopeptides (Uscls) | NA | NA | ||
| 37770629 | 2023 | KK{nt:palmitic — C16}{ct:Amid} | 2P | Amidation | palmitic — C16 | Linear | L | C16 = palmitic | 2 | Antimicrobial | 50 % Hemolysis at 55.21 ± 1.69 μg/mL | Human | Ultrashort Cationic Lipopeptides (Uscls) | NA | NA | ||
| 37770629 | 2023 | KKK{nt:palmitic — C16}{ct:Amid} | 3P | Amidation | palmitic — C16 | Linear | L | C16 = palmitic | 3 | Antimicrobial | 50 % Hemolysis at 135.46 ± 8.69 μg/mL | Human | Ultrashort Cationic Lipopeptides (Uscls) | NA | NA | ||
| 37770629 | 2023 | KKKK{nt:palmitic — C16}{ct:Amid} | 4P | Amidation | palmitic — C16 | Linear | L | C16 = palmitic | 4 | Antimicrobial | 50 % Hemolysis at >512 μg/mL | Human | Ultrashort Cationic Lipopeptides (Uscls) | NA | NA | ||
| 37770629 | 2023 | K{nt:stearic — C18}{ct:Amid} | 1S | Amidation | stearic — C18 | Linear | L | C18 = stearic | 1 | Antimicrobial | 50 % Hemolysis at >512 μg/mL | Human | Ultrashort Cationic Lipopeptides (Uscls) | NA | NA | ||
| 37770629 | 2023 | KK{nt:stearic — C18}{ct:Amid} | 2S | Amidation | stearic — C18 | Linear | L | C18 = stearic | 2 | Antimicrobial | 50 % Hemolysis at 21.88 ± 0.68 μg/mL | Human | Ultrashort Cationic Lipopeptides (Uscls) | NA | NA | ||
| 37770629 | 2023 | KKK{nt:stearic — C18}{ct:Amid} | 3S | Amidation | stearic — C18 | Linear | L | C18 = stearic | 3 | Antimicrobial | 50 % Hemolysis at 32.11 ± 1.54 μg/mL | Human | Ultrashort Cationic Lipopeptides (Uscls) | NA | NA | ||
| 37770629 | 2023 | KKKK{nt:stearic — C18}{ct:Amid} | 4S | Amidation | stearic — C18 | Linear | L | C18 = stearic, Me3 = trimethyl | 4 | Antimicrobial | 50 % Hemolysis at 48.44 ± 4.12 μg/mL | Human | Ultrashort Cationic Lipopeptides (Uscls) | NA | NA | ||
| 37770629 | 2023 | {nnr:C14}K({nnr:Me3}){nt:myristic — C14}{ct:Amid} | 1Mq | Amidation | myristic — C14 | Linear | L | C14 = myristic, Me3 = trimethyl | 1 | Antimicrobial | 50 % Hemolysis at 88.25 ± 1.57 μg/mL | Human | Ultrashort Cationic Lipopeptides (Uscls) | NA | NA | ||
| 37770629 | 2023 | {nnr:C14}K({nnr:Me3})K({nnr:Me3}){nt:myristic — C14}{ct:Amid} | 2Mq | Amidation | myristic — C14 | Linear | L | C14 = myristic, Me3 = trimethyl | 2 | Antimicrobial | 50 % Hemolysis at >512 μg/mL | Human | Ultrashort Cationic Lipopeptides (Uscls) | NA | NA | ||
| 37770629 | 2023 | {nnr:C14}K({nnr:Me3})K({nnr:Me3})K({nnr:Me3}){nt:myristic — C14}{ct:Amid} | 3Mq | Amidation | myristic — C14 | Linear | L | C14 = myristic, Me3 = trimethyl | 3 | Antimicrobial | 50 % Hemolysis at >512 μg/mL | Human | Ultrashort Cationic Lipopeptides (Uscls) | NA | NA | ||
| 37770629 | 2023 | {nnr:C14}K({nnr:Me3})K({nnr:Me3})K({nnr:Me3})K({nnr:Me3}){nt:myristic — C14}{ct:Amid} | 4Mq | Amidation | myristic — C14 | Linear | L | C14 = myristic, Me3 = trimethyl | 4 | Antimicrobial | 50 % Hemolysis at >512 μg/mL | Human | Ultrashort Cationic Lipopeptides (Uscls) | NA | NA | ||
| 37770629 | 2023 | {nnr:C16}K({nnr:Me3}){nt:palmitic — C16}{ct:Amid} | 1Pq | Amidation | palmitic — C16 | Linear | L | C16 = palmitic, Me3 = trimethyl | 1 | Antimicrobial | 50 % Hemolysis at 32.21 ± 1.97 μg/mL | Human | Ultrashort Cationic Lipopeptides (Uscls) | NA | NA | ||
| 37770629 | 2023 | {nnr:C16}K({nnr:Me3})K({nnr:Me3}){nt:palmitic — C16}{ct:Amid} | 2Pq | Amidation | palmitic — C16 | Linear | L | C16 = palmitic, Me3 = trimethyl | 2 | Antimicrobial | 50 % Hemolysis at 133.32 ± 6.27 μg/mL | Human | Ultrashort Cationic Lipopeptides (Uscls) | NA | NA | ||
| 37770629 | 2023 | {nnr:C16}K({nnr:Me3})K({nnr:Me3})K({nnr:Me3}){nt:palmitic — C16}{ct:Amid} | 3Pq | Amidation | palmitic — C16 | Linear | L | C16 = palmitic, Me3 = trimethyl | 3 | Antimicrobial | 50 % Hemolysis at >512 μg/mL | Human | Ultrashort Cationic Lipopeptides (Uscls) | NA | NA | ||
| 37770629 | 2023 | {nnr:C16}K({nnr:Me3})K({nnr:Me3})K({nnr:Me3})K({nnr:Me3}){nt:palmitic — C16}{ct:Amid} | 4Pq | Amidation | palmitic — C16 | Linear | L | C16 = palmitic, Me3 = trimethyl | 4 | Antimicrobial | 50 % Hemolysis at >512 μg/mL | Human | Ultrashort Cationic Lipopeptides (Uscls) | NA | NA | ||
| 37770629 | 2023 | {nnr:C18}K({nnr:Me3}){nt:stearic — C18}{ct:Amid} | 1Sq | Amidation | stearic — C18 | Linear | L | C18 = stearic, Me3 = trimethyl | 1 | Antimicrobial | 50 % Hemolysis at 16.13 ± 9.88 μg/mL | Human | Ultrashort Cationic Lipopeptides (Uscls) | NA | NA | ||
| 37770629 | 2023 | {nnr:C18}K({nnr:Me3})K({nnr:Me3}){nt:stearic — C18}{ct:Amid} | 2Sq | Amidation | stearic — C18 | Linear | L | C18 = stearic, Me3 = trimethyl | 2 | Antimicrobial | 50 % Hemolysis at 22.42 ± 0.98 μg/mL | Human | Ultrashort Cationic Lipopeptides (Uscls) | NA | NA | ||
| 37770629 | 2023 | {nnr:C18}K({nnr:Me3})K({nnr:Me3})K({nnr:Me3}){nt:stearic — C18}{ct:Amid} | 3Sq | Amidation | stearic — C18 | Linear | L | C18 = stearic, Me3 = trimethyl | 3 | Antimicrobial | 50 % Hemolysis at 385.50 ± 71.51 μg/mL | Human | Ultrashort Cationic Lipopeptides (Uscls) | NA | NA | ||
| 37770629 | 2023 | {nnr:C18}K({nnr:Me3})K({nnr:Me3})K({nnr:Me3})K({nnr:Me3}){nt:stearic — C18}{ct:Amid} | 4Sq | Amidation | stearic — C18 | Linear | L | C18 = stearic, Me3 = trimethyl | 4 | Antimicrobial | 50 % Hemolysis at >512 μg/mL | Human | Ultrashort Cationic Lipopeptides (Uscls) | NA | NA | ||
| 38663759 | 2024 | RRRW-{nnr:Dip}-{nnr:Dip}{cyc:N-C} | 1a | Free | Free | Cyclic | L | Dip = 3,3-diphenyl-L-alanine | 4 | Antimicrobial | 50 % Hemolysis at 50 μg/mL | Human | Synthetic | NA | NA | ||
| 38663759 | 2024 | RRR-{nnr:Dip}-W-{nnr:Dip}{cyc:N-C} | 1b | Free | Free | Cyclic | L | Dip = 3,3-diphenyl-L-alanine | 4 | Antimicrobial | 50 % Hemolysis at 75 μg/mL | Human | Synthetic | NA | NA | ||
| 38663759 | 2024 | RRR-{nnr:Dip}-{nnr:Dip}-W{cyc:N-C} | 1c | Free | Free | Cyclic | L | Dip = 3,3-diphenyl-L-alanine | 4 | Antimicrobial | 50 % Hemolysis at 65 μg/mL | Human | Synthetic | NA | NA | ||
| 38663759 | 2024 | RRRW-{nnr:Nal}-{nnr:Nal}{cyc:N-C} | 2a | Free | Free | Cyclic | L | Nal = 3-(2-naphthyl)-L-alanine | 4 | Antimicrobial | 50 % Hemolysis at 60 μg/mL | Human | Synthetic | NA | NA | ||
| 38663759 | 2024 | RRR-{nnr:Nal}-W-{nnr:Nal}{cyc:N-C} | 2b | Free | Free | Cyclic | L | Nal = 3-(2-naphthyl)-L-alanine | 4 | Antimicrobial | 50 % Hemolysis at 55 μg/mL | Human | Synthetic | NA | NA | ||
| 38663759 | 2024 | RRR-{nnr:Nal}-{nnr:Nal}-W{cyc:N-C} | 2c | Free | Free | Cyclic | L | Nal = 3-(2-naphthyl)-L-alanine | 4 | Antimicrobial | 50 % Hemolysis at 45 μg/mL | Human | Synthetic | NA | NA | ||
| 38663759 | 2024 | RRRRW-{nnr:Dip}-{nnr:Dip}{cyc:N-C} | 3a | Free | Free | Cyclic | L | Dip = 3,3-diphenyl-L-alanine | 5 | Antimicrobial | 50 % Hemolysis at 85 μg/mL | Human | Synthetic | NA | NA | ||
| 38663759 | 2024 | RRRR-{nnr:Dip}-W-{nnr:Dip}{cyc:N-C} | 3b | Free | Free | Cyclic | L | Dip = 3,3-diphenyl-L-alanine | 5 | Antimicrobial | 50 % Hemolysis at 230 μg/mL | Human | Synthetic | NA | NA | ||
| 38663759 | 2024 | RRRR-{nnr:Dip}-{nnr:Dip}-W{cyc:N-C} | 3c | Free | Free | Cyclic | L | Dip = 3,3-diphenyl-L-alanine | 5 | Antimicrobial | 50 % Hemolysis at 100 μg/mL | Human | Synthetic | NA | NA | ||
| 38663759 | 2024 | RRRRW-{nnr:Nal}-{nnr:Nal}{cyc:N-C} | 4a | Free | Free | Cyclic | L | Nal = 3-(2-naphthyl)-L-alanine | 5 | Antimicrobial | 50 % Hemolysis at 150 μg/mL | Human | Synthetic | NA | NA | ||
| 38663759 | 2024 | RRRR-{nnr:Nal}-W-{nnr:Nal}{cyc:N-C} | 4b | Free | Free | Cyclic | L | Nal = 3-(2-naphthyl)-L-alanine | 5 | Antimicrobial | 50 % Hemolysis at 175 μg/mL | Human | Synthetic | NA | NA | ||
| 38663759 | 2024 | RRRR-{nnr:Nal}-{nnr:Nal}-W{cyc:N-C} | 4c | Free | Free | Cyclic | L | Nal = 3-(2-naphthyl)-L-alanine | 5 | Antimicrobial | 50 % Hemolysis at 105 μg/mL | Human | Synthetic | NA | NA | ||
| 38663759 | 2024 | RRRRW-{nnr:Dip}-W{cyc:N-C} | 5a | Free | Free | Cyclic | L | Dip = 3,3-diphenyl-L-alanine | 6 | Antimicrobial | 50 % Hemolysis at 220 μg/mL | Human | Synthetic | NA | NA | ||
| 38663759 | 2024 | RRRRW-{nnr:Nal}-W{cyc:N-C} | 5b | Free | Free | Cyclic | L | Nal = 3-(2-naphthyl)-L-alanine | 6 | Antimicrobial | 50 % Hemolysis at 200 μg/mL | Human | Synthetic | NA | NA | ||
| 38663759 | 2024 | RRRR-{nnr:Dip}-L-{nnr:Dip}{cyc:N-C} | 6a | Free | Free | Cyclic | L | Dip = 3,3-diphenyl-L-alanine | 5 | Antimicrobial | 50 % Hemolysis at 155 μg/mL | Human | Synthetic | NA | NA | ||
| 38663759 | 2024 | RRRR-{nnr:Nal}-L-{nnr:Nal}{cyc:N-C} | 6b | Free | Free | Cyclic | L | Nal = 3-(2-naphthyl)-L-alanine | 5 | Antimicrobial | 50 % Hemolysis at 170 μg/mL | Human | Synthetic | NA | NA | ||
| 38663759 | 2024 | {nnr:Agp}-{nnr:Agp}-{nnr:Agp}-{nnr:Agp}-{nnr:Dip}-W-{nnr:Dip}{cyc:N-C} | 7a | Free | Free | Cyclic | L | Dip = 3,3-diphenyl-L-alanine, Agp = (S)−2-amino-3-guanidinopropionic acid | 1 | Antimicrobial | 50 % Hemolysis at 240 μg/mL | Human | Synthetic | NA | NA | ||
| 38663759 | 2024 | {nnr:Agb}-{nnr:Agb}-{nnr:Agb}-{nnr:Agb}-{nnr:Dip}-W-{nnr:Dip}{cyc:N-C} | 7b | Free | Free | Cyclic | L | Dip = 3,3-diphenyl-L-alanine, Agb = (S)−2-amino-4-guanidinobutyric acid | 1 | Antimicrobial | 50 % Hemolysis at 190 μg/mL | Human | Synthetic | NA | NA | ||
| 38663759 | 2024 | {nnr:hArg}R{nnr:hArg}R{nnr:Dip}W{nnr:Dip}{cyc:N-C} | 7c | Free | Free | Cyclic | L | Dip = 3,3-diphenyl-L-alanine, hArg = homo-arginine (S)−2-amino-6-guanidino-hexanoic acid | 7 | Antimicrobial | 50 % Hemolysis at 160 μg/mL | Human | Synthetic | NA | NA | ||
| 38663759 | 2024 | RRRR-{nnr:Dip}-{nnr:Dip}-{nnr:Dip}{cyc:N-C} | 8a | Free | Free | Cyclic | L | Dip = 3,3-diphenyl-L-alanine | 4 | Antimicrobial | 50 % Hemolysis at 70 μg/mL | Human | Synthetic | NA | NA | ||
| 38663759 | 2024 | RRRR-{nnr:Nal}-{nnr:Nal}-{nnr:Nal}{cyc:N-C} | 8b | Free | Free | Cyclic | L | Nal = 3-(2-naphthyl)-L-alanine | 4 | Antimicrobial | 50 % Hemolysis at 80 μg/mL | Human | Synthetic | NA | NA | ||
| 38467553 | 2024 | {nnr:GA}-YYLK{ct:Amid} | AB-10 | Amidation | Free | Linear | L | GA = gallic acid | 6 | Antioxidant (Antiradical) | 0 % Hemolysis at 1000 μg/mL | Human | Synthetic | NA | Non-hemolytic | ||
| 38467553 | 2024 | {nnr:GA}-YYLK{ct:Amid} | AB-10 | Amidation | Free | Linear | L | GA = gallic acid | 6 | Antioxidant (Antiradical) | 0 % Hemolysis at 500 μg/mL | Human | Synthetic | NA | Non-hemolytic | ||
| 38467553 | 2024 | {nnr:GA}-YYLK{ct:Amid} | AB-10 | Amidation | Free | Linear | L | GA = gallic acid | 6 | Antioxidant (Antiradical) | 0 % Hemolysis at 100 μg/mL | Human | Synthetic | NA | Non-hemolytic | ||
| 38467553 | 2024 | ({nnr:GA}-KKIRRLK){ct:Amid} | AB-11 | Amidation | Free | Linear | L | GA = gallic acid | 9 | Antioxidant (Antiradical) | <10 % Hemolysis at 1000 μg/mL | Human | Synthetic | NA | NA | ||
| 38467553 | 2024 | ({nnr:GA}-KKIRRLK){ct:Amid} | AB-11 | Amidation | Free | Linear | L | GA = gallic acid | 9 | Antioxidant (Antiradical) | <10 % Hemolysis at 500 μg/mL | Human | Synthetic | NA | NA | ||
| 38467553 | 2024 | ({nnr:GA}-KKIRRLK){ct:Amid} | AB-11 | Amidation | Free | Linear | L | GA = gallic acid | 9 | Antioxidant (Antiradical) | 0 % Hemolysis at 100 μg/mL | Human | Synthetic | NA | Non-hemolytic | ||
| 38467553 | 2024 | {nnr:GA}-KK{ct:Amid} | AST-1 | Amidation | Free | Linear | L | GA = gallic acid | 4 | Antioxidant (Antiradical) | 0 % Hemolysis at 1000 μg/mL | Human | Synthetic | NA | Non-hemolytic | ||
| 38467553 | 2024 | {nnr:GA}-KK{ct:Amid} | AST-1 | Amidation | Free | Linear | L | GA = gallic acid | 4 | Antioxidant (Antiradical) | 0 % Hemolysis at 500 μg/mL | Human | Synthetic | NA | Non-hemolytic | ||
| 38467553 | 2024 | {nnr:GA}-KK{ct:Amid} | AST-1 | Amidation | Free | Linear | L | GA = gallic acid | 4 | Antioxidant (Antiradical) | 0 % Hemolysis at 100 μg/mL | Human | Synthetic | NA | Non-hemolytic | ||
| 38755634 | 2024 | FLVKLIL{ct:Amid} | BiF | Amidation | Free | Linear | L | None | 7 | Antimicrobial, Antibiofilm | 10 % Hemolysis at 15.63 μg/mL | Human | Synthetic | α-Helical | NA | ||
| 37946110 | 2024 | WFKIIKK | AurH1 | Free | Free | Linear | L | None | 7 | Antifungal | <5 % Hemolysis at 1000 μg/mL | Human | Aurein1.2 | NA | NA | ||
| 37946110 | 2024 | WFKIIKK{nt:Acet} | Ac-AurH1 | Free | Acetylation | Linear | L | None | 7 | Antifungal | <5 % Hemolysis at 1000 μg/mL | Human | Form Of Aurh1 | NA | NA | ||
| 37946110 | 2024 | WFKIIKK{ct:Amid} | AurH1-NH2 | Amidation | Free | Linear | L | None | 7 | Antifungal | <5 % Hemolysis at 1000 μg/mL | Human | Form Of Aurh1 | NA | NA | ||
| 37946110 | 2024 | WFKIIKK | AurH1 | Free | Free | Linear | L | None | 7 | Antifungal | 50 % Hemolysis at 13484 μg/mL | Human | Aurein1.2 | NA | NA | ||
| 37946110 | 2024 | WFKIIKK{nt:Acet} | Ac-AurH1 | Free | Acetylation | Linear | L | None | 7 | Antifungal | 50 % Hemolysis at 10127 μg/mL | Human | Form Of Aurh1 | NA | NA | ||
| 37946110 | 2024 | WFKIIKK{ct:Amid} | AurH1-NH2 | Amidation | Free | Linear | L | None | 7 | Antifungal | 50 % Hemolysis at 14246 μg/mL | Human | Form Of Aurh1 | NA | NA | ||
| 29077406 | 2017 | {nnr:D-Hot═Tap}-V-{nnr:O}-L-F{d}-P-V-{nnr:O}-L{cyc:N-C} | dimethylketal modified GS analogue | Free | Free | Cyclic | Mix | O = Ornithine, Dyp = cis-dihydroxyproline, D-Hot═Tap = D-Hot═Tap, f = D-Phenylalanine | 9 | Antimicrobial | 90 % Hemolysis at >200 μg/mL | Human | Dihydroxylated Dipeptide D-Hot═Tap (D-Hydroxythreonine═Thiaproline With The “═” Representing The Two Covalent Ring Connections) | twisted β-Sheet structure | NA | ||
| 29196622 | 2017 | {nnr:Ntridec}-({nnr:NLys}-{nnr:Nspe}-{nnr:Nspe}-{nnr:NLys}){nt:H}{ct:Amid} | peptoid 1-C134mer | Amidation | H | Linear | L | Nlys = N-(4-aminobutyl)glycine, Nspe = N-(S)-(1-phenylethyl)glycine, Ntridec = N-(tridecyl)glycine | 4 | Antimicrobial | 10 % Hemolysis at 65 μM | Human | Synthetic | NA | NA | ||
| 29196622 | 2017 | {nnr:Ntridec}-({nnr:NLys}-{nnr:Nspe}-{nnr:Nspe}-{nnr:NLys}){nt:H}{ct:Amid} | peptoid 1-C134mer | Amidation | H | Linear | L | Nlys = N-(4-aminobutyl)glycine, Nspe = N-(S)-(1-phenylethyl)glycine, Ntridec = N-(tridecyl)glycine | 4 | Antimicrobial | 50 % Hemolysis at >200 μM | Human | Synthetic | NA | NA | ||
| 29210028 | 2017 | RVMFKWA | a | Free | Free | Linear | L | None | 7 | Antimicrobial peptides | 12.63 % Hemolysis at 256 μg/ml | mouse | Yak Milk | NA | NA | ||
| 29210028 | 2017 | KVISMI | b | Free | Free | Linear | L | None | 6 | Antimicrobial peptides | 20.81 % Hemolysis at 256 μg/ml | mouse | Yak Milk | NA | NA | ||
| 29136469 | 2017 | {nnr:Dab}I{nnr:Dab}F{d}L{nnr:Dab}V{d}LS{nt:R1}{ct:Amid} | C6-Pat | Amidation | R1 = hexanoyl | Linear | Mix | R1 = hexanoyl, Dab = 2,4-diaminobutyric acid | 9 | Antibacterial | 0.61 ± 0.25 % Hemolysis at 128 μg/ml | Rabbit | Synthetic Paenipeptins Analogues | NA | NA | ||
| 29136469 | 2017 | {nnr:Dab}V{nnr:Dab}F{d}L{nnr:Dab}V{d}LS{nt:R2}{ct:Amid} | C7Val2-Pat | Amidation | R2 = heptanoyl | Linear | Mix | R2 = heptanoyl, Dab = 2,4-diaminobutyric acid | 9 | ND = not detected | 0.95 ± 0.45 % Hemolysis at 128 μg/ml | Rabbit | Synthetic Paenipeptins Analogues | NA | NA | ||
| 29136469 | 2017 | {nnr:Dab}I{nnr:Dab}F{d}L{nnr:Dab}V{d}LS{nt:R2}{ct:Amid} | C7-Pat | Amidation | R2 = heptanoyl | Linear | Mix | R2 = heptanoyl, Dab = 2,4-diaminobutyric acid | 9 | Antibacterial | 1.77 ± 0.81 % Hemolysis at 128 μg/ml | Rabbit | Synthetic Paenipeptins Analogues | NA | NA | ||
| 29136469 | 2017 | {nnr:Dab}F{nnr:Dab}F{d}L{nnr:Dab}V{d}LS{nt:R2}{ct:Amid} | C7Phe2-Pat | Amidation | R2 = heptanoyl | Linear | Mix | R2 = heptanoyl, Dab = 2,4-diaminobutyric acid | 9 | ND = not detected | 1.28 ± 1.65 % Hemolysis at 128 μg/ml | Rabbit | Synthetic Paenipeptins Analogues | NA | NA | ||
| 29136469 | 2017 | {nnr:Dab}I{nnr:Dab}F{d}L{nnr:Dab}L{d}LS{nt:R2}{ct:Amid} | C7DLeu7-Pat | Amidation | R2 = heptanoyl | Linear | Mix | R2 = heptanoyl, Dab = 2,4-diaminobutyric acid | 9 | Antibacterial | 26.5 ± 4.45 % Hemolysis at 128 μg/ml | Rabbit | Synthetic Paenipeptins Analogues | NA | NA | ||
| 29136469 | 2017 | {nnr:Dab}F{nnr:Dab}F{d}L{nnr:Dab}L{d}LS{nt:R2}{ct:Amid} | C7Phe2DLeu7-Pat | Amidation | R2 = heptanoyl | Linear | Mix | R2 = heptanoyl, Dab = 2,4-diaminobutyric acid | 9 | Antibacterial | 8.34 ± 1.80 % Hemolysis at 128 μg/ml | Rabbit | Synthetic Paenipeptins Analogues | NA | Low hemolytic | ||
| 29136469 | 2017 | {nnr:Dab}F{nnr:Dab}F{d}L{nnr:Dab}L{d}FS{nt:R2}{ct:Amid} | C7Phe2DLeu7Phe8-Pat | Amidation | R2 = heptanoyl | Linear | Mix | R2 = heptanoyl, Dab = 2,4-diaminobutyric acid | 9 | Antibacterial | 64.2 ± 3.28 % Hemolysis at 128 μg/ml | Rabbit | Synthetic Paenipeptins Analogues | NA | NA | ||
| 29136469 | 2017 | {nnr:Dab}I{nnr:Dab}F{d}L{nnr:Dab}V{d}LS{nt:R3}{ct:Amid} | C8-Pat | Amidation | R3 = octanoyl | Linear | Mix | R3 = octanoyl, Dab = 2,4-diaminobutyric acid | 9 | Antibacterial | 25.3 ± 4.15 % Hemolysis at 128 μg/ml | Rabbit | Synthetic Paenipeptins Analogues | NA | NA | ||
| 29136469 | 2017 | {nnr:Dab}I{nnr:Dab}F{d}L{nnr:Dab}V{d}L{nnr:Dab}{nt:R3}{ct:Amid} | Dab9-Pat | Amidation | R3 = octanoyl | Linear | Mix | R3 = octanoyl, Dab = 2,4-diaminobutyric acid | 9 | ND = not detected | 2.25 ± 2.18 % Hemolysis at 128 μg/ml | Rabbit | Synthetic Paenipeptins Analogues | NA | NA | ||
| 29136469 | 2017 | {nnr:Dab}{nnr:Dab}{nnr:Dab}F{d}L{nnr:Dab}V{d}L{nnr:Dab}{nt:R3}{ct:Amid} | Dab2,9-Pat | Amidation | R3 = octanoyl | Linear | Mix | R3 = octanoyl, Dab = 2,4-diaminobutyric acid | 9 | ND = not detected | 0.80 ± 0.40 % Hemolysis at 128 μg/ml | Rabbit | Synthetic Paenipeptins Analogues | NA | Low hemolytic | ||
| 29136469 | 2017 | {nnr:O}I{nnr:O}F{d}L{nnr:O}V{d}LS{nt:R3}{ct:Amid} | Orn-Pat | Amidation | R3 = octanoyl | Linear | Mix | R3 = octanoyl, Orn = Ornithine | 9 | ND = not detected | 1.12 ± 0.47 % Hemolysis at 128 μg/ml | Rabbit | Synthetic Paenipeptins Analogues | NA | Low hemolytic | ||
| 29136469 | 2017 | {nnr:Dab}I{nnr:Dab}F{d}L{nnr:Dab}V{d}LS{nt:R4}{ct:Amid} | C10-Pat | Amidation | R4 = decanoyl | Linear | Mix | R4 = decanoyl, Dab = 2,4-diaminobutyric acid | 9 | Antibacterial | 93.9 ± 7.57 % Hemolysis at 128 μg/ml | Rabbit | Synthetic Paenipeptins Analogues | NA | NA | ||
| 29136469 | 2017 | {nnr:Dab}ITL{d}L{nnr:Dab}V{d}LS{nt:R4}{ct:Amid} | C10Thr3Leu4-Pat | Amidation | R4 = decanoyl | Linear | Mix | R4 = decanoyl, Dab = 2,4-diaminobutyric acid | 9 | ND = not detected | 24.9 ± 2.71 % Hemolysis at 128 μg/ml | Rabbit | Synthetic Paenipeptins Analogues | NA | NA | ||
| 29136469 | 2017 | {nnr:Dab}I{nnr:Dab}F{d}L{nnr:Dab}V{d}LS{nt:R5}{ct:Amid} | Benzoyl-Pat | Amidation | R5 = benzoyl | Linear | Mix | R5 = benzoyl, Dab = 2,4-diaminobutyric acid | 9 | Antimicrobial | 0.70 ± 0.34 % Hemolysis at 128 μg/ml | Rabbit | Synthetic Paenipeptins Analogues | NA | Low hemolytic | ||
| 29136469 | 2017 | {nnr:Dab}I{nnr:Dab}F{d}L{nnr:Dab}V{d}LS{nt:R6}{ct:Amid} | Cbz-Pat | Amidation | R6 = benzyloxycarbonyl | Linear | Mix | R6 = benzyloxycarbonyl, Dab = 2,4-diaminobutyric acid | 9 | Antimicrobial | 0.65 ± 0.29 % Hemolysis at 128 μg/ml | Rabbit | Synthetic Paenipeptins Analogues | NA | Low hemolytic | ||
| 29136469 | 2017 | {nnr:Dab}I{nnr:Dab}F{d}L{nnr:Dab}V{d}LS{nt:R7}{ct:Amid} | Cha-Pat | Amidation | R7 = 3-cyclohexylalanyl | Linear | Mix | R7 = 3-cyclohexylalanyl, Dab = 2,4-diaminobutyric acid | 9 | Antimicrobial | 1.63 ± 0.40 % Hemolysis at 128 μg/ml | Rabbit | Synthetic Paenipeptins Analogues | NA | Low hemolytic | ||
| 29136469 | 2017 | {nnr:Dab}F{nnr:Dab}F{d}L{nnr:Dab}L{d}FS{nt:R7}{ct:Amid} | ChaPhe2DLeu7Phe8-Pat | Amidation | R7 = 3-cyclohexylalanyl | Linear | Mix | R7 = 3-cyclohexylalanyl, Dab = 2,4-diaminobutyric acid | 9 | Antimicrobial | 34.6 ± 0.91 % Hemolysis at 128 μg/ml | Rabbit | Synthetic Paenipeptins Analogues | NA | NA | ||
| 29136469 | 2017 | {nnr:Dab}I{nnr:Dab}F{d}L{nnr:Dab}V{d}LS{nt:R1 = hexanoyl}{ct:{nt:R4}{ct:Amid}} | C6-Pat | Amidation | R1 = hexanoyl | Linear | Mix | R1 = hexanoyl, Dab = 2,4-diaminobutyric acid | 9 | Antibacterial | 0.08 ± 0.85 % Hemolysis at 64 μg/ml | Rabbit | Synthetic Paenipeptins Analogues | NA | Low hemolytic | ||
| 29136469 | 2017 | {nnr:Dab}V{nnr:Dab}F{d}L{nnr:Dab}V{d}LS{nt:R2 = heptanoyl}{ct:Amid} | C7Val2-Pat | Amidation | R2 = heptanoyl | Linear | Mix | R2 = heptanoyl, Dab = 2,4-diaminobutyric acid | 9 | ND = not detected | 0.79 ± 0.63 % Hemolysis at 64 μg/ml | Rabbit | Synthetic Paenipeptins Analogues | NA | Low hemolytic | ||
| 29136469 | 2017 | {nnr:Dab}I{nnr:Dab}F{d}L{nnr:Dab}V{d}LS{nt:R2 = heptanoyl}{ct:Amid} | C7-Pat | Amidation | R2 = heptanoyl | Linear | Mix | R2 = heptanoyl, Dab = 2,4-diaminobutyric acid | 9 | Antibacterial | 1.18 ± 0.68 % Hemolysis at 64 μg/ml | Rabbit | Synthetic Paenipeptins Analogues | NA | Low hemolytic | ||
| 29136469 | 2017 | {nnr:Dab}F{nnr:Dab}F{d}L{nnr:Dab}V{d}LS{nt:R2 = heptanoyl}{ct:Amid} | C7Phe2-Pat | Amidation | R2 = heptanoyl | Linear | Mix | R2 = heptanoyl, Dab = 2,4-diaminobutyric acid | 9 | ND = not detected | 0.60 ± 1.35 % Hemolysis at 64 μg/ml | Rabbit | Synthetic Paenipeptins Analogues | NA | Low hemolytic | ||
| 29136469 | 2017 | {nnr:Dab}I{nnr:Dab}F{d}L{nnr:Dab}L{d}LS{nt:R2 = heptanoyl}{ct:Amid} | C7DLeu7-Pat | Amidation | R2 = heptanoyl | Linear | Mix | R2 = heptanoyl, Dab = 2,4-diaminobutyric acid | 9 | Antibacterial | 4.86 ± 1.05 % Hemolysis at 64 μg/ml | Rabbit | Synthetic Paenipeptins Analogues | NA | Low hemolytic | ||
| 29136469 | 2017 | {nnr:Dab}F{nnr:Dab}F{d}L{nnr:Dab}L{d}LS{nt:R2 = heptanoyl}{ct:Amid} | C7Phe2DLeu7-Pat | Amidation | R2 = heptanoyl | Linear | Mix | R2 = heptanoyl, Dab = 2,4-diaminobutyric acid | 9 | Antibacterial | 2.03 ± 0.44 % Hemolysis at 64 μg/ml | Rabbit | Synthetic Paenipeptins Analogues | NA | Low hemolytic | ||
| 29136469 | 2017 | {nnr:Dab}F{nnr:Dab}F{d}L{nnr:Dab}L{d}FS{nt:R2 = heptanoyl}{ct:Amid} | C7Phe2DLeu7Phe8-Pat | Amidation | R2 = heptanoyl | Linear | Mix | R2 = heptanoyl, Dab = 2,4-diaminobutyric acid | 9 | Antibacterial | 18.8 ± 2.44 % Hemolysis at 64 μg/ml | Rabbit | Synthetic Paenipeptins Analogues | NA | NA | ||
| 29136469 | 2017 | {nnr:Dab}I{nnr:Dab}F{d}L{nnr:Dab}V{d}LS{nt:R3 = octanoyl}{ct:Amid} | C8-Pat | Amidation | R3 = octanoyl | Linear | Mix | R3 = octanoyl, Dab = 2,4-diaminobutyric acid | 9 | Antibacterial | 6.18 ± 2.48 % Hemolysis at 64 μg/ml | Rabbit | Synthetic Paenipeptins Analogues | NA | Low hemolytic | ||
| 29136469 | 2017 | {nnr:Dab}I{nnr:Dab}F{d}L{nnr:Dab}V{d}L{nnr:Dab}{nt:R3 = octanoyl}{ct:Amid} | Dab9-Pat | Amidation | R3 = octanoyl | Linear | Mix | R3 = octanoyl, Dab = 2,4-diaminobutyric acid | 9 | ND = not detected | 0.73 ± 0.50 % Hemolysis at 64 μg/ml | Rabbit | Synthetic Paenipeptins Analogues | NA | Low hemolytic | ||
| 29136469 | 2017 | {nnr:Dab}{nnr:Dab}{nnr:Dab}F{d}L{nnr:Dab}V{d}L{nnr:Dab}{nt:R3 = octanoyl}{ct:Amid} | Dab2,9-Pat | Amidation | R3 = octanoyl | Linear | Mix | R3 = octanoyl, Dab = 2,4-diaminobutyric acid | 9 | ND = not detected | 0.41 ± 0.53 % Hemolysis at 64 μg/ml | Rabbit | Synthetic Paenipeptins Analogues | NA | Low hemolytic | ||
| 29136469 | 2017 | {nnr:O}I{nnr:O}F{d}L{nnr:O}V{d}LS{nt:R3}{ct:Amid}{nt:R3 = octanoyl}{ct:Amid} | Orn-Pat | Amidation | R3 = octanoyl | Linear | Mix | R3 = octanoyl, Orn = Ornithine | 9 | ND = not detected | 0.69 ± 0.64 % Hemolysis at 64 μg/ml | Rabbit | Synthetic Paenipeptins Analogues | NA | Low hemolytic | ||
| 29136469 | 2017 | {nnr:Dab}I{nnr:Dab}F{d}L{nnr:Dab}V{d}LS{nt:R4 = decanoyl}{ct:Amid} | C10-Pat | Amidation | R4 = decanoyl | Linear | Mix | R4 = decanoyl, Dab = 2,4-diaminobutyric acid | 9 | Antibacterial | 73.4 ± 7.59 % Hemolysis at 64 μg/ml | Rabbit | Synthetic Paenipeptins Analogues | NA | NA | ||
| 29136469 | 2017 | {nnr:Dab}ITL{d}L{nnr:Dab}V{d}LS{nt:R4 = decanoyl}{ct:Amid} | C10Thr3Leu4-Pat | Amidation | R4 = decanoyl | Linear | Mix | R4 = decanoyl, Dab = 2,4-diaminobutyric acid | 9 | ND = not detected | 10.0 ± 1.03 % Hemolysis at 64 μg/ml | Rabbit | Synthetic Paenipeptins Analogues | NA | NA | ||
| 29136469 | 2017 | {nnr:Dab}I{nnr:Dab}F{d}L{nnr:Dab}V{d}LS{nt:R5 = benzoyl}{ct:Amid} | Benzoyl-Pat | Amidation | R5 = benzoyl | Linear | Mix | R5 = benzoyl, Dab = 2,4-diaminobutyric acid | 9 | Antimicrobial | 1.14 ± 1.05 % Hemolysis at 64 μg/ml | Rabbit | Synthetic Paenipeptins Analogues | NA | Low hemolytic | ||
| 29136469 | 2017 | {nnr:Dab}I{nnr:Dab}F{d}L{nnr:Dab}V{d}LS{nt:R6 = benzyloxycarbonyl}{ct:Amid} | Cbz-Pat | Amidation | R6 = benzyloxycarbonyl | Linear | Mix | R6 = benzyloxycarbonyl, Dab = 2,4-diaminobutyric acid | 9 | Antimicrobial | 0.54 ± 0.70 % Hemolysis at 64 μg/ml | Rabbit | Synthetic Paenipeptins Analogues | NA | Low hemolytic | ||
| 29136469 | 2017 | {nnr:Dab}I{nnr:Dab}F{d}L{nnr:Dab}V{d}LS{nt:R7 = 3-cyclohexylalanyl}{ct:Amid} | Cha-Pat | Amidation | R7 = 3-cyclohexylalanyl | Linear | Mix | R7 = 3-cyclohexylalanyl, Dab = 2,4-diaminobutyric acid | 9 | Antimicrobial | 0.65 ± 0.62 % Hemolysis at 64 μg/ml | Rabbit | Synthetic Paenipeptins Analogues | NA | Low hemolytic | ||
| 29136469 | 2017 | {nnr:Dab}F{nnr:Dab}F{d}L{nnr:Dab}L{d}FS{nt:R7 = 3-cyclohexylalanyl}{ct:Amid} | ChaPhe2DLeu7Phe8-Pat | Amidation | R7 = 3-cyclohexylalanyl | Linear | Mix | R7 = 3-cyclohexylalanyl, Dab = 2,4-diaminobutyric acid | 9 | Antimicrobial | 11.02 ± 0.99 % Hemolysis at 64 μg/ml | Rabbit | Synthetic Paenipeptins Analogues | NA | NA | ||
| 29136469 | 2017 | {nnr:Dab}I{nnr:Dab}F{d}L{nnr:Dab}V{d}LS{nt:R1 = hexanoyl}{ct:Amid} | C6-Pat | Amidation | R1 = hexanoyl | Linear | Mix | R1 = hexanoyl, Dab = 2,4-diaminobutyric acid | 9 | Antibacterial | 0.41 ± 0.58 % Hemolysis at 32 μg/ml | Rabbit | Synthetic Paenipeptins Analogues | NA | Low hemolytic | ||
| 29136469 | 2017 | {nnr:Dab}V{nnr:Dab}F{d}L{nnr:Dab}V{d}LS{nt:R2 = heptanoyl}{ct:Amid} | C7Val2-Pat | Amidation | R2 = heptanoyl | Linear | Mix | R2 = heptanoyl, Dab = 2,4-diaminobutyric acid | 9 | ND = not detected | 0.32 ± 0.74 % Hemolysis at 32 μg/ml | Rabbit | Synthetic Paenipeptins Analogues | NA | Low hemolytic | ||
| 29136469 | 2017 | {nnr:Dab}I{nnr:Dab}F{d}L{nnr:Dab}V{d}LS{nt:R2 = heptanoyl}{ct:Amid} | C7-Pat | Amidation | R2 = heptanoyl | Linear | Mix | R2 = heptanoyl, Dab = 2,4-diaminobutyric acid | 9 | Antibacterial | 0.78 ± 0.30 % Hemolysis at 32 μg/ml | Rabbit | Synthetic Paenipeptins Analogues | NA | Low hemolytic | ||
| 29136469 | 2017 | {nnr:Dab}F{nnr:Dab}F{d}L{nnr:Dab}V{d}LS{nt:R2 = heptanoyl}{ct:Amid} | C7Phe2-Pat | Amidation | R2 = heptanoyl | Linear | Mix | R2 = heptanoyl, Dab = 2,4-diaminobutyric acid | 9 | ND = not detected | 0.49 ± 1.22 % Hemolysis at 32 μg/ml | Rabbit | Synthetic Paenipeptins Analogues | NA | Low hemolytic | ||
| 29136469 | 2017 | {nnr:Dab}I{nnr:Dab}F{d}L{nnr:Dab}L{d}LS{nt:R2 = heptanoyl}{ct:Amid} | C7DLeu7-Pat | Amidation | R2 = heptanoyl | Linear | Mix | R2 = heptanoyl, Dab = 2,4-diaminobutyric acid | 9 | Antibacterial | 1.39 ± 0.55 % Hemolysis at 32 μg/ml | Rabbit | Synthetic Paenipeptins Analogues | NA | Low hemolytic | ||
| 29136469 | 2017 | {nnr:Dab}F{nnr:Dab}F{d}L{nnr:Dab}L{d}LS{nt:R2 = heptanoyl}{ct:Amid} | C7Phe2DLeu7-Pat | Amidation | R2 = heptanoyl | Linear | Mix | R2 = heptanoyl, Dab = 2,4-diaminobutyric acid | 9 | Antibacterial | 0.39 ± 0.30 % Hemolysis at 32 μg/ml | Rabbit | Synthetic Paenipeptins Analogues | NA | Low hemolytic | ||
| 29136469 | 2017 | {nnr:Dab}F{nnr:Dab}F{d}L{nnr:Dab}L{d}FS{nt:R2 = heptanoyl}{ct:Amid} | C7Phe2DLeu7Phe8-Pat | Amidation | R2 = heptanoyl | Linear | Mix | R2 = heptanoyl, Dab = 2,4-diaminobutyric acid | 9 | Antibacterial | 5.10 ± 1.26 % Hemolysis at 32 μg/ml | Rabbit | Synthetic Paenipeptins Analogues | NA | Low hemolytic | ||
| 29136469 | 2017 | {nnr:Dab}I{nnr:Dab}F{d}L{nnr:Dab}V{d}LS{nt:R3 = octanoyl}{ct:Amid} | C8-Pat | Amidation | R3 = octanoyl | Linear | Mix | R3 = octanoyl, Dab = 2,4-diaminobutyric acid | 9 | Antibacterial | 1.91 ± 0.25 % Hemolysis at 32 μg/ml | Rabbit | Synthetic Paenipeptins Analogues | NA | Low hemolytic | ||
| 29136469 | 2017 | {nnr:Dab}I{nnr:Dab}F{d}L{nnr:Dab}V{d}L{nnr:Dab}{nt:R3 = octanoyl}{ct:Amid} | Dab9-Pat | Amidation | R3 = octanoyl | Linear | Mix | R3 = octanoyl, Dab = 2,4-diaminobutyric acid | 9 | ND = not detected | 0.80 ± 0.68 % Hemolysis at 32 μg/ml | Rabbit | Synthetic Paenipeptins Analogues | NA | Low hemolytic | ||
| 29136469 | 2017 | {nnr:Dab}{nnr:Dab}{nnr:Dab}F{d}L{nnr:Dab}V{d}L{nnr:Dab}{nt:R3 = octanoyl}{ct:Amid} | Dab2,9-Pat | Amidation | R3 = octanoyl | Linear | Mix | R3 = octanoyl, Dab = 2,4-diaminobutyric acid | 9 | ND = not detected | 0.38 ± 0.62 % Hemolysis at 32 μg/ml | Rabbit | Synthetic Paenipeptins Analogues | NA | Low hemolytic | ||
| 29136469 | 2017 | {nnr:O}I{nnr:O}F{d}L{nnr:O}V{d}LS{nt:R3}{ct:Amid}{nt:R3 = octanoyl}{ct:Amid} | Orn-Pat | Amidation | R3 = octanoyl | Linear | Mix | R3 = octanoyl, Orn = Ornithine | 9 | ND = not detected | 0.44 ± 0.30 % Hemolysis at 32 μg/ml | Rabbit | Synthetic Paenipeptins Analogues | NA | Low hemolytic | ||
| 29136469 | 2017 | {nnr:Dab}I{nnr:Dab}F{d}L{nnr:Dab}V{d}LS{nt:R4 = decanoyl}{ct:Amid} | C10-Pat | Amidation | R4 = decanoyl | Linear | Mix | R4 = decanoyl, Dab = 2,4-diaminobutyric acid | 9 | broad Antibacterial activity | 37.2 ± 8.62 % Hemolysis at 32 μg/ml | Rabbit | Synthetic Paenipeptins Analogues | NA | NA | ||
| 29136469 | 2017 | {nnr:Dab}ITL{d}L{nnr:Dab}V{d}LS{nt:R4 = decanoyl}{ct:Amid} | C10Thr3Leu4-Pat | Amidation | R4 = decanoyl | Linear | Mix | R4 = decanoyl, Dab = 2,4-diaminobutyric acid | 9 | ND = not detected | 5.06 ± 1.14 % Hemolysis at 32 μg/ml | Rabbit | Synthetic Paenipeptins Analogues | NA | NA | ||
| 29136469 | 2017 | {nnr:Dab}I{nnr:Dab}F{d}L{nnr:Dab}V{d}LS{nt:R5 = benzoyl}{ct:Amid} | Benzoyl-Pat | Amidation | R5 = benzoyl | Linear | Mix | R5 = benzoyl, Dab = 2,4-diaminobutyric acid | 9 | Antimicrobial | 0.71 ± 0.82 % Hemolysis at 32 μg/ml | Rabbit | Synthetic Paenipeptins Analogues | NA | Low hemolytic | ||
| 29136469 | 2017 | {nnr:Dab}I{nnr:Dab}F{d}L{nnr:Dab}V{d}LS{nt:R6 = benzyloxycarbonyl}{ct:Amid} | Cbz-Pat | Amidation | R6 = benzyloxycarbonyl | Linear | Mix | R6 = benzyloxycarbonyl, Dab = 2,4-diaminobutyric acid | 9 | Antimicrobial | 0.41 ± 0.67 % Hemolysis at 32 μg/ml | Rabbit | Synthetic Paenipeptins Analogues | NA | Low hemolytic | ||
| 29136469 | 2017 | {nnr:Dab}I{nnr:Dab}F{d}L{nnr:Dab}V{d}LS{nt:R7 = 3-cyclohexylalanyl}{ct:Amid} | Cha-Pat | Amidation | R7 = 3-cyclohexylalanyl | Linear | Mix | R7 = 3-cyclohexylalanyl, Dab = 2,4-diaminobutyric acid | 9 | Antimicrobial | 0.33 ± 0.83 % Hemolysis at 32 μg/ml | Rabbit | Synthetic Paenipeptins Analogues | NA | Low hemolytic | ||
| 29136469 | 2017 | {nnr:Dab}F{nnr:Dab}F{d}L{nnr:Dab}L{d}FS{nt:R7 = 3-cyclohexylalanyl}{ct:Amid} | ChaPhe2DLeu7Phe8-Pat | Amidation | R7 = 3-cyclohexylalanyl | Linear | Mix | R7 = 3-cyclohexylalanyl, Dab = 2,4-diaminobutyric acid | 9 | Antimicrobial | 2.46 ± 0.34 % Hemolysis at 32 μg/ml | Rabbit | Synthetic Paenipeptins Analogues | NA | NA | ||
| 29136469 | 2017 | {nnr:Dab}I{nnr:Dab}F{d}L{nnr:Dab}V{d}LS{nt:R1 = hexanoyl}{ct:Amid} | C6-Pat | Amidation | R1 = hexanoyl | Linear | Mix | R1 = hexanoyl, Dab = 2,4-diaminobutyric acid | 9 | Antibacterial | 0.48 ± 0.64 % Hemolysis at 16 μg/ml | Rabbit | Synthetic Paenipeptins Analogues | NA | Low hemolytic | ||
| 29136469 | 2017 | {nnr:Dab}V{nnr:Dab}F{d}L{nnr:Dab}V{d}LS{nt:R2 = heptanoyl}{ct:Amid} | C7Val2-Pat | Amidation | R2 = heptanoyl | Linear | Mix | R2 = heptanoyl, Dab = 2,4-diaminobutyric acid | 9 | ND = not detected | −0.17 ± 0.19 % Hemolysis at 16 μg/ml | Rabbit | Synthetic Paenipeptins Analogues | NA | Low hemolytic | ||
| 29136469 | 2017 | {nnr:Dab}I{nnr:Dab}F{d}L{nnr:Dab}V{d}LS{nt:R2 = heptanoyl}{ct:Amid} | C7-Pat | Amidation | R2 = heptanoyl | Linear | Mix | R2 = heptanoyl, Dab = 2,4-diaminobutyric acid | 9 | Antibacterial | 0.18 ± 0.54 % Hemolysis at 16 μg/ml | Rabbit | Synthetic Paenipeptins Analogues | NA | Low hemolytic | ||
| 29136469 | 2017 | {nnr:Dab}F{nnr:Dab}F{d}L{nnr:Dab}V{d}LS{nt:R2 = heptanoyl}{ct:Amid} | C7Phe2-Pat | Amidation | R2 = heptanoyl | Linear | Mix | R2 = heptanoyl, Dab = 2,4-diaminobutyric acid | 9 | ND = not detected | 0.28 ± 1.11 % Hemolysis at 16 μg/ml | Rabbit | Synthetic Paenipeptins Analogues | NA | Low hemolytic | ||
| 29136469 | 2017 | {nnr:Dab}I{nnr:Dab}F{d}L{nnr:Dab}L{d}LS{nt:R2 = heptanoyl}{ct:Amid} | C7DLeu7-Pat | Amidation | R2 = heptanoyl | Linear | Mix | R2 = heptanoyl, Dab = 2,4-diaminobutyric acid | 9 | Antibacterial | 0.96 ± 0.59 % Hemolysis at 16 μg/ml | Rabbit | Synthetic Paenipeptins Analogues | NA | Low hemolytic | ||
| 29136469 | 2017 | {nnr:Dab}F{nnr:Dab}F{d}L{nnr:Dab}L{d}LS{nt:R2 = heptanoyl}{ct:Amid} | C7Phe2DLeu7-Pat | Amidation | R2 = heptanoyl | Linear | Mix | R2 = heptanoyl, Dab = 2,4-diaminobutyric acid | 9 | Antibacterial | 0.14 ± 0.20 % Hemolysis at 16 μg/ml | Rabbit | Synthetic Paenipeptins Analogues | NA | Low hemolytic | ||
| 29136469 | 2017 | {nnr:Dab}F{nnr:Dab}F{d}L{nnr:Dab}L{d}FS{nt:R2 = heptanoyl}{ct:Amid} | C7Phe2DLeu7Phe8-Pat | Amidation | R2 = heptanoyl | Linear | Mix | R2 = heptanoyl, Dab = 2,4-diaminobutyric acid | 9 | Antibacterial | 0.99 ± 0.31 % Hemolysis at 16 μg/ml | Rabbit | Synthetic Paenipeptins Analogues | NA | Low hemolytic | ||
| 29136469 | 2017 | {nnr:Dab}I{nnr:Dab}F{d}L{nnr:Dab}V{d}LS{nt:R3 = octanoyl}{ct:Amid} | C8-Pat | Amidation | R3 = octanoyl | Linear | Mix | R3 = octanoyl, Dab = 2,4-diaminobutyric acid | 9 | Antibacterial | 0.93 ± 0.45 % Hemolysis at 16 μg/ml | Rabbit | Synthetic Paenipeptins Analogues | NA | Low hemolytic | ||
| 29136469 | 2017 | {nnr:Dab}I{nnr:Dab}F{d}L{nnr:Dab}V{d}L{nnr:Dab}{nt:R3 = octanoyl}{ct:Amid} | Dab9-Pat | Amidation | R3 = octanoyl | Linear | Mix | R3 = octanoyl, Dab = 2,4-diaminobutyric acid | 9 | ND = not detected | 0.52 ± 0.58 % Hemolysis at 16 μg/ml | Rabbit | Synthetic Paenipeptins Analogues | NA | Low hemolytic | ||
| 29136469 | 2017 | {nnr:Dab}{nnr:Dab}{nnr:Dab}F{d}L{nnr:Dab}V{d}L{nnr:Dab}{nt:R3 = octanoyl}{ct:Amid} | Dab2,9-Pat | Amidation | R3 = octanoyl | Linear | Mix | R3 = octanoyl, Dab = 2,4-diaminobutyric acid | 9 | ND = not detected | 0.37 ± 0.62 % Hemolysis at 16 μg/ml | Rabbit | Synthetic Paenipeptins Analogues | NA | Low hemolytic | ||
| 29136469 | 2017 | {nnr:O}I{nnr:O}F{d}L{nnr:O}V{d}LS{nt:R3}{ct:Amid}{nt:R3 = octanoyl}{ct:Amid} | Orn-Pat | Amidation | R3 = octanoyl | Linear | Mix | R3 = octanoyl, Orn = Ornithine | 9 | ND = not detected | 0.86 ± 0.72 % Hemolysis at 16 μg/ml | Rabbit | Synthetic Paenipeptins Analogues | NA | Low hemolytic | ||
| 29136469 | 2017 | {nnr:Dab}I{nnr:Dab}F{d}L{nnr:Dab}V{d}LS{nt:R4 = decanoyl}{ct:Amid} | C10-Pat | Amidation | R4 = decanoyl | Linear | Mix | R4 = decanoyl, Dab = 2,4-diaminobutyric acid | 9 | Antibacterial | 14.3 ± 4.25 % Hemolysis at 16 μg/ml | Rabbit | Synthetic Paenipeptins Analogues | NA | NA | ||
| 29136469 | 2017 | {nnr:Dab}ITL{d}L{nnr:Dab}V{d}LS{nt:R4 = decanoyl}{ct:Amid} | C10Thr3Leu4-Pat | Amidation | R4 = decanoyl | Linear | Mix | R4 = decanoyl, Dab = 2,4-diaminobutyric acid | 9 | ND = not detected | 1.25 ± 0.71 % Hemolysis at 16 μg/ml | Rabbit | Synthetic Paenipeptins Analogues | NA | NA | ||
| 29136469 | 2017 | {nnr:Dab}I{nnr:Dab}F{d}L{nnr:Dab}V{d}LS{nt:R5 = benzoyl}{ct:Amid} | Benzoyl-Pat | Amidation | R5 = benzoyl | Linear | Mix | R5 = benzoyl, Dab = 2,4-diaminobutyric acid | 9 | Antimicrobial | 0.22 ± 0.17 % Hemolysis at 16 μg/ml | Rabbit | Synthetic Paenipeptins Analogues | NA | Low hemolytic | ||
| 29136469 | 2017 | {nnr:Dab}I{nnr:Dab}F{d}L{nnr:Dab}V{d}LS{nt:R6 = benzyloxycarbonyl}{ct:Amid} | Cbz-Pat | Amidation | R6 = benzyloxycarbonyl | Linear | Mix | R6 = benzyloxycarbonyl, Dab = 2,4-diaminobutyric acid | 9 | Antimicrobial | 0.77 ± 0.15 % Hemolysis at 16 μg/ml | Rabbit | Synthetic Paenipeptins Analogues | NA | Low hemolytic | ||
| 29136469 | 2017 | {nnr:Dab}I{nnr:Dab}F{d}L{nnr:Dab}V{d}LS{nt:R7 = 3-cyclohexylalanyl}{ct:Amid} | Cha-Pat | Amidation | R7 = 3-cyclohexylalanyl | Linear | Mix | R7 = 3-cyclohexylalanyl, Dab = 2,4-diaminobutyric acid | 9 | Antimicrobial | 0.55 ± 0.75 % Hemolysis at 16 μg/ml | Rabbit | Synthetic Paenipeptins Analogues | NA | Low hemolytic | ||
| 29136469 | 2017 | {nnr:Dab}F{nnr:Dab}F{d}L{nnr:Dab}L{d}FS{nt:R7 = 3-cyclohexylalanyl}{ct:Amid} | ChaPhe2DLeu7Phe8-Pat | Amidation | R7 = 3-cyclohexylalanyl | Linear | Mix | R7 = 3-cyclohexylalanyl, Dab = 2,4-diaminobutyric acid | 9 | Antimicrobial | 0.60 ± 0.18 % Hemolysis at 16 μg/ml | Rabbit | Synthetic Paenipeptins Analogues | NA | Low hemolytic | ||
| 28887200 | 2018 | FLFTVA-{nnr:Dhb}{ct:Acet} | ASP-1 | Acetylation | Free | Linear | L | Dhb = dehydrobutyrine | 7 | Antibacterial, Anti-MRSA, Antibiofilm | ~6 % Hemolysis at 128 μg/ml | Human | Bacillus Subtilis Urid 12.1 | β-Sheet | Low hemolytic | ||
| 28887200 | 2018 | FLFTVA-{nnr:Dhb}{ct:Acet} | ASP-1 | Acetylation | Free | Linear | L | Dhb = dehydrobutyrine | 7 | Antimicrobial, Anti-MRSA | 31.5 % Hemolysis at 256 μg/ml | Human | Bacillus Subtilis Urid 12.1 | β-Sheet | Low hemolytic | ||
| 29038271 | 2018 | NPYNQTS{nnr:X}{cyc:N-C}{ct:Xaa - β-amino fatty acid variant} | AF3 | Xaa - β-amino fatty acid variant | Free | Cyclic | L | X = Xaa is a β-amino fatty acid variant for AF3-anteiso-C17 | 8 | Antifungal | 10 % Hemolysis at 8 μg/ml | Human | Bacillus Subtilis Rlid 12.1 | NA | NA | ||
| 29038271 | 2018 | NPYNQTS{nnr:X}{cyc:N-C}{ct:Xaa - β-amino fatty acid variant} | AF3 | Xaa - β-amino fatty acid variant | Free | Cyclic | L | X = Xaa is a β-amino fatty acid variant for AF3-anteiso-C17 | 8 | Antifungal | 50 % Hemolysis at 16.4 μg/ml | Human | Bacillus Subtilis Rlid 12.1 | NA | NA | ||
| 29038271 | 2018 | NPYNQTS{nnr:X}{cyc:N-C}{ct:Xaa - β-amino fatty acid variant} | AF4 | Xaa - β-amino fatty acid variant | Free | Cyclic | L | X = Xaa is a β-amino fatty acid variant for AF4-iso-C17 | 8 | Antifungal | ∼5.6 % Hemolysis at 8 μg/ml | Human | Bacillus Subtilis Rlid 12.1 | NA | NA | ||
| 29038271 | 2018 | NPYNQTS{nnr:X}{cyc:N-C}{ct:Xaa - β-amino fatty acid variant} | AF4 | Xaa - β-amino fatty acid variant | Free | Cyclic | L | X = Xaa is a β-amino fatty acid variant for AF4-iso-C17 | 8 | Antifungal | 50 % Hemolysis at 17.7 μg/ml | Human | Bacillus Subtilis Rlid 12.1 | NA | NA | ||
| 29038271 | 2018 | NPYNQTS{nnr:X}{cyc:N-C}{ct:Xaa - β-amino fatty acid variant} | AF5 | Xaa - β-amino fatty acid variant | Free | Cyclic | L | X = Xaa is a β-amino fatty acid variant for AF5-iso-C18 | 8 | Antifungal | 50 % Hemolysis at 8 μg/ml | Human | Bacillus Subtilis Rlid 12.1 | NA | NA | ||
| 32624860 | 2018 | KIIIPPLFH | barleycin | Free | Free | Linear | L | None | 9 | Antibacterial | 0 % Hemolysis at 64 μg/mL | Human | Highland Barley Or Tibetan Barley | α-Helix | Non-hemolytic | ||
| 32624860 | 2018 | KIIIPPLFH | barleycin | Free | Free | Linear | L | None | 9 | Antibacterial | 0 % Hemolysis at 128 μg/mL | Human | Highland Barley Or Tibetan Barley | α-Helix | Non-hemolytic | ||
| 32624860 | 2018 | KIIIPPLFH | barleycin | Free | Free | Linear | L | None | 9 | Antibacterial | 3.2 ± 1.7 % Hemolysis at 256 μg/mL | Human | Highland Barley Or Tibetan Barley | α-Helix | NA | ||
| 32624860 | 2018 | KIIIPPLFH | barleycin | Free | Free | Linear | L | None | 9 | Antibacterial | 19.5 ± 3.5 % Hemolysis at 512 μg/mL | Human | Highland Barley Or Tibetan Barley | α-Helix | NA | ||
| 28918200 | 2018 | KIKEKLIEA{ct:Carboxyl (COO-)} | Pep-5 | Carboxyl (COO-) | Free | Linear | L | None | 9 | ND | 0 % Hemolysis at 125 μM | Rat | Scorpion Tityus Obscurus | NA | Non-hemolytic | ||
| 28918200 | 2018 | KPVEPVG{ct:Carboxyl (COO-)} | Pep-9 | Carboxyl (COO-) | Free | Linear | L | None | 7 | ND | ~25 % Hemolysis at 125 μM | Rat | Scorpion Tityus Obscurus | NA | NA | ||
| 28918200 | 2018 | KETNAKPP{ct:Carboxyl (COO-)} | Pep-18 | Carboxyl (COO-) | Free | Linear | L | None | 8 | ND | 0 % Hemolysis at 125 μM | Rat | Scorpion Tityus Obscurus | NA | Non-hemolytic | ||
| 29198866 | 2018 | {nnr:Nlys}-{nnr:Nspe}-{nnr:Nspe}-{nnr:Nlys}-{nnr:Nspe}-{nnr:Nspe}-{nnr:Nlys}-{nnr:Nspe}-{nnr:Nspe}{nt:H}{ct:Amid} | Peptoid - 2 | Amidation | H | Linear | NA | Nlys = N-(4-aminobutyl)glycine, Nspe = N-(S)-(1-phenylethyl)glycine | 9 | Antibacterial | 38.7 ± 5.4 % Hemolysis at 200 mM | Rat | Synthetic Peptoid | α-Helical | NA | ||
| 29198866 | 2018 | {nnr:Nlys}-{nnr:Nspe}-{nnr:Nspe}-{nnr:Nlys}-{nnr:Nspe}-{nnr:Nspe}-{nnr:Nlys}-{nnr:Nspe}-{nnr:Nspe}{nt:H}{ct:Amid} | Peptoid - 2 | Amidation | H | Linear | NA | Nlys = N-(4-aminobutyl)glycine, Nspe = N-(S)-(1-phenylethyl)glycine | 9 | Antibacterial | 10 % Hemolysis at 119.5 μM | Rat | Synthetic Peptoid | α-Helical | NA | ||
| 29198866 | 2018 | {nnr:Nlys}-{nnr:Nspe}-{nnr:Nspe}-{nnr:Nlys}-{nnr:Nspe}-{nnr:Nspe}-{nnr:Nlys}-{nnr:Nspe}-{nnr:Nspe}{nt:H}{ct:Amid} | Peptoid - 2 | Amidation | H | Linear | NA | Nlys = N-(4-aminobutyl)glycine, Nspe = N-(S)-(1-phenylethyl)glycine | 9 | Antibacterial | 50 % Hemolysis at 1>200 μM | Rat | Synthetic Peptoid | α-Helical | NA | ||
| 29127809 | 2018 | OOYY{nt:H}{ct:Amid} | O3TR | Amidation | H | Linear | L | O = Orn = Ornithine, Y = Trp = Tryptophan | 4 | Antifungal | 20 % Hemolysis at 200 μg/ml | Sheep | Synthetic Peptide | mix of α-Helical structures and Random coil | NA | ||
| 29127809 | 2018 | {conj:C12H23O}OOYY{ct:NH2(C12O3TR)} | C12O3TR | NH2(C12O3TR) | Free | Linear | L | O = Orn = Ornithine, Y = Trp = Tryptophan, C12O3TR = lipopeptide | 4 | Antifungal | 100 % Hemolysis at 200 μg/ml | Sheep | Synthetic Peptide With Conjugate | comprised α-Helix and β-Turn structural element | NA | ||
| 29360748 | 2018 | CSAIPLPIC{cyc:1-9}{ct:Amid} | tigerinin-cyclic | Amidation | Free | Cyclic | L | C–C in parentheses means that the two Cys residues in the sequences form intermolecular disulfide bond | 9 | Non-toxic insulin-releasing peptide | <2 % Hemolysis at 250 μM | Human | Tigerinin-1R Analogs | Random coil | Non-hemolytic | ||
| 29101485 | 2018 | PFKLSLHL{ct:Amid} | Jelleine-I | Amidation | Free | Linear | L | None | 8 | Antimicrobial and Antifungal activity | <2 % Hemolysis at 100 μM | Mouse | Royal Jelly Of Honeybees (Apis Mellifera) | NA | Low hemolytic | ||
| 29101485 | 2018 | PFKLSLHL{ct:Amid} | Jelleine-I | Amidation | Free | Linear | L | None | 8 | Antimicrobial and Antifungal activity | ≤5 % Hemolysis at 256 μM | Mouse | Royal Jelly Of Honeybees (Apis Mellifera) | NA | Low hemolytic | ||
| 29551999 | 2018 | RRWQWR | Monomer LfcinB (20–25) | Free | Free | Linear | L | None | 6 | Antibacterial | 7.1 % Hemolysis at 25 µM | Human | Bovine Lfcinb -Lactoferricin B (Lfcinb)-Based Synthetic Peptides | NA | NA | ||
| 29551999 | 2018 | RWQWRWQWR | Palindromic (PLS) | Free | Free | Linear | L | None | 9 | Antibacterial | 24.8 % Hemolysis at 100 µM | Human | Bovine Lfcinb -Lactoferricin B (Lfcinb)-Based Synthetic Peptides | NA | NA | ||
| 29551999 | 2018 | RRWQWR | Monomer LfcinB (20–25) | Free | Free | Linear | L | None | 6 | Antibacterial | 50 % Hemolysis at >100 µM | Human | Bovine Lfcinb -Lactoferricin B (Lfcinb)-Based Synthetic Peptides | NA | NA | ||
| 29551999 | 2018 | RWQWRWQWR | Palindromic (PLS) | Free | Free | Linear | L | None | 9 | Antibacterial | 50 % Hemolysis at >100 µM | Human | Bovine Lfcinb -Lactoferricin B (Lfcinb)-Based Synthetic Peptides | NA | NA | ||
| 29264738 | 2018 | K{nt:C16}{ct:Amid} | 1 | Amidation | C16 | Linear | L | C16 | 1 | Antibacterial | 10 % Hemolysis at 512 µg/mL | Human | Synthetic Lipopeptides | NA | Low hemolytic | ||
| 29264738 | 2018 | KK{nt:C16}{ct:Amid} | 2 | Amidation | C16 | Linear | L | C16 | 2 | Antibacterial | 10 % Hemolysis at 256 µg/mL | Human | Synthetic Lipopeptides | NA | NA | ||
| 29264738 | 2018 | KKK{nt:C16}{ct:Amid} | 3 | Amidation | C16 | Linear | L | C16 | 3 | Antibacterial | 10 % Hemolysis at 32 µg/mL | Human | Synthetic Lipopeptides | NA | NA | ||
| 29264738 | 2018 | KKKK{nt:C16}{ct:Amid} | 4 | Amidation | C16 | Linear | L | C16 | 4 | Antibacterial | 10 % Hemolysis at 16 µg/mL | Human | Synthetic Lipopeptides | NA | NA | ||
| 29264738 | 2018 | KG{nt:C16}{ct:Amid} | 5 | Amidation | C16 | Linear | L | C16 | 2 | Antibacterial | 10 % Hemolysis at 256 µg/mL | Human | Synthetic Lipopeptides | NA | NA | ||
| 29264738 | 2018 | KGK{nt:C16}{ct:Amid} | 6 | Amidation | C16 | Linear | L | C16 | 3 | Antibacterial | 10 % Hemolysis at 64 µg/mL | Human | Synthetic Lipopeptides | NA | NA | ||
| 29264738 | 2018 | KGKG{nt:C16}{ct:Amid} | 7 | Amidation | C16 | Linear | L | C16 | 4 | Antibacterial | 10 % Hemolysis at 64 µg/mL | Human | Synthetic Lipopeptides | NA | NA | ||
| 29264738 | 2018 | K{nt:C14}{ct:Amid} | 8 | Amidation | C14 | Linear | L | C14 | 1 | Antibacterial | 10 % Hemolysis at 512 µg/mL | Human | Synthetic Lipopeptides | NA | Low hemolytic | ||
| 29264738 | 2018 | KK{nt:C14}{ct:Amid} | 9 | Amidation | C14 | Linear | L | C14 | 2 | Antibacterial | 10 % Hemolysis at 128 µg/mL | Human | Synthetic Lipopeptides | NA | NA | ||
| 29264738 | 2018 | KKK{nt:C14}{ct:Amid} | 10 | Amidation | C14 | Linear | L | C14 | 3 | Antibacterial | 10 % Hemolysis at 256 µg/mL | Human | Synthetic Lipopeptides | NA | NA | ||
| 29264738 | 2018 | KKKK{nt:C14}{ct:Amid} | 11 | Amidation | C14 | Linear | L | C14 | 4 | Antibacterial | 10 % Hemolysis at 256 µg/mL | Human | Synthetic Lipopeptides | NA | NA | ||
| 29264738 | 2018 | KG{nt:C14}{ct:Amid} | 12 | Amidation | C14 | Linear | L | C14 | 2 | Antibacterial | 10 % Hemolysis at >1000 µg/mL | Human | Synthetic Lipopeptides | NA | Low hemolytic | ||
| 29264738 | 2018 | KGK{nt:C14}{ct:Amid} | 13 | Amidation | C14 | Linear | L | C14 | 3 | Antibacterial | 10 % Hemolysis at 128 µg/mL | Human | Synthetic Lipopeptides | NA | NA | ||
| 29264738 | 2018 | KGKG{nt:C14}{ct:Amid} | 14 | Amidation | C14 | Linear | L | C14 | 4 | Antibacterial | 10 % Hemolysis at 512 µg/mL | Human | Synthetic Lipopeptides | NA | Low hemolytic | ||
| 29264738 | 2018 | K{nt:C12}{ct:Amid} | 15 | Amidation | C12 | Linear | L | C12 | 1 | Antibacterial | 10 % Hemolysis at >1000 µg/mL | Human | Synthetic Lipopeptides | NA | Low hemolytic | ||
| 29264738 | 2018 | KK{nt:C12}{ct:Amid} | 16 | Amidation | C12 | Linear | L | C12 | 2 | Antibacterial | 10 % Hemolysis at >4000 µg/mL | Human | Synthetic Lipopeptides | NA | Low hemolytic | ||
| 29264738 | 2018 | KKK{nt:C12}{ct:Amid} | 17 | Amidation | C12 | Linear | L | C12 | 3 | Antibacterial | 10 % Hemolysis at 512 µg/mL | Human | Synthetic Lipopeptides | NA | Low hemolytic | ||
| 29264738 | 2018 | KKKK{nt:C12}{ct:Amid} | 18 | Amidation | C12 | Linear | L | C12 | 4 | Antibacterial | 10 % Hemolysis at >1000 µg/mL | Human | Synthetic Lipopeptides | NA | Low hemolytic | ||
| 29264738 | 2018 | KG{nt:C12}{ct:Amid} | 19 | Amidation | C12 | Linear | L | C12 | 2 | Antibacterial | 10 % Hemolysis at >1000 µg/mL | Human | Synthetic Lipopeptides | NA | Low hemolytic | ||
| 29264738 | 2018 | KGK{nt:C12}{ct:Amid} | 20 | Amidation | C12 | Linear | L | C12 | 3 | Antibacterial | 10 % Hemolysis at >1000 µg/mL | Human | Synthetic Lipopeptides | NA | Low hemolytic | ||
| 29264738 | 2018 | KGKG{nt:C12}{ct:Amid} | 21 | Amidation | C12 | Linear | L | C12 | 4 | Antibacterial | 10 % Hemolysis at 256 µg/mL | Human | Synthetic Lipopeptides | NA | NA | ||
| 29264738 | 2018 | K{nt:C10}{ct:Amid} | 22 | Amidation | C10 | Linear | L | C10 | 1 | Antibacterial | 10 % Hemolysis at >4000 µg/mL | Human | Synthetic Lipopeptides | NA | Low hemolytic | ||
| 29264738 | 2018 | KK{nt:C10}{ct:Amid} | 23 | Amidation | C10 | Linear | L | C10 | 2 | Antibacterial | 10 % Hemolysis at >4000 µg/mL | Human | Synthetic Lipopeptides | NA | Low hemolytic | ||
| 29264738 | 2018 | KKK{nt:C10}{ct:Amid} | 24 | Amidation | C10 | Linear | L | C10 | 3 | Antibacterial | 10 % Hemolysis at >4000 µg/mL | Human | Synthetic Lipopeptides | NA | Low hemolytic | ||
| 29264738 | 2018 | KKKK{nt:C10}{ct:Amid} | 25 | Amidation | C10 | Linear | L | C10 | 4 | Antibacterial | 10 % Hemolysis at >4000 µg/mL | Human | Synthetic Lipopeptides | NA | Low hemolytic | ||
| 29264738 | 2018 | KG{nt:C10}{ct:Amid} | 26 | Amidation | C10 | Linear | L | C10 | 2 | Antibacterial | 10 % Hemolysis at >4000 µg/mL | Human | Synthetic Lipopeptides | NA | Low hemolytic | ||
| 29264738 | 2018 | KGK{nt:C10}{ct:Amid} | 27 | Amidation | C10 | Linear | L | C10 | 3 | Antibacterial | 10 % Hemolysis at >4000 µg/mL | Human | Synthetic Lipopeptides | NA | Low hemolytic | ||
| 29264738 | 2018 | KGKG{nt:C10}{ct:Amid} | 28 | Amidation | C10 | Linear | L | C10 | 4 | Antibacterial | 10 % Hemolysis at >4000 µg/mL | Human | Synthetic Lipopeptides | NA | Low hemolytic | ||
| 29264738 | 2018 | K{nt:C8}{ct:Amid} | 29 | Amidation | C8 | Linear | L | C8 | 1 | Antibacterial | 10 % Hemolysis at >4000 µg/mL | Human | Synthetic Lipopeptides | NA | Low hemolytic | ||
| 29264738 | 2018 | KK{nt:C8}{ct:Amid} | 30 | Amidation | C8 | Linear | L | C8 | 2 | Antibacterial | 10 % Hemolysis at >4000 µg/mL | Human | Synthetic Lipopeptides | NA | Low hemolytic | ||
| 29264738 | 2018 | KKK{nt:C8}{ct:Amid} | 31 | Amidation | C8 | Linear | L | C8 | 3 | Antibacterial | 10 % Hemolysis at >4000 µg/mL | Human | Synthetic Lipopeptides | NA | Low hemolytic | ||
| 29264738 | 2018 | KKKK{nt:C8}{ct:Amid} | 32 | Amidation | C8 | Linear | L | C8 | 4 | Antibacterial | 10 % Hemolysis at >4000 µg/mL | Human | Synthetic Lipopeptides | NA | Low hemolytic | ||
| 29264738 | 2018 | KG{nt:C8}{ct:Amid} | 33 | Amidation | C8 | Linear | L | C8 | 2 | Antibacterial | 10 % Hemolysis at >4000 µg/mL | Human | Synthetic Lipopeptides | NA | Low hemolytic | ||
| 29264738 | 2018 | KGK{nt:C8}{ct:Amid} | 34 | Amidation | C8 | Linear | L | C8 | 3 | Antibacterial | 10 % Hemolysis at >4000 µg/mL | Human | Synthetic Lipopeptides | NA | Low hemolytic | ||
| 29264738 | 2018 | KGKG{nt:C8}{ct:Amid} | 35 | Amidation | C8 | Linear | L | C8 | 4 | Antibacterial | 10 % Hemolysis at >4000 µg/mL | Human | Synthetic Lipopeptides | NA | Low hemolytic | ||
| 29501941 | 2018 | {nnr:AzPro}-P-{nnr:AzPro}-P-{nnr:AzPro}-P-{nnr:AzPro}-P{nt:Cbz}{ct:OtBu} | 18 | OtBu | Cbz | Linear | L | AzPro = azaproline, OtBu = ortho-tert-butyl, Cbz = carboxybenzyl | 8 | Antibacterial | 0 % Hemolysis at 50 µM | Human | Gas Shorter Peptide Analogs | β 6.3-Helical | Non-hemolytic | ||
| 29501941 | 2018 | {nnr:AzPro}-P-{nnr:AzPro}-P-{nnr:AzPro}-P-{nnr:AzPro}-P{nt:Cbz}{ct:OH} | 19 | OH | Cbz | Linear | L | AzPro = azaproline, Cbz = carboxybenzyl, OH = Hydroxyl | 8 | Antibacterial | 0 % Hemolysis at 50 µM | Human | Gas Shorter Peptide Analogs | β 6.3-Helical | Non-hemolytic | ||
| 29501941 | 2018 | {nnr:AzPro}-P-{nnr:AzPro}-P-{nnr:AzPro}-P-{nnr:AzPro}-P{nt:H}{ct:OtBu} | 20 | OtBu | H | Linear | L | AzPro = azaproline, OtBu = ortho-tert-butyl, H = Hydrogen | 8 | Antibacterial | 0 % Hemolysis at 50 µM | Human | Gas Shorter Peptide Analogs | β 6.3-Helical | Non-hemolytic | ||
| 29501941 | 2018 | P-{nnr:AzPro}-P-{nnr:AzPro}-P-{nnr:AzPro}-P-{nnr:AzPro}{nt:Boc}{ct:Cbz} | 21 | Cbz | Boc | Linear | L | AzPro = azaproline, Cbz = carboxybenzyl, Boc = tert-butyloxycarbonyl | 8 | Antibacterial | 0 % Hemolysis at 50 µM | Human | Gas Shorter Peptide Analogs | β 6.3-Helical | Non-hemolytic | ||
| 29501941 | 2018 | P-{nnr:AzPro}-P-{nnr:AzPro}-P-{nnr:AzPro}-P-{nnr:AzPro}{nt:Boc}{ct:H} | 22 | H | Boc | Linear | L | AzPro = azaproline, Boc = tert-butyloxycarbonyl, H = Hydrogen | 8 | Antibacterial | 0 % Hemolysis at 50 µM | Human | Gas Shorter Peptide Analogs | β 6.3-Helical | Non-hemolytic | ||
| 29501941 | 2018 | P-{nnr:AzPro}-P-{nnr:AzPro}-P-{nnr:AzPro}-P-{nnr:AzPro}{nt:HCl.H}{ct:Cbz} | 23 | Cbz | HCl.H | Linear | L | AzPro = azaproline, Cbz = carboxybenzyl, HCl = hydrochloric acid | 8 | Antibacterial | 0 % Hemolysis at 50 µM | Human | Gas Shorter Peptide Analogs | β 6.3-Helical | Non-hemolytic | ||
| 29411917 | 2018 | aza-β3Lys-K-{nnr:aza-β3-1Nal}-K-{nnr:aza-β3-1Nal}-L{cyc:N-C} | ACPP20 | Free | Free | Cyclic | L | aza-β3-Lys = aza-β3-Lysine, aza-β3-1Nal = aza-β3-1-Naphthylalanine | 6 | Antimicrobial cyclic pseudopeptides (ACPPs) | 1.5 % Hemolysis at 100 µM | Sheep | Synthesis Of Mixed Aza-Β3-Pseudopeptides | NA | Low hemolytic | ||
| 29411917 | 2018 | aza-β3Lys-K-{nnr:aza-β3-2Nal}-L-{nnr:aza-β3-2Nal}-L{cyc:N-C} | ACPP21 | Free | Free | Cyclic | L | aza-β3-Lys = aza-β3-Lysine, aza-β3-2Nal = aza-β3-2-Naphthylalanine | 6 | Antimicrobial cyclic pseudopeptides (ACPPs) | 8 % Hemolysis at 100 µM | Sheep | Synthesis Of Mixed Aza-Β3-Pseudopeptides | NA | NA | ||
| 29411917 | 2018 | aza-β3Lys-K-{nnr:aza-β3-1Nal}-L-{nnr:aza-β3-4Fluo-1Nal}-L{cyc:N-C} | ACPP22 | Free | Free | Cyclic | L | aza-β3-Leu = aza-β3-Leucine, aza-β3-1Nal = aza-β3-1-Naphthylalanine, aza-β3-4Fluo-1Nal = aza-β3-4Fluoro-1-Nahphtylalanine | 6 | Antimicrobial cyclic pseudopeptides (ACPPs) | 5 % Hemolysis at 100 µM | Sheep | Synthesis Of Mixed Aza-Β3-Pseudopeptides | NA | Low hemolytic | ||
| 29411917 | 2018 | K-aza-β3Lys-L-{nnr:aza-β3-1Nal}-aza-β3Leu-{nnr:aza-β3-1Nal}{cyc:N-C} | ACPP23 | Free | Free | Cyclic | L | aza-β3-Lys = aza-β3-Lysine, aza-β3-1Nal = aza-β3-1-Naphthylalanine, aza-β3-Leu = aza-β3-Leucine, aza-β3-1Nal = aza-β3-1-Naphthylalanine | 6 | Antimicrobial cyclic pseudopeptides (ACPPs) | 6 % Hemolysis at 100 µM | Sheep | Synthesis Of Mixed Aza-Β3-Pseudopeptides | NA | NA | ||
| 29411917 | 2018 | aza-β3Arg-R-{nnr:aza-β3-1Nal}-L-{nnr:aza-β3-1Nal}-L{cyc:N-C} | ACPP24 | Free | Free | Cyclic | L | aza-β3-Arg = aza-β3-Arginine, aza-β3-1Nal = aza-β3-1-Naphthylalanine | 6 | Antimicrobial cyclic pseudopeptides (ACPPs) | 12 % Hemolysis at 100 µM | Sheep | Synthesis Of Mixed Aza-Β3-Pseudopeptides | NA | NA | ||
| 29411917 | 2018 | aza-β3Lys-R-{nnr:aza-β3-2Nal}-F-{nnr:aza-β3-2Nal}-F{cyc:N-C} | ACPP25 | Free | Free | Cyclic | L | aza-β3-Lys = aza-β3-Lysine, aza-β3-2Nal = aza-β3-2-Naphthylalanine | 6 | Antimicrobial cyclic pseudopeptides (ACPPs) | 50 % Hemolysis at 100 µM | Sheep | Synthesis Of Mixed Aza-Β3-Pseudopeptides | NA | NA | ||
| 29266746 | 2018 | WLSKTAKKL{ct:Amid} | WL1 | Amidation | Free | Linear | L | None | 9 | Antimicrobial | >5 % Hemolysis at >128 µM | Human | Tandem Repeat Cecropin P1 | unordered conformations | Non-hemolytic | ||
| 29266746 | 2018 | WLSKTAKKLWLSKTAKKL{ct:Amid} | WL2 | Amidation | Free | Linear | L | None | 9 | Antimicrobial | >5 % Hemolysis at >128 µM | Human | Tandem Repeat Cecropin P1 | Random coil at aq, α-Helical at 50% TFE solution | Non-hemolytic | ||
| 29266746 | 2018 | WLSKTAKKLWLSKTAKKLWLSKTAKKL{ct:Amid} | WL3 | Amidation | Free | Linear | L | None | 9 | Antimicrobial | >5 % Hemolysis at >128 µM | Human | Tandem Repeat Cecropin P1 | Random coil at aq, α-Helical at 50% TFE solution | Non-hemolytic | ||
| 29648811 | 2018 | RLRLLLRLR{ct:Amid} | 1 - L4 | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 10 % Hemolysis at >128 µM | Human | Synthetic Peptide - Developed Based On The Imperfectly Amphipathic Palindromic Structure Rn(Xrxxxrx)Rn (N = 1, 2; X Represents L, I, F, Or W) | α-Helical at membrane-mimetic environments | Low hemolytic | ||
| 29648811 | 2018 | LLRRLRRLL{ct:Amid} | 2 - L4pf | Amidation | Free | Linear | L | pf = perfect amphipathicity peptides | 9 | Antimicrobial | 10 % Hemolysis at >128 µM | Human | Synthetic Peptide - Developed Based On The Imperfectly Amphipathic Palindromic Structure Rn(Xrxxxrx)Rn (N = 1, 2; X Represents L, I, F, Or W) | α-Helical | Low hemolytic | ||
| 29648811 | 2018 | RFRFFFRFR{ct:Amid} | 3 - F4 | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 10 % Hemolysis at >128 µM | Human | Synthetic Peptide - Developed Based On The Imperfectly Amphipathic Palindromic Structure Rn(Xrxxxrx)Rn (N = 1, 2; X Represents L, I, F, Or W) | α-Helical | Low hemolytic | ||
| 29648811 | 2018 | FFRRFRRFF{ct:Amid} | 4 - F4pf | Amidation | Free | Linear | L | pf = perfect amphipathicity peptides | 9 | Antimicrobial | 10 % Hemolysis at >128 µM | Human | Synthetic Peptide - Developed Based On The Imperfectly Amphipathic Palindromic Structure Rn(Xrxxxrx)Rn (N = 1, 2; X Represents L, I, F, Or W) | α-Helical | Low hemolytic | ||
| 29648811 | 2018 | RIRIIIRIR{ct:Amid} | 5 - I4 | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 10 % Hemolysis at >128 µM | Human | Synthetic Peptide - Developed Based On The Imperfectly Amphipathic Palindromic Structure Rn(Xrxxxrx)Rn (N = 1, 2; X Represents L, I, F, Or W) | α-Helical | Low hemolytic | ||
| 29648811 | 2018 | IIRRIRRII{ct:Amid} | 6 - I4pf | Amidation | Free | Linear | L | pf = perfect amphipathicity peptides | 9 | Antimicrobial | 10 % Hemolysis at >128 µM | Human | Synthetic Peptide - Developed Based On The Imperfectly Amphipathic Palindromic Structure Rn(Xrxxxrx)Rn (N = 1, 2; X Represents L, I, F, Or W) | α-Helical | Low hemolytic | ||
| 29648811 | 2018 | RWRWWWRWR{ct:Amid} | 7 - W4 | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 10 % Hemolysis at >128 µM | Human | Synthetic Peptide - Developed Based On The Imperfectly Amphipathic Palindromic Structure Rn(Xrxxxrx)Rn (N = 1, 2; X Represents L, I, F, Or W) | α-Helical | Low hemolytic | ||
| 29648811 | 2018 | WWRRWRRWW{ct:Amid} | 8 - W4pf | Amidation | Free | Linear | L | pf = perfect amphipathicity peptides | 9 | Antimicrobial | 10 % Hemolysis at >128 µM | Human | Synthetic Peptide - Developed Based On The Imperfectly Amphipathic Palindromic Structure Rn(Xrxxxrx)Rn (N = 1, 2; X Represents L, I, F, Or W) | α-Helical | Low hemolytic | ||
| 30674824 | 2018 | {nnr:Nap}FFKK-{nnr:OH}{nt:(Naphthalene-2-ly)-Acetylation}{ct:OH} | (naphthalene-2-ly)-acetyl-diphenylalanine-dilysine-OH | OH | (Naphthalene-2-ly)-Acetylation | Linear | L | OH = Hydroxy, Nap = (Naphthalene-2-ly)-acetyl | 4 | Antifungal and hydrogel forming properties | <2 % Hemolysis at 500 µM | Horse | Synthetic Ultrashort Peptide | β-Sheet | Non-hemolytic | ||
| 29614317 | 2018 | GLLKRIKTL{nt:palmitoyl group (C16)}{ct:Amid} | Pal-ano-9 | Amidation | palmitoyl group (C16) | Linear | L | C16 = palmitoyl group | 9 | Antifungal | 50 % Hemolysis at 18.92 μg/mL | Human | Truncated Analogues Of Pal-Anoplin | water = Helical, TFE/H2O(30%) = Helical | NA | ||
| 29614317 | 2018 | GLLKRIKT{nt:palmitoyl group (C16)}{ct:Amid} | Pal-ano-8 | Amidation | palmitoyl group (C16) | Linear | L | C16 = palmitoyl group | 8 | Antimicrobial | 50 % Hemolysis at 33.74 μg/mL | Human | Truncated Analogues Of Pal-Anoplin | water = Random coil, TFE/H2O(30%) = Helical | NA | ||
| 29614317 | 2018 | GLLKRIK{nt:palmitoyl group (C16)}{ct:Amid} | Pal-ano-7 | Amidation | palmitoyl group (C16) | Linear | L | C16 = palmitoyl group | 7 | Antimicrobial | 50 % Hemolysis at 37.7 μg/mL | Human | Truncated Analogues Of Pal-Anoplin | water = Random coil, TFE/H2O(30%) = Helical | NA | ||
| 29614317 | 2018 | GLLKRI{nt:palmitoyl group (C16)}{ct:Amid} | Pal-ano-6 | Amidation | palmitoyl group (C16) | Linear | L | C16 = palmitoyl group | 6 | Antifungal | 50 % Hemolysis at 7.51 μg/mL | Human | Truncated Analogues Of Pal-Anoplin | water = Helical, TFE/H2O(30%) = Helical | NA | ||
| 29614317 | 2018 | GLLKR{nt:palmitoyl group (C16)}{ct:Amid} | Pal-ano-5 | Amidation | palmitoyl group (C16) | Linear | L | C16 = palmitoyl group | 5 | Antimicrobial | 50 % Hemolysis at 66.12 μg/mL | Human | Truncated Analogues Of Pal-Anoplin | water = Random coil, TFE/H2O(30%) = Random coil | NA | ||
| 29621496 | 2018 | {nnr:Nap}{nnr:Npm}{nnr:Nap}{nnr:Npm}{nnr:Nap}{nnr:Npm}{cyc:N-C} | C1 | Free | Free | Cyclic | Mix | Nap = N-(3-aminopropyl)glycine, Npm = N-(1-phenylmethyl)glycine | 6 | Antibacterial | 10 % Hemolysis at 250 μg/mL | Human | Synthetic Peptoids Mimic Antimicrobial Peptides | NA | NA | ||
| 29621496 | 2018 | {nnr:Nap}{nnr:Ndmb}{nnr:Nap}{nnr:Ndmb}{nnr:Nap}{nnr:Ndmb}{cyc:N-C} | C2 | Free | Free | Cyclic | Mix | Nap = N-(3-aminopropyl)glycine, Ndmb = N-(3,5-dimethylbenzyl)glycine | 6 | Antibacterial | 10 % Hemolysis at 125 μg/mL | Human | Synthetic Peptoids Mimic Antimicrobial Peptides | NA | NA | ||
| 29621496 | 2018 | {nnr:Nap}{nnr:Nsne}{nnr:Nap}{nnr:Nsne}{nnr:Nap}{nnr:Nsne}{cyc:N-C} | C3 | Free | Free | Cyclic | Mix | Nap = N-(3-aminopropyl)glycine, Nsne = (S)-N-(1-naphthylethyl)glycine | 6 | Antibacterial | 10 % Hemolysis | Human | Synthetic Peptoids Mimic Antimicrobial Peptides | NA | NA | ||
| 29621496 | 2018 | {nnr:Nap}{nnr:Ndp}{nnr:Nap}{nnr:Ndp}{nnr:Nap}{nnr:Ndp}{cyc:N-C} | C4 | Free | Free | Cyclic | Mix | Nap = N-(3-aminopropyl)glycine, Ndp = N-(2,2-diphenylethyl)glycine | 6 | Antibacterial | 10 % Hemolysis at 31.3 μg/mL | Human | Synthetic Peptoids Mimic Antimicrobial Peptides | NA | NA | ||
| 29621496 | 2018 | {nnr:Nap}{nnr:Nbtfmb}{nnr:Nap}{nnr:Nbtfmb}{nnr:Nap}{nnr:Nbtfmb}{cyc:N-C} | C5 | Free | Free | Cyclic | Mix | Nap = N-(3-aminopropyl)glycine, Nbtfmb = N-(3,5-bis-trifluoromethylbenzyl)glycine | 6 | Antibacterial | 10 % Hemolysis at 31.3 μg/mL | Human | Synthetic Peptoids Mimic Antimicrobial Peptides | NA | NA | ||
| 30108987 | 2018 | KRWWKWIRW{nt:H}{ct:Amid} | HHC10 | Amidation | H | Linear | L | None | 9 | Antimicrobial | 14.3 ± 3.6 % Hemolysis at 512 μM | Horse | Phosphonium Based Cationic Amphiphilic Peptides | NA | NA | ||
| 29984236 | 2018 | RRWQWR | Motif | Free | Free | Linear | L | None | 6 | Antibacterial | 7.1 % Hemolysis at 25 μM | Human | Bovine Lactoferricin | branched conformation | NA | ||
| 29984236 | 2018 | RWQWR WQWR | Palindromic | Free | Free | Linear | L | None | 9 | Antibacterial | 24.8 % Hemolysis at 100 μM | Human | Synthesised From Motif | NA | NA | ||
| 29197569 | 2018 | KWKLFKK | cecropin A(1-7) | Free | Free | Linear | L | None | 7 | Antibacterial | 5 % Hemolysis at >64 μM | Human | Hemolymph Of Giant Silk | NA | NA | ||
| 30011202 | 2018 | FRTSCSAC | M1 | Free | Free | Linear | L | None | 8 | Antioxidant and tyrosinase inhibition | 2 % Hemolysis at 150 μM | Human | Designed As Shortened Variants Of Mfl | NA | NA | ||
| 30011202 | 2018 | FRTCRSVC | M2 | Free | Free | Linear | L | None | 8 | Antioxidant and tyrosinase inhibition | 3 % Hemolysis at 150 μM | Human | Designed As Shortened Variants Of Mfl | NA | Non-hemolytic | ||
| 30011202 | 2018 | FFRSCRVC | M3 | Free | Free | Linear | L | None | 8 | Antioxidant and tyrosinase inhibition | 2 % Hemolysis at 150 μM | Human | Designed As Shortened Variants Of Mfl | NA | Non-hemolytic | ||
| 30011202 | 2018 | TRAFRCVS | A1 | Free | Free | Linear | L | None | 8 | Antioxidant and tyrosinase inhibition | 1 % Hemolysis at 150 μM | Human | Designed As Shortened Variants Of Afl | NA | Non-hemolytic | ||
| 30011202 | 2018 | TRCFRVCS | A2 | Free | Free | Linear | L | None | 8 | Antioxidant and tyrosinase inhibition | 1 % Hemolysis at 150 μM | Human | Designed As Shortened Variants Of Afl | NA | Non-hemolytic | ||
| 30011202 | 2018 | TSRCFRVC | A3 | Free | Free | Linear | L | None | 8 | Antioxidant and tyrosinase inhibition | 1 % Hemolysis at 150 μM | Human | Designed As Shortened Variants Of Afl | NA | Non-hemolytic | ||
| 30105347 | 2018 | ADLPFE{d}F | PapR7-dE | Free | Free | Linear | Mix | e = D-glutamic acid | 7 | NA | 50 % Hemolysis at 1 μM | Human | Synthetic Peptide | NA | NA | ||
| 30070835 | 2018 | LKWLKKL{nt:Amid}{ct:Amid} | P4 | Amidation | Amidation | Linear | L | None | 7 | Antimicrobial, Antifungal | < 10 % Hemolysis at 200 μM | Human | Salt Tolerant De Novo Designed Leucine-Lysine Based Peptides | water = Random coil | Low hemolytic | ||
| 30070835 | 2018 | LRWLRRL{nt:Amid}{ct:Amid} | P5 | Amidation | Amidation | Linear | L | None | 7 | Antimicrobial, Antifungal | < 10 % Hemolysis at 200 μM | Human | Salt Tolerant De Novo Designed Leucine-Lysine Based Peptides | water = Random coil | Low hemolytic | ||
| 30070835 | 2018 | LKWLKKL{nt:Amid}{ct:Amid} | P4 | Amidation | Amidation | Linear | L | None | 7 | Antimicrobial, Antifungal | >2 % Hemolysis at 1 μM | Human | Salt Tolerant De Novo Designed Leucine-Lysine Based Peptides | water = Random coil | Non-hemolytic | ||
| 30070835 | 2018 | LRWLRRL{nt:Amid}{ct:Amid} | P5 | Amidation | Amidation | Linear | L | None | 7 | Antimicrobial, Antifungal | >2 % Hemolysis at 1 μM | Human | Salt Tolerant De Novo Designed Leucine-Lysine Based Peptides | water = Random coil | Non-hemolytic | ||
| 30112781 | 2018 | K{nnr:β}{nnr:cf}KK{cyc:N-C} | 5a | Free | Free | Cyclic | Mix | β = lipophilic β2,2‐amino acid, cf = 4-CF3 (β-phenylalanine derivative has a trifluoromethyl CF3 ) | 4 | Antibacterial | 50 % Hemolysis at >500 μg/mL | Human | Synthetic Cyclic Amps | NA | NA | ||
| 30112781 | 2018 | K{nnr:β}{nnr:cf}GK{cyc:N-C} | 5b | Free | Free | Cyclic | Mix | β = lipophilic β2,2‐amino acid, cf = 4-CF3 (β-phenylalanine derivative has a trifluoromethyl CF3 ) | 4 | Antibacterial | 50 % Hemolysis at >500 μg/mL | Human | Synthetic Cyclic Amps | NA | NA | ||
| 30112781 | 2018 | K{nnr:β}{nnr:cf}AK{cyc:N-C} | 5c | Free | Free | Cyclic | Mix | β = lipophilic β2,2‐amino acid, cf = 4-CF3 (β-phenylalanine derivative has a trifluoromethyl CF3 ) | 4 | Antibacterial | 50 % Hemolysis at >500 μg/mL | Human | Synthetic Cyclic Amps | NA | NA | ||
| 30112781 | 2018 | K{nnr:β}{nnr:cf}FK{cyc:N-C} | 5d | Free | Free | Cyclic | Mix | β = lipophilic β2,2‐amino acid, cf = 4-CF3 (β-phenylalanine derivative has a trifluoromethyl CF3 ) | 4 | Antibacterial | 50 % Hemolysis at 88 μg/mL | Human | Synthetic Cyclic Amps | NA | NA | ||
| 30112781 | 2018 | K{nnr:β}{nnr:dicf}KK{cyc:N-C} | 6a | Free | Free | Cyclic | Mix | β = β^(2,2), dicf = 3,5diCF3(β-phenylalanine derivative has trifluoromethyl CF3 groups) | 4 | Antibacterial | 50 % Hemolysis at 216 μg/mL | Human | Synthetic Cyclic Amps | NA | NA | ||
| 30112781 | 2018 | K{nnr:β}{nnr:dicf}GK{cyc:N-C} | 6b | Free | Free | Cyclic | Mix | β = β^(2,2), dicf = 3,5diCF3(β-phenylalanine derivative has trifluoromethyl CF3 groups) | 4 | Antibacterial | 50 % Hemolysis at 100 μg/mL | Human | Synthetic Cyclic Amps | NA | NA | ||
| 30112781 | 2018 | K{nnr:β}{nnr:dicf}AK{cyc:N-C} | 6c | Free | Free | Cyclic | Mix | β = β^(2,2), dicf = 3,5diCF3(β-phenylalanine derivative has trifluoromethyl CF3 groups) | 4 | Antibacterial | 50 % Hemolysis at 67 μg/mL | Human | Synthetic Cyclic Amps | NA | NA | ||
| 30112781 | 2018 | K{nnr:β}{nnr:dicf}FK{cyc:N-C} | 6d | Free | Free | Cyclic | Mix | β = β^(2,2), dicf = 3,5diCF3(β-phenylalanine derivative has trifluoromethyl CF3 groups) | 4 | Antibacterial | 50 % Hemolysis at 84 μg/mL | Human | Synthetic Cyclic Amps | NA | NA | ||
| 30135470 | 2018 | {nnr:R}-{nnr:dab}V{nnr:dab}FL{nnr:dab}VLS{cyc:N-C} | PGP-E | Free | Free | Cyclic | Mix | Dab = Diaminobutyric acid, R = CH2CH2CH3(propyl group) | 9 | Antimicrobial | <50 % Hemolysis at 200 µM | Human | Bacteria Paenibacillus Elgii Bc34-6 | NA | NA | ||
| 30325566 | 2018 | TELLVDLL{nt:Amid}{ct:Amid} | SP1 | Amidation | Amidation | Linear | L | None | 8 | Antibacterial | 0 % Hemolysis at 100 µM | Human | Synthetic Peptide | NA | Non-hemolytic | ||
| 30325566 | 2018 | SELLVDLL{nt:Amid}{ct:Amid} | SP2 | Amidation | Amidation | Linear | L | None | 8 | Antibacterial | 0 % Hemolysis at 100 µM | Human | Synthetic Peptide | NA | Non-hemolytic | ||
| 30325566 | 2018 | EELLVDLL{nt:Amid}{ct:Amid} | SP3 | Amidation | Amidation | Linear | L | None | 8 | Antibacterial | 0 % Hemolysis at 100 µM | Human | Synthetic Peptide | NA | Non-hemolytic | ||
| 30325566 | 2018 | TCELLVDLLC{nt:Amid}{ct:Amid} | SP4 | Amidation | Amidation | Linear | L | None | 8 | Antibacterial | 0 % Hemolysis at 100 µM | Human | Synthetic Peptide | NA | Non-hemolytic | ||
| 30325566 | 2018 | ELL{d}VDL{d}L{cyc:N-C}{nt:Amid} | surfactin | Free | Amidation | Cyclic | Mix | l = D-Leucine | 7 | Antimicrobial | high % Hemolysis at 100 µM | Human | Bacteria Bacillus Subtilis | NA | NA | ||
| 30361948 | 2018 | K{nnr:*}WK{nnr:Nle}{nnr:*}K{ct:Amid} | KKK | Amidation | Free | Linear | Mix | Nle = Norleucine, oct4-enyl = hydrocarbon staple, * = shows the staple site | 7 | Antibacterial | 3 % Hemolysis at 50 µM | Human | Synthetic Stapled Heptapeptides | ɑ-Helix | Low hemolytic | ||
| 30361948 | 2018 | R{nnr:*}WK{nnr:Nle}{nnr:*}K{ct:Amid} | RKK | Amidation | Free | Linear | Mix | Nle = Norleucine, oct4-enyl = hydrocarbon staple, * = shows the staple site | 7 | Antibacterial | 4.3 % Hemolysis at 50 µM | Human | Synthetic Stapled Heptapeptides | ɑ-Helix | NA | ||
| 30361948 | 2018 | K{nnr:*}WR{nnr:Nle}{nnr:*}K{ct:Amid} | KRK | Amidation | Free | Linear | Mix | Nle = Norleucine, oct4-enyl = hydrocarbon staple, * = shows the staple site | 7 | Antibacterial | 2 % Hemolysis at 50 µM | Human | Synthetic Stapled Heptapeptides | ɑ-Helix | Low hemolytic | ||
| 30361948 | 2018 | K{nnr:*}WK{nnr:Nle}{nnr:*}R{ct:Amid} | KKR | Amidation | Free | Linear | Mix | Nle = Norleucine, oct4-enyl = hydrocarbon staple, * = shows the staple site | 7 | Antibacterial | 5.4 % Hemolysis at 50 µM | Human | Synthetic Stapled Heptapeptides | ɑ-Helix | NA | ||
| 30361948 | 2018 | R{nnr:*}WR{nnr:Nle}{nnr:*}K{ct:Amid} | RRK | Amidation | Free | Linear | Mix | Nle = Norleucine, oct4-enyl = hydrocarbon staple, * = shows the staple site | 7 | Antibacterial | <1 % Hemolysis at 50 µM | Human | Synthetic Stapled Heptapeptides | ɑ-Helix | Non-hemolytic | ||
| 30361948 | 2018 | R{nnr:*}WK{nnr:Nle}{nnr:*}R{ct:Amid} | RKR | Amidation | Free | Linear | Mix | Nle = Norleucine, oct4-enyl = hydrocarbon staple, * = shows the staple site | 7 | Antibacterial | 17 % Hemolysis at 50 µM | Human | Synthetic Stapled Heptapeptides | ɑ-Helix | NA | ||
| 30361948 | 2018 | K{nnr:*}WR{nnr:Nle}{nnr:*}R{ct:Amid} | KRR | Amidation | Free | Linear | Mix | Nle = Norleucine, oct4-enyl = hydrocarbon staple, * = shows the staple site | 7 | Antibacterial | 5.6 % Hemolysis at 50 µM | Human | Synthetic Stapled Heptapeptides | ɑ-Helix | NA | ||
| 30361948 | 2018 | R{nnr:*}WR{nnr:Nle}{nnr:*}R{ct:Amid} | RRR | Amidation | Free | Linear | Mix | Nle = Norleucine, oct4-enyl = hydrocarbon staple, * = shows the staple site | 7 | Antibacterial | 3.2 % Hemolysis at 50 µM | Human | Synthetic Stapled Heptapeptides | ɑ-Helix | NA | ||
| 30361948 | 2018 | K{nnr:*}WK{nnr:Nle}{nnr:*}K{ct:Amid} | KKK | Amidation | Free | Linear | Mix | Nle = Norleucine, oct4-enyl = hydrocarbon staple, * = shows the staple site | 7 | Antibacterial | 1.5 % Hemolysis at 25 µM | Human | Synthetic Stapled Heptapeptides | ɑ-Helix | Low hemolytic | ||
| 30361948 | 2018 | R{nnr:*}WK{nnr:Nle}{nnr:*}K{ct:Amid} | RKK | Amidation | Free | Linear | Mix | Nle = Norleucine, oct4-enyl = hydrocarbon staple, * = shows the staple site | 7 | Antibacterial | 1.5 % Hemolysis at 25 µM | Human | Synthetic Stapled Heptapeptides | ɑ-Helix | Low hemolytic | ||
| 30361948 | 2018 | K{nnr:*}WR{nnr:Nle}{nnr:*}K{ct:Amid} | KRK | Amidation | Free | Linear | Mix | Nle = Norleucine, oct4-enyl = hydrocarbon staple, * = shows the staple site | 7 | Antibacterial | < 1 % Hemolysis at 25 µM | Human | Synthetic Stapled Heptapeptides | ɑ-Helix | Non-hemolytic | ||
| 30361948 | 2018 | K{nnr:*}WK{nnr:Nle}{nnr:*}R{ct:Amid} | KKR | Amidation | Free | Linear | Mix | Nle = Norleucine, oct4-enyl = hydrocarbon staple, * = shows the staple site | 7 | Antibacterial | 1.4 % Hemolysis at 25 µM | Human | Synthetic Stapled Heptapeptides | ɑ-Helix | Low hemolytic | ||
| 30361948 | 2018 | R{nnr:*}WR{nnr:Nle}{nnr:*}K{ct:Amid} | RRK | Amidation | Free | Linear | Mix | Nle = Norleucine, oct4-enyl = hydrocarbon staple, * = shows the staple site | 7 | Antibacterial | < 1 % Hemolysis at 25 µM | Human | Synthetic Stapled Heptapeptides | ɑ-Helix | Non-hemolytic | ||
| 30361948 | 2018 | R{nnr:*}WK{nnr:Nle}{nnr:*}R{ct:Amid} | RKR | Amidation | Free | Linear | Mix | Nle = Norleucine, oct4-enyl = hydrocarbon staple, * = shows the staple site | 7 | Antibacterial | 8.2 % Hemolysis at 25 µM | Human | Synthetic Stapled Heptapeptides | ɑ-Helix | NA | ||
| 30361948 | 2018 | K{nnr:*}WR{nnr:Nle}{nnr:*}R{ct:Amid} | KRR | Amidation | Free | Linear | Mix | Nle = Norleucine, oct4-enyl = hydrocarbon staple, * = shows the staple site | 7 | Antibacterial | 1.8 % Hemolysis at 25 µM | Human | Synthetic Stapled Heptapeptides | ɑ-Helix | Low hemolytic | ||
| 30361948 | 2018 | R{nnr:*}WR{nnr:Nle}{nnr:*}R{ct:Amid} | RRR | Amidation | Free | Linear | Mix | Nle = Norleucine, oct4-enyl = hydrocarbon staple, * = shows the staple site | 7 | Antibacterial | < 1 % Hemolysis at 25 µM | Human | Synthetic Stapled Heptapeptides | ɑ-Helix | Non-hemolytic | ||
| 30409520 | 2018 | RRRR{nt:C16 - palmitic acid}{ct:Amid} | C16-4R | Amidation | C16 - palmitic acid | Linear | L | C16 = palmitic acid | 4 | Antifungal, Antibacterial | 6.3 % Hemolysis at 32 μg/mL | Human | Synthetic Arginine-Rich Lipopeptides | NA | NA | ||
| 30409520 | 2018 | RRRR{nt:C16 - palmitic acid}{ct:Amid} | C16-4R | Amidation | C16 - palmitic acid | Linear | L | C16 = palmitic acid | 4 | Antifungal, Antibacterial | 36.1 % Hemolysis at 64 μg/mL | Human | Synthetic Arginine-Rich Lipopeptides | NA | NA | ||
| 30409520 | 2018 | RRRR{nt:C16 - palmitic acid}{ct:Amid} | C16-4R | Amidation | C16 - palmitic acid | Linear | L | C16 = palmitic acid | 4 | Antifungal, Antibacterial | 82.8 % Hemolysis at 128 μg/mL | Human | Synthetic Arginine-Rich Lipopeptides | NA | NA | ||
| 30409520 | 2018 | RRRR{nt:C16 - palmitic acid}{ct:Amid} | C16-4R | Amidation | C16 - palmitic acid | Linear | L | C16 = palmitic acid | 4 | Antifungal, Antibacterial | 96.4 % Hemolysis at 256 μg/mL | Human | Synthetic Arginine-Rich Lipopeptides | NA | NA | ||
| 30409520 | 2018 | RRRR{nt:C16 - palmitic acid}{ct:Amid} | C16-4R | Amidation | C16 - palmitic acid | Linear | L | C16 = palmitic acid | 4 | Antifungal, Antibacterial | 100 % Hemolysis at 512 μg/mL | Human | Synthetic Arginine-Rich Lipopeptides | NA | NA | ||
| 30409520 | 2018 | RRRR{nt:C14 - myristic acid}{ct:Amid} | C14-4R | Amidation | C14 - myristic acid | Linear | L | C14 = myristic acid | 4 | Antifungal, Antibacterial | 0 % Hemolysis at 32 μg/mL | Human | Synthetic Arginine-Rich Lipopeptides | NA | Non-hemolytic | ||
| 30409520 | 2018 | RRRR{nt:C14 - myristic acid}{ct:Amid} | C14-4R | Amidation | C14 - myristic acid | Linear | L | C14 = myristic acid | 4 | Antifungal, Antibacterial | 0 % Hemolysis at 64 μg/mL | Human | Synthetic Arginine-Rich Lipopeptides | NA | Non-hemolytic | ||
| 30409520 | 2018 | RRRR{nt:C14 - myristic acid}{ct:Amid} | C14-4R | Amidation | C14 - myristic acid | Linear | L | C14 = myristic acid | 4 | Antifungal, Antibacterial | 3.6 % Hemolysis at 128 μg/mL | Human | Synthetic Arginine-Rich Lipopeptides | NA | NA | ||
| 30409520 | 2018 | RRRR{nt:C14 - myristic acid}{ct:Amid} | C14-4R | Amidation | C14 - myristic acid | Linear | L | C14 = myristic acid | 4 | Antifungal, Antibacterial | 18.6 % Hemolysis at 256 μg/mL | Human | Synthetic Arginine-Rich Lipopeptides | NA | NA | ||
| 30409520 | 2018 | RRRR{nt:C14 - myristic acid}{ct:Amid} | C14-4R | Amidation | C14 - myristic acid | Linear | L | C14 = myristic acid | 4 | Antifungal, Antibacterial | 63.7 % Hemolysis at 512 μg/mL | Human | Synthetic Arginine-Rich Lipopeptides | NA | NA | ||
| 30409520 | 2018 | RRRR{nt:C12 - lauric acid}{ct:Amid} | C12-4R | Amidation | C12 - lauric acid | Linear | L | C12 = lauric acid | 4 | Antifungal, Antibacterial | 0 % Hemolysis at 32 μg/mL | Human | Synthetic Arginine-Rich Lipopeptides | NA | Non-hemolytic | ||
| 30409520 | 2018 | RRRR{nt:C12 - lauric acid}{ct:Amid} | C12-4R | Amidation | C12 - lauric acid | Linear | L | C12 = lauric acid | 4 | Antifungal, Antibacterial | 0 % Hemolysis at 64 μg/mL | Human | Synthetic Arginine-Rich Lipopeptides | NA | Non-hemolytic | ||
| 30409520 | 2018 | RRRR{nt:C12 - lauric acid}{ct:Amid} | C12-4R | Amidation | C12 - lauric acid | Linear | L | C12 = lauric acid | 4 | Antifungal, Antibacterial | 0 % Hemolysis at 128 μg/mL | Human | Synthetic Arginine-Rich Lipopeptides | NA | Non-hemolytic | ||
| 30409520 | 2018 | RRRR{nt:C12 - lauric acid}{ct:Amid} | C12-4R | Amidation | C12 - lauric acid | Linear | L | C12 = lauric acid | 4 | Antifungal, Antibacterial | 0 % Hemolysis at 256 μg/mL | Human | Synthetic Arginine-Rich Lipopeptides | NA | Non-hemolytic | ||
| 30409520 | 2018 | RRRR{nt:C12 - lauric acid}{ct:Amid} | C12-4R | Amidation | C12 - lauric acid | Linear | L | C12 = lauric acid | 4 | Antifungal, Antibacterial | 0 % Hemolysis at 512 μg/mL | Human | Synthetic Arginine-Rich Lipopeptides | NA | Non-hemolytic | ||
| 30409520 | 2018 | PRRR{nt:C16 - palmitic acid}{ct:Amid} | C16-P3R | Amidation | C16 - palmitic acid | Linear | L | C16 = palmitic acid | 4 | Antifungal, Antibacterial | 0 % Hemolysis at 14 μg/mL | Human | Synthetic Arginine-Rich Lipopeptides | NA | Non-hemolytic | ||
| 30409520 | 2018 | PRRR{nt:C16 - palmitic acid}{ct:Amid} | C16-P3R | Amidation | C16 - palmitic acid | Linear | L | C16 = palmitic acid | 4 | Antifungal, Antibacterial | 12.6 % Hemolysis at 30 μg/mL | Human | Synthetic Arginine-Rich Lipopeptides | NA | NA | ||
| 30409520 | 2018 | PRRR{nt:C16 - palmitic acid}{ct:Amid} | C16-P3R | Amidation | C16 - palmitic acid | Linear | L | C16 = palmitic acid | 4 | Antifungal, Antibacterial | 57.6 % Hemolysis at 60 μg/mL | Human | Synthetic Arginine-Rich Lipopeptides | NA | NA | ||
| 30409520 | 2018 | PRRR{nt:C16 - palmitic acid}{ct:Amid} | C16-P3R | Amidation | C16 - palmitic acid | Linear | L | C16 = palmitic acid | 4 | Antifungal, Antibacterial | 91 % Hemolysis at 128 μg/mL | Human | Synthetic Arginine-Rich Lipopeptides | NA | NA | ||
| 30409520 | 2018 | PRRR{nt:C16 - palmitic acid}{ct:Amid} | C16-P3R | Amidation | C16 - palmitic acid | Linear | L | C16 = palmitic acid | 4 | Antifungal, Antibacterial | 97.1 % Hemolysis at 256 μg/mL | Human | Synthetic Arginine-Rich Lipopeptides | NA | NA | ||
| 30409520 | 2018 | PRRR{nt:C16 - palmitic acid}{ct:Amid} | C16-P3R | Amidation | C16 - palmitic acid | Linear | L | C16 = palmitic acid | 4 | Antifungal, Antibacterial | 100 % Hemolysis at 512 μg/mL | Human | Synthetic Arginine-Rich Lipopeptides | NA | NA | ||
| 30393205 | 2019 | LLWIALRKK{ct:Amid} | CopW | Amidation | Free | Linear | L | None | 9 | Antibacterial | 0.08 ± 0.04 % Hemolysis at 100 µM | Human | Derived From Coprisin Dung Beetle Copris Tripartitus | NA | Non-hemolytic | ||
| 30393205 | 2019 | LLWIALRKK{conj:C10:0}{ct:Amid} | CopW3 | Amidation | Free | Linear | L | C10 = decanoic acid | 9 | Antibacterial | 11.84 ± 0.46 % Hemolysis at 100 µM | Human | Synthetic Copw With Fatty Acid-Conjugated | NA | NA | ||
| 30393205 | 2019 | L{d}L{d}W{d}I{d}A{d}L{d}R{d}K{d}K{d}{ct:Amid} | dCopW | Amidation | Free | Linear | D | None | 9 | Antibacterial | 2.32 ± 0.78 % Hemolysis at 100 µM | Human | Synthetic Copw With D-Amino | NA | Non-hemolytic | ||
| 30393205 | 2019 | L{d}L{d}W{d}I{d}A{d}L{d}R{d}K{d}K{d}{conj:C6:0}{ct:Amid} | dCopW1 | Amidation | Free | Linear | D | C6 = hexanoic acid | 9 | Antibacterial | 0.39 ± 0.66 % Hemolysis at 100 µM | Human | Synthetic Copw With Fatty Acid-Conjugated | NA | Non-hemolytic | ||
| 30393205 | 2019 | L{d}L{d}W{d}I{d}A{d}L{d}R{d}K{d}K{d}{conj:C8:0}{ct:Amid} | dCopW2 | Amidation | Free | Linear | D | C8 = Octanoic Acid | 9 | Antibacterial | 0.68 ± 0.47 % Hemolysis at 100 µM | Human | Synthetic Copw With Fatty Acid-Conjugated | NA | Non-hemolytic | ||
| 30393205 | 2019 | L{d}L{d}W{d}I{d}A{d}L{d}R{d}K{d}K{d}{conj:C10:0}{ct:Amid} | dCopW3 | Amidation | Free | Linear | D | C10 = decanoic acid | 9 | Antibacterial | 3.66 ± 0.39 % Hemolysis at 100 µM | Human | Synthetic Copw With Fatty Acid-Conjugated | NA | Non-hemolytic | ||
| 30393205 | 2019 | L{d}L{d}W{d}I{d}A{d}L{d}R{d}K{d}K{d}{conj:C12:0}{ct:Amid} | dCopW4 | Amidation | Free | Linear | D | C12 = Dodecanoic Acid | 9 | Antibacterial | 7.10 ± 0.32 % Hemolysis at 100 µM | Human | Synthetic Copw With Fatty Acid-Conjugated | NA | NA | ||
| 30393205 | 2019 | L{d}L{d}W{d}I{d}A{d}L{d}R{d}K{d}K{d}{conj:C14:0}{ct:Amid} | dCopW5 | Amidation | Free | Linear | D | C14 = Tetradecanoic Acid | 9 | Antibacterial | 8.36 ± 0.26 % Hemolysis at 100 µM | Human | Synthetic Copw With Fatty Acid-Conjugated | NA | NA | ||
| 30393205 | 2019 | L{d}L{d}W{d}I{d}A{d}L{d}R{d}K{d}K{d}{conj:C16:0}{ct:Amid} | dCopW6 | Amidation | Free | Linear | D | C16 = hexadecanoic acid | 9 | Antibacterial | 11.67 ± 0.55 % Hemolysis at 100 µM | Human | Synthetic Copw With Fatty Acid-Conjugated | NA | NA | ||
| 30393205 | 2019 | K{d}{conj:C10:0}K{d}R{d}L{d}A{d}I{d}W{d}L{d}L{d}{ct:Amid} | Retro-dCopW3 | Amidation | Free | Linear | D | C10 = decanoic acid | 9 | Antibacterial | 20.88 ± 1.15 % Hemolysis at 100 µM | Human | Synthetic Copw With Fatty Acid-Conjugated | NA | NA | ||
| 30389515 | 2019 | CPAIQRCC | Mo-CBP3-PepI | Free | Free | Linear | L | None | 8 | Antibacterial, Anticandidal | 0 % Hemolysis at 70 µM | Human | Plant Moringa Oleifera Seeds | 75% α-Helix and 25% β-Turns | Non-hemolytic | ||
| 30389515 | 2019 | NIQPPCRCC | Mo-CBP3-PepII | Free | Free | Linear | L | None | 9 | Antibacterial, Anticandidal | 0 % Hemolysis at 70 µM | Human | Plant Moringa Oleifera Seeds | 60% α-Helix and 40% β-Turns | Non-hemolytic | ||
| 30389515 | 2019 | AIQRCC | Mo-CBP3-PepIII | Free | Free | Linear | L | None | 6 | Antibacterial, Anticandidal | 0 % Hemolysis at 70 µM | Human | Plant Moringa Oleifera Seeds | 75% α-Helix and 25% β-Turns | Non-hemolytic | ||
| 30389515 | 2019 | CPAIQRCC | Mo-CBP3-PepI | Free | Free | Linear | L | None | 8 | Antibacterial, Anticandidal | 0 % Hemolysis at 280 µM | Human | Plant Moringa Oleifera Seeds | 75% α-Helix and 25% β-Turns | Non-hemolytic | ||
| 30389515 | 2019 | NIQPPCRCC | Mo-CBP3-PepII | Free | Free | Linear | L | None | 9 | Antibacterial, Anticandidal | 0 % Hemolysis at 280 µM | Human | Plant Moringa Oleifera Seeds | 60% α-Helix and 40% β-Turns | Non-hemolytic | ||
| 30389515 | 2019 | AIQRCC | Mo-CBP3-PepIII | Free | Free | Linear | L | None | 6 | Antibacterial, Anticandidal | 0 % Hemolysis at 280 µM | Human | Plant Moringa Oleifera Seeds | 75% α-Helix and 25% β-Turns | Non-hemolytic | ||
| 30500360 | 2019 | PFKLSLHL{ct:Amid} | Jelleine-I | Amidation | Free | Linear | L | None | 8 | Antibiofilm, Antimicrobial | ~5 % Hemolysis at 256 µM | Mouse | Royal Jelly Of Honeybees (Apis Mellifera) | NA | Low hemolytic | ||
| 30500360 | 2019 | P{nnr:Fc}KLSLHL{ct:Amid} | fluorine-Jelleine-I (F-J-I) | Amidation | Free | Linear | L | Fc = 4-F-phe-amino acid | 8 | Antibiofilm, Antimicrobial | 3 % Hemolysis at 256 µM | Mouse | Jelleine-I Halogenated Derivatives | NA | Low hemolytic | ||
| 30500360 | 2019 | P{nnr:Fd}KLSLHL{ct:Amid} | chlorine-Jelleine-I (Cl-J-I) | Amidation | Free | Linear | L | Fd = 4-Cl-phe-amino acid | 8 | Antibiofilm, Antimicrobial | 2 % Hemolysis at 256 µM | Mouse | Jelleine-I Halogenated Derivatives | NA | Low hemolytic | ||
| 30500360 | 2019 | P{nnr:Fe}KLSLHL{ct:Amid} | bromine-Jelleine-I (Br-J-I) | Amidation | Free | Linear | L | Fe = 4-Br-phe-amino acid | 8 | Antibiofilm, Antimicrobial | ~4 % Hemolysis at 256 µM | Mouse | Jelleine-I Halogenated Derivatives | NA | Low hemolytic | ||
| 30500360 | 2019 | P{nnr:Ff}KLSLHL{ct:Amid} | iodine-Jelleine-I (I-J-I) | Amidation | Free | Linear | L | Ff = 4-I-phe-amino acid | 8 | Antibiofilm, Antimicrobial | ~10 % Hemolysis at 256 µM | Mouse | Jelleine-I Halogenated Derivatives | NA | Low hemolytic | ||
| 30384016 | 2019 | SISLL | BRCA1(782–786) | Free | Free | Linear | L | None | 5 | Antibacterial | 5 % Hemolysis at >250 μg/ml | Human | Synthetic Peptide | NA | Non-hemolytic | ||
| 30789942 | 2019 | RIWR{nt:Lau}{ct:Amid} | Lp-I | Amidation | Lau | Linear | L | l = Lau(lauric acid (C12)) | 4 | Antibacterial, Antifungal | ≤10 % Hemolysis at 25 μg/mL | Human | Synthetic Argrich Ultra-Short Cationic Lipopeptides | NA | NA | ||
| 30789942 | 2019 | RRIWRR{nt:Lau}{ct:Amid} | Lp-IRR | Amidation | Lau | Linear | L | l = Lau(lauric acid (C12)) | 6 | Antibacterial, Antifungal | ≤10 % Hemolysis at 25 μg/mL | Human | Synthetic Argrich Ultra-Short Cationic Lipopeptides | NA | NA | ||
| 30789942 | 2019 | RIWR{nt:Lau}{ct:Amid} | Lp-I | Amidation | Lau | Linear | L | l = Lau(lauric acid (C12)) | 4 | Antibacterial, Antifungal | ≤60 % Hemolysis at 50 μg/mL | Human | Synthetic Argrich Ultra-Short Cationic Lipopeptides | NA | NA | ||
| 30789942 | 2019 | RRIWRR{nt:Lau}{ct:Amid} | Lp-IRR | Amidation | Lau | Linear | L | l = Lau(lauric acid (C12)) | 6 | Antibacterial, Antifungal | ≤10 % Hemolysis at 50 μg/mL | Human | Synthetic Argrich Ultra-Short Cationic Lipopeptides | NA | NA | ||
| 30789942 | 2019 | RIWR{nt:Lau}{ct:Amid} | Lp-I | Amidation | Lau | Linear | L | l = Lau(lauric acid (C12)) | 4 | Antibacterial, Antifungal | 100 % Hemolysis at 100 μg/mL | Human | Synthetic Argrich Ultra-Short Cationic Lipopeptides | NA | NA | ||
| 30789942 | 2019 | RRIWRR{nt:Lau}{ct:Amid} | Lp-IRR | Amidation | Lau | Linear | L | l = Lau(lauric acid (C12)) | 6 | Antibacterial, Antifungal | ≤60 % Hemolysis at 100 μg/mL | Human | Synthetic Argrich Ultra-Short Cationic Lipopeptides | NA | NA | ||
| 32254776 | 2019 | KLAKLAKKLAKLAK | KLA | Free | Free | Linear | L | None | 7 | Antibacterial | 0.025 % Hemolysis at 50 μM | mouse | Synthetic Peptide | α-Helix | Non-hemolytic | ||
| 32254776 | 2019 | {conj:PpIX}-{conj:PEG8}-KLAKLAKKLAKLAK-{conj:PEG8}-KLAKLAKKLAKLAK | PPK | Free | Free | Linear | L | conjugating a photosensitizer PpIX = photosensitizer protoporphyrin IX conjugating, PEG = Polyethylene glycol linker | 7 | Antibacterial | 0.025 % Hemolysis at 50 μM | mouse | Chimeric Synthetic Peptide | α-Helix | Non-hemolytic | ||
| 30392097 | 2019 | KKKK{nt:Dilipid C7 acylation}{ct:Amid} | 1 | Amidation | Dilipid C7 acylation | Linear | L | None | 4 | Antibacterial | 1.03 % Hemolysis at 50 μg/mL | Pig | Synthetic Dilipid Ultrashort Cationic Lipopeptides | NA | Non-hemolytic | ||
| 30392097 | 2019 | KKKK{nt:Dilipid C9 acylation}{ct:Amid} | 2 | Amidation | Dilipid C9 acylation | Linear | L | None | 4 | Antibacterial | 1.53 % Hemolysis at 50 μg/mL | Pig | Synthetic Dilipid Ultrashort Cationic Lipopeptides | NA | Non-hemolytic | ||
| 30392097 | 2019 | KKKK{nt:Dilipid C11 acylation}{ct:Amid} | 3 | Amidation | Dilipid C11 acylation | Linear | L | None | 4 | Antibacterial | 2.32 % Hemolysis at 50 μg/mL | Pig | Synthetic Dilipid Ultrashort Cationic Lipopeptides | NA | Non-hemolytic | ||
| 30392097 | 2019 | KKKK{nt:Dilipid C14 acylation}{ct:Amid} | 4 | Amidation | Dilipid C14 acylation | Linear | L | None | 4 | Antibacterial | 1 % Hemolysis at 50 μg/mL | Pig | Synthetic Dilipid Ultrashort Cationic Lipopeptides | NA | Non-hemolytic | ||
| 30392097 | 2019 | KKGK{nt:Dilipid C7 acylation}{ct:Amid} | 5 | Amidation | Dilipid C7 acylation | Linear | L | None | 4 | Antibacterial | 1 % Hemolysis at 50 μg/mL | Pig | Synthetic Dilipid Ultrashort Cationic Lipopeptides | NA | Non-hemolytic | ||
| 30392097 | 2019 | KKGK{nt:Dilipid C9 acylation}{ct:Amid} | 6 | Amidation | Dilipid C9 acylation | Linear | L | None | 4 | Antibacterial | 1.21 % Hemolysis at 50 μg/mL | Pig | Synthetic Dilipid Ultrashort Cationic Lipopeptides | NA | Non-hemolytic | ||
| 30392097 | 2019 | KKGK{nt:Dilipid C11 acylation}{ct:Amid} | 7 | Amidation | Dilipid C11 acylation | Linear | L | None | 4 | Antibacterial | 13.66 % Hemolysis at 50 μg/mL | Pig | Synthetic Dilipid Ultrashort Cationic Lipopeptides | NA | NA | ||
| 30392097 | 2019 | KKGK{nt:Dilipid C14 acylation}{ct:Amid} | 8 | Amidation | Dilipid C14 acylation | Linear | L | None | 4 | Antibacterial | 22.23 % Hemolysis at 50 μg/mL | Pig | Synthetic Dilipid Ultrashort Cationic Lipopeptides | NA | NA | ||
| 30392097 | 2019 | KKKK{nt:Dilipid C7 acylation}{ct:Amid} | 1 | Amidation | Dilipid C7 acylation | Linear | L | None | 4 | Antibacterial | 0.75 % Hemolysis at 100 μg/mL | Pig | Synthetic Dilipid Ultrashort Cationic Lipopeptides | NA | Non-hemolytic | ||
| 30392097 | 2019 | KKKK{nt:Dilipid C9 acylation}{ct:Amid} | 2 | Amidation | Dilipid C9 acylation | Linear | L | None | 4 | Antibacterial | 2.07 % Hemolysis at 100 μg/mL | Pig | Synthetic Dilipid Ultrashort Cationic Lipopeptides | NA | Non-hemolytic | ||
| 30392097 | 2019 | KKKK{nt:Dilipid C11 acylation}{ct:Amid} | 3 | Amidation | Dilipid C11 acylation | Linear | L | None | 4 | Antibacterial | 23.72 % Hemolysis at 100 μg/mL | Pig | Synthetic Dilipid Ultrashort Cationic Lipopeptides | NA | NA | ||
| 30392097 | 2019 | KKKK{nt:Dilipid C14 acylation}{ct:Amid} | 4 | Amidation | Dilipid C14 acylation | Linear | L | None | 4 | Antibacterial | 42.1 % Hemolysis at 100 μg/mL | Pig | Synthetic Dilipid Ultrashort Cationic Lipopeptides | NA | NA | ||
| 30392097 | 2019 | KKGK{nt:Dilipid C7 acylation}{ct:Amid} | 5 | Amidation | Dilipid C7 acylation | Linear | L | None | 4 | Antibacterial | 1.1 % Hemolysis at 100 μg/mL | Pig | Synthetic Dilipid Ultrashort Cationic Lipopeptides | NA | Non-hemolytic | ||
| 30392097 | 2019 | KKGK{nt:Dilipid C9 acylation}{ct:Amid} | 6 | Amidation | Dilipid C9 acylation | Linear | L | None | 4 | Antibacterial | 3.78 % Hemolysis at 100 μg/mL | Pig | Synthetic Dilipid Ultrashort Cationic Lipopeptides | NA | NA | ||
| 30392097 | 2019 | KKGK{nt:Dilipid C11 acylation}{ct:Amid} | 7 | Amidation | Dilipid C11 acylation | Linear | L | None | 4 | Antibacterial | 19.73 % Hemolysis at 100 μg/mL | Pig | Synthetic Dilipid Ultrashort Cationic Lipopeptides | NA | NA | ||
| 30392097 | 2019 | KKGK{nt:Dilipid C14 acylation}{ct:Amid} | 8 | Amidation | Dilipid C14 acylation | Linear | L | None | 4 | Antibacterial | 30.5 % Hemolysis at 100 μg/mL | Pig | Synthetic Dilipid Ultrashort Cationic Lipopeptides | NA | NA | ||
| 30392097 | 2019 | KKKK{nt:Dilipid C7 acylation}{ct:Amid} | 1 | Amidation | Dilipid C7 acylation | Linear | L | None | 4 | Antibacterial | 1.03 % Hemolysis at 500 μg/mL | Pig | Synthetic Dilipid Ultrashort Cationic Lipopeptides | NA | Non-hemolytic | ||
| 30392097 | 2019 | KKKK{nt:Dilipid C9 acylation}{ct:Amid} | 2 | Amidation | Dilipid C9 acylation | Linear | L | None | 4 | Antibacterial | 22.44 % Hemolysis at 500 μg/mL | Pig | Synthetic Dilipid Ultrashort Cationic Lipopeptides | NA | NA | ||
| 30392097 | 2019 | KKKK{nt:Dilipid C11 acylation}{ct:Amid} | 3 | Amidation | Dilipid C11 acylation | Linear | L | None | 4 | Antibacterial | 96.4 % Hemolysis at 500 μg/mL | Pig | Synthetic Dilipid Ultrashort Cationic Lipopeptides | NA | NA | ||
| 30392097 | 2019 | KKKK{nt:Dilipid C14 acylation}{ct:Amid} | 4 | Amidation | Dilipid C14 acylation | Linear | L | None | 4 | Antibacterial | 97.97 % Hemolysis at 500 μg/mL | Pig | Synthetic Dilipid Ultrashort Cationic Lipopeptides | NA | NA | ||
| 30392097 | 2019 | KKGK{nt:Dilipid C7 acylation}{ct:Amid} | 5 | Amidation | Dilipid C7 acylation | Linear | L | None | 4 | Antibacterial | 2.21 % Hemolysis at 500 μg/mL | Pig | Synthetic Dilipid Ultrashort Cationic Lipopeptides | NA | Non-hemolytic | ||
| 30392097 | 2019 | KKGK{nt:Dilipid C9 acylation}{ct:Amid} | 6 | Amidation | Dilipid C9 acylation | Linear | L | None | 4 | Antibacterial | 74.28 % Hemolysis at 500 μg/mL | Pig | Synthetic Dilipid Ultrashort Cationic Lipopeptides | NA | NA | ||
| 30392097 | 2019 | KKGK{nt:Dilipid C11 acylation}{ct:Amid} | 7 | Amidation | Dilipid C11 acylation | Linear | L | None | 4 | Antibacterial | 36.78 % Hemolysis at 500 μg/mL | Pig | Synthetic Dilipid Ultrashort Cationic Lipopeptides | NA | NA | ||
| 30392097 | 2019 | KKGK{nt:Dilipid C14 acylation}{ct:Amid} | 8 | Amidation | Dilipid C14 acylation | Linear | L | None | 4 | Antibacterial | 77 % Hemolysis at 500 μg/mL | Pig | Synthetic Dilipid Ultrashort Cationic Lipopeptides | NA | NA | ||
| 30842436 | 2019 | K-K-{nnr:(NBu)Gly}-K-{nnr:(N1-Nal)Gly}-{nnr:(N4-MeBn)Gly}-{nnr:(N1-Nal)Gly} | B1 | Free | Free | Linear | L | (NBu)Gly = N-(4-aminobutyl)glycine, (N1-Nal)Gly = N-(1-naphthyl)glycine, (N4-MeBn)Gly = N-(4-methylbenzyl)glycine | 7 | Antimicrobial | 32 % Hemolysis at 150 µM | Human | Synthetic Peptide-Peptoid Hybrid | Random coil | NA | ||
| 30842436 | 2019 | K-K-{nnr:(NBu)Gly}-K-{nnr:(N1-Nal)Gly}-{nnr:(NPhe)Gly}-{nnr:(N1-Nal)Gly} | 2 | Free | Free | Linear | L | (NBu)Gly = N-(4-aminobutyl)glycine, (N1-Nal)Gly = N-(1-naphthyl)glycine, (NPhe)Gly = N-Phenylalanine glycine | 7 | Antibacterial | <8 % Hemolysis at 150 µM | Human | Synthetic Peptide-Peptoid Hybrid | Random coil | Low hemolytic | ||
| 30842436 | 2019 | K-K-K-{nnr:(NBu)Gly}-{nnr:(N1-Nal)Gly}-{nnr:(NPhe)Gly}-{nnr:(N1-Nal)Gly} | 3 | Free | Free | Linear | L | (NBu)Gly = N-(4-aminobutyl)glycine, (N1-Nal)Gly = N-(1-naphthyl)glycine, (NPhe)Gly = N-Phenylalanine glycine | 7 | Antibacterial | <8 % Hemolysis at 150 µM | Human | Synthetic Peptide-Peptoid Hybrid | Random coil | Low hemolytic | ||
| 30842436 | 2019 | {nnr:(N1-Nal)Gly}-{nnr:(NPhe)Gly}-{nnr:(N1-Nal)Gly}-{nnr:(NBu)Gly}-K-K-K | 4 | Free | Free | Linear | L | (NBu)Gly = N-(4-aminobutyl)glycine, (N1-Nal)Gly = N-(1-naphthyl)glycine, (NPhe)Gly = N-Phenylalanine glycine | 7 | Antibacterial | 24 % Hemolysis at 150 µM | Human | Synthetic Peptide-Peptoid Hybrid | Random coil | NA | ||
| 30842436 | 2019 | {nnr:(N1-Nal)Gly}-{nnr:(NPhe)Gly}-{nnr:(N1-Nal)Gly}-K-{nnr:(NBu)Gly}-K-K | 5 | Free | Free | Linear | L | (NBu)Gly = N-(4-aminobutyl)glycine, (N1-Nal)Gly = N-(1-naphthyl)glycine, (NPhe)Gly = N-Phenylalanine glycine | 7 | Antibacterial | <8 % Hemolysis at 150 µM | Human | Synthetic Peptide-Peptoid Hybrid | Random coil | Low hemolytic | ||
| 30842436 | 2019 | K-K-L-K-{nnr:(1-Nal)Ala}-F-{nnr:(1-Nal)Ala} | 6 | Free | Free | Linear | L | (1-Nal)Ala = 1-Naphthylalanine | 7 | Antibacterial | 96 % Hemolysis at 150 µM | Human | Synthetic Peptide-Peptoid Hybrid | Random coil | NA | ||
| 30842436 | 2019 | K-K-K-L-{nnr:(1-Nal)Ala}-F-{nnr:(1-Nal)Ala} | 7 | Free | Free | Linear | L | (1-Nal)Ala = 1-Naphthylalanine | 7 | Antibacterial | 55 % Hemolysis at 150 µM | Human | Synthetic Peptide-Peptoid Hybrid | Random coil | NA | ||
| 30842436 | 2019 | K-K-L-K-{nnr:(2-Nal)Ala}-F-{nnr:(2-Nal)Ala} | 8 | Free | Free | Linear | L | (2-Nal)Ala = 2-Naphthylalanine | 7 | Antibacterial | 34 % Hemolysis at 150 µM | Human | Synthetic Peptide-Peptoid Hybrid | Random coil | NA | ||
| 30842436 | 2019 | K-K-K-L-{nnr:(2-Nal)Ala}-F-{nnr:(2-Nal)Ala} | 9 | Free | Free | Linear | L | (2-Nal)Ala = 2-Naphthylalanine | 7 | Antibacterial | 39 % Hemolysis at 150 µM | Human | Synthetic Peptide-Peptoid Hybrid | Random coil | NA | ||
| 30842436 | 2019 | {nnr:(1-Nal)Ala}-F-{nnr:(1-Nal)Ala}-K-L-K-K | 10 | Free | Free | Linear | L | (1-Nal)Ala = 1-Naphthylalanine | 7 | Antibacterial | <8 % Hemolysis at 150 µM | Human | Synthetic Peptide-Peptoid Hybrid | Random coil | Low hemolytic | ||
| 30842436 | 2019 | {nnr:(2-Nal)Ala}-F -{nnr:(2-Nal)Ala}-K-L-K-K | 11 | Free | Free | Linear | L | (2-Nal)Ala = 2-Naphthylalanine | 7 | Antibacterial | <8 % Hemolysis at 150 µM | Human | Synthetic Peptide-Peptoid Hybrid | Random coil | Low hemolytic | ||
| 30842436 | 2019 | {nnr:(1-Nal)Ala}-F-{nnr:(1-Nal)Ala}-L-K-K-K | 12 | Free | Free | Linear | L | (1-Nal)Ala = 1-Naphthylalanine | 7 | Antibacterial | <8 % Hemolysis at 150 µM | Human | Synthetic Peptide-Peptoid Hybrid | Random coil | Low hemolytic | ||
| 30842436 | 2019 | {nnr:(2-Nal)Ala}-F-{nnr:(2-Nal)Ala}-L-K-K-K | 13 | Free | Free | Linear | L | (2-Nal)Ala = 2-Naphthylalanine | 7 | Antibacterial | 15 % Hemolysis at 150 µM | Human | Synthetic Peptide-Peptoid Hybrid | Random coil | NA | ||
| 30842436 | 2019 | K-K-L-K-{nnr:(1-Nal)ala}-F{d}-{nnr:(1-Nal)ala} | 14 | Free | Free | Linear | Mix | (1-Nal)ala = D-1-Naphthylalanine | 7 | Antibacterial | 58 % Hemolysis at 150 µM | Human | Synthetic Peptide-Peptoid Hybrid | Random coil | NA | ||
| 30842436 | 2019 | K-K-K-L{d}-{nnr:(1-Nal)ala}-F{d}-{nnr:(1-Nal)ala} | 15 | Free | Free | Linear | Mix | (1-Nal)ala = D-1-Naphthylalanine | 7 | Antibacterial | 88 % Hemolysis at 150 µM | Human | Synthetic Peptide-Peptoid Hybrid | Random coil | NA | ||
| 30842436 | 2019 | K-K-K-L{d}-{nnr:(2-Nal)ala}-F{d}-{nnr:(2-Nal)ala} | 16 | Free | Free | Linear | Mix | (2-Nal)ala = D-2-Naphthylalanine | 7 | Antibacterial | 60 % Hemolysis at 150 µM | Human | Synthetic Peptide-Peptoid Hybrid | Random coil | NA | ||
| 30842436 | 2019 | K-K-L{d}-K-{nnr:(2-Nal)ala}-F{d}-{nnr:(2-Nal)ala} | 17 | Free | Free | Linear | Mix | (2-Nal)ala = D-2-Naphthylalanine | 7 | Antibacterial | 40 % Hemolysis at 150 µM | Human | Synthetic Peptide-Peptoid Hybrid | Random coil | NA | ||
| 30842436 | 2019 | {nnr:(2-Nal)ala}-F{d}-{nnr:(2-Nal)ala}-K-L{d}-K-K | 18 | Free | Free | Linear | Mix | (2-Nal)ala = D-2-Naphthylalanine | 7 | Antibacterial | <8 % Hemolysis at 150 µM | Human | Synthetic Peptide-Peptoid Hybrid | Random coil | Low hemolytic | ||
| 30842436 | 2019 | {nnr:(2-Nal)ala}-F{d}-{nnr:(2-Nal)ala}-L{d}-K-K-K | 19 | Free | Free | Linear | Mix | (2-Nal)ala = D-2-Naphthylalanine | 7 | Antibacterial | <8 % Hemolysis at 150 µM | Human | Synthetic Peptide-Peptoid Hybrid | Random coil | Low hemolytic | ||
| 30842436 | 2019 | {nnr:(1-Nal)ala}-F{d}-{nnr:(1-Nal)ala}-K-L{d}-K-K | 20 | Free | Free | Linear | Mix | (1-Nal)ala = D-1-Naphthylalanine | 7 | Antibacterial | <8 % Hemolysis at 150 µM | Human | Synthetic Peptide-Peptoid Hybrid | Random coil | Low hemolytic | ||
| 30842436 | 2019 | {nnr:(1-Nal)ala}-F{d}-{nnr:(1-Nal)ala}-L{d}-K-K-K | 21 | Free | Free | Linear | Mix | (1-Nal)ala = D-1-Naphthylalanine | 7 | Antibacterial | <8 % Hemolysis at 150 µM | Human | Synthetic Peptide-Peptoid Hybrid | Random coil | Low hemolytic | ||
| 30842436 | 2019 | K-K-K-L-{nnr:(2-Nal)Ala}-Y-{nnr:(2-Nal)Ala} | 22 | Free | Free | Linear | L | (2-Nal)Ala = 2-Naphthylalanine | 7 | Antibacterial | 14 % Hemolysis at 150 µM | Human | Synthetic Peptide-Peptoid Hybrid | Random coil | NA | ||
| 30842436 | 2019 | K-K-K-{nnr:Nle}-{nnr:(2-Nal)Ala}-F-{nnr:(2-Nal)Ala} | 23 | Free | Free | Linear | L | (2-Nal)Ala = 2-Naphthylalanine | 7 | Antimicrobial | 59 % Hemolysis at 150 µM | Human | Synthetic Peptide-Peptoid Hybrid | Random coil | NA | ||
| 30842436 | 2019 | K-K-K-{nnr:Nle}-{nnr:(1-Nal)Ala}-F-{nnr:(1-Nal)Ala} | 24 | Free | Free | Linear | L | (1-Nal)Ala = 1-Naphthylalanine, Nle= norleucine | 7 | Antibacterial | 60 % Hemolysis at 150 µM | Human | Synthetic Peptide-Peptoid Hybrid | Random coil | NA | ||
| 30842436 | 2019 | K-K-K-L{d}-{nnr:(1-Nal)ala}-Y{d}-{nnr:(1-Nal)ala} | 25 | Free | Free | Linear | Mix | (1-Nal)ala = D-1-Naphthylalanine | 7 | Antibacterial | 53 % Hemolysis at 150 µM | Human | Synthetic Peptide-Peptoid Hybrid | Random coil | NA | ||
| 30842436 | 2019 | K-K-K-{nnr:nle}-(1-Nal)ala-F{d}-(1-Nal)ala | 26 | Free | Free | Linear | Mix | nle = D-Norleucine, (1-Nal)Ala = 1-Naphthylalanine | 7 | Antimicrobial | 56 % Hemolysis at 150 µM | Human | Synthetic Peptide-Peptoid Hybrid | Random coil | NA | ||
| 30842436 | 2019 | K-K-K-{nnr:Nle}-{nnr:(2-Nal)Ala}-Y-{nnr:(2-Nal)Ala} | 27 | Free | Free | Linear | L | (2-Nal)Ala = 2-Naphthylalanine, Nle= norleucine | 7 | Antibacterial | 54 % Hemolysis at 150 µM | Human | Synthetic Peptide-Peptoid Hybrid | Random coil | NA | ||
| 30842436 | 2019 | K-K-K-L{d}-(2-Nal)ala-Y{d}-(2-Nal)ala | 28 | Free | Free | Linear | Mix | (1-Nal)ala = D-1-Naphthylalanine | 7 | Antibacterial | 64 % Hemolysis at 150 µM | Human | Synthetic Peptide-Peptoid Hybrid | Random coil | NA | ||
| 30842436 | 2019 | {nnr:NLys}-{nnr:NLys}-{nnr:NLys}-L-{nnr:(2-Nal)Ala}-F-{nnr:(2-Nal)Ala} | 29 | Free | Free | Linear | L | (2-Nal)Ala = D-2-Naphthylalanine, NLys | 7 | Antibacterial | 46 % Hemolysis at 150 µM | Human | Synthetic Peptide-Peptoid Hybrid | Random coil | NA | ||
| 30842436 | 2019 | K-K-{nnr:(NBu)Gly}-K-{nnr:(N1-Nal)Gly}-{nnr:(N4-MeBn)Gly}-{nnr:(N1-Nal)Gly} | B1 | Free | Free | Linear | L | (NBu)Gly = N-(4-aminobutyl)glycine, (N1-Nal)Gly = N-(1-naphthyl)glycine, (N4-MeBn)Gly = N-(4-methylbenzyl)glycine | 7 | Antimicrobial | 10 % Hemolysis at 64 µM | Human | Synthetic Peptide-Peptoid Hybrid | Random coil | NA | ||
| 30842436 | 2019 | {nnr:(N1-Nal)Gly}-{nnr:(NPhe)Gly}-{nnr:(N1-Nal)Gly}-{nnr:(NBu)Gly}-K-K-K | 4 | Free | Free | Linear | L | (NBu)Gly = N-(4-aminobutyl)glycine, (N1-Nal)Gly = N-(1-naphthyl)glycine, (NPhe)Gly = N-Phenylalanine glycine | 7 | Antibacterial | 10 % Hemolysis at 54 µM | Human | Synthetic Peptide-Peptoid Hybrid | Random coil | NA | ||
| 30842436 | 2019 | K-K-L-K-{nnr:(1-Nal)Ala}-F-{nnr:(1-Nal)Ala} | 6 | Free | Free | Linear | L | (1-Nal)Ala = 1-Naphthylalanine | 7 | Antibacterial | 10 % Hemolysis at 5 µM | Human | Synthetic Peptide-Peptoid Hybrid | Random coil | Low hemolytic | ||
| 30842436 | 2019 | K-K-K-L-{nnr:(1-Nal)Ala}-F-{nnr:(1-Nal)Ala} | 7 | Free | Free | Linear | L | (1-Nal)Ala = 1-Naphthylalanine | 7 | Antibacterial | 10 % Hemolysis at 8 µM | Human | Synthetic Peptide-Peptoid Hybrid | Random coil | NA | ||
| 30842436 | 2019 | K-K-L-K-{nnr:(2-Nal)Ala}-F-{nnr:(2-Nal)Ala} | 8 | Free | Free | Linear | L | (2-Nal)Ala = 2-Naphthylalanine | 7 | Antibacterial | 10 % Hemolysis at 56 µM | Human | Synthetic Peptide-Peptoid Hybrid | Random coil | NA | ||
| 30842436 | 2019 | K-K-K-L-{nnr:(2-Nal)Ala}-F-{nnr:(2-Nal)Ala} | 9 | Free | Free | Linear | L | (2-Nal)Ala = 2-Naphthylalanine | 7 | Antibacterial | 10 % Hemolysis at 46 µM | Human | Synthetic Peptide-Peptoid Hybrid | Random coil | NA | ||
| 30842436 | 2019 | {nnr:(2-Nal)Ala}-F-{nnr:(2-Nal)Ala}-L-K-K-K | 13 | Free | Free | Linear | L | (2-Nal)Ala = 2-Naphthylalanine | 7 | Antibacterial | 10 % Hemolysis at 110 µM | Human | Synthetic Peptide-Peptoid Hybrid | Random coil | NA | ||
| 30842436 | 2019 | K-K-L-K-{nnr:(1-Nal)ala}-F{d}-{nnr:(1-Nal)ala} | 14 | Free | Free | Linear | Mix | (1-Nal)ala = D-1-Naphthylalanine | 7 | Antibacterial | 10 % Hemolysis at 28 µM | Human | Synthetic Peptide-Peptoid Hybrid | Random coil | NA | ||
| 30842436 | 2019 | K-K-K-L{d}-{nnr:(1-Nal)ala}-F{d}-{nnr:(1-Nal)ala} | 15 | Free | Free | Linear | Mix | (1-Nal)ala = D-1-Naphthylalanine | 7 | Antibacterial | 10 % Hemolysis at 8 µM | Human | Synthetic Peptide-Peptoid Hybrid | Random coil | NA | ||
| 30842436 | 2019 | K-K-K-L{d}-{nnr:(2-Nal)ala}-F{d}-{nnr:(2-Nal)ala} | 16 | Free | Free | Linear | Mix | (2-Nal)ala = D-2-Naphthylalanine | 7 | Antibacterial | 10 % Hemolysis at 18 µM | Human | Synthetic Peptide-Peptoid Hybrid | Random coil | NA | ||
| 30842436 | 2019 | K-K-L{d}-K-{nnr:(2-Nal)ala}-F{d}-{nnr:(2-Nal)ala} | 17 | Free | Free | Linear | Mix | (2-Nal)ala = D-2-Naphthylalanine | 7 | Antibacterial | 10 % Hemolysis at 8 µM | Human | Synthetic Peptide-Peptoid Hybrid | Random coil | NA | ||
| 30842436 | 2019 | K-K-K-L-{nnr:(2-Nal)Ala}-Y-{nnr:(2-Nal)Ala} | 22 | Free | Free | Linear | L | (2-Nal)Ala = 2-Naphthylalanine | 7 | Antibacterial | 10 % Hemolysis at 117 µM | Human | Synthetic Peptide-Peptoid Hybrid | Random coil | NA | ||
| 30842436 | 2019 | K-K-K-{nnr:Nle}-{nnr:(2-Nal)Ala}-F-{nnr:(2-Nal)Ala} | 23 | Free | Free | Linear | L | (2-Nal)Ala = 2-Naphthylalanine | 7 | Antimicrobial | 10 % Hemolysis at 14 µM | Human | Synthetic Peptide-Peptoid Hybrid | Random coil | NA | ||
| 30842436 | 2019 | K-K-K-{nnr:Nle}-{nnr:(1-Nal)Ala}-F-{nnr:(1-Nal)Ala} | 24 | Free | Free | Linear | L | (1-Nal)Ala = 1-Naphthylalanine, Nle= norleucine | 7 | Antibacterial | 10 % Hemolysis at 3 µM | Human | Synthetic Peptide-Peptoid Hybrid | Random coil | Low hemolytic | ||
| 30842436 | 2019 | K-K-K-L{d}-{nnr:(1-Nal)ala}-Y{d}-{nnr:(1-Nal)ala} | 25 | Free | Free | Linear | Mix | (1-Nal)ala = D-1-Naphthylalanine | 7 | Antibacterial | 10 % Hemolysis at 38 µM | Human | Synthetic Peptide-Peptoid Hybrid | Random coil | NA | ||
| 30842436 | 2019 | K-K-K-{nnr:Nle}-{nnr:(2-Nal)Ala}-Y-{nnr:(2-Nal)Ala} | 27 | Free | Free | Linear | L | (2-Nal)Ala = 2-Naphthylalanine, Nle= norleucine | 7 | Antibacterial | 10 % Hemolysis at 3 µM | Human | Synthetic Peptide-Peptoid Hybrid | Random coil | Low hemolytic | ||
| 30842436 | 2019 | K-K-K-L{d}-{nnr:(2-Nal)ala}-Y{d}-{nnr:(2-Nal)ala} | 28 | Free | Free | Linear | Mix | (1-Nal)ala = D-1-Naphthylalanine | 7 | Antibacterial | 10 % Hemolysis at 6 µM | Human | Synthetic Peptide-Peptoid Hybrid | Random coil | NA | ||
| 30842436 | 2019 | NLys-NLys-NLys-L-{nnr:(2-Nal)Ala}-F-{nnr:(2-Nal)Ala} | 29 | Free | Free | Linear | L | (2-Nal)Ala = D-2-Naphthylalanine, NLys | 7 | Antibacterial | 10 % Hemolysis at 9 µM | Human | Synthetic Peptide-Peptoid Hybrid | Random coil | NA | ||
| 30842436 | 2019 | K-K-{nnr:(NBu)Gly}-K-{nnr:(N1-Nal)Gly}-{nnr:(N4-MeBn)Gly}-{nnr:(N1-Nal)Gly} | B1 | Free | Free | Linear | L | (NBu)Gly = N-(4-aminobutyl)glycine, (N1-Nal)Gly = N-(1-naphthyl)glycine, (N4-MeBn)Gly = N-(4-methylbenzyl)glycine | 7 | Antimicrobial | 50 % Hemolysis at 230 µM | Human | Synthetic Peptide-Peptoid Hybrid | Random coil | NA | ||
| 30842436 | 2019 | K-K-L-K-{nnr:(1-Nal)Ala}-F-{nnr:(1-Nal)Ala} | 6 | Free | Free | Linear | L | (1-Nal)Ala = 1-Naphthylalanine | 7 | Antibacterial | 50 % Hemolysis at 58 µM | Human | Synthetic Peptide-Peptoid Hybrid | Random coil | NA | ||
| 30842436 | 2019 | K-K-K-L-{nnr:(1-Nal)Ala}-F-{nnr:(1-Nal)Ala} | 7 | Free | Free | Linear | L | (1-Nal)Ala = 1-Naphthylalanine | 7 | Antibacterial | 50 % Hemolysis at 140 µM | Human | Synthetic Peptide-Peptoid Hybrid | Random coil | NA | ||
| 30842436 | 2019 | K-K-L-K-{nnr:(1-Nal)ala}-F{d}-{nnr:(1-Nal)ala} | 14 | Free | Free | Linear | Mix | (1-Nal)ala = D-1-Naphthylalanine | 7 | Antibacterial | 50 % Hemolysis at 128 µM | Human | Synthetic Peptide-Peptoid Hybrid | Random coil | NA | ||
| 30842436 | 2019 | K-K-K-L{d}-{nnr:(1-Nal)ala}-F{d}-{nnr:(1-Nal)ala} | 15 | Free | Free | Linear | Mix | (1-Nal)ala = D-1-Naphthylalanine | 7 | Antibacterial | 50 % Hemolysis at 40 µM | Human | Synthetic Peptide-Peptoid Hybrid | Random coil | NA | ||
| 30842436 | 2019 | K-K-K-L{d}-{nnr:(2-Nal)ala}-F{d}-{nnr:(2-Nal)ala} | 16 | Free | Free | Linear | Mix | (2-Nal)ala = D-2-Naphthylalanine | 7 | Antibacterial | 50 % Hemolysis at 118 µM | Human | Synthetic Peptide-Peptoid Hybrid | Random coil | NA | ||
| 30842436 | 2019 | K-K-K-{nnr:Nle}-{nnr:(2-Nal)Ala}-F-{nnr:(2-Nal)Ala} | 23 | Free | Free | Linear | L | (2-Nal)Ala = 2-Naphthylalanine | 7 | Antimicrobial | 50 % Hemolysis at 104 µM | Human | Synthetic Peptide-Peptoid Hybrid | Random coil | NA | ||
| 30842436 | 2019 | K-K-K-{nnr:Nle}-{nnr:(1-Nal)Ala}-F-{nnr:(1-Nal)Ala} | 24 | Free | Free | Linear | L | (1-Nal)Ala = 1-Naphthylalanine, Nle= norleucine | 7 | Antibacterial | 50 % Hemolysis at 41 µM | Human | Synthetic Peptide-Peptoid Hybrid | Random coil | NA | ||
| 30842436 | 2019 | K-K-K-L{d}-{nnr:(1-Nal)ala}-Y{d}-{nnr:(1-Nal)ala} | 25 | Free | Free | Linear | Mix | (1-Nal)ala = D-1-Naphthylalanine | 7 | Antibacterial | 50 % Hemolysis at 138 µM | Human | Synthetic Peptide-Peptoid Hybrid | Random coil | NA | ||
| 30842436 | 2019 | K-K-K-{nnr:nle}-{nnr:(1-Nal)ala}-F{d}-{nnr:(1-Nal)ala} | 26 | Free | Free | Linear | Mix | nle = D-Norleucine, (1-Nal)Ala = 1-Naphthylalanine | 7 | Antimicrobial | 50 % Hemolysis at 63 µM | Human | Synthetic Peptide-Peptoid Hybrid | Random coil | NA | ||
| 30842436 | 2019 | K-K-K-{nnr:Nle}-{nnr:(2-Nal)Ala}-Y-{nnr:(2-Nal)Ala} | 27 | Free | Free | Linear | L | (2-Nal)Ala = 2-Naphthylalanine, Nle= norleucine | 7 | Antibacterial | 50 % Hemolysis at 56 µM | Human | Synthetic Peptide-Peptoid Hybrid | Random coil | NA | ||
| 30842436 | 2019 | K-K-K-L{d}-{nnr:(2-Nal)ala}-Y{d}-{nnr:(2-Nal)ala} | 28 | Free | Free | Linear | Mix | (1-Nal)ala = D-1-Naphthylalanine | 7 | Antibacterial | 50 % Hemolysis at 50 µM | Human | Synthetic Peptide-Peptoid Hybrid | Random coil | NA | ||
| 30337232 | 2019 | KFNKYGR | FSB-KFN | Free | Free | Linear | L | None | 7 | LPS-neutralizing and angiogenic activities | <0.10 % Hemolysis at 500 µM | Sheep | Putative Uncharacterized Protein | NA | Non-hemolytic | ||
| 30337232 | 2019 | QRFDQRSPQ | FSB-QRF | Free | Free | Linear | L | None | 9 | LPS-neutralizing and angiogenic activities | <0.10 % Hemolysis at 500 µM | Sheep | Uncharacterized Protein | NA | Non-hemolytic | ||
| 30973929 | 2019 | EVL{d}ADL{d}V{cyc:N-C}{nt:Palmityl}{ct:Amid} | SLP1 | Amidation | Palmityl | Cyclic | Mix | None | 7 | Anti-viral, Anti-PEDV(Porcine epidemic diarrhea virus) | 40 % Hemolysis at 10 μg/mL | Porcine | Synthetic Surfactin Lipopeptide Analogues | NA | NA | ||
| 30973929 | 2019 | EVL{d}DL{d}V{cyc:N-C}{nt:Palmityl}{ct:Amid} | SLP2 | Amidation | Palmityl | Cyclic | Mix | None | 6 | Anti-viral, Anti-PEDV(Porcine epidemic diarrhea virus) | 100 % Hemolysis at 10 μg/mL | Porcine | Synthetic Surfactin Lipopeptide Analogues | NA | NA | ||
| 30973929 | 2019 | EVL{d}DL{d}{cyc:N-C}{nt:Palmityl}{ct:Amid} | SLP3 | Amidation | Palmityl | Cyclic | Mix | None | 5 | Anti-viral, Anti-PEDV(Porcine epidemic diarrhea virus) | 80 % Hemolysis at 10 μg/mL | Porcine | Synthetic Surfactin Lipopeptide Analogues | NA | NA | ||
| 30973929 | 2019 | EVL{d}L{d}{cyc:N-C}{nt:Palmityl}{ct:Amid} | SLP4 | Amidation | Palmityl | Cyclic | Mix | None | 4 | Anti-viral, Anti-PEDV(Porcine epidemic diarrhea virus) | 5 % Hemolysis at 10 μg/mL | Porcine | Synthetic Surfactin Lipopeptide Analogues | NA | Low hemolytic | ||
| 30973929 | 2019 | EVL{d}DL{d}{nt:Palmityl}{ct:Amid} | SLP5 | Amidation | Palmityl | Linear | Mix | None | 5 | Anti-viral, Anti-PEDV(Porcine epidemic diarrhea virus) | 25 % Hemolysis at 10 μg/mL | Porcine | Synthetic Surfactin Lipopeptide Analogues | NA | NA | ||
| 30973929 | 2019 | KVL{d}KL{d}{cyc:N-C}{nt:Palmityl}{ct:Amid} | SLP6 | Amidation | Palmityl | Cyclic | Mix | None | 5 | Anti-viral, Anti-PEDV(Porcine epidemic diarrhea virus) | 90 % Hemolysis at 10 μg/mL | Porcine | Synthetic Surfactin Lipopeptide Analogues | NA | NA | ||
| 30973929 | 2019 | EVLDL{cyc:N-C}{nt:Palmityl}{ct:Amid} | SLP7 | Amidation | Palmityl | Cyclic | L | None | 5 | Anti-viral, Anti-PEDV(Porcine epidemic diarrhea virus) | 30 % Hemolysis at 10 μg/mL | Porcine | Synthetic Surfactin Lipopeptide Analogues | NA | NA | ||
| 30973929 | 2019 | EVL{d}L{d}D{cyc:N-C}{nt:Palmityl}{ct:Amid} | SLP8 | Amidation | Palmityl | Cyclic | Mix | None | 5 | Anti-viral, Anti-PEDV(Porcine epidemic diarrhea virus) | 100 % Hemolysis at 10 μg/mL | Porcine | Synthetic Surfactin Lipopeptide Analogues | NA | NA | ||
| 30973929 | 2019 | EDVL{d}L{d}{cyc:N-C}{nt:Palmityl}{ct:Amid} | SLP9 | Amidation | Palmityl | Cyclic | Mix | None | 5 | Anti-viral, Anti-PEDV(Porcine epidemic diarrhea virus) | 50 % Hemolysis at 10 μg/mL | Porcine | Synthetic Surfactin Lipopeptide Analogues | NA | NA | ||
| 30973929 | 2019 | EVlDl{cyc:N-C}{nt:Heptaalkyl-biphenyl-acid}{ct:Amid} | SLP10 | Amidation | Heptaalkyl-biphenyl-acid | Cyclic | Mix | Heptaalkyl-biphenyl-acid | 5 | Anti-viral, Anti-PEDV(Porcine epidemic diarrhea virus) | 55 % Hemolysis at 10 μg/mL | Porcine | Synthetic Surfactin Lipopeptide Analogues | NA | NA | ||
| 30919848 | 2019 | KKLGWGLKK{ct:Amid} | F3 | Amidation | Free | Linear | L | None | 9 | Antibacterial | <5 % Hemolysis at 128 µM | Human | Synthetic Peptide | 30 mM SDS and 50% TFE = unordered conformations | Non-hemolytic | ||
| 30951211 | 2019 | {nnr:Nlys}-{nnr:Ntrp}-{nnr:Nlys}-{nnr:Nlys}-{nnr:Ntrp}-{nnr:Ntrp}-{nnr:Nlys}-{nnr:Ntrp}-{nnr:Nile}{nt:H}{ct:Amid} | GN-2 | Amidation | H | Linear | L | Nlys = Nlys, Ntrp = Ntrp, Nile = Nile | 9 | Antibiofilm, Antibacterial | <10 % Hemolysis at 128 μg/mL | Human | Synthetic Peptoids Of Gn-2 | NA | Low hemolytic | ||
| 30951211 | 2019 | {nnr:Nlys}-{nnr:Nlys}-{nnr:Nlys}-{nnr:Nlys}-{nnr:Ntrp}-{nnr:Ntrp}-{nnr:Ntrp}-{nnr:Ntrp}-{nnr:Nile}{nt:H}{ct:Amid} | GN-2-Nlys1-4Ntrp5-8 | Amidation | H | Linear | L | Nlys = Nlys, Ntrp = Ntrp, Nile = Nile | 9 | Antibiofilm, Antibacterial | <10 % Hemolysis at 128 μg/mL | Human | Synthetic Peptoids Of Gn-2 | NA | Low hemolytic | ||
| 30951211 | 2019 | {nnr:Nlys}-{nnr:Ntrp}-{nnr:Nlys}-{nnr:Nlys}-{nnr:Ntrp}-{nnr:Ntrp}-{nnr:Nlys}-{nnr:Ntrp}-{nnr:Npm}{nt:H}{ct:Amid} | GN-2-Npm9 | Amidation | H | Linear | L | Nlys = Nlys, Ntrp = Ntrp, Npm = Npm | 9 | Antibiofilm, Antibacterial | <10 % Hemolysis at 128 μg/mL | Human | Synthetic Peptoids Of Gn-2 | NA | NA | ||
| 30951211 | 2019 | RWKRWWRWI{ct:Amid} | GN-2 | Amidation | Free | Linear | L | None | 9 | Antibiofilm, Antibacterial | <10 % Hemolysis at 128 μg/mL | Human | Synthetic Peptide | water = α-Helix, TFE = α-Helix | NA | ||
| 30951211 | 2019 | RWRRWWRWI{ct:Amid} | GN-2-Arg1,3,4,7 | Amidation | Free | Linear | L | None | 9 | Antibiofilm, Antibacterial | <10 % Hemolysis at 128 μg/mL | Human | Synthetic Analogue Peptide | water = Random coil, TFE = Random coil | Low hemolytic | ||
| 30951211 | 2019 | KWKKWWKWI{ct:Amid} | GN-2-Lys1,3,4,7 | Amidation | Free | Linear | L | None | 9 | Antibiofilm, Antibacterial | <10 % Hemolysis at 128 μg/mL | Human | Synthetic Analogue Peptide | water = Random coil, TFE = Random coil | Low hemolytic | ||
| 30951211 | 2019 | KKKKWWWWI{ct:Amid} | GN-2-Lys1-4Trp5-8 | Amidation | Free | Linear | L | None | 9 | Antibiofilm, Antibacterial | <10 % Hemolysis at 128 μg/mL | Human | Synthetic Analogue Peptide | NA | Low hemolytic | ||
| 30951211 | 2019 | KWKKWWKWF{ct:Amid} | GN-2-Lys1,3,4,7Phe9 | Amidation | Free | Linear | L | None | 9 | Antibiofilm, Antibacterial | <10 % Hemolysis at 128 μg/mL | Human | Synthetic Analogue Peptide | water = Random coil, TFE = Random coil | NA | ||
| 31199859 | 2019 | FIGAIARLL | BmKn-24 | Free | Free | Linear | L | None | 9 | Antibiofilm, Antibacterial | 0 % Hemolysis at 800 μM | Sheep | Bmkn–2 Truncated Derivatives | NA | Non-hemolytic | ||
| 31199859 | 2019 | FIGAIARL | BmKn-25 | Free | Free | Linear | L | None | 8 | Antibiofilm, Antibacterial | 10 % Hemolysis at 800 μM | Sheep | Bmkn–2 Truncated Derivatives | NA | Low hemolytic | ||
| 31199859 | 2019 | FIGAIAR | BmKn-26 | Free | Free | Linear | L | None | 7 | Antibiofilm, Antibacterial | 0 % Hemolysis at 800 μM | Sheep | Bmkn–2 Truncated Derivatives | NA | Non-hemolytic | ||
| 31241636 | 2019 | YNHNF | F3-3-a | Free | Free | Linear | L | None | 5 | Antibacterial | 3.89±0.18 % Hemolysis at 300 μM | Mouse | Laba Garlic (Allium Sativum L.) | PBS = Random coil, PBS+50%TFE = α-Helix, PBS+50%TFE+methanol = β-Sheet | Low hemolytic | ||
| 31241636 | 2019 | WPTSFT | F3-3-b | Free | Free | Linear | L | None | 6 | Antibacterial | 4.73±0.23 % Hemolysis at 300 μM | Mouse | Laba Garlic (Allium Sativum L.) | PBS = Random coil, PBS+50%TFE = α-Helix, PBS+50%TFE+methanol = β-Sheet | Low hemolytic | ||
| 31241636 | 2019 | AVDRAV | F3-3-c | Free | Free | Linear | L | None | 6 | Antibacterial | 4.71±0.21 % Hemolysis at 300 μM | Mouse | Laba Garlic (Allium Sativum L.) | PBS = Random coil, PBS+50%TFE = α-Helix, PBS+50%TFE+methanol = β-Sheet | Low hemolytic | ||
| 31241636 | 2019 | YNHNF | F3-3-a | Free | Free | Linear | L | None | 5 | Antibacterial | 2.86±0.11 % Hemolysis at 150 μM | Mouse | Laba Garlic (Allium Sativum L.) | PBS = Random coil, PBS+50%TFE = α-Helix, PBS+50%TFE+methanol = β-Sheet | Low hemolytic | ||
| 31241636 | 2019 | WPTSFT | F3-3-b | Free | Free | Linear | L | None | 6 | Antibacterial | 3.60±0.20 % Hemolysis at 150 μM | Mouse | Laba Garlic (Allium Sativum L.) | PBS = Random coil, PBS+50%TFE = α-Helix, PBS+50%TFE+methanol = β-Sheet | Low hemolytic | ||
| 31241636 | 2019 | AVDRAV | F3-3-c | Free | Free | Linear | L | None | 6 | Antibacterial | 2.07±0.07 % Hemolysis at 150 μM | Mouse | Laba Garlic (Allium Sativum L.) | PBS = Random coil, PBS+50%TFE = α-Helix, PBS+50%TFE+methanol = β-Sheet | Low hemolytic | ||
| 31241636 | 2019 | YNHNF | F3-3-a | Free | Free | Linear | L | None | 5 | Antibacterial | 2.02±0.03 % Hemolysis at 10 μM | Mouse | Laba Garlic (Allium Sativum L.) | PBS = Random coil, PBS+50%TFE = α-Helix, PBS+50%TFE+methanol = β-Sheet | Low hemolytic | ||
| 31241636 | 2019 | WPTSFT | F3-3-b | Free | Free | Linear | L | None | 6 | Antibacterial | 2.53±0.11 % Hemolysis at 10 μM | Mouse | Laba Garlic (Allium Sativum L.) | PBS = Random coil, PBS+50%TFE = α-Helix, PBS+50%TFE+methanol = β-Sheet | Low hemolytic | ||
| 31241636 | 2019 | AVDRAV | F3-3-c | Free | Free | Linear | L | None | 6 | Antibacterial | 1.32±0.03 % Hemolysis at 10 μM | Mouse | Laba Garlic (Allium Sativum L.) | PBS = Random coil, PBS+50%TFE = α-Helix, PBS+50%TFE+methanol = β-Sheet | Non-hemolytic | ||
| 31241636 | 2019 | YNHNF | F3-3-a | Free | Free | Linear | L | None | 5 | Antibacterial | 3.91 ± 0.21 % Hemolysis at 250 μM | Mouse | Laba Garlic (Allium Sativum L.) | PBS = Random coil, PBS+50%TFE = α-Helix, PBS+50%TFE+methanol = β-Sheet | Low hemolytic | ||
| 31241636 | 2019 | WPTSFT | F3-3-b | Free | Free | Linear | L | None | 6 | Antibacterial | 4.24 ± 0.13 % Hemolysis at 250 μM | Mouse | Laba Garlic (Allium Sativum L.) | PBS = Random coil, PBS+50%TFE = α-Helix, PBS+50%TFE+methanol = β-Sheet | Low hemolytic | ||
| 31241636 | 2019 | AVDRAV | F3-3-c | Free | Free | Linear | L | None | 6 | Antibacterial | 3.82 ± 0.09 % Hemolysis at 250 μM | Mouse | Laba Garlic (Allium Sativum L.) | PBS = Random coil, PBS+50%TFE = α-Helix, PBS+50%TFE+methanol = β-Sheet | Low hemolytic | ||
| 31241636 | 2019 | YNHNF | F3-3-a | Free | Free | Linear | L | None | 5 | Antibacterial | 3.56 ± 0.09 % Hemolysis at 200 μM | Mouse | Laba Garlic (Allium Sativum L.) | PBS = Random coil, PBS+50%TFE = α-Helix, PBS+50%TFE+methanol = β-Sheet | Low hemolytic | ||
| 31241636 | 2019 | WPTSFT | F3-3-b | Free | Free | Linear | L | None | 6 | Antibacterial | 3.63 ± 0.09 % Hemolysis at 200 μM | Mouse | Laba Garlic (Allium Sativum L.) | PBS = Random coil, PBS+50%TFE = α-Helix, PBS+50%TFE+methanol = β-Sheet | Low hemolytic | ||
| 31241636 | 2019 | AVDRAV | F3-3-c | Free | Free | Linear | L | None | 6 | Antibacterial | 2.31 ± 0.03 % Hemolysis at 200 μM | Mouse | Laba Garlic (Allium Sativum L.) | PBS = Random coil, PBS+50%TFE = α-Helix, PBS+50%TFE+methanol = β-Sheet | Low hemolytic | ||
| 31241636 | 2019 | YNHNF | F3-3-a | Free | Free | Linear | L | None | 5 | Antibacterial | 2.24 ± 0.03 % Hemolysis at 100 μM | Mouse | Laba Garlic (Allium Sativum L.) | PBS = Random coil, PBS+50%TFE = α-Helix, PBS+50%TFE+methanol = β-Sheet | Low hemolytic | ||
| 31241636 | 2019 | WPTSFT | F3-3-b | Free | Free | Linear | L | None | 6 | Antibacterial | 3.19 ± 0.18 % Hemolysis at 100 μM | Mouse | Laba Garlic (Allium Sativum L.) | PBS = Random coil, PBS+50%TFE = α-Helix, PBS+50%TFE+methanol = β-Sheet | Low hemolytic | ||
| 31241636 | 2019 | AVDRAV | F3-3-c | Free | Free | Linear | L | None | 6 | Antibacterial | 1.41± 0.12 % Hemolysis at 100 μM | Mouse | Laba Garlic (Allium Sativum L.) | PBS = Random coil, PBS+50%TFE = α-Helix, PBS+50%TFE+methanol = β-Sheet | Low hemolytic | ||
| 31241636 | 2019 | YNHNF | F3-3-a | Free | Free | Linear | L | None | 5 | Antibacterial | 2.15 ± 0.05 % Hemolysis at 50 μM | Mouse | Laba Garlic (Allium Sativum L.) | PBS = Random coil, PBS+50%TFE = α-Helix, PBS+50%TFE+methanol = β-Sheet | Low hemolytic | ||
| 31241636 | 2019 | WPTSFT | F3-3-b | Free | Free | Linear | L | None | 6 | Antibacterial | 2.97 ± 0.14 % Hemolysis at 50 μM | Mouse | Laba Garlic (Allium Sativum L.) | PBS = Random coil, PBS+50%TFE = α-Helix, PBS+50%TFE+methanol = β-Sheet | Low hemolytic | ||
| 31241636 | 2019 | AVDRAV | F3-3-c | Free | Free | Linear | L | None | 6 | Antibacterial | 1.41 ± 0.08 % Hemolysis at 50 μM | Mouse | Laba Garlic (Allium Sativum L.) | PBS = Random coil, PBS+50%TFE = α-Helix, PBS+50%TFE+methanol = β-Sheet | Non-hemolytic | ||
| 31775224 | 2019 | IRPIRP{cyc:N-C} | OIR1 | Free | Free | Cyclic | L | None | 6 | Antibacterial | ≥5 % Hemolysis at >128 µM | Human | Synthetic Cyclic Amps | aqueous = unordered, β-Hairpin | Low hemolytic | ||
| 31775224 | 2019 | IRPIRP | IR1 | Free | Free | Linear | L | None | 6 | Antibacterial | ≥5 % Hemolysis at >128 µM | Human | Synthetic Linear Amps | aqueous = unordered, 30 mM anionic = unordered | Low hemolytic | ||
| 31775224 | 2019 | IRP{d}IRP{d} | DIR1 | Free | Free | Linear | Mix | p = D-Proline | 6 | Antibacterial | ≥5 % Hemolysis at >128 µM | Human | Synthetic D-Proline Amps | 50% TFE = β-Sheet | Low hemolytic | ||
| 31668583 | 2019 | {nnr:Dap}-KKK{nt:(C12)2}{ct:Amid} | 1 | Amidation | (C12)2 | Linear | L | Dap = 2,3-diaminopropionic, C12 = lauric acid | 4 | Antimicrobial | 50 % Hemolysis at 128 µg/mL | Human | Lipopeptides With Surfactant | NA | NA | ||
| 31668583 | 2019 | {nnr:Dab}-KKK{nt:(C12)2}{ct:Amid} | 2 | Amidation | (C12)2 | Linear | L | Dab = 2,4-diaminobutyric, C12 = lauric acid | 4 | Antimicrobial | 13 % Hemolysis at 128 µg/mL | Human | Lipopeptides With Surfactant | NA | Low hemolytic | ||
| 31827113 | 2019 | {nnr:dab}-FEI-{nnr:aIle}-S | M11 | Free | Free | Linear | Mix | dab = D-2,4-diaminobutyric acid (D-Dab), aile = D-aIle, Dab = 2,4-diaminobutyric acid | 6 | Antibacterial | 50 % Hemolysis at 128 µg/ml | Rabbit | Variants Of Tridecaptin M | NA | NA | ||
| 31847173 | 2019 | K{d}K{d}({nnr:1-nal})F{d}K{d}({nnr:1-nal})K{d}({nnr:nle}){ct:Amid} | D2D | Amidation | Free | Linear | D | 1-nal = D-1-naphthylalanine, nle = D-Norleucine, D-amino acid | 8 | Antimicrobial | 23 % Hemolysis at 150 µM | Human | Synthetic All D-Peptide Analogue Peptide | TFE = α-Helical | NA | ||
| 31847173 | 2019 | A{d}K{d}({nnr:1-nal})F{d}K{d}({nnr:1-nal})K{d}({nnr:nle}){ct:Amid} | D2D analog-1 | Amidation | Free | Linear | D | 1-nal = D-1-naphthylalanine, nle = D-Norleucine, D-amino acid | 8 | Antimicrobial | 41 % Hemolysis at 150 µM | Human | D2D Analogues | α-Helical | NA | ||
| 31847173 | 2019 | K{d}A{d}({nnr:1-nal})F{d}K{d}({nnr:1-nal})K{d}({nnr:nle}){ct:Amid} | D2D analog-2 | Amidation | Free | Linear | D | 1-nal = D-1-naphthylalanine, nle = D-Norleucine, D-amino acid | 8 | Antimicrobial | 59 % Hemolysis at 150 µM | Human | D2D Analogues | α-Helical | NA | ||
| 31847173 | 2019 | K{d}K{d}A{d}F{d}K{d}({nnr:1-nal})K{d}({nnr:nle}){ct:Amid} | D2D analog-3 | Amidation | Free | Linear | D | 1-nal = D-1-naphthylalanine, nle = D-Norleucine, D-amino acid | 8 | Antimicrobial | 2 % Hemolysis at 150 µM | Human | D2D Analogues | α-Helical | Low hemolytic | ||
| 31847173 | 2019 | K{d}K{d}({nnr:1-nal})A{d}K{d}({nnr:1-nal})K{d}({nnr:nle}){ct:Amid} | D2D analog-4 | Amidation | Free | Linear | D | 1-nal = D-1-naphthylalanine, nle = D-Norleucine, D-amino acid | 8 | Antimicrobial | 22 % Hemolysis at 150 µM | Human | D2D Analogues | α-Helical | NA | ||
| 31847173 | 2019 | K{d}K{d}({nnr:1-nal})F{d}A{d}({nnr:1-nal})K{d}({nnr:nle}){ct:Amid} | D2D analog-5 | Amidation | Free | Linear | D | 1-nal = D-1-naphthylalanine, nle = D-Norleucine, D-amino acid | 8 | Antimicrobial | 47 % Hemolysis at 150 µM | Human | D2D Analogues | α-Helical | NA | ||
| 31847173 | 2019 | K{d}K{d}({nnr:1-nal})F{d}K{d}A{d}K{d}({nnr:nle}){ct:Amid} | D2D analog-6 | Amidation | Free | Linear | D | 1-nal = D-1-naphthylalanine, nle = D-Norleucine, D-amino acid | 8 | Antimicrobial | 10 % Hemolysis at 150 µM | Human | D2D Analogues | α-Helical | NA | ||
| 31847173 | 2019 | K{d}K{d}({nnr:1-nal})F{d}K{d}({nnr:1-nal})A{d}({nnr:nle}){ct:Amid} | D2D analog-7 | Amidation | Free | Linear | D | 1-nal = D-1-naphthylalanine, nle = D-Norleucine, D-amino acid | 8 | Antimicrobial | 67 % Hemolysis at 150 µM | Human | D2D Analogues | α-Helical | NA | ||
| 31847173 | 2019 | K{d}K{d}({nnr:1-nal})F{d}K{d}({nnr:1-nal})K{d}A{d}{ct:Amid} | D2D analog-8 | Amidation | Free | Linear | D | 1-nal = D-1-naphthylalanine, nle = D-Norleucine, D-amino acid | 8 | Antimicrobial | 5 % Hemolysis at 150 µM | Human | D2D Analogues | α-Helical | Low hemolytic | ||
| 31847173 | 2019 | K{d}K{d}({nnr:1-nal})F{d}({nnr:1-nal})({nnr:1-nal})K{d}({nnr:nle}){ct:Amid} | D2D analog-9 | Amidation | Free | Linear | D | 1-nal = D-1-naphthylalanine, nle = D-Norleucine, D-amino acid | 8 | Antimicrobial | 20 % Hemolysis at 150 µM | Human | D2D Analogues | NA | NA | ||
| 31847173 | 2019 | K{d}K{d}({nnr:1-nal})F{d}({nnr:dap})({nnr:1-nal})K{d}({nnr:nle}){ct:Amid} | D2D analog-10 | Amidation | Free | Linear | D | 1-nal = D-1-naphthylalanine, nle = D-Norleucine, dap = Diaminopropionic acid, D-amino acid | 8 | Antimicrobial | 28 % Hemolysis at 150 µM | Human | D2D Analogues | NA | NA | ||
| 31847173 | 2019 | K{d}K{d}({nnr:1-nal})F{d}({nnr:nle})({nnr:1-nal})K{d}({nnr:nle}){ct:Amid} | D2D analog-11 | Amidation | Free | Linear | D | 1-nal = D-1-naphthylalanine, nle = D-Norleucine, D-amino acid | 8 | Antimicrobial | 33 % Hemolysis at 150 µM | Human | D2D Analogues | NA | NA | ||
| 31847173 | 2019 | K{d}K{d}({nnr:1-nal})F{d}F{d}({nnr:1-nal})K{d}({nnr:nle}){ct:Amid} | D2D analog-12 | Amidation | Free | Linear | D | 1-nal = D-1-naphthylalanine, nle = D-Norleucine, D-amino acid | 8 | Antimicrobial | 74 % Hemolysis at 150 µM | Human | D2D Analogues | NA | NA | ||
| 31847173 | 2019 | K{d}K{d}({nnr:1-nal})F{d}S{d}({nnr:1-nal})K{d}({nnr:nle}){ct:Amid} | D2D analog-13 | Amidation | Free | Linear | D | 1-nal = D-1-naphthylalanine, nle = D-Norleucine, D-amino acid | 8 | Antimicrobial | 29 % Hemolysis at 150 µM | Human | D2D Analogues | NA | NA | ||
| 31847173 | 2019 | K{d}K{d}({nnr:1-nal})F{d}T{d}({nnr:1-nal})K{d}({nnr:nle}){ct:Amid} | D2D analog-14 | Amidation | Free | Linear | D | 1-nal = D-1-naphthylalanine, nle = D-Norleucine, D-amino acid | 8 | Antimicrobial | 28 % Hemolysis at 150 µM | Human | D2D Analogues | NA | NA | ||
| 31847173 | 2019 | K{d}K{d}({nnr:1-nal})F{d}Y{d}({nnr:1-nal})K{d}({nnr:nle}){ct:Amid} | D2D analog-15 | Amidation | Free | Linear | D | 1-nal = D-1-naphthylalanine, nle = D-Norleucine, D-amino acid | 8 | Antimicrobial | 40 % Hemolysis at 150 µM | Human | D2D Analogues | NA | NA | ||
| 31847173 | 2019 | K{d}K{d}({nnr:1-nal})F{d}V{d}({nnr:1-nal})K{d}({nnr:nle}){ct:Amid} | D2D analog-16 | Amidation | Free | Linear | D | 1-nal = D-1-naphthylalanine, nle = D-Norleucine, D-amino acid | 8 | Antimicrobial | 54 % Hemolysis at 150 µM | Human | D2D Analogues | NA | NA | ||
| 31847173 | 2019 | K{d}K{d}({nnr:1-nal})F{d}K{d}({nnr:1-nal})({nnr:1-nal})({nnr:nle}){ct:Amid} | D2D analog-17 | Amidation | Free | Linear | D | 1-nal = D-1-naphthylalanine, nle = D-Norleucine, D-amino acid | 8 | Antimicrobial | 89 % Hemolysis at 150 µM | Human | D2D Analogues | NA | NA | ||
| 31847173 | 2019 | K{d}K{d}({nnr:1-nal})F{d}K{d}({nnr:1-nal})({nnr:dap})({nnr:nle}){ct:Amid} | D2D analog-18 | Amidation | Free | Linear | D | 1-nal = D-1-naphthylalanine, nle = D-Norleucine, dap = Diaminopropionic acid, D-amino acid | 8 | Antimicrobial | 21 % Hemolysis at 150 µM | Human | D2D Analogues | NA | NA | ||
| 31847173 | 2019 | K{d}K{d}({nnr:1-nal})F{d}K{d}({nnr:1-nal})({nnr:nle})({nnr:nle}){ct:Amid} | D2D analog-19 | Amidation | Free | Linear | D | 1-nal = D-1-naphthylalanine, nle = D-Norleucine, D-amino acid | 8 | Antimicrobial | 56 % Hemolysis at 150 µM | Human | D2D Analogues | NA | NA | ||
| 31847173 | 2019 | K{d}K{d}({nnr:1-nal})F{d}K{d}({nnr:1-nal})F{d}({nnr:nle}){ct:Amid} | D2D analog-20 | Amidation | Free | Linear | D | 1-nal = D-1-naphthylalanine, nle = D-Norleucine, D-amino acid | 8 | Antimicrobial | 91 % Hemolysis at 150 µM | Human | D2D Analogues | NA | NA | ||
| 31847173 | 2019 | K{d}K{d}({nnr:1-nal})F{d}K{d}({nnr:1-nal})S{d}({nnr:nle}){ct:Amid} | D2D analog-21 | Amidation | Free | Linear | D | 1-nal = D-1-naphthylalanine, nle = D-Norleucine, D-amino acid | 8 | Antimicrobial | 85 % Hemolysis at 150 µM | Human | D2D Analogues | NA | NA | ||
| 31847173 | 2019 | K{d}K{d}({nnr:1-nal})F{d}K{d}({nnr:1-nal})T{d}({nnr:nle}){ct:Amid} | D2D analog-22 | Amidation | Free | Linear | D | 1-nal = D-1-naphthylalanine, nle = D-Norleucine, D-amino acid | 8 | Antimicrobial | 66 % Hemolysis at 150 µM | Human | D2D Analogues | NA | NA | ||
| 31847173 | 2019 | K{d}K{d}({nnr:1-nal})F{d}K{d}({nnr:1-nal})Y{d}({nnr:nle}){ct:Amid} | D2D analog-23 | Amidation | Free | Linear | D | 1-nal = D-1-naphthylalanine, nle = D-Norleucine, D-amino acid | 8 | Antimicrobial | 74 % Hemolysis at 150 µM | Human | D2D Analogues | NA | NA | ||
| 31847173 | 2019 | K{d}K{d}({nnr:1-nal})F{d}K{d}({nnr:1-nal})V{d}({nnr:nle}){ct:Amid} | D2D analog-24 | Amidation | Free | Linear | D | 1-nal = D-1-naphthylalanine, nle = D-Norleucine, D-amino acid | 8 | Antimicrobial | 50 % Hemolysis at 150 µM | Human | D2D Analogues | NA | NA | ||
| 31847173 | 2019 | K{d}K{d}({nnr:1-nal})F{d}K{d}K{d}({nnr:1-nal})({nnr:nle}){ct:Amid} | D2D analog-25 | Amidation | Free | Linear | D | 1-nal = D-1-naphthylalanine, nle = D-Norleucine, D-amino acid | 8 | Antimicrobial | 50 % Hemolysis at 150 µM | Human | D2D Analogues | NA | NA | ||
| 31847173 | 2019 | K{d}K{d}({nnr:1-nal})F{d}K{d}({nnr:1-nal})({nnr:nle})K{d}{ct:Amid} | D2D analog-26 | Amidation | Free | Linear | D | 1-nal = D-1-naphthylalanine, nle = D-Norleucine, D-amino acid | 8 | Antimicrobial | 18 % Hemolysis at 150 µM | Human | D2D Analogues | NA | NA | ||
| 31847173 | 2019 | K{d}({nnr:1-nal})F{d}K{d}({nnr:1-nal})K{d}({nnr:nle}){ct:Amid} | D2D analog-27 | Amidation | Free | Linear | D | 1-nal = D-1-naphthylalanine, nle = D-Norleucine, D-amino acid | 7 | Antimicrobial | 49 % Hemolysis at 150 µM | Human | D2D Analogues | NA | NA | ||
| 31847173 | 2019 | ({nnr:1-nal})F{d}K{d}({nnr:1-nal})K{d}({nnr:nle}){ct:Amid} | D2D analog-28 | Amidation | Free | Linear | D | 1-nal = D-1-naphthylalanine, nle = D-Norleucine, D-amino acid | 6 | Antimicrobial | 62 % Hemolysis at 150 µM | Human | D2D Analogues | NA | NA | ||
| 31847173 | 2019 | F{d}K{d}({nnr:1-nal})K{d}({nnr:nle}){ct:Amid} | D2D analog-29 | Amidation | Free | Linear | D | 1-nal = D-1-naphthylalanine, nle = D-Norleucine, D-amino acid | 5 | Antimicrobial | 12 % Hemolysis at 150 µM | Human | D2D Analogues | NA | NA | ||
| 31847173 | 2019 | K{d}K{d}({nnr:1-nal})F{d}K{d}({nnr:1-nal})K{d}{ct:Amid} | D2D analog-30 | Amidation | Free | Linear | D | 1-nal = D-1-naphthylalanine, D-amino acid | 7 | Antimicrobial | 11 % Hemolysis at 150 µM | Human | D2D Analogues | NA | NA | ||
| 31847173 | 2019 | K{d}K{d}({nnr:1-nal})F{d}K{d}({nnr:1-nal}){ct:Amid} | D2D analog-31 | Amidation | Free | Linear | D | 1-nal = D-1-naphthylalanine, D-amino acid | 6 | Antimicrobial | 20 % Hemolysis at 150 µM | Human | D2D Analogues | NA | NA | ||
| 31847173 | 2019 | K{d}K{d}({nnr:1-nal})F{d}K{d}{ct:Amid} | D2D analog-32 | Amidation | Free | Linear | D | 1-nal = D-1-naphthylalanine, D-amino acid | 5 | Antimicrobial | 5 % Hemolysis at 150 µM | Human | D2D Analogues | NA | Low hemolytic | ||
| 31847173 | 2019 | R{d}K{d}({nnr:1-nal})F{d}K{d}({nnr:1-nal})K{d}({nnr:nle}){ct:Amid} | D2D analog-33 | Amidation | Free | Linear | D | 1-nal = D-1-naphthylalanine, nle = D-Norleucine, D-amino acid | 8 | Antimicrobial | 60 % Hemolysis at 150 µM | Human | D2D Analogues | NA | NA | ||
| 31847173 | 2019 | K{d}R{d}({nnr:1-nal})F{d}K{d}({nnr:1-nal})K{d}({nnr:nle}){ct:Amid} | D2D analog-34 | Amidation | Free | Linear | D | 1-nal = D-1-naphthylalanine, nle = D-Norleucine, D-amino acid | 8 | Antimicrobial | 35 % Hemolysis at 150 µM | Human | D2D Analogues | NA | NA | ||
| 31847173 | 2019 | K{d}K{d}({nnr:1-nal})F{d}R{d}({nnr:1-nal})K{d}({nnr:nle}){ct:Amid} | D2D analog-35 | Amidation | Free | Linear | D | 1-nal = D-1-naphthylalanine, nle = D-Norleucine, D-amino acid | 8 | Antimicrobial | 49 % Hemolysis at 150 µM | Human | D2D Analogues | NA | NA | ||
| 31847173 | 2019 | K{d}K{d}({nnr:1-nal})F{d}K{d}({nnr:1-nal})R{d}({nnr:nle}){ct:Amid} | D2D analog-36 | Amidation | Free | Linear | D | 1-nal = D-1-naphthylalanine, nle = D-Norleucine, D-amino acid | 8 | Antimicrobial | 51 % Hemolysis at 150 µM | Human | D2D Analogues | NA | NA | ||
| 31324383 | 2019 | VRK{d}RPLVAL | SBH-VRK | Free | Free | Linear | L | None | 9 | ND = not detected | 1.61 % Hemolysis at 1000 µM | Sheep | Soybean Uncharacterized Protein | NA | Non-hemolytic | ||
| 31324383 | 2019 | F{d}K{d}NQYGHVR | SBH-FKN | Free | Free | Linear | L | None | 9 | ND = not detected | 0.84 % Hemolysis at 1000 µM | Sheep | Soybean Beta-Conglycinin Alpha’ Chain | NA | Non-hemolytic | ||
| 31936341 | 2020 | {conj:C12 = Dodecanoic acid}RR{ct:Amid} | 3 | Amidation | C12 = Dodecanoic acid | Linear | L | None | 2 | Antimicrobial | 50 % Hemolysis at >256 μg/ml | Human | Synthetic Ultrashort Cationic Lipopeptides | NA | Low hemolytic | ||
| 31936341 | 2020 | {conj:C14 = tetradecanoic acid}RR{ct:Amid} | 4 | Amidation | C14 = tetradecanoic acid | Linear | L | None | 2 | Antimicrobial | 50 % Hemolysis at 68.43(±1.41) μg/ml | Human | Synthetic Ultrashort Cationic Lipopeptides | NA | NA | ||
| 31936341 | 2020 | {conj:C16 = hexadecanoic acid}RR{ct:Amid} | 5 | Amidation | C16 = hexadecanoic acid | Linear | L | None | 2 | Antimicrobial | 50 % Hemolysis at 22.91(±1.18) μg/ml | Human | Synthetic Ultrashort Cationic Lipopeptides | NA | NA | ||
| 31936341 | 2020 | {conj:C18 = octadecanoic acid}RR{ct:Amid} | 6 | Amidation | C18 = octadecanoic acid | Linear | L | None | 2 | Antimicrobial | 50 % Hemolysis at 25.19(±0.67) μg/ml | Human | Synthetic Ultrashort Cationic Lipopeptides | NA | NA | ||
| 31936341 | 2020 | {conj:C14 = tetradecanoic acid}{nnr:A}RR{ct:Amid} | 10 | Amidation | C14 = tetradecanoic acid | Linear | L | A = non-proteinogenic amino acid A | 3 | Antimicrobial | 50 % Hemolysis at 41.08(±0.62) μg/ml | Human | Synthetic Ultrashort Cationic Lipopeptides | NA | NA | ||
| 31936341 | 2020 | {conj:C14 = tetradecanoic acid}{nnr:C(Acm)}RR{ct:Amid} | 14 | Amidation | C14 = tetradecanoic acid | Linear | L | C(Acm) = Acm = S-acetamidomethyl group(non-proteinogenic Amino acid) | 3 | Antimicrobial | 50 % Hemolysis at 39.72(±1.25) μg/ml | Human | Synthetic Ultrashort Cationic Lipopeptides | NA | NA | ||
| 31936341 | 2020 | {conj:C14 = tetradecanoic acid}{nnr:D}RR{ct:Amid} | 18 | Amidation | C14 = tetradecanoic acid | Linear | L | D = non-proteinogenic amino acid D | 3 | Antimicrobial | 50 % Hemolysis at 49.95(±1.00) μg/ml | Human | Synthetic Ultrashort Cationic Lipopeptides | NA | NA | ||
| 31936341 | 2020 | {conj:C14 = tetradecanoic acid}{nnr:E}RR{ct:Amid} | 22 | Amidation | C14 = tetradecanoic acid | Linear | L | E = non-proteinogenic amino acid E | 3 | Antimicrobial | 50 % Hemolysis at 59.51(±4.00) μg/ml | Human | Synthetic Ultrashort Cationic Lipopeptides | NA | NA | ||
| 31936341 | 2020 | {conj:C10 = decanoic}{nnr:F}RR{ct:Amid} | 24 | Amidation | C10 = decanoic | Linear | L | F = non-proteinogenic amino acid F | 3 | Antimicrobial | 50 % Hemolysis at >256 μg/ml | Human | Synthetic Ultrashort Cationic Lipopeptides | NA | Low hemolytic | ||
| 31936341 | 2020 | {conj:C12 = Dodecanoic acid}{nnr:F}RR{ct:Amid} | 25 | Amidation | C12 = Dodecanoic acid | Linear | L | F = non-proteinogenic amino acid F | 3 | Antimicrobial | 50 % Hemolysis at 91.21(±16.38) μg/ml | Human | Synthetic Ultrashort Cationic Lipopeptides | NA | NA | ||
| 31936341 | 2020 | {conj:C14 = tetradecanoic acid}{nnr:F}RR{ct:Amid} | 26 | Amidation | C14 = tetradecanoic acid | Linear | L | F = non-proteinogenic amino acid F | 3 | Antimicrobial | 50 % Hemolysis at 39.09(±1.18) μg/ml | Human | Synthetic Ultrashort Cationic Lipopeptides | NA | NA | ||
| 31936341 | 2020 | {conj:C12 = Dodecanoic acid}{nnr:G}RR{ct:Amid} | 29 | Amidation | C12 = Dodecanoic acid | Linear | L | G = non-proteinogenic amino acid G | 3 | Antimicrobial | 50 % Hemolysis at >256 μg/ml | Human | Synthetic Ultrashort Cationic Lipopeptides | NA | Low hemolytic | ||
| 31936341 | 2020 | {conj:C14 = tetradecanoic acid}{nnr:G}RR{ct:Amid} | 30 | Amidation | C14 = tetradecanoic acid | Linear | L | G = non-proteinogenic amino acid G | 3 | Antimicrobial | 50 % Hemolysis at 31.94(±1.99) μg/ml | Human | Synthetic Ultrashort Cationic Lipopeptides | NA | NA | ||
| 31936341 | 2020 | {conj:C14 = tetradecanoic acid}{nnr:H}RR{ct:Amid} | 34 | Amidation | C14 = tetradecanoic acid | Linear | L | H = non-proteinogenic amino acid H | 3 | Antimicrobial | 50 % Hemolysis at 50.31(±0.52) μg/ml | Human | Synthetic Ultrashort Cationic Lipopeptides | NA | NA | ||
| 31936341 | 2020 | {conj:C12 = Dodecanoic acid}{nnr:I}RR{ct:Amid} | 37 | Amidation | C12 = Dodecanoic acid | Linear | L | I = non-proteinogenic amino acid I | 3 | Antimicrobial | 50 % Hemolysis at 120.40(±1.55) μg/ml | Human | Synthetic Ultrashort Cationic Lipopeptides | NA | NA | ||
| 31936341 | 2020 | {conj:C14 = tetradecanoic acid}{nnr:I}RR{ct:Amid} | 38 | Amidation | C14 = tetradecanoic acid | Linear | L | I = non-proteinogenic amino acid I | 3 | Antimicrobial | 50 % Hemolysis at 78.92(±4.38) μg/ml | Human | Synthetic Ultrashort Cationic Lipopeptides | NA | NA | ||
| 31936341 | 2020 | {conj:C14 = tetradecanoic acid}{nnr:K}RR{ct:Amid} | 42 | Amidation | C14 = tetradecanoic acid | Linear | L | K = non-proteinogenic amino acid K | 3 | Antimicrobial | 50 % Hemolysis at 212.08(±6.12) μg/ml | Human | Synthetic Ultrashort Cationic Lipopeptides | NA | Low hemolytic | ||
| 31936341 | 2020 | {conj:C12 = Dodecanoic acid}{nnr:L}RR{ct:Amid} | 45 | Amidation | C12 = Dodecanoic acid | Linear | L | L = non-proteinogenic amino acid L | 3 | Antimicrobial | 50 % Hemolysis at 112.81(±1.39) μg/ml | Human | Synthetic Ultrashort Cationic Lipopeptides | NA | NA | ||
| 31936341 | 2020 | {conj:C14 = tetradecanoic acid}{nnr:L}RR{ct:Amid} | 46 | Amidation | C14 = tetradecanoic acid | Linear | L | L = non-proteinogenic amino acid L | 3 | Antimicrobial | 50 % Hemolysis at 29.50(±1.05) μg/ml | Human | Synthetic Ultrashort Cationic Lipopeptides | NA | NA | ||
| 31936341 | 2020 | {conj:C12 = Dodecanoic acid}{nnr:M}RR{ct:Amid} | 49 | Amidation | C12 = Dodecanoic acid | Linear | L | M = non-proteinogenic amino acid M | 3 | Antimicrobial | 50 % Hemolysis at 206.50(±9.14) μg/ml | Human | Synthetic Ultrashort Cationic Lipopeptides | NA | Low hemolytic | ||
| 31936341 | 2020 | {conj:C14 = tetradecanoic acid}{nnr:M}RR{ct:Amid} | 50 | Amidation | C14 = tetradecanoic acid | Linear | L | M = non-proteinogenic amino acid M | 3 | Antimicrobial | 50 % Hemolysis at 35.11(±0.90) μg/ml | Human | Synthetic Ultrashort Cationic Lipopeptides | NA | NA | ||
| 31936341 | 2020 | {conj:C14 = tetradecanoic acid}{nnr:M(O)}RR{ct:Amid} | 54 | Amidation | C14 = tetradecanoic acid | Linear | L | Met(O)/M(O) = methionine sulfoxide(non-proteinogenic Amino acid) | 3 | Antimicrobial | 50 % Hemolysis at 116.28(±1.77) μg/ml | Human | Synthetic Ultrashort Cationic Lipopeptides | NA | NA | ||
| 31936341 | 2020 | {conj:C14 = tetradecanoic acid}{nnr:M(O2)}RR{ct:Amid} | 58 | Amidation | C14 = tetradecanoic acid | Linear | L | Met(O2)/M(O2) = methionine sulfone(non-proteinogenic Amino acid) | 3 | Antimicrobial | 50 % Hemolysis at 70.11(±2.93) μg/ml | Human | Synthetic Ultrashort Cationic Lipopeptides | NA | NA | ||
| 31936341 | 2020 | {conj:C14 = tetradecanoic acid}{nnr:N}RR{ct:Amid} | 62 | Amidation | C14 = tetradecanoic acid | Linear | L | N = non-proteinogenic amino acid N | 3 | Antimicrobial | 50 % Hemolysis at 64.37(±2.23) μg/ml | Human | Synthetic Ultrashort Cationic Lipopeptides | NA | NA | ||
| 31936341 | 2020 | {conj:C10 = decanoic}{nnr:Nle}RR{ct:Amid} | 64 | Amidation | C10 = decanoic | Linear | L | Nle = Norleucine(non-proteinogenic Amino acid) | 3 | Antimicrobial | 50 % Hemolysis at >256 μg/ml | Human | Synthetic Ultrashort Cationic Lipopeptides | NA | Low hemolytic | ||
| 31936341 | 2020 | {conj:C12 = Dodecanoic acid}{nnr:Nle}RR{ct:Amid} | 65 | Amidation | C12 = Dodecanoic acid | Linear | L | Nle = Norleucine(non-proteinogenic Amino acid) | 3 | Antimicrobial | 50 % Hemolysis at >256 μg/ml | Human | Synthetic Ultrashort Cationic Lipopeptides | NA | Low hemolytic | ||
| 31936341 | 2020 | {conj:C14 = tetradecanoic acid}{nnr:Nle}RR{ct:Amid} | 66 | Amidation | C14 = tetradecanoic acid | Linear | L | Nle = Norleucine(non-proteinogenic Amino acid) | 3 | Antimicrobial | 50 % Hemolysis at 37.54(±1.39) μg/ml | Human | Synthetic Ultrashort Cationic Lipopeptides | NA | NA | ||
| 31936341 | 2020 | {conj:C12 = Dodecanoic acid}{nnr:Nva}RR{ct:Amid} | 69 | Amidation | C12 = Dodecanoic acid | Linear | L | Nva = Norvaline(non-proteinogenic Amino acid) | 3 | Antimicrobial | 50 % Hemolysis at 207.62(±5.27) μg/ml | Human | Synthetic Ultrashort Cationic Lipopeptides | NA | Low hemolytic | ||
| 31936341 | 2020 | {conj:C14 = tetradecanoic acid}{nnr:Nva}RR{ct:Amid} | 70 | Amidation | C14 = tetradecanoic acid | Linear | L | Nva = Norvaline(non-proteinogenic Amino acid) | 3 | Antimicrobial | 50 % Hemolysis at 42.04(±1.38) μg/ml | Human | Synthetic Ultrashort Cationic Lipopeptides | NA | NA | ||
| 31936341 | 2020 | {conj:C12 = Dodecanoic acid}{nnr:P}RR{ct:Amid} | 73 | Amidation | C12 = Dodecanoic acid | Linear | L | P = non-proteinogenic amino acid P | 3 | Antimicrobial | 50 % Hemolysis at >256 μg/ml | Human | Synthetic Ultrashort Cationic Lipopeptides | NA | Low hemolytic | ||
| 31936341 | 2020 | {conj:C14 = tetradecanoic acid}{nnr:P}RR{ct:Amid} | 74 | Amidation | C14 = tetradecanoic acid | Linear | L | P = non-proteinogenic amino acid P | 3 | Antimicrobial | 50 % Hemolysis at 53.41(±1.84) μg/ml | Human | Synthetic Ultrashort Cationic Lipopeptides | NA | NA | ||
| 31936341 | 2020 | {conj:C14 = tetradecanoic acid}{nnr:Q}RR{ct:Amid} | 78 | Amidation | C14 = tetradecanoic acid | Linear | L | Q = non-proteinogenic amino acid Q | 3 | Antimicrobial | 50 % Hemolysis at 72.31(±3.00) μg/ml | Human | Synthetic Ultrashort Cationic Lipopeptides | NA | NA | ||
| 31936341 | 2020 | {conj:C12 = Dodecanoic acid}{nnr:R}{nnr:R}{nnr:R}{ct:Amid} | 81 | Amidation | C12 = Dodecanoic acid | Linear | L | R = non-proteinogenic amino acid R | 3 | Antimicrobial | 50 % Hemolysis at >256 μg/ml | Human | Synthetic Ultrashort Cationic Lipopeptides | NA | Low hemolytic | ||
| 31936341 | 2020 | {conj:C14 = tetradecanoic acid}{nnr:R}{nnr:R}{nnr:R}{ct:Amid} | 82 | Amidation | C14 = tetradecanoic acid | Linear | L | R = non-proteinogenic amino acid R | 3 | Antimicrobial | 50 % Hemolysis at 211.32(±9.57) μg/ml | Human | Synthetic Ultrashort Cationic Lipopeptides | NA | Low hemolytic | ||
| 31936341 | 2020 | {conj:C14 = tetradecanoic acid}{nnr:S}RR{ct:Amid} | 86 | Amidation | C14 = tetradecanoic acid | Linear | L | S = non-proteinogenic amino acid S | 3 | Antimicrobial | 50 % Hemolysis at 41.54(±1.29) μg/ml | Human | Synthetic Ultrashort Cationic Lipopeptides | NA | NA | ||
| 31936341 | 2020 | {conj:C12 = Dodecanoic acid}{nnr:T}RR{ct:Amid} | 89 | Amidation | C12 = Dodecanoic acid | Linear | L | T = non-proteinogenic amino acid T | 3 | Antimicrobial | 50 % Hemolysis at >256 μg/ml | Human | Synthetic Ultrashort Cationic Lipopeptides | NA | Low hemolytic | ||
| 31936341 | 2020 | {conj:C14 = tetradecanoic acid}{nnr:T}RR{ct:Amid} | 90 | Amidation | C14 = tetradecanoic acid | Linear | L | T = non-proteinogenic amino acid T | 3 | Antimicrobial | 50 % Hemolysis at 43.43(±0.90) μg/ml | Human | Synthetic Ultrashort Cationic Lipopeptides | NA | NA | ||
| 31936341 | 2020 | {conj:C12 = Dodecanoic acid}{nnr:V}RR{ct:Amid} | 93 | Amidation | C12 = Dodecanoic acid | Linear | L | V = non-proteinogenic amino acid V | 3 | Antimicrobial | 50 % Hemolysis at 246.30(±14.12) μg/ml | Human | Synthetic Ultrashort Cationic Lipopeptides | NA | Low hemolytic | ||
| 31936341 | 2020 | {conj:C14 = tetradecanoic acid}{nnr:V}RR{ct:Amid} | 94 | Amidation | C14 = tetradecanoic acid | Linear | L | V = non-proteinogenic amino acid V | 3 | Antimicrobial | 50 % Hemolysis at 30.73(±0.41) μg/ml | Human | Synthetic Ultrashort Cationic Lipopeptides | NA | NA | ||
| 31936341 | 2020 | {conj:C10 = decanoic}{nnr:W}RR{ct:Amid} | 96 | Amidation | C10 = decanoic | Linear | L | W = non-proteinogenic amino acid W | 3 | Antimicrobial | 50 % Hemolysis at >256 μg/ml | Human | Synthetic Ultrashort Cationic Lipopeptides | NA | Low hemolytic | ||
| 31936341 | 2020 | {conj:C12 = Dodecanoic acid}{nnr:W}RR{ct:Amid} | 97 | Amidation | C12 = Dodecanoic acid | Linear | L | W = non-proteinogenic amino acid W | 3 | Antimicrobial | 50 % Hemolysis at 42.42(±0.57) μg/ml | Human | Synthetic Ultrashort Cationic Lipopeptides | NA | NA | ||
| 31936341 | 2020 | {conj:C14 = tetradecanoic acid}{nnr:W}RR{ct:Amid} | 98 | Amidation | C14 = tetradecanoic acid | Linear | L | W = non-proteinogenic amino acid W | 3 | Antimicrobial | 50 % Hemolysis at 36.91 (±0.89) μg/ml | Human | Synthetic Ultrashort Cationic Lipopeptides | NA | NA | ||
| 31936341 | 2020 | {conj:C12 = Dodecanoic acid}{nnr:Y}RR{ct:Amid} | 101 | Amidation | C12 = Dodecanoic acid | Linear | L | Y = non-proteinogenic amino acid Y | 3 | Antimicrobial | 50 % Hemolysis at 123.08 (±1.12) μg/ml | Human | Synthetic Ultrashort Cationic Lipopeptides | NA | NA | ||
| 31936341 | 2020 | {conj:C14 = tetradecanoic acid}{nnr:Y}RR{ct:Amid} | 102 | Amidation | C14 = tetradecanoic acid | Linear | L | Y = non-proteinogenic amino acid Y | 3 | Antimicrobial | 50 % Hemolysis at 46.52 (±5.24) μg/ml | Human | Synthetic Ultrashort Cationic Lipopeptides | NA | NA | ||
| 31936341 | 2020 | {conj:C10(6) = 2‐hexyldecanoic}RR{ct:Amid} | 105 | Amidation | C10(6) = 2‐hexyldecanoic | Linear | L | C10(6) = 2‐hexyldecanoic | 2 | Antimicrobial | 50 % Hemolysis at 200.25 (±16.07) μg/ml | Human | Synthetic Ultrashort Cationic Lipopeptides | NA | Low hemolytic | ||
| 33479615 | 2020 | GHR{d}KPAQP | P1 | Free | Free | Linear | Mix | None | 8 | Neuraminidase inhibitor, Anti-influenza (H1N1 influenza virus), Antiviral | 50 % Hemolysis at >50 µM | Rabbit | Synthetic Peptide | NA | Low hemolytic | ||
| 33479615 | 2020 | E{d}R{d}R{d}KPAQP | P2 | Free | Free | Linear | Mix | None | 8 | Neuraminidase inhibitor, Anti-influenza (H1N1 influenza virus), Antiviral | 0 % Hemolysis at 100 µM | Rabbit | Synthetic Peptide | NA | Low hemolytic | ||
| 33479615 | 2020 | E{d}E{d}EKPAQP | P4 | Free | Free | Linear | Mix | None | 8 | Neuraminidase inhibitor, Anti-influenza (H1N1 influenza virus), Antiviral | 50 % Hemolysis at >50 µM | Rabbit | Synthetic Peptide | NA | Low hemolytic | ||
| 33479615 | 2020 | E{d}F{d}R{d}TMVHPK | P5 | Free | Free | Linear | Mix | None | 9 | Neuraminidase inhibitor, Anti-influenza (H1N1 influenza virus), Antiviral | 0 % Hemolysis at 100 µM | Rabbit | Synthetic Peptide | NA | Low hemolytic | ||
| 33479615 | 2020 | E{d}D{d}RKHAQA | P8 | Free | Free | Linear | Mix | None | 8 | Neuraminidase inhibitor, Anti-influenza (H1N1 influenza virus), Antiviral | 50 % Hemolysis at >40 µM | Rabbit | Synthetic Peptide | NA | Low hemolytic | ||
| 33479615 | 2020 | K{d}EFHKTAQP | P9 | Free | Free | Linear | Mix | None | 9 | Neuraminidase inhibitor, Anti-influenza (H1N1 influenza virus), Antiviral | 50 % Hemolysis at >60 µM | Rabbit | Synthetic Peptide | NA | Low hemolytic | ||
| 33479615 | 2020 | F{d}R{d}R{d}RPLRA | P13 | Free | Free | Linear | Mix | None | 8 | Neuraminidase inhibitor, Anti-influenza (H1N1 influenza virus), Antiviral | 0 % Hemolysis at 100 µM | Rabbit | Synthetic Peptide | NA | Low hemolytic | ||
| 33479615 | 2020 | DD{d}H{d}KTAHQ | P14 | Free | Free | Linear | Mix | None | 8 | Neuraminidase inhibitor, Anti-influenza (H1N1 influenza virus), Antiviral | 50 % Hemolysis at >40 µM | Rabbit | Synthetic Peptide | NA | Low hemolytic | ||
| 33479615 | 2020 | GW{d}RKPAQP | P16 | Free | Free | Linear | Mix | None | 8 | Neuraminidase inhibitor, Anti-influenza (H1N1 influenza virus), Antiviral | 0 % Hemolysis at 100 µM | Rabbit | Synthetic Peptide | NA | Low hemolytic | ||
| 33479615 | 2020 | W{d}KR{d}LHHKPA | P18 | Free | Free | Linear | Mix | None | 9 | Neuraminidase inhibitor, Anti-influenza (H1N1 influenza virus), Antiviral | 0 % Hemolysis at 100 µM | Rabbit | Synthetic Peptide | NA | Low hemolytic | ||
| 31862270 | 2020 | PFKISIHL | Jellein | Free | Free | Linear | L | None | 8 | Antibacterial, Anti-leishmanial activity, inhibition of Leishmania major promastigotes | 8 % Hemolysis at 500 μg/ml | Human | Royal Jelly Of Honeybee | NA | Low hemolytic | ||
| 31862270 | 2020 | {conj:Lauric acid}PFKISIHL | Lauric acid – Jellein (L-Jellein) | Free | Lauric acid | Linear | L | None | 8 | Anti-leishmanial | 0 % Hemolysis at 500 μg/ml | Human | Lauric Acid Conjugated Jellein | NA | Non-hemolytic | ||
| 31585860 | 2020 | AAIGSSKPK | LPR-AAI | Free | Free | Linear | L | None | 9 | Antimicrobial, LPS-neutralizing, angiogenic | 1.37 % Hemolysis at 500 μM | Sheep | Rice Protein Uncharacterized Protein | NA | Low hemolytic | ||
| 31585860 | 2020 | LVPRPRR | LPR-LVP | Free | Free | Linear | L | None | 7 | Antimicrobial, LPS-neutralizing, angiogenic | 2.46 % Hemolysis at 500 μM | Sheep | Rice Protein Uncharacterized Protein | NA | Low hemolytic | ||
| 32367434 | 2020 | PFKISIHL{ct:Amid} | JI (Jelleine-I) | Amidation | Free | Linear | L | None | 8 | Antibacterial, Antifungal | 50 % Hemolysis at 500 µmol /L | Human | Buffer = Random Coil, Anionic Environments = Β-Strands | octapeptide royal jelly honey bee | Low hemolytic | ||
| 32367434 | 2020 | PWKISIHL{ct:Amid} | JIF2W | Amidation | Free | Linear | L | None | 8 | Antibacterial, Antifungal | 50 % Hemolysis at 500 µmol /L | Human | Buffer = Random Coil, Anionic Environments = Β-Strands | analogs of Jelleine-I | Low hemolytic | ||
| 32367434 | 2020 | PWRISIRL{ct:Amid} | JIF2WR | Amidation | Free | Linear | L | None | 8 | Antibacterial, Antifungal | 50 % Hemolysis at 91 µmol /L | Human | Buffer = Random Coil, Anionic Environments = Β-Strands | analogs of Jelleine-I | NA | ||
| 32521823 | 2020 | YIKLLKE{ct:Amid} | 35409-7 | Amidation | Free | Linear | L | None | 7 | Antibacterial | 10 % Hemolysis at >200 μM | Human | 35409 Seven Truncated Modification Sequence Peptide | 1X PBS = Disordered, PBS with 10 mM SDS = distorted trend (195 and 210nm) | Non-hemolytic | ||
| 32521823 | 2020 | RYRRKKK{ct:Amid} | 35409-12 | Amidation | Free | Linear | L | None | 7 | Antibacterial | 10 % Hemolysis at >200 μM | Human | 35409 Five Truncated Modification Sequence Peptide | 1X PBS = Disordered, PBS with 10 mM SDS = distorted trend (195 and 210nm) | Non-hemolytic | ||
| 32521823 | 2020 | KMKKALQY{ct:Amid} | 35409-16 | Amidation | Free | Linear | L | None | 8 | Antibacterial | 10 % Hemolysis at >200 μM | Human | 35409 Four Truncated Modification Sequence Peptide | 1X PBS = Disordered, PBS with 10 mM SDS = distorted trend (195 and 210nm) | Non-hemolytic | ||
| 32334835 | 2020 | QAK{nt:Amid} | QAK | Free | Amidation | Linear | L | None | 3 | Antibacterial, Antibiofilm | 12 % Hemolysis at 30 µg/ml | Rabbit | Hemolymph Non-Mulberry Silkworm Antheraea Mylitta | NA | NA | ||
| 32334835 | 2020 | QAK{nt:Amid} | QAK | Free | Amidation | Linear | L | None | 3 | Antibacterial, Antibiofilm | 18 % Hemolysis at 60 µg/ml | Rabbit | Hemolymph Non-Mulberry Silkworm Antheraea Mylitta | NA | NA | ||
| 32334835 | 2020 | QAK{nt:Acet}{ct:Acet} | acetylated-QAK | Acetylation | Acetylation | Linear | L | None | 3 | Antibacterial, Antibiofilm | 1 % Hemolysis at 3.75 µg/ml | Rabbit | Synthesized-Qak | NA | Low hemolytic | ||
| 32334835 | 2020 | QAK{nt:Acet}{ct:Acet} | acetylated-QAK | Acetylation | Acetylation | Linear | L | None | 3 | Antibacterial, Antibiofilm | 2 % Hemolysis at 7.5 µg/ml | Rabbit | Synthesized-Qak | NA | Low hemolytic | ||
| 32334835 | 2020 | QAK{nt:Acet}{ct:Acet} | acetylated-QAK | Acetylation | Acetylation | Linear | L | None | 3 | Antibacterial, Antibiofilm | 19.55 % Hemolysis at 100 µg/ml | Rabbit | Synthesized-Qak | NA | Low hemolytic | ||
| 32334835 | 2020 | QAK{nt:Acet}{ct:Acet} | acetylated-QAK | Acetylation | Acetylation | Linear | L | None | 3 | Antibacterial, Antibiofilm | 38.28 % Hemolysis at 200 µg/ml | Rabbit | Synthesized-Qak | NA | NA | ||
| 32629881 | 2020 | K{nnr:Nal}KK{nnr:Bip}-{nnr:O2Oc}-{nnr:Nal}KN{cyc:N-C} | BSI-9 | Free | Free | Cyclic | L | Bip = L‐biphenylalanine, Nal = 3‐(2‐Naphthyl)‐L‐alanine, O2Oc = 8‐amino‐3,6‐dioxaoctanoic acid | 9 | Antibacterial | 33 % Hemolysis at 150 μM | Human | Synthetic Cyclic Amp | NA | NA | ||
| 32629881 | 2020 | K{nnr:Nal}KK{nnr:Bip}-{nnr:O2Oc}-{nnr:Nal}NK{cyc:N-C} | BSI-9 stage-1 (1) | Free | Free | Cyclic | L | Bip = L‐biphenylalanine, Nal = 3‐(2‐Naphthyl)‐L‐alanine, O2Oc = 8‐amino‐3,6‐dioxaoctanoic acid | 9 | Antibacterial | Hemolysis at 150 μM | Human | Analogues Of Bsi-9 | NA | NA | ||
| 32629881 | 2020 | K{nnr:Nal}KN{nnr:Bip}-{nnr:O2Oc}-{nnr:Nal}KK{cyc:N-C} | BSI-9 stage-1 (2) | Free | Free | Cyclic | L | Bip = L‐biphenylalanine, Nal = 3‐(2‐Naphthyl)‐L‐alanine, O2Oc = 8‐amino‐3,6‐dioxaoctanoic acid | 9 | Antibacterial | Hemolysis at 150 μM | Human | Analogues Of Bsi-9 | NA | NA | ||
| 32629881 | 2020 | K{nnr:Nal}NK{nnr:Bip}-{nnr:O2Oc}-{nnr:Nal}KK{cyc:N-C} | BSI-9 stage-1 (3) | Free | Free | Cyclic | L | Bip = L‐biphenylalanine, Nal = 3‐(2‐Naphthyl)‐L‐alanine, O2Oc = 8‐amino‐3,6‐dioxaoctanoic acid | 9 | Antibacterial | Hemolysis at 150 μM | Human | Analogues Of Bsi-9 | NA | NA | ||
| 32629881 | 2020 | N{nnr:Nal}KK{nnr:Bip}-{nnr:O2Oc}-{nnr:Nal}KK{cyc:N-C} | BSI-9 stage-1 (4) | Free | Free | Cyclic | L | Bip = L‐biphenylalanine, Nal = 3‐(2‐Naphthyl)‐L‐alanine, O2Oc = 8‐amino‐3,6‐dioxaoctanoic acid | 9 | Antibacterial | Hemolysis at 150 μM | Human | Analogues Of Bsi-9 | NA | NA | ||
| 32629881 | 2020 | KFKK{nnr:Bip}-{nnr:O2Oc}-{nnr:Nal}KN{cyc:N-C} | BSI-9 stage-2 (5) | Free | Free | Cyclic | L | Bip = L‐biphenylalanine, Nal = 3‐(2‐Naphthyl)‐L‐alanine, O2Oc = 8‐amino‐3,6‐dioxaoctanoic acid | 9 | Antibacterial | 4 % Hemolysis at 150 μM | Human | Analogues Of Bsi-9 | NA | Non-hemolytic | ||
| 32629881 | 2020 | K{nnr:Nal}KKF-{nnr:O2Oc}-{nnr:Nal}KN{cyc:N-C} | BSI-9 stage-2 (6) | Free | Free | Cyclic | L | Nal = 3‐(2‐Naphthyl)‐L‐alanine, O2Oc = 8‐amino‐3,6‐dioxaoctanoic acid | 9 | Antibacterial | 6 % Hemolysis at 150 μM | Human | Analogues Of Bsi-9 | NA | Non-hemolytic | ||
| 32629881 | 2020 | K{nnr:Nal}KK{nnr:Bip}-{nnr:O2Oc}-FKN{cyc:N-C} | BSI-9 stage-2 (7) | Free | Free | Cyclic | L | Bip = L‐biphenylalanine, Nal = 3‐(2‐Naphthyl)‐L‐alanine, O2Oc = 8‐amino‐3,6‐dioxaoctanoic acid | 9 | Antibacterial | 7 % Hemolysis at 150 μM | Human | Analogues Of Bsi-9 | NA | Non-hemolytic | ||
| 32629881 | 2020 | KFKKF-{nnr:O2Oc}-FKN{cyc:N-C} | BSI-9 stage-2 (8) | Free | Free | Cyclic | L | O2Oc = 8‐amino‐3,6‐dioxaoctanoic acid | 9 | Antibacterial | 3 % Hemolysis at 150 μM | Human | Analogues Of Bsi-9 | NA | Non-hemolytic | ||
| 32629881 | 2020 | {nnr:Dab}{nnr:Nal}{nnr:Dab}{nnr:Dab}{nnr:Bip}-{nnr:O2Oc}-{nnr:Nal}{nnr:Dab}N{cyc:N-C} | BSI-9 stage-2 (9) | Free | Free | Cyclic | L | Bip = L‐biphenylalanine, Nal = 3‐(2‐Naphthyl)‐L‐alanine, O2Oc = 8‐amino‐3,6‐dioxaoctanoic acid, Dab = L‐2,4‐diaminobutyric acid | 9 | Antibacterial | 76 % Hemolysis at 150 μM | Human | Analogues Of Bsi-9 | NA | NA | ||
| 32629881 | 2020 | R{nnr:Nal}{nnr:Dab}{nnr:Dab}{nnr:Bip}-{nnr:O2Oc}-{nnr:Nal}{nnr:Dab}N{cyc:N-C} | BSI-9 stage-3 (10) | Free | Free | Cyclic | L | Bip = L‐biphenylalanine, Nal = 3‐(2‐Naphthyl)‐L‐alanine, O2Oc = 8‐amino‐3,6‐dioxaoctanoic acid, Dab = L‐2,4‐diaminobutyric acid | 9 | Antibacterial | 66 % Hemolysis at 150 μM | Human | Analogues Of Bsi-9 | NA | NA | ||
| 32629881 | 2020 | {nnr:Dab}{nnr:Nal}R{nnr:Dab}{nnr:Bip}-{nnr:O2Oc}-{nnr:Nal}{nnr:Dab}N{cyc:N-C} | BSI-9 stage-3 (11) | Free | Free | Cyclic | L | Bip = L‐biphenylalanine, Nal = 3‐(2‐Naphthyl)‐L‐alanine, O2Oc = 8‐amino‐3,6‐dioxaoctanoic acid, Dab = L‐2,4‐diaminobutyric acid | 9 | Antibacterial | 36 % Hemolysis at 150 μM | Human | Analogues Of Bsi-9 | NA | NA | ||
| 32629881 | 2020 | {nnr:Dab}{nnr:Nal}{nnr:Dab}R{nnr:Bip}-{nnr:O2Oc}-{nnr:Nal}{nnr:Dab}N{cyc:N-C} | BSI-9 stage-3 (12) | Free | Free | Cyclic | L | Bip = L‐biphenylalanine, Nal = 3‐(2‐Naphthyl)‐L‐alanine, O2Oc = 8‐amino‐3,6‐dioxaoctanoic acid, Dab = L‐2,4‐diaminobutyric acid | 9 | Antibacterial | 98 % Hemolysis at 150 μM | Human | Analogues Of Bsi-9 | NA | NA | ||
| 32629881 | 2020 | {nnr:Dab}{nnr:Nal}{nnr:Dab}{nnr:Dab}{nnr:Bip}-{nnr:O2Oc}-{nnr:Nal}RN{cyc:N-C} | BSI-9 stage-3 (13) | Free | Free | Cyclic | L | Bip = L‐biphenylalanine, Nal = 3‐(2‐Naphthyl)‐L‐alanine, O2Oc = 8‐amino‐3,6‐dioxaoctanoic acid, Dab = L‐2,4‐diaminobutyric acid | 9 | Antibacterial | 80 % Hemolysis at 150 μM | Human | Analogues Of Bsi-9 | NA | NA | ||
| 32629881 | 2020 | R{nnr:Nal}RR{nnr:Bip}-{nnr:O2Oc}-{nnr:Nal}RN{cyc:N-C} | BSI-9 stage-3 (14) | Free | Free | Cyclic | L | Bip = L‐biphenylalanine, Nal = 3‐(2‐Naphthyl)‐L‐alanine, O2Oc = 8‐amino‐3,6‐dioxaoctanoic acid | 9 | Antibacterial | 68 % Hemolysis at 150 μM | Human | Analogues Of Bsi-9 | NA | NA | ||
| 32629881 | 2020 | R{nnr:Nal}RDap{nnr:Bip}-{nnr:O2Oc}-{nnr:Nal}{nnr:Dab}N{cyc:N-C} | BSI-9 stage-4 (15) | Free | Free | Cyclic | L | Bip = L‐biphenylalanine, Nal = 3‐(2‐Naphthyl)‐L‐alanine, O2Oc = 8‐amino‐3,6‐dioxaoctanoic acid, Dab = L‐2,4‐diaminobutyric acid | 9 | Antibacterial | 100 % Hemolysis at 150 μM | Human | Analogues Of Bsi-9 | NA | NA | ||
| 32629881 | 2020 | R{nnr:Nal}R{nnr:Dab}F-{nnr:O2Oc}-{nnr:Nal}{nnr:Dab}N{cyc:N-C} | BSI-9 stage-4 (16) | Free | Free | Cyclic | L | Nal = 3‐(2‐Naphthyl)‐L‐alanine, O2Oc = 8‐amino‐3,6‐dioxaoctanoic acid, Dab = L‐2,4‐diaminobutyric acid | 9 | Antibacterial | 16 % Hemolysis at 150 μM | Human | Analogues Of Bsi-9 | NA | NA | ||
| 32629881 | 2020 | R{nnr:Nal}{nnr:Dab}{nnr:Dab}F-{nnr:O2Oc}-{nnr:Nal}{nnr:Dab}N{cyc:N-C} | BSI-9 stage-4 (17) | Free | Free | Cyclic | L | Nal = 3‐(2‐Naphthyl)‐L‐alanine, O2Oc = 8‐amino‐3,6‐dioxaoctanoic acid, Dab = L‐2,4‐diaminobutyric acid | 9 | Antibacterial | 3 % Hemolysis at 150 μM | Human | Analogues Of Bsi-9 | NA | Non-hemolytic | ||
| 32629881 | 2020 | {nnr:Dab}{nnr:Nal}R{nnr:Dab}F-{nnr:O2Oc}-{nnr:Nal}{nnr:Dab}N{cyc:N-C} | BSI-9 stage-4 (18) | Free | Free | Cyclic | L | Nal = 3‐(2‐Naphthyl)‐L‐alanine, O2Oc = 8‐amino‐3,6‐dioxaoctanoic acid, Dab = L‐2,4‐diaminobutyric acid | 9 | Antibacterial | 30 % Hemolysis at 150 μM | Human | Analogues Of Bsi-9 | NA | NA | ||
| 32543191 | 2020 | AAAAMAGPK{ct:Amid} | Rice-derived-peptide-3 (RDP3) | Amidation | Free | Linear | L | None | 9 | Anti-gout, Anti-inflammation | 4.5±0.13 % Hemolysis at 100 µg/mL | Human | Shelled Oryza Sativa Fruits | NA | Non-hemolytic | ||
| 32543191 | 2020 | AAAAMAGPK{ct:Amid} | Rice-derived-peptide-3 (RDP3) | Amidation | Free | Linear | L | None | 9 | Anti-gout, Anti-inflammation | 5.0±0.07 % Hemolysis at 500 µg/mL | Human | Shelled Oryza Sativa Fruits | NA | Non-hemolytic | ||
| 32543191 | 2020 | AAAAMAGPK{ct:Amid} | Rice-derived-peptide-3 (RDP3) | Amidation | Free | Linear | L | None | 9 | Anti-gout, Anti-inflammation | 4.5±0.15 % Hemolysis at 1 mg/mL | Human | Shelled Oryza Sativa Fruits | NA | Non-hemolytic | ||
| 32704013 | 2020 | KLKLKL{ct:Amid} | KL6 | Amidation | Free | Linear | L | None | 6 | Antibacterial | 0 % Hemolysis at 1 µg/mL | Human | Kl Peptides | Water (pH ≈ 6), Water (pH ≈ 10), 10 mM Phosphate Buffer (pH = 7.0), DMPC (pH ≈ 6) = Random coil, DMPC/DMPG (4/1) (pH ≈ 6), POPC/POPG (1/1) (pH ≈ 6) = Mixture (Random coil + β-Sheet) | Non-hemolytic | ||
| 32704013 | 2020 | KLKLKL{ct:Amid} | KL6 | Amidation | Free | Linear | L | None | 6 | Antibacterial | 1 % Hemolysis at 2 µg/mL | Human | Kl Peptides | Water (pH ≈ 6), Water (pH ≈ 10), 10 mM Phosphate Buffer (pH = 7.0), DMPC (pH ≈ 6) = Random coil, DMPC/DMPG (4/1) (pH ≈ 6), POPC/POPG (1/1) (pH ≈ 6) = Mixture (Random coil + β-Sheet) | NA | ||
| 32704013 | 2020 | KLKLKL{ct:Amid} | KL6 | Amidation | Free | Linear | L | None | 6 | Antibacterial | 1 % Hemolysis at 4 µg/mL | Human | Kl Peptides | Water (pH ≈ 6), Water (pH ≈ 10), 10 mM Phosphate Buffer (pH = 7.0), DMPC (pH ≈ 6) = Random coil, DMPC/DMPG (4/1) (pH ≈ 6), POPC/POPG (1/1) (pH ≈ 6) = Mixture (Random coil + β-Sheet) | NA | ||
| 32704013 | 2020 | KLKLKL{ct:Amid} | KL6 | Amidation | Free | Linear | L | None | 6 | Antibacterial | 3 % Hemolysis at 8 µg/mL | Human | Kl Peptides | Water (pH ≈ 6), Water (pH ≈ 10), 10 mM Phosphate Buffer (pH = 7.0), DMPC (pH ≈ 6) = Random coil, DMPC/DMPG (4/1) (pH ≈ 6), POPC/POPG (1/1) (pH ≈ 6) = Mixture (Random coil + β-Sheet) | NA | ||
| 32704013 | 2020 | KLKLKL{ct:Amid} | KL6 | Amidation | Free | Linear | L | None | 6 | Antibacterial | 2 % Hemolysis at 16 µg/mL | Human | Kl Peptides | Water (pH ≈ 6), Water (pH ≈ 10), 10 mM Phosphate Buffer (pH = 7.0), DMPC (pH ≈ 6) = Random coil, DMPC/DMPG (4/1) (pH ≈ 6), POPC/POPG (1/1) (pH ≈ 6) = Mixture (Random coil + β-Sheet) | NA | ||
| 32704013 | 2020 | KLKLKL{ct:Amid} | KL6 | Amidation | Free | Linear | L | None | 6 | Antibacterial | 2 % Hemolysis at 32 µg/mL | Human | Kl Peptides | Water (pH ≈ 6), Water (pH ≈ 10), 10 mM Phosphate Buffer (pH = 7.0), DMPC (pH ≈ 6) = Random coil, DMPC/DMPG (4/1) (pH ≈ 6), POPC/POPG (1/1) (pH ≈ 6) = Mixture (Random coil + β-Sheet) | NA | ||
| 32704013 | 2020 | KLKLKL{ct:Amid} | KL6 | Amidation | Free | Linear | L | None | 6 | Antibacterial | 4 % Hemolysis at 64 µg/mL | Human | Kl Peptides | Water (pH ≈ 6), Water (pH ≈ 10), 10 mM Phosphate Buffer (pH = 7.0), DMPC (pH ≈ 6) = Random coil, DMPC/DMPG (4/1) (pH ≈ 6), POPC/POPG (1/1) (pH ≈ 6) = Mixture (Random coil + β-Sheet) | NA | ||
| 32704013 | 2020 | KLKLKL{ct:Amid} | KL6 | Amidation | Free | Linear | L | None | 6 | Antibacterial | 6 % Hemolysis at 128 µg/mL | Human | Kl Peptides | Water (pH ≈ 6), Water (pH ≈ 10), 10 mM Phosphate Buffer (pH = 7.0), DMPC (pH ≈ 6) = Random coil, DMPC/DMPG (4/1) (pH ≈ 6), POPC/POPG (1/1) (pH ≈ 6) = Mixture (Random coil + β-Sheet) | NA | ||
| 32704013 | 2020 | KLKLKL{ct:Amid} | KL6 | Amidation | Free | Linear | L | None | 6 | Antibacterial | 7 % Hemolysis at 256 µg/mL | Human | Kl Peptides | Water (pH ≈ 6), Water (pH ≈ 10), 10 mM Phosphate Buffer (pH = 7.0), DMPC (pH ≈ 6) = Random coil, DMPC/DMPG (4/1) (pH ≈ 6), POPC/POPG (1/1) (pH ≈ 6) = Mixture (Random coil + β-Sheet) | NA | ||
| 32126228 | 2020 | RRWWRF{nt:Acet}{ct:Amid} | Combi-1 | Amidation | Acetylation | Linear | L | None | 6 | Anticancer | 50 % Hemolysis at ≥65 μM | Human | Antimicrobial Peptides | NA | NA | ||
| 32126228 | 2020 | FRWWHR{nt:Acet}{ct:Amid} | Combi-2 | Amidation | Acetylation | Linear | L | None | 6 | Anticancer | 50 % Hemolysis at ≥65 μM | Human | Antimicrobial Peptides | NA | NA | ||
| 32126228 | 2020 | RAWVAWR{ct:Amid} | LysH | Amidation | Free | Linear | L | None | 7 | Anticancer | 50 % Hemolysis at ≥65 μM | Human | Antimicrobial Peptides | NA | NA | ||
| 32130974 | 2020 | RIRIRWIIR{nt:Amid}{ct:Amid} | A1 | Amidation | Amidation | Linear | L | None | 9 | Antibacterial | 50 % Hemolysis at >250 µg/mL | Human | Synthetic Amp | NA | Low hemolytic | ||
| 32130974 | 2020 | RIRIRWIIR{nt:(β-Ala)(β-Ala)(Lys)}{ct:Amid} | A2 | Amidation | (β-Ala)(β-Ala)(Lys) | Linear | L | Ala spacers and Lys | 9 | Antibacterial | 50 % Hemolysis at >250 µg/mL | Human | Modification Of A1 With Ala Spacers And Lys | NA | Low hemolytic | ||
| 32130974 | 2020 | RIRIRWIIR{nt:Caprylic acid (C8)}{ct:Amid} | A3 | Amidation | Caprylic acid (C8) | Linear | L | C8 = Caprylic acid | 9 | Antibacterial | 50 % Hemolysis at 132 µg/mL | Human | Modification Of A1 With Caprylic Acid (C8) | NA | NA | ||
| 32130974 | 2020 | RIRIRWIIR{nt:Capric acid (C10)}{ct:Amid} | A4 | Amidation | Capric acid (C10) | Linear | L | C10 = Capric acid | 9 | Antibacterial | 50 % Hemolysis at 73 µg/mL | Human | Modification Of A1 With Capric Acid (C10) | NA | NA | ||
| 32130974 | 2020 | RIRIRWIIR{nt:Lauric acid (C12)}{ct:Amid} | A5 | Amidation | Lauric acid (C12) | Linear | L | C12 = Lauric acid | 9 | Antibacterial | 50 % Hemolysis at 35 µg/mL | Human | Modification Of A1 With Lauric Acid (C12) | NA | NA | ||
| 32130974 | 2020 | RIRIRWIIR{nt:Myristic acid (C14)}{ct:Amid} | A6 | Amidation | Myristic acid (C14) | Linear | L | C14 = Myristic acid | 9 | Antibacterial | 50 % Hemolysis at 28 µg/mL | Human | Modification Of A1 With Myristic Acid (C14) | NA | NA | ||
| 32130974 | 2020 | RIRIRWIIR{nt:Ser-Glucose}{ct:Amid} | A7 | Amidation | Ser-Glucose | Linear | L | Glucose = Glucose | 9 | Antibacterial | 50 % Hemolysis at >250 µg/mL | Human | Modification Of A1 With Glucose | NA | Low hemolytic | ||
| 32130974 | 2020 | RIRIRWIIR{nt:Ser-N-Acetylglucosamine (GlcNac)}{ct:Amid} | A8 | Amidation | Ser-N-Acetylglucosamine (GlcNac) | Linear | L | GlcNAc = GlcNAc | 9 | Antibacterial | 50 % Hemolysis at >250 µg/mL | Human | Modification Of A1 With Glcnac | NA | Low hemolytic | ||
| 32130974 | 2020 | RIRIRWIIR{nt:Ser-Galactose}{ct:Amid} | A9 | Amidation | Ser-Galactose | Linear | L | Galactose = Galactose | 9 | Antibacterial | 50 % Hemolysis at >250 µg/mL | Human | Modification Of A1 With Galactose | NA | Low hemolytic | ||
| 32130974 | 2020 | RIRIRWIIR{nt:Ser-Mannose}{ct:Amid} | A10 | Amidation | Ser-Mannose | Linear | L | Mannose = Mannose | 9 | Antibacterial | 50 % Hemolysis at >250 µg/mL | Human | Modification Of A1 With Mannose | NA | Low hemolytic | ||
| 32130974 | 2020 | RIRIRWIIR{nt:Ser-Lactose}{ct:Amid} | A11 | Amidation | Ser-Lactose | Linear | L | Lactose = Lactose | 9 | Antibacterial | 50 % Hemolysis at >250 µg/mL | Human | Modification Of A1 With Lactose | NA | Low hemolytic | ||
| 32130974 | 2020 | RIRIRWIIR{nt:Meo-PEG}{ct:Amid} | A12 | Amidation | Meo-PEG | Linear | L | PEG = PEG | 9 | Antibacterial | 50 % Hemolysis at >250 µg/mL | Human | Modification Of A1 With Peg | NA | Low hemolytic | ||
| 32130974 | 2020 | KRRVRWIIW{nt:Amid}{ct:Amid} | B1 | Amidation | Amidation | Linear | L | None | 9 | Antibacterial | 50 % Hemolysis at >250 µg/mL | Human | Synthetic Amp | NA | Low hemolytic | ||
| 32130974 | 2020 | KRRVRWIIW{nt:(β-Ala)(β-Ala)(Lys)}{ct:Amid} | B2 | Amidation | (β-Ala)(β-Ala)(Lys) | Linear | L | Ala spacers and Lys | 9 | Antibacterial | 50 % Hemolysis at >250 µg/mL | Human | Modification Of B1 With Ala Spacers And Lys | NA | Low hemolytic | ||
| 32130974 | 2020 | KRRVRWIIW{nt:Caprylic acid (C8)}{ct:Amid} | B3 | Amidation | Caprylic acid (C8) | Linear | L | C8 = Caprylic acid | 9 | Antibacterial | 50 % Hemolysis at >250 µg/mL | Human | Modification Of B1 With Caprylic Acid (C8) | NA | Low hemolytic | ||
| 32130974 | 2020 | KRRVRWIIW{nt:Capric acid (C10)}{ct:Amid} | B4 | Amidation | Capric acid (C10) | Linear | L | C10 = Capric acid | 9 | Antibacterial | 50 % Hemolysis at 50 µg/mL | Human | Modification Of B1 With Capric Acid (C10) | NA | NA | ||
| 32130974 | 2020 | KRRVRWIIW{nt:Lauric acid (C12)}{ct:Amid} | B5 | Amidation | Lauric acid (C12) | Linear | L | C12 = Lauric acid | 9 | Antibacterial | 50 % Hemolysis at 38 µg/mL | Human | Modification Of B1 With Lauric Acid (C12) | NA | NA | ||
| 32130974 | 2020 | KRRVRWIIW{nt:Myristic acid (C14)}{ct:Amid} | B6 | Amidation | Myristic acid (C14) | Linear | L | C14 = Myristic acid | 9 | Antibacterial | 50 % Hemolysis at 25 µg/mL | Human | Modification Of B1 With Myristic Acid (C14) | NA | NA | ||
| 32764602 | 2020 | K-K-L-K-{nnr:(2-Nal)Ala}-F-{nnr:(2-Nal-)Ala} | 1 | Free | Free | Linear | L | (2-Nal)Ala = 2-napthylalanine | 7 | Antibacterial, Anticancer | <8 % Hemolysis at 150 µM | Human | Synthetic Amps | NA | Low hemolytic | ||
| 32764602 | 2020 | {nnr:(N1-Nal)Gly}-{nnr:(N-Phe)Gly}-{nnr:(N1-Nal)Gly}-{nnr:(N-Bu)Gly}-K-K-K | 2 | Free | Free | Linear | L | (N-Phe)Gly = N-benzylglycine, (N1-Nal)Gly = N-1-naphthylmethylglycine, (N-Bu)Gly = N-butylglycine | 7 | Antibacterial, Anticancer | 78.1 % Hemolysis at 150 µM | Human | Synthetic Amps | NA | NA | ||
| 32764602 | 2020 | {nnr:(2-nal)ala}-F{d}-{nnr:(2-nal)ala}-K-L{d}-K-K | 3 | Free | Free | Linear | Mix | (2-nal)ala = D-2-napthylalanin, f = D-phenylalanine, l = D-Leu | 7 | Antibacterial | <8 % Hemolysis at 150 µM | Human | Synthetic Amps | NA | Low hemolytic | ||
| 32764602 | 2020 | {nnr:(2-nal)ala}-F{d}-{nnr:(2-nal)ala}-L{d}-K-K-K | 4 | Free | Free | Linear | Mix | (2-nal)ala = D-2-napthylalanin, f = D-phenylalanine, l = D-Leu | 7 | Antibacterial, Anticancer | <8 % Hemolysis at 150 µM | Human | Synthetic Amps | NA | Low hemolytic | ||
| 32764602 | 2020 | {nnr:(1-Nal)Ala}-F-{nnr:(1-Nal)Ala}-L-K-K-K | 5 | Free | Free | Linear | L | (1-Nal)Ala = 1-napthylalanine | 7 | Antibacterial, Anticancer | 36 % Hemolysis at 150 µM | Human | Synthetic Amps | NA | NA | ||
| 32764602 | 2020 | K-K-L-K-{nnr:(1-Nal)Ala}-F-{nnr:(1-Nal)Ala} | 6 | Free | Free | Linear | L | (1-Nal)Ala = 1-napthylalanine | 7 | Antibacterial | 42.7 % Hemolysis at 150 µM | Human | Synthetic Amps | NA | NA | ||
| 32764602 | 2020 | K-K-K-L-{nnr:(1-Nal)Ala}-F{nnr:(1-Nal)Ala} | 7 | Free | Free | Linear | L | (1-Nal)Ala = 1-napthylalanine | 7 | Antibacterial | 83.8 % Hemolysis at 150 µM | Human | Synthetic Amps | NA | NA | ||
| 32764602 | 2020 | {nnr:(1-nal)ala}-F{d}-{nnr:(1-nal)ala}-K-L{d}-K-K | 8 | Free | Free | Linear | Mix | (1-nal)ala = D-1-napthylalanine, f = D-phenylalanine, l = D-Leu | 7 | Antibacterial | 34.3 % Hemolysis at 150 µM | Human | Synthetic Amps | NA | NA | ||
| 32764602 | 2020 | {nnr:(1-nal)ala}-F{d}-{nnr:(1-nal)ala}-L{d}-K-K-K | 9 | Free | Free | Linear | Mix | (1-nal)ala = D-1-napthylalanine, f = D-phenylalanine, l = D-Leu | 7 | Antibacterial | 30.8 % Hemolysis at 150 µM | Human | Synthetic Amps | NA | NA | ||
| 32764602 | 2020 | K-K-L{d}-K-{nnr:(1-nal)ala}-F{d}-{nnr:(1-nal)ala} | 10 | Free | Free | Linear | Mix | (1-nal)ala = D-1-napthylalanine, f = D-phenylalanine, l = D-Leu | 7 | Antibacterial | <8 % Hemolysis at 150 µM | Human | Synthetic Amps | NA | Low hemolytic | ||
| 32764602 | 2020 | K-K-K-L{d}-{nnr:(1-nal)ala}-F{d}-{nnr:(1-nal)ala} | 11 | Free | Free | Linear | Mix | (1-nal)ala = D-1-napthylalanine, f = D-phenylalanine, l = D-Leu | 7 | Antibacterial, Anticancer | 33.3 % Hemolysis at 150 µM | Human | Synthetic Amps | NA | NA | ||
| 32764602 | 2020 | K-K-K-L{d}-{nnr:(2-nal)ala}-F{d}-{nnr:(2-nal)ala} | 12 | Free | Free | Linear | Mix | (2-nal)ala = D-2-napthylalanin, f = D-phenylalanine, l = D-Leu | 7 | Antibacterial | 43.5 % Hemolysis at 150 µM | Human | Synthetic Amps | NA | NA | ||
| 32764602 | 2020 | {nnr:(2-Nal)Ala}-F-{nnr:(2-Nal)Ala}-K-L-K-K | 13 | Free | Free | Linear | L | (2-Nal)Ala = 2-napthylalanine | 7 | Antibacterial | 55.3 % Hemolysis at 150 µM | Human | Synthetic Amps | NA | NA | ||
| 32764602 | 2020 | K-K-{nnr:(N-Bu)Gly}-K-{nnr:(N1-Nal)Gly}-{nnr:(N-Phe)Gly}-{nnr:(N1-Nal)Gly} | 14 | Free | Free | Linear | L | (N-Bu)Gly = N-butylglycine, (N1-Nal)Gly = N-1-napthylmethylglycine, (N-Phe)Gly = N-benyzylglycine | 7 | Antibacterial | 66.4 % Hemolysis at 150 µM | Human | Synthetic Amps | NA | NA | ||
| 32764602 | 2020 | K-K-K-{nnr:(N-Bu)Gly}-{nnr:(N1-Nal)Gly}-{nnr:(N-Phe)Gly}-{nnr:(N1-Nal)Gly} | 15 | Free | Free | Linear | L | (N-Bu)Gly = N-butylglycine, (N1-Nal)Gly = N-1-napthylmethylglycine, (N-Phe)Gly = N-benyzylglycine | 7 | Antibacterial, Anticancer | 94.2 % Hemolysis at 150 µM | Human | Synthetic Amps | NA | NA | ||
| 32764602 | 2020 | {nnr:(1-Nal)Ala}-F-{nnr:(1-Nal)Ala}-K-L-K-K | 16 | Free | Free | Linear | L | (1-Nal)Ala = 1-napthylalanine | 7 | Antibacterial | 55.5 % Hemolysis at 150 µM | Human | Synthetic Amps | NA | NA | ||
| 32764602 | 2020 | K-K-K-L-{nnr:(2-Nal)Ala}-Y-{nnr:(2-Nal)Ala} | 17 | Free | Free | Linear | L | (2-Nal)Ala = 2-napthylalanine | 7 | Antibacterial | 78.1 % Hemolysis at 150 µM | Human | Synthetic Amps | NA | NA | ||
| 32764602 | 2020 | K-K-K-{nnr:Nle}-{nnr:(2-Nal)Ala}-F-{nnr:(2-Nal)Ala} | 18 | Free | Free | Linear | L | (2-Nal)Ala = 2-napthylalanine, Nle= norleucine | 7 | Antibacterial | 58.8 % Hemolysis at 150 µM | Human | Synthetic Amps | NA | NA | ||
| 32764602 | 2020 | K-K-K-Leu{nnr:(1-Nal)Ala}-Y-{nnr:(1-Nal)Ala} | 19 | Free | Free | Linear | L | (1-Nal)Ala = 1-napthylalanine | 7 | Antibacterial | 82.7 % Hemolysis at 150 µM | Human | Synthetic Amps | NA | NA | ||
| 32764602 | 2020 | K-K-K-{nnr:Nle}-{nnr:(1-Nal)Ala}-F-{nnr:(1-Nal)Ala} | 20 | Free | Free | Linear | L | (1-Nal)Ala = 1-napthylalanine, Nle= norleucine | 7 | Antibacterial | 27.5 % Hemolysis at 150 µM | Human | Synthetic Amps | NA | NA | ||
| 32764602 | 2020 | K-K-K-l--{nnr:(1-nal)ala}-Y{d}-{nnr:(1-nal)ala} | 21 | Free | Free | Linear | Mix | (1-nal)ala = D-1-napthylalanine, y = D-Tyr | 7 | Antibacterial | <8 % Hemolysis at 150 µM | Human | Synthetic Amps | NA | Low hemolytic | ||
| 32764602 | 2020 | K-K-K-{nnr:Nle}-{nnr:(2-Nal)Ala}-Y-{nnr:(2-Nal)Ala} | 22 | Free | Free | Linear | L | (2-Nal)Ala = 2-napthylalanine, Nle= norleucine | 7 | Antibacterial | 23.7 % Hemolysis at 150 µM | Human | Synthetic Amps | NA | NA | ||
| 32764602 | 2020 | {nnr:N-Lys}-{nnr:N-Lys}-{nnr:N-Lys}-L-{nnr:(2-Nal)Ala}-F-{nnr:(2-Nal)Ala} | 23 | Free | Free | Linear | L | N-Lys = N-(4-aminobutyl)glycine, (2-Nal)Ala = 2-napthylalanine | 7 | Antibacterial | 35.9 % Hemolysis at 150 µM | Human | Synthetic Amps | NA | NA | ||
| 32764602 | 2020 | K-K-K-L{d}-{nnr:(2-nal)ala}-Y{d}-{nnr:(2-nal)ala} | 24 | Free | Free | Linear | Mix | (2-nal)ala = D-2-napthylalanine, y = D-Tyr, l = D-Leu | 7 | Antibacterial | 23.4 % Hemolysis at 150 µM | Human | Synthetic Amps | NA | NA | ||
| 32764602 | 2020 | K-K-L-K-{nnr:(2-Nal)Ala}-F-{nnr:(2-Nal-)Ala} | 1 | Free | Free | Linear | L | (2-Nal)Ala = 2-napthylalanine | 7 | Antibacterial, Anticancer | 19.7 % Hemolysis at 150 µM | Canine | Synthetic Amps | NA | NA | ||
| 32764602 | 2020 | {nnr:(N1-Nal)Gly}-{nnr:(N-Phe)Gly}-{nnr:(N1-Nal)Gly}-{nnr:(N-Bu)Gly}-K-K-K | 2 | Free | Free | Linear | L | (N-Phe)Gly = N-benzylglycine, (N1-Nal)Gly = N-1-naphthylmethylglycine, (N-Bu)Gly = N-butylglycine | 7 | Antibacterial, Anticancer | 100.1 % Hemolysis at 150 µM | Canine | Synthetic Amps | NA | NA | ||
| 32764602 | 2020 | {nnr:(2-nal)ala}-F{d}-{nnr:(2-nal)ala}-K-L{d}-K-K | 3 | Free | Free | Linear | Mix | (2-nal)ala = D-2-napthylalanin, f = D-phenylalanine, l = D-Leu | 7 | Antibacterial | 10.5 % Hemolysis at 150 µM | Canine | Synthetic Amps | NA | NA | ||
| 32764602 | 2020 | {nnr:(2-nal)ala}-F{d}-{nnr:(2-nal)ala}-L{d}-K-K-K | 4 | Free | Free | Linear | Mix | (2-nal)ala = D-2-napthylalanin, f = D-phenylalanine, l = D-Leu | 7 | Antibacterial, Anticancer | <8 % Hemolysis at 150 µM | Canine | Synthetic Amps | NA | Low hemolytic | ||
| 32764602 | 2020 | {nnr:(1-Nal)Ala}-F-{nnr:(1-Nal)Ala}-L-K-K-K | 5 | Free | Free | Linear | L | (1-Nal)Ala = 1-napthylalanine | 7 | Antibacterial, Anticancer | 22.5 % Hemolysis at 150 µM | Canine | Synthetic Amps | NA | NA | ||
| 32764602 | 2020 | K-K-L-K-{nnr:(1-Nal)Ala}-F-{nnr:(1-Nal)Ala} | 6 | Free | Free | Linear | L | (1-Nal)Ala = 1-napthylalanine | 7 | Antibacterial | 101.2 % Hemolysis at 150 µM | Canine | Synthetic Amps | NA | NA | ||
| 32764602 | 2020 | K-K-K-L-{nnr:(1-Nal)Ala}-F{nnr:(1-Nal)Ala} | 7 | Free | Free | Linear | L | (1-Nal)Ala = 1-napthylalanine | 7 | Antibacterial | 102.1 % Hemolysis at 150 µM | Canine | Synthetic Amps | NA | NA | ||
| 32764602 | 2020 | {nnr:(1-nal)ala}-F{d}-{nnr:(1-nal)ala}-K-L{d}-K-K | 8 | Free | Free | Linear | Mix | (1-nal)ala = D-1-napthylalanine, f = D-phenylalanine, l = D-Leu | 7 | Antibacterial | 25.8 % Hemolysis at 150 µM | Canine | Synthetic Amps | NA | NA | ||
| 32764602 | 2020 | {nnr:(1-nal)ala}-F{d}-{nnr:(1-nal)ala}-L{d}-K-K-K | 9 | Free | Free | Linear | Mix | (1-nal)ala = D-1-napthylalanine, f = D-phenylalanine, l = D-Leu | 7 | Antibacterial | 25.5 % Hemolysis at 150 µM | Canine | Synthetic Amps | NA | NA | ||
| 32764602 | 2020 | K-K-L{d}-K-{nnr:(1-nal)ala}-F{d}-{nnr:(1-nal)ala} | 10 | Free | Free | Linear | Mix | (1-nal)ala = D-1-napthylalanine, f = D-phenylalanine, l = D-Leu | 7 | Antibacterial | 36.3 % Hemolysis at 150 µM | Canine | Synthetic Amps | NA | NA | ||
| 32764602 | 2020 | K-K-K-L{d}-{nnr:(1-nal)ala}-F{d}-{nnr:(1-nal)ala} | 11 | Free | Free | Linear | Mix | (1-nal)ala = D-1-napthylalanine, f = D-phenylalanine, l = D-Leu | 7 | Antibacterial, Anticancer | 40.7 % Hemolysis at 150 µM | Canine | Synthetic Amps | NA | NA | ||
| 32764602 | 2020 | K-K-K-L{d}-{nnr:(2-nal)ala}-F{d}-{nnr:(2-nal)ala} | 12 | Free | Free | Linear | Mix | (2-nal)ala = D-2-napthylalanin, f = D-phenylalanine, l = D-Leu | 7 | Antibacterial | 50.2 % Hemolysis at 150 µM | Canine | Synthetic Amps | NA | NA | ||
| 32764602 | 2020 | {nnr:(2-Nal)Ala}-F-{nnr:(2-Nal)Ala}-K-L-K-K | 13 | Free | Free | Linear | L | (2-Nal)Ala = 2-napthylalanine | 7 | Antibacterial | 27.4 % Hemolysis at 150 µM | Canine | Synthetic Amps | NA | NA | ||
| 32764602 | 2020 | K-K-{nnr:(N-Bu)Gly}-K-{nnr:(N1-Nal)Gly}-{nnr:(N-Phe)Gly}-{nnr:(N1-Nal)Gly} | 14 | Free | Free | Linear | L | (N-Bu)Gly = N-butylglycine, (N1-Nal)Gly = N-1-napthylmethylglycine, (N-Phe)Gly = N-benyzylglycine | 7 | Antibacterial | 28.1 % Hemolysis at 150 µM | Canine | Synthetic Amps | NA | NA | ||
| 32764602 | 2020 | K-K-K-{nnr:(N-Bu)Gly}-{nnr:(N1-Nal)Gly}-{nnr:(N-Phe)Gly}-{nnr:(N1-Nal)Gly} | 15 | Free | Free | Linear | L | (N-Bu)Gly = N-butylglycine, (N1-Nal)Gly = N-1-napthylmethylglycine, (N-Phe)Gly = N-benyzylglycine | 7 | Antibacterial, Anticancer | 87.1 % Hemolysis at 150 µM | Canine | Synthetic Amps | NA | NA | ||
| 32764602 | 2020 | {nnr:(1-Nal)Ala}-F-{nnr:(1-Nal)Ala}-K-L-K-K | 16 | Free | Free | Linear | L | (1-Nal)Ala = 1-napthylalanine | 7 | Antibacterial | 27.7 % Hemolysis at 150 µM | Canine | Synthetic Amps | NA | NA | ||
| 32764602 | 2020 | K-K-K-L-{nnr:(2-Nal)Ala}-Y-{nnr:(2-Nal)Ala} | 17 | Free | Free | Linear | L | (2-Nal)Ala = 2-napthylalanine | 7 | Antibacterial | 100 % Hemolysis at 150 µM | Canine | Synthetic Amps | NA | NA | ||
| 32764602 | 2020 | K-K-K-{nnr:Nle}-{nnr:(2-Nal)Ala}-F-{nnr:(2-Nal)Ala} | 18 | Free | Free | Linear | L | (2-Nal)Ala = 2-napthylalanine, Nle= norleucine | 7 | Antibacterial | 100.7 % Hemolysis at 150 µM | Canine | Synthetic Amps | NA | NA | ||
| 32764602 | 2020 | K-K-K-Leu{nnr:(1-Nal)Ala}-Y-{nnr:(1-Nal)Ala} | 19 | Free | Free | Linear | L | (1-Nal)Ala = 1-napthylalanine | 7 | Antibacterial | 100.8 % Hemolysis at 150 µM | Canine | Synthetic Amps | NA | NA | ||
| 32764602 | 2020 | K-K-K-{nnr:Nle}-{nnr:(1-Nal)Ala}-F-{nnr:(1-Nal)Ala} | 20 | Free | Free | Linear | L | (1-Nal)Ala = 1-napthylalanine, Nle= norleucine | 7 | Antibacterial | 36 % Hemolysis at 150 µM | Canine | Synthetic Amps | NA | NA | ||
| 32764602 | 2020 | K-K-K-l--{nnr:(1-nal)ala}-Y{d}-{nnr:(1-nal)ala} | 21 | Free | Free | Linear | Mix | (1-nal)ala = D-1-napthylalanine, y = D-Tyr | 7 | Antibacterial | 19.9 % Hemolysis at 150 µM | Canine | Synthetic Amps | NA | NA | ||
| 32764602 | 2020 | K-K-K-{nnr:Nle}-{nnr:(2-Nal)Ala}-Y-{nnr:(2-Nal)Ala} | 22 | Free | Free | Linear | L | (2-Nal)Ala = 2-napthylalanine, Nle= norleucine | 7 | Antibacterial | 83 % Hemolysis at 150 µM | Canine | Synthetic Amps | NA | NA | ||
| 32764602 | 2020 | {nnr:N-Lys}-{nnr:N-Lys}-{nnr:N-Lys}-L-{nnr:(2-Nal)Ala}-F-{nnr:(2-Nal)Ala} | 23 | Free | Free | Linear | L | N-Lys = N-(4-aminobutyl)glycine, (2-Nal)Ala = 2-napthylalanine | 7 | Antibacterial | 35.1 % Hemolysis at 150 µM | Canine | Synthetic Amps | NA | NA | ||
| 32764602 | 2020 | K-K-K-L{d}-{nnr:(2-nal)ala}-Y{d}-{nnr:(2-nal)ala} | 24 | Free | Free | Linear | Mix | (2-nal)ala = D-2-napthylalanine, y = D-Tyr, l = D-Leu | 7 | Antibacterial | 38.5 % Hemolysis at 150 µM | Canine | Synthetic Amps | NA | NA | ||
| 32764602 | 2020 | K-K-L-K-{nnr:(2-Nal)Ala}-F-{nnr:(2-Nal-)Ala} | 1 | Free | Free | Linear | L | (2-Nal)Ala = 2-napthylalanine | 7 | Antibacterial, Anticancer | <8 % Hemolysis at 150 µM | Rat | Synthetic Amps | NA | Low hemolytic | ||
| 32764602 | 2020 | {nnr:(N1-Nal)Gly}-{nnr:(N-Phe)Gly}-{nnr:(N1-Nal)Gly}-{nnr:(N-Bu)Gly}-K-K-K | 2 | Free | Free | Linear | L | (N-Phe)Gly = N-benzylglycine, (N1-Nal)Gly = N-1-naphthylmethylglycine, (N-Bu)Gly = N-butylglycine | 7 | Antibacterial, Anticancer | 100 % Hemolysis at 150 µM | Rat | Synthetic Amps | NA | NA | ||
| 32764602 | 2020 | {nnr:(2-nal)ala}-F{d}-{nnr:(2-nal)ala}-K-L{d}-K-K | 3 | Free | Free | Linear | Mix | (2-nal)ala = D-2-napthylalanin, f = D-phenylalanine, l = D-Leu | 7 | Antibacterial | <8 % Hemolysis at 150 µM | Rat | Synthetic Amps | NA | Low hemolytic | ||
| 32764602 | 2020 | {nnr:(2-nal)ala}-F{d}-{nnr:(2-nal)ala}-L{d}-K-K-K | 4 | Free | Free | Linear | Mix | (2-nal)ala = D-2-napthylalanin, f = D-phenylalanine, l = D-Leu | 7 | Antibacterial, Anticancer | <8 % Hemolysis at 150 µM | Rat | Synthetic Amps | NA | Low hemolytic | ||
| 32764602 | 2020 | {nnr:(1-Nal)Ala}-F-{nnr:(1-Nal)Ala}-L-K-K-K | 5 | Free | Free | Linear | L | (1-Nal)Ala = 1-napthylalanine | 7 | Antibacterial, Anticancer | 10.2 % Hemolysis at 150 µM | Rat | Synthetic Amps | NA | NA | ||
| 32764602 | 2020 | K-K-L-K-{nnr:(1-Nal)Ala}-F-{nnr:(1-Nal)Ala} | 6 | Free | Free | Linear | L | (1-Nal)Ala = 1-napthylalanine | 7 | Antibacterial | 18.2 % Hemolysis at 150 µM | Rat | Synthetic Amps | NA | NA | ||
| 32764602 | 2020 | K-K-K-L-{nnr:(1-Nal)Ala}-F{nnr:(1-Nal)Ala} | 7 | Free | Free | Linear | L | (1-Nal)Ala = 1-napthylalanine | 7 | Antibacterial | 54.3 % Hemolysis at 150 µM | Rat | Synthetic Amps | NA | NA | ||
| 32764602 | 2020 | {nnr:(1-nal)ala}-F{d}-{nnr:(1-nal)ala}-K-L{d}-K-K | 8 | Free | Free | Linear | Mix | (1-nal)ala = D-1-napthylalanine, f = D-phenylalanine, l = D-Leu | 7 | Antibacterial | <8 % Hemolysis at 150 µM | Rat | Synthetic Amps | NA | Low hemolytic | ||
| 32764602 | 2020 | {nnr:(1-nal)ala}-F{d}-{nnr:(1-nal)ala}-L{d}-K-K-K | 9 | Free | Free | Linear | Mix | (1-nal)ala = D-1-napthylalanine, f = D-phenylalanine, l = D-Leu | 7 | Antibacterial | <8 % Hemolysis at 150 µM | Rat | Synthetic Amps | NA | Low hemolytic | ||
| 32764602 | 2020 | K-K-L{d}-K-{nnr:(1-nal)ala}-F{d}-{nnr:(1-nal)ala} | 10 | Free | Free | Linear | Mix | (1-nal)ala = D-1-napthylalanine, f = D-phenylalanine, l = D-Leu | 7 | Antibacterial | <8 % Hemolysis at 150 µM | Rat | Synthetic Amps | NA | NA | ||
| 32764602 | 2020 | K-K-K-L{d}-{nnr:(1-nal)ala}-F{d}-{nnr:(1-nal)ala} | 11 | Free | Free | Linear | Mix | (1-nal)ala = D-1-napthylalanine, f = D-phenylalanine, l = D-Leu | 7 | Antibacterial, Anticancer | 11.3 % Hemolysis at 150 µM | Rat | Synthetic Amps | NA | NA | ||
| 32764602 | 2020 | K-K-K-L{d}-{nnr:(2-nal)ala}-F{d}-{nnr:(2-nal)ala} | 12 | Free | Free | Linear | Mix | (2-nal)ala = D-2-napthylalanin, f = D-phenylalanine, l = D-Leu | 7 | Antibacterial | 17.9 % Hemolysis at 150 µM | Rat | Synthetic Amps | NA | NA | ||
| 32764602 | 2020 | {nnr:(2-Nal)Ala}-F-{nnr:(2-Nal)Ala}-K-L-K-K | 13 | Free | Free | Linear | L | (2-Nal)Ala = 2-napthylalanine | 7 | Antibacterial | <8 % Hemolysis at 150 µM | Rat | Synthetic Amps | NA | Low hemolytic | ||
| 32764602 | 2020 | K-K-{nnr:(N-Bu)Gly}-K-{nnr:(N1-Nal)Gly}-{nnr:(N-Phe)Gly}-{nnr:(N1-Nal)Gly} | 14 | Free | Free | Linear | L | (N-Bu)Gly = N-butylglycine, (N1-Nal)Gly = N-1-napthylmethylglycine, (N-Phe)Gly = N-benyzylglycine | 7 | Antibacterial | 31.6 % Hemolysis at 150 µM | Rat | Synthetic Amps | NA | NA | ||
| 32764602 | 2020 | K-K-K-{nnr:(N-Bu)Gly}-{nnr:(N1-Nal)Gly}-{nnr:(N-Phe)Gly}-{nnr:(N1-Nal)Gly} | 15 | Free | Free | Linear | L | (N-Bu)Gly = N-butylglycine, (N1-Nal)Gly = N-1-napthylmethylglycine, (N-Phe)Gly = N-benyzylglycine | 7 | Antibacterial, Anticancer | 99.5 % Hemolysis at 150 µM | Rat | Synthetic Amps | NA | NA | ||
| 32764602 | 2020 | {nnr:(1-Nal)Ala}-F-{nnr:(1-Nal)Ala}-K-L-K-K | 16 | Free | Free | Linear | L | (1-Nal)Ala = 1-napthylalanine | 7 | Antibacterial | 11 % Hemolysis at 150 µM | Rat | Synthetic Amps | NA | NA | ||
| 32764602 | 2020 | K-K-K-L-{nnr:(2-Nal)Ala}-Y-{nnr:(2-Nal)Ala} | 17 | Free | Free | Linear | L | (2-Nal)Ala = 2-napthylalanine | 7 | Antibacterial | 100.1 % Hemolysis at 150 µM | Rat | Synthetic Amps | NA | NA | ||
| 32764602 | 2020 | K-K-K-{nnr:Nle}-{nnr:(2-Nal)Ala}-F-{nnr:(2-Nal)Ala} | 18 | Free | Free | Linear | L | (2-Nal)Ala = 2-napthylalanine, Nle= norleucine | 7 | Antibacterial | 98.6 % Hemolysis at 150 µM | Rat | Synthetic Amps | NA | NA | ||
| 32764602 | 2020 | K-K-K-Leu{nnr:(1-Nal)Ala}-Y-{nnr:(1-Nal)Ala} | 19 | Free | Free | Linear | L | (1-Nal)Ala = 1-napthylalanine | 7 | Antibacterial | 100.6 % Hemolysis at 150 µM | Rat | Synthetic Amps | NA | NA | ||
| 32764602 | 2020 | K-K-K-{nnr:Nle}-{nnr:(1-Nal)Ala}-F-{nnr:(1-Nal)Ala} | 20 | Free | Free | Linear | L | (1-Nal)Ala = 1-napthylalanine, Nle= norleucine | 7 | Antibacterial | <8 % Hemolysis at 150 µM | Rat | Synthetic Amps | NA | Low hemolytic | ||
| 32764602 | 2020 | K-K-K-l--{nnr:(1-nal)ala}-Y{d}-{nnr:(1-nal)ala} | 21 | Free | Free | Linear | Mix | (1-nal)ala = D-1-napthylalanine, y = D-Tyr | 7 | Antibacterial | <8 % Hemolysis at 150 µM | Rat | Synthetic Amps | NA | Low hemolytic | ||
| 32764602 | 2020 | K-K-K-{nnr:Nle}-{nnr:(2-Nal)Ala}-Y-{nnr:(2-Nal)Ala} | 22 | Free | Free | Linear | L | (2-Nal)Ala = 2-napthylalanine, Nle= norleucine | 7 | Antibacterial | 24.2 % Hemolysis at 150 µM | Rat | Synthetic Amps | NA | NA | ||
| 32764602 | 2020 | {nnr:N-Lys}-{nnr:N-Lys}-{nnr:N-Lys}-L-{nnr:(2-Nal)Ala}-F-{nnr:(2-Nal)Ala} | 23 | Free | Free | Linear | L | N-Lys = N-(4-aminobutyl)glycine, (2-Nal)Ala = 2-napthylalanine | 7 | Antibacterial | <8 % Hemolysis at 150 µM | Rat | Synthetic Amps | NA | Low hemolytic | ||
| 32764602 | 2020 | K-K-K-L{d}-{nnr:(2-nal)ala}-Y{d}-{nnr:(2-nal)ala} | 24 | Free | Free | Linear | Mix | (2-nal)ala = D-2-napthylalanine, y = D-Tyr, l = D-Leu | 7 | Antibacterial | <8 % Hemolysis at 150 µM | Rat | Synthetic Amps | NA | Low hemolytic | ||
| 32764602 | 2020 | K-K-L-K-{nnr:(2-Nal)Ala}-F-{nnr:(2-Nal-)Ala} | 1 | Free | Free | Linear | L | (2-Nal)Ala = 2-napthylalanine | 7 | Antibacterial, Anticancer | 32.5 % Hemolysis at 150 µM | Bovine | Synthetic Amps | NA | NA | ||
| 32764602 | 2020 | {nnr:(N1-Nal)Gly}-{nnr:(N-Phe)Gly}-{nnr:(N1-Nal)Gly}-{nnr:(N-Bu)Gly}-K-K-K | 2 | Free | Free | Linear | L | (N-Phe)Gly = N-benzylglycine, (N1-Nal)Gly = N-1-naphthylmethylglycine, (N-Bu)Gly = N-butylglycine | 7 | Antibacterial, Anticancer | <8 % Hemolysis at 150 µM | Bovine | Synthetic Amps | NA | Low hemolytic | ||
| 32764602 | 2020 | {nnr:(2-nal)ala}-F{d}-{nnr:(2-nal)ala}-K-L{d}-K-K | 3 | Free | Free | Linear | Mix | (2-nal)ala = D-2-napthylalanin, f = D-phenylalanine, l = D-Leu | 7 | Antibacterial | <8 % Hemolysis at 150 µM | Bovine | Synthetic Amps | NA | Low hemolytic | ||
| 32764602 | 2020 | {nnr:(2-nal)ala}-F{d}-{nnr:(2-nal)ala}-L{d}-K-K-K | 4 | Free | Free | Linear | Mix | (2-nal)ala = D-2-napthylalanin, f = D-phenylalanine, l = D-Leu | 7 | Antibacterial, Anticancer | <8 % Hemolysis at 150 µM | Bovine | Synthetic Amps | NA | Low hemolytic | ||
| 32764602 | 2020 | {nnr:(1-Nal)Ala}-F-{nnr:(1-Nal)Ala}-L-K-K-K | 5 | Free | Free | Linear | L | (1-Nal)Ala = 1-napthylalanine | 7 | Antibacterial, Anticancer | <8 % Hemolysis at 150 µM | Bovine | Synthetic Amps | NA | Low hemolytic | ||
| 32764602 | 2020 | K-K-L-K-{nnr:(1-Nal)Ala}-F-{nnr:(1-Nal)Ala} | 6 | Free | Free | Linear | L | (1-Nal)Ala = 1-napthylalanine | 7 | Antibacterial | 39.9 % Hemolysis at 150 µM | Bovine | Synthetic Amps | NA | NA | ||
| 32764602 | 2020 | K-K-K-L-{nnr:(1-Nal)Ala}-F{nnr:(1-Nal)Ala} | 7 | Free | Free | Linear | L | (1-Nal)Ala = 1-napthylalanine | 7 | Antibacterial | 16 % Hemolysis at 150 µM | Bovine | Synthetic Amps | NA | NA | ||
| 32764602 | 2020 | {nnr:(1-nal)ala}-F{d}-{nnr:(1-nal)ala}-K-L{d}-K-K | 8 | Free | Free | Linear | Mix | (1-nal)ala = D-1-napthylalanine, f = D-phenylalanine, l = D-Leu | 7 | Antibacterial | <8 % Hemolysis at 150 µM | Bovine | Synthetic Amps | NA | Low hemolytic | ||
| 32764602 | 2020 | {nnr:(1-nal)ala}-F{d}-{nnr:(1-nal)ala}-L{d}-K-K-K | 9 | Free | Free | Linear | Mix | (1-nal)ala = D-1-napthylalanine, f = D-phenylalanine, l = D-Leu | 7 | Antibacterial | <8 % Hemolysis at 150 µM | Bovine | Synthetic Amps | NA | Low hemolytic | ||
| 32764602 | 2020 | K-K-L{d}-K-{nnr:(1-nal)ala}-F{d}-{nnr:(1-nal)ala} | 10 | Free | Free | Linear | Mix | (1-nal)ala = D-1-napthylalanine, f = D-phenylalanine, l = D-Leu | 7 | Antibacterial | <8 % Hemolysis at 150 µM | Bovine | Synthetic Amps | NA | Low hemolytic | ||
| 32764602 | 2020 | K-K-K-L{d}-{nnr:(1-nal)ala}-F{d}-{nnr:(1-nal)ala} | 11 | Free | Free | Linear | Mix | (1-nal)ala = D-1-napthylalanine, f = D-phenylalanine, l = D-Leu | 7 | Antibacterial, Anticancer | 17.4 % Hemolysis at 150 µM | Bovine | Synthetic Amps | NA | NA | ||
| 32764602 | 2020 | K-K-K-L{d}-{nnr:(2-nal)ala}-F{d}-{nnr:(2-nal)ala} | 12 | Free | Free | Linear | Mix | (2-nal)ala = D-2-napthylalanin, f = D-phenylalanine, l = D-Leu | 7 | Antibacterial | <8 % Hemolysis at 150 µM | Bovine | Synthetic Amps | NA | Low hemolytic | ||
| 32764602 | 2020 | {nnr:(2-Nal)Ala}-F-{nnr:(2-Nal)Ala}-K-L-K-K | 13 | Free | Free | Linear | L | (2-Nal)Ala = 2-napthylalanine | 7 | Antibacterial | 17.6 % Hemolysis at 150 µM | Bovine | Synthetic Amps | NA | NA | ||
| 32764602 | 2020 | K-K-{nnr:(N-Bu)Gly}-K-{nnr:(N1-Nal)Gly}-{nnr:(N-Phe)Gly}-{nnr:(N1-Nal)Gly} | 14 | Free | Free | Linear | L | (N-Bu)Gly = N-butylglycine, (N1-Nal)Gly = N-1-napthylmethylglycine, (N-Phe)Gly = N-benyzylglycine | 7 | Antibacterial | 13.9 % Hemolysis at 150 µM | Bovine | Synthetic Amps | NA | NA | ||
| 32764602 | 2020 | K-K-K-{nnr:(N-Bu)Gly}-{nnr:(N1-Nal)Gly}-{nnr:(N-Phe)Gly}-{nnr:(N1-Nal)Gly} | 15 | Free | Free | Linear | L | (N-Bu)Gly = N-butylglycine, (N1-Nal)Gly = N-1-napthylmethylglycine, (N-Phe)Gly = N-benyzylglycine | 7 | Antibacterial, Anticancer | <8 % Hemolysis at 150 µM | Bovine | Synthetic Amps | NA | Low hemolytic | ||
| 32764602 | 2020 | {nnr:(1-Nal)Ala}-F-{nnr:(1-Nal)Ala}-K-L-K-K | 16 | Free | Free | Linear | L | (1-Nal)Ala = 1-napthylalanine | 7 | Antibacterial | 30.6 % Hemolysis at 150 µM | Bovine | Synthetic Amps | NA | NA | ||
| 32764602 | 2020 | K-K-K-L-{nnr:(2-Nal)Ala}-Y-{nnr:(2-Nal)Ala} | 17 | Free | Free | Linear | L | (2-Nal)Ala = 2-napthylalanine | 7 | Antibacterial | 19.9 % Hemolysis at 150 µM | Bovine | Synthetic Amps | NA | NA | ||
| 32764602 | 2020 | K-K-K-{nnr:Nle}-{nnr:(2-Nal)Ala}-F-{nnr:(2-Nal)Ala} | 18 | Free | Free | Linear | L | (2-Nal)Ala = 2-napthylalanine, Nle= norleucine | 7 | Antibacterial | <8 % Hemolysis at 150 µM | Bovine | Synthetic Amps | NA | Low hemolytic | ||
| 32764602 | 2020 | K-K-K-Leu{nnr:(1-Nal)Ala}-Y-{nnr:(1-Nal)Ala} | 19 | Free | Free | Linear | L | (1-Nal)Ala = 1-napthylalanine | 7 | Antibacterial | <8 % Hemolysis at 150 µM | Bovine | Synthetic Amps | NA | Low hemolytic | ||
| 32764602 | 2020 | K-K-K-{nnr:Nle}-{nnr:(1-Nal)Ala}-F-{nnr:(1-Nal)Ala} | 20 | Free | Free | Linear | L | (1-Nal)Ala = 1-napthylalanine, Nle= norleucine | 7 | Antibacterial | 20.1 % Hemolysis at 150 µM | Bovine | Synthetic Amps | NA | NA | ||
| 32764602 | 2020 | K-K-K-l--{nnr:(1-nal)ala}-Y{d}-{nnr:(1-nal)ala} | 21 | Free | Free | Linear | Mix | (1-nal)ala = D-1-napthylalanine, y = D-Tyr | 7 | Antibacterial | 16 % Hemolysis at 150 µM | Bovine | Synthetic Amps | NA | NA | ||
| 32764602 | 2020 | K-K-K-{nnr:Nle}-{nnr:(2-Nal)Ala}-Y-{nnr:(2-Nal)Ala} | 22 | Free | Free | Linear | L | (2-Nal)Ala = 2-napthylalanine, Nle= norleucine | 7 | Antibacterial | <8 % Hemolysis at 150 µM | Bovine | Synthetic Amps | NA | Low hemolytic | ||
| 32764602 | 2020 | {nnr:N-Lys}-{nnr:N-Lys}-{nnr:N-Lys}-L-{nnr:(2-Nal)Ala}-F-{nnr:(2-Nal)Ala} | 23 | Free | Free | Linear | L | N-Lys = N-(4-aminobutyl)glycine, (2-Nal)Ala = 2-napthylalanine | 7 | Antibacterial | 11.1 % Hemolysis at 150 µM | Bovine | Synthetic Amps | NA | NA | ||
| 32764602 | 2020 | K-K-K-L{d}-{nnr:(2-nal)ala}-Y{d}-{nnr:(2-nal)ala} | 24 | Free | Free | Linear | Mix | (2-nal)ala = D-2-napthylalanine, y = D-Tyr, l = D-Leu | 7 | Antibacterial | 29.8 % Hemolysis at 150 µM | Bovine | Synthetic Amps | NA | NA | ||
| 32823798 | 2020 | {nnr:Dab}-{nnr:Nal}-R-{nnr:Dab}-{nnr:Bip}-{nnr:O2Oc}-{nnr:Nal}-{nnr:Dab}-N{cyc:N-C} | S3(B) | Free | Free | Cyclic | L | Dab = l-2,4-diaminobutyric acid, Nal = 3-(2-Naphthyl)-l-alanine, Bip = l-biphenylalanine, O2Oc = 8-amino-3,6-dioxaoctanoic acid | 9 | Antibacterial | 77 % Hemolysis at 150 μM | Human | Cyclic Antimicrobial Peptide S3(B) | NA | NA | ||
| 32823798 | 2020 | {nnr:Dab(C10)}-{nnr:Nal}-R-{nnr:Dab}-{nnr:Bip}-{nnr:O2Oc}-{nnr:Nal}-{nnr:Dab}-N{cyc:N-C} | (C10)1 | Free | Free | Cyclic | L | Dab(C10) = Dab(C10), Dab = l-2,4-diaminobutyric acid, Nal = 3-(2-Naphthyl)-l-alanine, Bip = l-biphenylalanine, O2Oc = 8-amino-3,6-dioxaoctanoic acid | 9 | Antibacterial | 100 % Hemolysis at 150 μM | Human | Lipidated Analogues Of S3(B) | NA | NA | ||
| 32823798 | 2020 | {nnr:Dab}-{nnr:Dab(C10)}-R-{nnr:Dab}-{nnr:Bip}-{nnr:O2Oc}-{nnr:Nal}-{nnr:Dab}-N{cyc:N-C} | (C10)2 | Free | Free | Cyclic | L | Dab(C10) = Dab(C10), Dab = l-2,4-diaminobutyric acid, Nal = 3-(2-Naphthyl)-l-alanine, Bip = l-biphenylalanine, O2Oc = 8-amino-3,6-dioxaoctanoic acid | 9 | Antibacterial | 100 % Hemolysis at 150 μM | Human | Lipidated Analogues Of S3(B) | NA | NA | ||
| 32823798 | 2020 | {nnr:Dab}-{nnr:Dab(C12)}-R-{nnr:Dab}-{nnr:Bip}-{nnr:O2Oc}-{nnr:Nal}-{nnr:Dab}-N{cyc:N-C} | (C12)2 | Free | Free | Cyclic | L | Dab(C12) = Dab(C12), Dab = l-2,4-diaminobutyric acid, Nal = 3-(2-Naphthyl)-l-alanine, Bip = l-biphenylalanine, O2Oc = 8-amino-3,6-dioxaoctanoic acid | 9 | Antibacterial | 100 % Hemolysis at 150 μM | Human | Lipidated Analogues Of S3(B) | NA | NA | ||
| 32823798 | 2020 | {nnr:Dab}-{nnr:Dab(C14)}-R-{nnr:Dab}-{nnr:Bip}-{nnr:O2Oc}-{nnr:Nal}-{nnr:Dab}-N{cyc:N-C} | (C14)2 | Free | Free | Cyclic | L | Dab(C14) = Dab(C14), Dab = l-2,4-diaminobutyric acid, Nal = 3-(2-Naphthyl)-l-alanine, Bip = l-biphenylalanine, O2Oc = 8-amino-3,6-dioxaoctanoic acid | 9 | Antibacterial | 100 % Hemolysis at 150 μM | Human | Lipidated Analogues Of S3(B) | NA | NA | ||
| 32823798 | 2020 | {nnr:Dab}-{nnr:Nal}-R-{nnr:Dab(C10)}-{nnr:Bip}-{nnr:O2Oc}-{nnr:Nal}-{nnr:Dab}-N{cyc:N-C} | (C10)4 | Free | Free | Cyclic | L | Dab(C10) = Dab(C10), Dab = l-2,4-diaminobutyric acid, Nal = 3-(2-Naphthyl)-l-alanine, Bip = l-biphenylalanine, O2Oc = 8-amino-3,6-dioxaoctanoic acid | 9 | Antibacterial | 100 % Hemolysis at 150 μM | Human | Lipidated Analogues Of S3(B) | NA | NA | ||
| 32823798 | 2020 | {nnr:Dab}-{nnr:Nal}-R-{nnr:Dab}-{nnr:Dab(C4)}-{nnr:O2Oc}-{nnr:Nal}-{nnr:Dab}-N{cyc:N-C} | (C4)5 | Free | Free | Cyclic | L | Dab(C4) = Dab(C4), Dab = l-2,4-diaminobutyric acid, Nal = 3-(2-Naphthyl)-l-alanine, Bip = l-biphenylalanine, O2Oc = 8-amino-3,6-dioxaoctanoic acid | 9 | Antibacterial | 5 % Hemolysis at 150 μM | Human | Lipidated Analogues Of S3(B) | NA | Low hemolytic | ||
| 32823798 | 2020 | {nnr:Dab}-{nnr:Nal}-R-{nnr:Dab}-{nnr:Dab(C6)}-{nnr:O2Oc}-{nnr:Nal}-{nnr:Dab}-N{cyc:N-C} | (C6)5 | Free | Free | Cyclic | L | Dab(C6) = Dab(C6), Dab = l-2,4-diaminobutyric acid, Nal = 3-(2-Naphthyl)-l-alanine, Bip = l-biphenylalanine, O2Oc = 8-amino-3,6-dioxaoctanoic acid | 9 | Antibacterial | 13 % Hemolysis at 150 μM | Human | Lipidated Analogues Of S3(B) | NA | NA | ||
| 32823798 | 2020 | {nnr:Dab}-{nnr:Nal}-R-{nnr:Dab}-{nnr:Dab(C8)}-{nnr:O2Oc}-{nnr:Nal}-{nnr:Dab}-N{cyc:N-C} | (C8)5 | Free | Free | Cyclic | L | Dab(C8) = Dab(C8), Dab = l-2,4-diaminobutyric acid, Nal = 3-(2-Naphthyl)-l-alanine, Bip = l-biphenylalanine, O2Oc = 8-amino-3,6-dioxaoctanoic acid | 9 | Antibacterial | 42 % Hemolysis at 150 μM | Human | Lipidated Analogues Of S3(B) | NA | NA | ||
| 32823798 | 2020 | {nnr:Dab}-{nnr:Nal}-R-{nnr:Dab}-{nnr:Dab(C10)}-{nnr:O2Oc}-{nnr:Nal}-{nnr:Dab}-N{cyc:N-C} | (C10)5 | Free | Free | Cyclic | L | Dab(C10) = Dab(C10), Dab = l-2,4-diaminobutyric acid, Nal = 3-(2-Naphthyl)-l-alanine, Bip = l-biphenylalanine, O2Oc = 8-amino-3,6-dioxaoctanoic acid | 9 | Antibacterial | 100 % Hemolysis at 150 μM | Human | Lipidated Analogues Of S3(B) | NA | NA | ||
| 32823798 | 2020 | {nnr:Dab}-{nnr:Nal}-R-{nnr:Dab}-{nnr:Dab(C12)}-{nnr:O2Oc}-{nnr:Nal}-{nnr:Dab}-N{cyc:N-C} | (C12)5 | Free | Free | Cyclic | L | Dab(C12) = Dab(C12), Dab = l-2,4-diaminobutyric acid, Nal = 3-(2-Naphthyl)-l-alanine, Bip = l-biphenylalanine, O2Oc = 8-amino-3,6-dioxaoctanoic acid | 9 | Antibacterial | 100 % Hemolysis at 150 μM | Human | Lipidated Analogues Of S3(B) | NA | NA | ||
| 32823798 | 2020 | {nnr:Dab}-{nnr:Nal}-R-{nnr:Dab}-{nnr:Dab(C14)}-{nnr:O2Oc}-{nnr:Nal}-{nnr:Dab}-N{cyc:N-C} | (C14)5 | Free | Free | Cyclic | L | Dab(C14) = Dab(C14), Dab = l-2,4-diaminobutyric acid, Nal = 3-(2-Naphthyl)-l-alanine, Bip = l-biphenylalanine, O2Oc = 8-amino-3,6-dioxaoctanoic acid | 9 | Antibacterial | 100 % Hemolysis at 150 μM | Human | Lipidated Analogues Of S3(B) | NA | NA | ||
| 32823798 | 2020 | {nnr:Dab}-{nnr:Nal}-R-{nnr:Dab}-{nnr:Bip}-{nnr:O2Oc}-{nnr:Dab(C4)}-{nnr:Dab}-N{cyc:N-C} | (C4)7 | Free | Free | Cyclic | L | Dab(C4) = Dab(C4), Dab = l-2,4-diaminobutyric acid, Nal = 3-(2-Naphthyl)-l-alanine, Bip = l-biphenylalanine, O2Oc = 8-amino-3,6-dioxaoctanoic acid | 9 | Antibacterial | 4 % Hemolysis at 150 μM | Human | Lipidated Analogues Of S3(B) | NA | Low hemolytic | ||
| 32823798 | 2020 | {nnr:Dab}-{nnr:Nal}-R-{nnr:Dab}-{nnr:Bip}-{nnr:O2Oc}-{nnr:Dab(C6)}-{nnr:Dab}-N{cyc:N-C} | (C6)7 | Free | Free | Cyclic | L | Dab(C6) = Dab(C6), Dab = l-2,4-diaminobutyric acid, Nal = 3-(2-Naphthyl)-l-alanine, Bip = l-biphenylalanine, O2Oc = 8-amino-3,6-dioxaoctanoic acid | 9 | Antibacterial | 8 % Hemolysis at 150 μM | Human | Lipidated Analogues Of S3(B) | NA | NA | ||
| 32823798 | 2020 | {nnr:Dab}-{nnr:Nal}-R-{nnr:Dab}-{nnr:Bip}-{nnr:O2Oc}-{nnr:Dab(C8)}-{nnr:Dab}-N{cyc:N-C} | (C8)7 | Free | Free | Cyclic | L | Dab(C8) = Dab(C8), Dab = l-2,4-diaminobutyric acid, Nal = 3-(2-Naphthyl)-l-alanine, Bip = l-biphenylalanine, O2Oc = 8-amino-3,6-dioxaoctanoic acid | 9 | Antibacterial | 56 % Hemolysis at 150 μM | Human | Lipidated Analogues Of S3(B) | NA | NA | ||
| 32823798 | 2020 | {nnr:Dab}-{nnr:Nal}-R-{nnr:Dab}-{nnr:Bip}-{nnr:O2Oc}-{nnr:Dab(C10)}-{nnr:Dab}-N{cyc:N-C} | (C10)7 | Free | Free | Cyclic | L | Dab(C10) = Dab(C10), Dab = l-2,4-diaminobutyric acid, Nal = 3-(2-Naphthyl)-l-alanine, Bip = l-biphenylalanine, O2Oc = 8-amino-3,6-dioxaoctanoic acid | 9 | Antibacterial | 100 % Hemolysis at 150 μM | Human | Lipidated Analogues Of S3(B) | NA | NA | ||
| 32823798 | 2020 | {nnr:Dab}-{nnr:Nal}-R-{nnr:Dab}-{nnr:Bip}-{nnr:O2Oc}-{nnr:Dab(C12)}-{nnr:Dab}-N{cyc:N-C} | (C12)7 | Free | Free | Cyclic | L | Dab(C12) = Dab(C12), Dab = l-2,4-diaminobutyric acid, Nal = 3-(2-Naphthyl)-l-alanine, Bip = l-biphenylalanine, O2Oc = 8-amino-3,6-dioxaoctanoic acid | 9 | Antibacterial | 96 % Hemolysis at 150 μM | Human | Lipidated Analogues Of S3(B) | NA | NA | ||
| 32823798 | 2020 | {nnr:Dab}-{nnr:Nal}-R-{nnr:Dab}-{nnr:Bip}-{nnr:O2Oc}-{nnr:Dab(C14)}-{nnr:Dab}-N{cyc:N-C} | (C14)7 | Free | Free | Cyclic | L | Dab(C14) = Dab(C14), Dab = l-2,4-diaminobutyric acid, Nal = 3-(2-Naphthyl)-l-alanine, Bip = l-biphenylalanine, O2Oc = 8-amino-3,6-dioxaoctanoic acid | 9 | Antibacterial | 98 % Hemolysis at 150 μM | Human | Lipidated Analogues Of S3(B) | NA | NA | ||
| 32823798 | 2020 | {nnr:Dab}-{nnr:Nal}-R-{nnr:Dab}-{nnr:Bip}-{nnr:O2Oc}-{nnr:Nal}-{nnr:Dab(C10)}-N{cyc:N-C} | (C10)8 | Free | Free | Cyclic | L | Dab(C10) = Dab(C10), Dab = l-2,4-diaminobutyric acid, Nal = 3-(2-Naphthyl)-l-alanine, Bip = l-biphenylalanine, O2Oc = 8-amino-3,6-dioxaoctanoic acid | 9 | Antibacterial | 100 % Hemolysis at 150 μM | Human | Lipidated Analogues Of S3(B) | NA | NA | ||
| 32673701 | 2020 | R{d}RR{d}RR{d}RRR | rR8 | Free | Free | Linear | Mix | None | 8 | Antimalarial | 0 % Hemolysis at 5 μM | Human | Derived From A Cell-Penetrating Peptide | Random coil | Non-hemolytic | ||
| 32673701 | 2020 | R{d}RR{d}RR{d}RRR | rR8 | Free | Free | Linear | Mix | None | 8 | Antimalarial | 0 % Hemolysis at 10 μM | Human | Derived From A Cell-Penetrating Peptide | Random coil | Non-hemolytic | ||
| 32673701 | 2020 | R{d}RR{d}RR{d}RRR | rR8 | Free | Free | Linear | Mix | None | 8 | Antimalarial | 0.8 % Hemolysis at 20 μM | Human | Derived From A Cell-Penetrating Peptide | Random coil | Non-hemolytic | ||
| 32673701 | 2020 | R{d}RR{d}RR{d}RRR | rR8 | Free | Free | Linear | Mix | None | 8 | Antimalarial | 1.3 % Hemolysis at 40 μM | Human | Derived From A Cell-Penetrating Peptide | Random coil | Non-hemolytic | ||
| 33085895 | 2020 | F{d}{nnr:X}{nnr:X}L{nt:C16} | C16-fXXL | Free | C16 | Linear | Mix | X = L-2,4-diaminobutyric acid, f = D-phenylalanine | 4 | Antibacterial | ~10 % Hemolysis at 5 μg/mL | Horse | Synthetic Lipopeptide | NA | NA | ||
| 33085895 | 2020 | F{d}{nnr:X}{nnr:X}L{nt:C14} | C14-fXXL | Free | C14 | Linear | Mix | X = L-2,4-diaminobutyric acid, f = D-phenylalanine | 4 | Antibacterial | ~10 % Hemolysis at 5 μg/mL | Horse | Synthetic Lipopeptide | NA | NA | ||
| 33085895 | 2020 | F{d}{nnr:X}{nnr:X}{nnr:L}{nt:C12} | C12-fXXL | Free | C12 | Linear | Mix | X = L-2,4-diaminobutyric acid, f = D-phenylalanine, L = L-leucine | 4 | Antibacterial | <5 % Hemolysis at 5 μg/mL | Horse | Synthetic Lipopeptide | NA | NA | ||
| 33085895 | 2020 | F{d}{nnr:X}{nnr:X}L{nt:C16} | C16-fXXL | Free | C16 | Linear | Mix | X = L-2,4-diaminobutyric acid, f = D-phenylalanine | 4 | Antibacterial | <5 % Hemolysis at 5 μg/mL | Sheep | Synthetic Lipopeptide | NA | NA | ||
| 33085895 | 2020 | F{d}{nnr:X}{nnr:X}L{nt:C14} | C14-fXXL | Free | C14 | Linear | Mix | X = L-2,4-diaminobutyric acid, f = D-phenylalanine | 4 | Antibacterial | ~10 % Hemolysis at 5 μg/mL | Sheep | Synthetic Lipopeptide | NA | NA | ||
| 33085895 | 2020 | F{d}{nnr:X}{nnr:X}{nnr:L}{nt:C12} | C12-fXXL | Free | C12 | Linear | Mix | X = L-2,4-diaminobutyric acid, f = D-phenylalanine, L = L-leucine | 4 | Antibacterial | 0 % Hemolysis at 5 μg/mL | Sheep | Synthetic Lipopeptide | NA | Non-hemolytic | ||
| 33049300 | 2021 | CGWKY | Gj-CATH3-(38–42)-peptide | Free | Free | Linear | L | None | 5 | Antioxidant, Wound healing | 0.7 ± 0.14 % Hemolysis at 80 μM | Sheep | Gj-Cath3 Analogues | NA | Non-hemolytic | ||
| 33296183 | 2021 | FLKILKKLL{ct:Amid} | Feleucin-K46 | Amidation | Free | Linear | L | None | 9 | Antibacterial | <10 % Hemolysis at 128 μg/mL | Mouse | Feleucin-K3 Analogues (Frog Bombina Orientalis) | 50% TFE = α-Helix | Low hemolytic | ||
| 33296183 | 2021 | FLKFLKKLL{ct:Amid} | Feleucin-K48 | Amidation | Free | Linear | L | None | 9 | Antibacterial | ≥20 % Hemolysis at 128 μg/mL | Mouse | Feleucin-K3 Analogues (Frog Bombina Orientalis) | TFE = α-Helix | NA | ||
| 33296183 | 2021 | FLKWLKKLL{ct:Amid} | Feleucin-K52 | Amidation | Free | Linear | L | None | 9 | Antibacterial | ≥60 % Hemolysis at 128 μg/mL | Mouse | Feleucin-K3 Analogues (Frog Bombina Orientalis) | TFE = α-Helix | NA | ||
| 33296183 | 2021 | FLKYLKKLL{ct:Amid} | Feleucin-K53 | Amidation | Free | Linear | L | None | 9 | Antibacterial | ≥10 % Hemolysis at 128 μg/mL | Mouse | Feleucin-K3 Analogues (Frog Bombina Orientalis) | TFE = α-Helix | Low hemolytic | ||
| 33296183 | 2021 | FLK{nnr:L-2-Nal}LKKLL{ct:Amid} | Feleucin-K55 | Amidation | Free | Linear | L | L-2-NAL = L-2-NAL | 9 | Antibacterial | ≥80 % Hemolysis at 128 μg/mL | Mouse | Feleucin-K3 Analogues (Frog Bombina Orientalis) | TFE = α-Helix | NA | ||
| 33296183 | 2021 | FLK{nnr:D-2-NaI}LKKLL{ct:Amid} | Feleucin-K56 | Amidation | Free | Linear | Mix | D-2-nal = D-2-nal | 9 | Antibacterial | ≥10 % Hemolysis at 128 μg/mL | Mouse | Feleucin-K3 Analogues (Frog Bombina Orientalis) | TFE = α-Helix | Low hemolytic | ||
| 33296183 | 2021 | FLK{nnr:α-(4-pentenyl)-Ala}LKKLL{ct:Amid} | Feleucin-K59 | Amidation | Free | Linear | L | α-(4-pentenyl)-Ala | 9 | Antibacterial, Antibiofilm | ≥60 % Hemolysis at 128 μg/mL | Mouse | Feleucin-K3 Analogues (Frog Bombina Orientalis) | TFE = α-Helix | NA | ||
| 33669976 | 2021 | {nnr:Methyldecanoyl}-{nnr:MePro}-{nnr:AHMOD}-A-{nnr:Aib}-I-{nnr:Iva}-{nnr:βAla}-Alaol-{nnr:Glyol}{nt:amino group}{ct:hydroxyl} | EmiA | hydroxyl | amino group | Linear | L | MePro = Methylproline, AHMOD = 2-Amino-3-hydroxy-4-methyl-2-pentenoic acid, Aib = α-Amino isobutyric acid, Iva = Isovaline, βAla = β-Alanine{nnr:Bala} – β-Alanine , Glyol = Glycine with a hydroxyl modification, Methyldecanoyl = Methyldecanoyl | 9 | Antifungal, Anticancer | 12.6 % Hemolysis at 20 µM | Human | Derived From The Alkalophilic Fungus Emericellopsis Alkalina | NA | NA | ||
| 33676184 | 2021 | KWKLFKKI | CMt2 | Free | Free | Linear | L | None | 8 | Antifungal | 5 % Hemolysis at 500 μg/ml | Human | C-Terminal Truncated Derivatives | α-Helix Random coil | Low hemolytic | ||
| 33676184 | 2021 | KWKLFK | CMt3 | Free | Free | Linear | L | None | 6 | Antifungal | 5 % Hemolysis at 500 μg/ml | Human | C-Terminal Truncated Derivatives | Random coil | Low hemolytic | ||
| 34069651 | 2021 | LKLLKKLL{nt:α-(4-pentenyl)-Ala}{ct:Amid} | Feleucin-K65 | Amidation | α-(4-pentenyl)-Ala | Linear | L | α-(4-pentenyl)-Ala | 9 | Antimicrobial, Antibiofilm | 9.08 % Hemolysis at 64 μg/ml | Mouse | Feleucin-K3 Analogs (Frog Bombina Orientalis) | 50% TFE = α-Helical | NA | ||
| 34069651 | 2021 | LKLLKKLL{nt:α-(4-pentenyl)-Ala}{ct:Amid} | Feleucin-K65 | Amidation | α-(4-pentenyl)-Ala | Linear | L | α-(4-pentenyl)-Ala | 9 | Antimicrobial, Antibiofilm | 31.6 % Hemolysis at 128 μg/ml | Mouse | Feleucin-K3 Analogs (Frog Bombina Orientalis) | 50% TFE = α-Helical | NA | ||
| 34069651 | 2021 | FLKLLKKL{nnr:α-(4-pentenyl)-Ala}{ct:Amid} | Feleucin-K70 | Amidation | Free | Linear | L | α-(4-pentenyl)-Ala | 9 | Antimicrobial, Antibiofilm | 1 % Hemolysis at 128 μg/ml | Mouse | Feleucin-K3 Analogs (Frog Bombina Orientalis) | 50% TFE = α-Helical | Non-hemolytic | ||
| 33890759 | 2021 | KRIWQRIK{nt:C14}{ct:Amid} | C14-KR8 | Amidation | C14 | Linear | L | None | 8 | Antibacterial | 50 % Hemolysis at <25 μM | Human | Synthetic Peptide | NA | NA | ||
| 33890759 | 2021 | KRIWQR{nt:C14}{ct:Amid} | C14-KR6 | Amidation | C14 | Linear | L | None | 6 | Antibacterial | 50 % Hemolysis at <25 μM | Human | Synthetic Peptide | NA | NA | ||
| 33890759 | 2021 | KRIW{nt:C14}{ct:Amid} | C14-KR4 | Amidation | C14 | Linear | L | None | 4 | Antibacterial | 50 % Hemolysis at <25 μM | Human | Synthetic Peptide | NA | NA | ||
| 33890759 | 2021 | KRIWQRIK{nt:C12}{ct:Amid} | C12-KR8 | Amidation | C12 | Linear | L | None | 8 | Antibacterial | 50 % Hemolysis at 35 μM | Human | Synthetic Peptide | NA | NA | ||
| 33890759 | 2021 | KRIWQR{nt:C12}{ct:Amid} | C12-KR6 | Amidation | C12 | Linear | L | None | 6 | Antibacterial | 50 % Hemolysis at 75 μM | Human | Synthetic Peptide | NA | NA | ||
| 33890759 | 2021 | KRIW{nt:C12}{ct:Amid} | C12-KR4 | Amidation | C12 | Linear | L | None | 4 | Antibacterial | 50 % Hemolysis at 30 μM | Human | Synthetic Peptide | NA | NA | ||
| 33890759 | 2021 | KRIWQRIK{nt:C10}{ct:Amid} | C10-KR8 | Amidation | C10 | Linear | L | None | 8 | Antibacterial | 50 % Hemolysis at 300 μM | Human | Synthetic Peptide | Helical | Low hemolytic | ||
| 33890759 | 2021 | K{d}R{d}I{d}W{d}Q{d}R{d}I{d}K{d}{nt:C10}{ct:Amid} | C10-KR8d | Amidation | C10 | Linear | D | None | 8 | Antibacterial | 50 % Hemolysis at 300 μM | Human | Synthetic Peptide | NA | Low hemolytic | ||
| 33890759 | 2021 | KRIWQR{nt:C10}{ct:Amid} | C10-KR6 | Amidation | C10 | Linear | L | None | 6 | Antibacterial | 50 % Hemolysis at >340 μM | Human | Synthetic Peptide | NA | Low hemolytic | ||
| 33890759 | 2021 | KRIW{nt:C10}{ct:Amid} | C10-KR4 | Amidation | C10 | Linear | L | None | 4 | Antibacterial | 50 % Hemolysis at 150 μM | Human | Synthetic Peptide | NA | NA | ||
| 33890759 | 2021 | KRIWQRIK{nt:C8}{ct:Amid} | C8-KR8 | Amidation | C8 | Linear | L | None | 8 | Antibacterial | 50 % Hemolysis at >200 μM | Human | Synthetic Peptide | NA | Low hemolytic | ||
| 33890759 | 2021 | KRIWQR{nt:C8}{ct:Amid} | C8-KR6 | Amidation | C8 | Linear | L | None | 6 | Antibacterial | 50 % Hemolysis at >200 μM | Human | Synthetic Peptide | NA | Low hemolytic | ||
| 33890759 | 2021 | KRIW{nt:C8}{ct:Amid} | C8-KR4 | Amidation | C8 | Linear | L | None | 4 | Antibacterial | 50 % Hemolysis at >200 μM | Human | Synthetic Peptide | NA | Low hemolytic | ||
| 33890759 | 2021 | KRIWQRIK{nt:C6}{ct:Amid} | C6-KR8 | Amidation | C6 | Linear | L | None | 8 | Antibacterial | 50 % Hemolysis at >200 μM | Human | Synthetic Peptide | NA | Low hemolytic | ||
| 33890759 | 2021 | KRIWQR{nt:C6}{ct:Amid} | C6-KR6 | Amidation | C6 | Linear | L | None | 6 | Antibacterial | 50 % Hemolysis at >200 μM | Human | Synthetic Peptide | NA | Low hemolytic | ||
| 33890759 | 2021 | KRIW{nt:C6}{ct:Amid} | C6-KR4 | Amidation | C6 | Linear | L | None | 4 | Antibacterial | 50 % Hemolysis at >200 μM | Human | Synthetic Peptide | NA | Low hemolytic | ||
| 33878564 | 2021 | PFKLSLHL | jelleine-1 | Free | Free | Linear | L | None | 8 | Antimicrobial | 1 % Hemolysis at 256 μM | Human | Royal Jelly Of Honeybees | NA | Non-hemolytic | ||
| 33878564 | 2021 | PFRLRLRL | 7 | Free | Free | Linear | L | None | 8 | Antimicrobial | 1 % Hemolysis at 256 μM | Human | Jelleine-1Analog | NA | Non-hemolytic | ||
| 33878564 | 2021 | PWRLRLRL | 15 | Free | Free | Linear | L | None | 8 | Antimicrobial | 1 % Hemolysis at 256 μM | Human | Jelleine-1Analog | NA | Non-hemolytic | ||
| 34436290 | 2021 | CAGSLRLTC{ct:OH} | A0 | OH | Free | Linear | L | None | 9 | Antimicrobial | 1 % Hemolysis at 100 µg/ml | Human | American Oyster Defensin (Aod) Analog | Extended Strand Random coil | Non-hemolytic | ||
| 34436290 | 2021 | CAGWRRLRC{nt:Acet}{ct:Amid} | A1 | Amidation | Acetylation | Linear | L | None | 9 | Antimicrobial | 1 % Hemolysis at 100 µg/ml | Human | American Oyster Defensin (Aod) Analog | Extended Strand Random coil | Non-hemolytic | ||
| 34436290 | 2021 | CRWRLRLRC{ct:OH} | A2 | OH | Free | Linear | L | None | 9 | Antimicrobial | 1 % Hemolysis at 100 µg/ml | Human | American Oyster Defensin (Aod) Analog | Extended Strand Random coil | Non-hemolytic | ||
| 34436290 | 2021 | CRRWRRRRC{ct:OH} | A3 | OH | Free | Linear | L | None | 9 | Antimicrobial | 1 % Hemolysis at 100 µg/ml | Human | American Oyster Defensin (Aod) Analog | Extended Strand Random coil | Non-hemolytic | ||
| 34436290 | 2021 | CRRWGWRRC{ct:Amid} | A4 | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 1 % Hemolysis at 100 µg/ml | Human | American Oyster Defensin (Aod) Analog | Extended Strand Random coil | Non-hemolytic | ||
| 34227804 | 2021 | {nnr:NLys}-W-{nnr:NLys}-W-{nnr:NLys}-W-{nnr:NLys}-W{nt:H}{ct:Amid} | CEP-246 | Amidation | H | Linear | L | NLys = N-(4-aminobutyl)glycine | 8 | Antibacterial | 4.6 (±3) % Hemolysis at 400 μg/mL | Human | Synthetic Peptidomimetics | NA | Low hemolytic | ||
| 34227804 | 2021 | {nnr:NLys}-{nnr:Cha}-{nnr:NLys}-{nnr:Cha}-{nnr:NLys}-{nnr:Cha}{nt:H}{ct:Amid} | CEP-391 | Amidation | H | Linear | L | NLys = N-(4-aminobutyl)glycine, Cha = Cha | 6 | Antibacterial | 22.6 (±2) % Hemolysis at 400 μg/mL | Human | Synthetic Peptidomimetics | NA | NA | ||
| 34577539 | 2021 | CRRRGSPHC | mCA4-4 | Free | Free | Linear | L | None | 9 | Antibacterial | <6 % Hemolysis at 100 µM | Chicken | Chicken Angiogenin 4 (Chang4) | NA | Low hemolytic | ||
| 34028137 | 2021 | VRLLRRRI{nt:H}{ct:Amid} | SAMP-A4 | Amidation | H | Linear | L | None | 8 | Antibacterial, Antifungal, Antibiofilm | 5 % Hemolysis at 69.26 μg/ml | Human | Synthesized Antimicrobial Peptide A4 | NA | Low hemolytic | ||
| 34028137 | 2021 | VRLLRRRI{nt:Acet}{ct:Amid} | SAMP-A4-C2 | Amidation | Acetylation | Linear | L | None | 8 | Antibacterial, Antifungal, Antibiofilm | 5 % Hemolysis at 34.56 μg/ml | Human | Samp-A4 Analogue | NA | Low hemolytic | ||
| 34028137 | 2021 | VRLLRRRI{nt:Butyryl}{ct:Amid} | SAMP-A4-C4 | Amidation | Butyryl | Linear | L | None | 8 | Antibacterial, Antifungal, Antibiofilm | 5 % Hemolysis at 73.84 μg/ml | Human | Samp-A4 Analogue | NA | Low hemolytic | ||
| 34028137 | 2021 | VRLLRRRI{nt:Hexanoyl}{ct:Amid} | SAMP-A4-C6 | Amidation | Hexanoyl | Linear | L | None | 8 | Antibacterial, Antifungal, Antibiofilm | 5 % Hemolysis at 84.98 μg/ml | Human | Samp-A4 Analogue | NA | Low hemolytic | ||
| 34028137 | 2021 | VRLLRRRI{nt:PEG}{ct:Amid} | SAMP-A4-PEG3 | Amidation | PEG | Linear | L | None | 8 | Antibacterial, Antifungal, Antibiofilm | 5 % Hemolysis at 19.95 μg/ml | Human | Samp-A4 Analogue | NA | Low hemolytic | ||
| 34028137 | 2021 | VRLLRRRI{nt:Gluconyl}{ct:Amid} | SAMP-A4-GlcA | Amidation | Gluconyl | Linear | L | None | 8 | Antibacterial, Antifungal, Antibiofilm | 5 % Hemolysis at 22.16 μg/ml | Human | Samp-A4 Analogue | NA | Low hemolytic | ||
| 34482475 | 2021 | {nnr:Z}QPVSSPK | Pep-Bax8 | Free | Free | Linear | L | Z = pyroglutamic acid | 8 | Antibacterial | 1.6 % Hemolysis at 250 μg/mL | Human | Snake Venom Of Bothrops Atrox | NA | Non-hemolytic | ||
| 34482475 | 2021 | {nnr:Z}KW | SVMPi-Bax/Bj | Free | Free | Linear | L | Z = pyroglutamic acid | 3 | Antibacterial | 1.7 % Hemolysis at 250 μg/mL | Human | Snake Venoms Of Bothrops Atrox And Bothrops Jararacussu | NA | Non-hemolytic | ||
| 34635758 | 2021 | CTKTDVHFC{cyc:N-C} | CP2 | Free | Free | Cyclic | L | None | 9 | Antiviral against WNV (West Nile virus) | 0.2 % Hemolysis at 6 μM | Sheep | Synthetic Cyclic Peptide | NA | Low hemolytic | ||
| 34635758 | 2021 | CIHSSTRAC{cyc:N-C} | CP4 | Free | Free | Cyclic | L | None | 9 | Antiviral against WNV (West Nile virus) | 0.2 % Hemolysis at 6 μM | Sheep | Synthetic Cyclic Peptide | NA | Low hemolytic | ||
| 34635758 | 2021 | CTYENHRTC{cyc:N-C} | CP12 | Free | Free | Cyclic | L | None | 9 | Antiviral against WNV (West Nile virus) | 0.2 % Hemolysis at 6 μM | Sheep | Synthetic Cyclic Peptide | NA | Low hemolytic | ||
| 34635758 | 2021 | CLAQSHPLC{cyc:N-C} | CP16 | Free | Free | Cyclic | L | None | 9 | Antiviral against WNV (West Nile virus) | 0.2 % Hemolysis at 6 μM | Sheep | Synthetic Cyclic Peptide | NA | Low hemolytic | ||
| 34819923 | 2021 | KQFRIRVRV{ct:Amid} | 1029 | Amidation | Free | Linear | L | None | 9 | Antimicrobial, Antibiofilm | 2.3 ± 0.7 % Hemolysis at 150 μM | Horse | Synthetic Peptide | NA | Low hemolytic | ||
| 34819923 | 2021 | KRFRIRVRV{ct:Amid} | 1037 | Amidation | Free | Linear | L | None | 9 | Antimicrobial, Antibiofilm | 2.4 ± 0.4 % Hemolysis at 150 μM | Horse | Synthetic Peptide | NA | Low hemolytic | ||
| 34819923 | 2021 | FRIRVRV{ct:Amid} | FV7 | Amidation | Free | Linear | L | None | 7 | Antimicrobial, Antibiofilm | 3.7 ± 0.4 % Hemolysis at 150 μM | Horse | Synthetic Peptide | α-Helical | Low hemolytic | ||
| 34819923 | 2021 | KQFRIRVRV{ct:Amid} | 1029 | Amidation | Free | Linear | L | None | 9 | Antimicrobial, Antibiofilm | 3.5 ± 0.7 % Hemolysis at 250 μM | Horse | Synthetic Peptide | NA | Low hemolytic | ||
| 34819923 | 2021 | KRFRIRVRV{ct:Amid} | 1037 | Amidation | Free | Linear | L | None | 9 | Antimicrobial, Antibiofilm | 3.3 ± 0.7 % Hemolysis at 250 μM | Horse | Synthetic Peptide | NA | Low hemolytic | ||
| 34819923 | 2021 | FRIRVRV{ct:Amid} | FV7 | Amidation | Free | Linear | L | None | 7 | Antimicrobial, Antibiofilm | 4.4 ± 0.3 % Hemolysis at 250 μM | Horse | Synthetic Peptide | α-Helical | Low hemolytic | ||
| 34819923 | 2021 | KQFRIRVRV{ct:Amid} | 1029 | Amidation | Free | Linear | L | None | 9 | Antimicrobial, Antibiofilm | 3.4 ± 0.6 % Hemolysis at 375 μM | Horse | Synthetic Peptide | NA | Low hemolytic | ||
| 34819923 | 2021 | KRFRIRVRV{ct:Amid} | 1037 | Amidation | Free | Linear | L | None | 9 | Antimicrobial, Antibiofilm | 4.9 ± 0.2 % Hemolysis at 375 μM | Horse | Synthetic Peptide | NA | Low hemolytic | ||
| 34819923 | 2021 | FRIRVRV{ct:Amid} | FV7 | Amidation | Free | Linear | L | None | 7 | Antimicrobial, Antibiofilm | 9.5 ± 1.4 % Hemolysis at 375 μM | Horse | Synthetic Peptide | α-Helical | Low hemolytic | ||
| 34966279 | 2021 | KIILRIRWR{ct:Amid} | optP1 | Amidation | Free | Linear | L | None | 9 | Antibacterial | 50 % Hemolysis at 205 μM | Human | Optimized 9Mer | NA | Low hemolytic | ||
| 34966279 | 2021 | KRRVRWIIW{ct:Amid} | optP7 | Amidation | Free | Linear | L | None | 9 | Antibacterial | 50 % Hemolysis at >195 μM | Human | Optimized 9Mer | NA | Low hemolytic | ||
| 34966367 | 2021 | G-{nnr:S5}-LKR-{nnr:S5}-KTLL{ct:Amid} | Anoplin[2-6] | Amidation | Free | Stapled | L | S5 = Olefinic | 8 | Antibacterial | 9.1 % Hemolysis at 64 μM | Sheep | Anoplin Analogs | phosphate buffer = α-Helical, membrane-mimicking environments = α-Helical | NA | ||
| 34966367 | 2021 | G-{nnr:S5}-LKR-{nnr:S5}-KTLL{ct:Amid} | Anoplin[2-6] | Amidation | Free | Stapled | L | S5 = Olefinic | 8 | Antibacterial | 4 % Hemolysis at 32 μM | Sheep | Anoplin Analogs | phosphate buffer = α-Helical, membrane-mimicking environments = α-Helical | NA | ||
| 34966367 | 2021 | G-{nnr:S5}-LKR-{nnr:S5}-KTLL{ct:Amid} | Anoplin[2-6] | Amidation | Free | Stapled | L | S5 = Olefinic | 8 | Antibacterial | 2.8 % Hemolysis at 16 μM | Sheep | Anoplin Analogs | phosphate buffer = α-Helical, membrane-mimicking environments = α-Helical | NA | ||
| 34966367 | 2021 | G-{nnr:S5}-LKR-{nnr:S5}-KTLL{ct:Amid} | Anoplin[2-6] | Amidation | Free | Stapled | L | S5 = Olefinic | 8 | Antibacterial | 2.4 % Hemolysis at 8 μM | Sheep | Anoplin Analogs | phosphate buffer = α-Helical, membrane-mimicking environments = α-Helical | NA | ||
| 34966367 | 2021 | G-{nnr:S5}-LKR-{nnr:S5}-KTLL{ct:Amid} | Anoplin[2-6] | Amidation | Free | Stapled | L | S5 = Olefinic | 8 | Antibacterial | 2.1 % Hemolysis at 4 μM | Sheep | Anoplin Analogs | phosphate buffer = α-Helical, membrane-mimicking environments = α-Helical | NA | ||
| 34966367 | 2021 | GLLK-{nnr:S5}-IKT-{nnr:S5}-L{ct:Amid} | Anoplin[5-9] | Amidation | Free | Stapled | L | S5 = Olefinic | 8 | Antibacterial | 62.7 % Hemolysis at 64 μM | Sheep | Anoplin Analogs | phosphate buffer = α-Helical, membrane-mimicking environments = α-Helical | NA | ||
| 34966367 | 2021 | GLLK-{nnr:S5}-IKT-{nnr:S5}-L{ct:Amid} | Anoplin[5-9] | Amidation | Free | Stapled | L | S5 = Olefinic | 8 | Antibacterial | 43.2 % Hemolysis at 32 μM | Sheep | Anoplin Analogs | phosphate buffer = α-Helical, membrane-mimicking environments = α-Helical | NA | ||
| 34966367 | 2021 | GLLK-{nnr:S5}-IKT-{nnr:S5}-L{ct:Amid} | Anoplin[5-9] | Amidation | Free | Stapled | L | S5 = Olefinic | 8 | Antibacterial | 29.8 % Hemolysis at 16 μM | Sheep | Anoplin Analogs | phosphate buffer = α-Helical, membrane-mimicking environments = α-Helical | NA | ||
| 34966367 | 2021 | GLLK-{nnr:S5}-IKT-{nnr:S5}-L{ct:Amid} | Anoplin[5-9] | Amidation | Free | Stapled | L | S5 = Olefinic | 8 | Antibacterial | 16.6 % Hemolysis at 8 μM | Sheep | Anoplin Analogs | phosphate buffer = α-Helical, membrane-mimicking environments = α-Helical | NA | ||
| 34966367 | 2021 | GLLK-{nnr:S5}-IKT-{nnr:S5}-L{ct:Amid} | Anoplin[5-9] | Amidation | Free | Stapled | L | S5 = Olefinic | 8 | Antibacterial | 6.5 % Hemolysis at 4 μM | Sheep | Anoplin Analogs | phosphate buffer = α-Helical, membrane-mimicking environments = α-Helical | NA | ||
| 34966367 | 2021 | GLLK-{nnr:S5}-IKT-{nnr:S5}-L{ct:Amid} | AnoplinS5(5,9) | Amidation | Free | Linear | L | S5 = Olefinic | 8 | Antibacterial | 14.2 % Hemolysis at 64 μM | Sheep | Anoplin Analogs | phosphate buffer = α-Helical, membrane-mimicking environments = α-Helical | NA | ||
| 34966367 | 2021 | GLLK-{nnr:S5}-IKT-{nnr:S5}-L{ct:Amid} | AnoplinS5(5,9) | Amidation | Free | Linear | L | S5 = Olefinic | 8 | Antibacterial | 11.9 % Hemolysis at 32 μM | Sheep | Anoplin Analogs | phosphate buffer = α-Helical, membrane-mimicking environments = α-Helical | NA | ||
| 34966367 | 2021 | GLLK-{nnr:S5}-IKT-{nnr:S5}-L{ct:Amid} | AnoplinS5(5,9) | Amidation | Free | Linear | L | S5 = Olefinic | 8 | Antibacterial | 8.9 % Hemolysis at 16 μM | Sheep | Anoplin Analogs | phosphate buffer = α-Helical, membrane-mimicking environments = α-Helical | NA | ||
| 34966367 | 2021 | GLLK-{nnr:S5}-IKT-{nnr:S5}-L{ct:Amid} | AnoplinS5(5,9) | Amidation | Free | Linear | L | S5 = Olefinic | 8 | Antibacterial | 7.2 % Hemolysis at 8 μM | Sheep | Anoplin Analogs | phosphate buffer = α-Helical, membrane-mimicking environments = α-Helical | NA | ||
| 34966367 | 2021 | GLLK-{nnr:S5}-IKT-{nnr:S5}-L{ct:Amid} | AnoplinS5(5,9) | Amidation | Free | Linear | L | S5 = Olefinic | 8 | Antibacterial | 6.7 % Hemolysis at 4 μM | Sheep | Anoplin Analogs | phosphate buffer = α-Helical, membrane-mimicking environments = α-Helical | NA | ||
| 33749557 | 2022 | {conj:RhoB}-KRFKKFFKK{ct:Amid} | RhoB-Ctn[1-9] | Amidation | RhoB | Linear | L | RhoB = rhodamine B (N termianl conjugate) Crotalicidin fragment, residues 1 to 9, with a N-terminal conjugated rhodamine B | 9 | Antibacterial, Antifungal | 0.6 % Hemolysis at 12.5 μM | Human | Crotalicidin (Rattlesnake (Crotalus Durissus Terrificus))-Derived Peptides | Helical | Low hemolytic | ||
| 33749557 | 2022 | {conj:RhoB}-KRFKKFFKK{ct:Amid} | RhoB-Ctn[1-9] | Amidation | RhoB | Linear | L | RhoB = rhodamine B (N termianl conjugate) Crotalicidin fragment, residues 1 to 9, with a N-terminal conjugated rhodamine B | 9 | Antibacterial, Antifungal | 1.6 % Hemolysis at 25 μM | Human | Crotalicidin (Rattlesnake (Crotalus Durissus Terrificus))-Derived Peptides | Helical | Low hemolytic | ||
| 34978443 | 2022 | R-R-R-{nnr:Bip}-{nnr:Bip}-{nnr:Bip}{nt:Amid}{ct:OH} | 1L | OH | Amidation | Linear | L | Bip = 4,4′-biphenyl-L-alanine | 6 | Antibacterial | 50 % Hemolysis | Human | Synthetic Peptide | NA | NA | ||
| 34978443 | 2022 | R-R-R-{nnr:Dip}-{nnr:Dip}-{nnr:Dip}{nt:Amid}{ct:OH} | 2L | OH | Amidation | Linear | L | Dip = 3,3-diphenyl-L-alanine | 6 | Antibacterial | 50 % Hemolysis at 120 μM | Human | Synthetic Peptide | NA | NA | ||
| 34978443 | 2022 | R-R-R-{nnr:Nal}-{nnr:Nal}-{nnr:Nal}{nt:Amid}{ct:OH} | 3L | OH | Amidation | Linear | L | Nal = 3-(2-naphthyl)-L-alanine | 6 | Antibacterial | 50 % Hemolysis at 105 μM | Human | Synthetic Peptide | NA | NA | ||
| 34978443 | 2022 | R-R-R-R-{nnr:Bip}-{nnr:Bip}-{nnr:Bip}-{nnr:Bip}{nt:Amid}{ct:OH} | 4L | OH | Amidation | Linear | L | Bip = 4,4′-biphenyl-L-alanine | 8 | Antibacterial | 50 % Hemolysis | Human | Synthetic Peptide | NA | NA | ||
| 34978443 | 2022 | R-R-R-R-{nnr:Dip}-{nnr:Dip}-{nnr:Dip}-{nnr:Dip}{nt:Amid}{ct:OH} | 5L | OH | Amidation | Linear | L | Dip = 3,3-diphenyl-L-alanine | 8 | Antibacterial | 50 % Hemolysis at 75 μM | Human | Synthetic Peptide | NA | NA | ||
| 34978443 | 2022 | R-R-R-R-{nnr:Nal}-{nnr:Nal}-{nnr:Nal}-{nnr:Nal}{nt:Amid}{ct:OH} | 6L | OH | Amidation | Linear | L | Nal = 3-(2-naphthyl)-L-alanine | 8 | Antibacterial | 50 % Hemolysis at 70 μM | Human | Synthetic Peptide | NA | NA | ||
| 34978443 | 2022 | R-R-R-R-{nnr:Bip}-{nnr:Bip}-{nnr:Bip}{nt:Amid}{ct:OH} | 7L | OH | Amidation | Linear | L | Bip = 4,4′-biphenyl-L-alanine | 7 | Antibacterial | 50 % Hemolysis | Human | Synthetic Peptide | NA | NA | ||
| 34978443 | 2022 | R-R-R-R-{nnr:Dip}-{nnr:Dip}-{nnr:Dip}{nt:Amid}{ct:OH} | 8L | OH | Amidation | Linear | L | Dip = 3,3-diphenyl-L-alanine | 7 | Antibacterial | 50 % Hemolysis at 145 μM | Human | Synthetic Peptide | NA | NA | ||
| 34978443 | 2022 | R-R-R-R-{nnr:Nal}-{nnr:Nal}-{nnr:Nal}{nt:Amid}{ct:OH} | 9L | OH | Amidation | Linear | L | Nal = 3-(2-naphthyl)-L-alanine | 7 | Antibacterial | 50 % Hemolysis at 130 μM | Human | Synthetic Peptide | NA | NA | ||
| 34978443 | 2022 | R-R-R-R-{nnr:Dip}-{nnr:Dip}{nt:Amid}{ct:OH} | 10L | OH | Amidation | Linear | L | Dip = 3,3-diphenyl-L-alanine | 6 | Antibacterial | 50 % Hemolysis at 185 μM | Human | Synthetic Peptide | NA | NA | ||
| 34978443 | 2022 | R-R-R-R-{nnr:Nal}-{nnr:Nal}{nt:Amid}{ct:OH} | 11L | OH | Amidation | Linear | L | Nal = 3-(2-naphthyl)-L-alanine | 6 | Antibacterial | 50 % Hemolysis at 180 μM | Human | Synthetic Peptide | NA | NA | ||
| 34978443 | 2022 | R-R-R-R-R-{nnr:Dip}-{nnr:Dip}-{nnr:Dip}{nt:Amid}{ct:OH} | 12L | OH | Amidation | Linear | L | Dip = 3,3-diphenyl-L-alanine | 8 | Antibacterial | 50 % Hemolysis at 165 μM | Human | Synthetic Peptide | NA | NA | ||
| 34978443 | 2022 | R-R-R-R-R-{nnr:Nal}-{nnr:Nal}-{nnr:Nal}{nt:Amid}{ct:OH} | 13L | OH | Amidation | Linear | L | Nal = 3-(2-naphthyl)-L-alanine | 8 | Antibacterial | 50 % Hemolysis at 190 μM | Human | Synthetic Peptide | NA | NA | ||
| 34978443 | 2022 | K-K-K-K-{nnr:Dip}-{nnr:Dip}-{nnr:Dip}{nt:Amid}{ct:OH} | 14L | OH | Amidation | Linear | L | Dip = 3,3-diphenyl-L-alanine | 7 | Antibacterial | 50 % Hemolysis at 255 μM | Human | Synthetic Peptide | NA | NA | ||
| 34978443 | 2022 | K-K-K-K-K-{nnr:Dip}-{nnr:Dip}-{nnr:Dip}{nt:Amid}{ct:OH} | 15L | OH | Amidation | Linear | L | Dip = 3,3-diphenyl-L-alanine | 8 | Antibacterial | 50 % Hemolysis at 280 μM | Human | Synthetic Peptide | NA | NA | ||
| 34978443 | 2022 | R-{nnr:Dip}-R-R-{nnr:Dip}-{nnr:Dip}-R{nt:Amid}{ct:OH} | 16L | OH | Amidation | Linear | L | Dip = 3,3-diphenyl-L-alanine | 7 | Antibacterial | 50 % Hemolysis at 220 μM | Human | Synthetic Peptide | NA | NA | ||
| 34978443 | 2022 | R-R-{nnr:Dip}-{nnr:Dip}-R-R-{nnr:Dip}{nt:Amid}{ct:OH} | 17L | OH | Amidation | Linear | L | Dip = 3,3-diphenyl-L-alanine | 7 | Antibacterial | 50 % Hemolysis at 240 μM | Human | Synthetic Peptide | NA | NA | ||
| 34978443 | 2022 | R-{nnr:Nal}-R-R-{nnr:Nal}-{nnr:Nal}-R{nt:Amid}{ct:OH} | 18L | OH | Amidation | Linear | L | Nal = 3-(2-naphthyl)-L-alanine | 7 | Antibacterial | 50 % Hemolysis at 205 μM | Human | Synthetic Peptide | NA | NA | ||
| 34978443 | 2022 | R-R-{nnr:Nal}-{nnr:Nal}-R-R-{nnr:Nal}{nt:Amid}{ct:OH} | 19L | OH | Amidation | Linear | L | Nal = 3-(2-naphthyl)-L-alanine | 7 | Antibacterial | 50 % Hemolysis at 195 μM | Human | Synthetic Peptide | NA | NA | ||
| 34978443 | 2022 | R-R-R-{nnr:Bip}-{nnr:Bip}-{nnr:Bip}{cyc:N-C} | 1C | Free | Free | Cyclic | L | Bip = 4,4′-biphenyl-L-alanine | 6 | Antibacterial | 50 % Hemolysis | Human | Synthetic Peptide | NA | NA | ||
| 34978443 | 2022 | R-R-R-{nnr:Dip}-{nnr:Dip}-{nnr:Dip}{cyc:N-C} | 2C | Free | Free | Cyclic | L | Dip = 3,3-diphenyl-L-alanine | 6 | Antibacterial | 50 % Hemolysis at 45 μM | Human | Synthetic Peptide | NA | NA | ||
| 34978443 | 2022 | R-R-R-{nnr:Nal}-{nnr:Nal}-{nnr:Nal}{cyc:N-C} | 3C | Free | Free | Cyclic | L | Nal = 3-(2-naphthyl)-L-alanine | 6 | Antibacterial | 50 % Hemolysis at 50 μM | Human | Synthetic Peptide | NA | NA | ||
| 34978443 | 2022 | R-R-R-R-{nnr:Bip}-{nnr:Bip}-{nnr:Bip}-{nnr:Bip}{cyc:N-C} | 4C | Free | Free | Cyclic | L | Bip = 4,4′-biphenyl-L-alanine | 8 | Antibacterial | 50 % Hemolysis | Human | Synthetic Peptide | NA | NA | ||
| 34978443 | 2022 | R-R-R-R-{nnr:Dip}-{nnr:Dip}-{nnr:Dip}-{nnr:Dip}{cyc:N-C} | 5C | Free | Free | Cyclic | L | Dip = 3,3-diphenyl-L-alanine | 8 | Antibacterial | 50 % Hemolysis at 40 μM | Human | Synthetic Peptide | NA | NA | ||
| 34978443 | 2022 | R-R-R-R-{nnr:Nal}-{nnr:Nal}-{nnr:Nal}-{nnr:Nal}{cyc:N-C} | 6C | Free | Free | Cyclic | L | Nal = 3-(2-naphthyl)-L-alanine | 8 | Antibacterial | 50 % Hemolysis at 30 μM | Human | Synthetic Peptide | NA | NA | ||
| 34978443 | 2022 | R-R-R-R-{nnr:Bip}-{nnr:Bip}-{nnr:Bip}{cyc:N-C} | 7C | Free | Free | Cyclic | L | Bip = 4,4′-biphenyl-L-alanine | 7 | Antibacterial | 50 % Hemolysis | Human | Synthetic Peptide | NA | NA | ||
| 34978443 | 2022 | R-R-R-R-{nnr:Dip}-{nnr:Dip}-{nnr:Dip}{cyc:N-C} | 8C | Free | Free | Cyclic | L | Dip = 3,3-diphenyl-L-alanine | 7 | Antibacterial | 50 % Hemolysis at 70 μM | Human | Synthetic Peptide | NA | NA | ||
| 34978443 | 2022 | R-R-R-R-{nnr:Nal}-{nnr:Nal}-{nnr:Nal}{cyc:N-C} | 9C | Free | Free | Cyclic | L | Nal = 3-(2-naphthyl)-L-alanine | 7 | Antibacterial | 50 % Hemolysis at 80 μM | Human | Synthetic Peptide | NA | NA | ||
| 34978443 | 2022 | R-R-R-R-{nnr:Dip}-{nnr:Dip}{cyc:N-C} | 10C | Free | Free | Cyclic | L | Dip = 3,3-diphenyl-L-alanine | 6 | Antibacterial | 50 % Hemolysis at 110 μM | Human | Synthetic Peptide | NA | NA | ||
| 34978443 | 2022 | R-R-R-R-{nnr:Nal}-{nnr:Nal}{cyc:N-C} | 11C | Free | Free | Cyclic | L | Nal = 3-(2-naphthyl)-L-alanine | 6 | Antibacterial | 50 % Hemolysis at 125 μM | Human | Synthetic Peptide | NA | NA | ||
| 34978443 | 2022 | R-R-R-R-R-{nnr:Dip}-{nnr:Dip}-{nnr:Dip}{cyc:N-C} | 12C | Free | Free | Cyclic | L | Dip = 3,3-diphenyl-L-alanine | 8 | Antibacterial | 50 % Hemolysis at 100 μM | Human | Synthetic Peptide | NA | NA | ||
| 34978443 | 2022 | R-R-R-R-R-{nnr:Nal}-{nnr:Nal}-{nnr:Nal}{cyc:N-C} | 13C | Free | Free | Cyclic | L | Nal = 3-(2-naphthyl)-L-alanine | 8 | Antibacterial | 50 % Hemolysis at 90 μM | Human | Synthetic Peptide | NA | NA | ||
| 34978443 | 2022 | K-K-K-K-{nnr:Dip}-{nnr:Dip}-{nnr:Dip}{cyc:N-C} | 14C | Free | Free | Cyclic | L | Dip = 3,3-diphenyl-L-alanine | 7 | Antibacterial | 50 % Hemolysis at 165 μM | Human | Synthetic Peptide | NA | NA | ||
| 34978443 | 2022 | K-K-K-K-K-{nnr:Dip}-{nnr:Dip}-{nnr:Dip}{cyc:N-C} | 15C | Free | Free | Cyclic | L | Dip = 3,3-diphenyl-L-alanine | 8 | Antibacterial | 50 % Hemolysis at 180 μM | Human | Synthetic Peptide | NA | NA | ||
| 34978443 | 2022 | R-{nnr:Dip}-R-R-{nnr:Dip}-{nnr:Dip}-R{cyc:N-C} | 16C | Free | Free | Cyclic | L | Dip = 3,3-diphenyl-L-alanine | 7 | Antibacterial | 50 % Hemolysis at 130 μM | Human | Synthetic Peptide | NA | NA | ||
| 34978443 | 2022 | R-R-{nnr:Dip}-{nnr:Dip}-R-R-{nnr:Dip}{cyc:N-C} | 17C | Free | Free | Cyclic | L | Dip = 3,3-diphenyl-L-alanine | 7 | Antibacterial | 50 % Hemolysis at 145 μM | Human | Synthetic Peptide | NA | NA | ||
| 34978443 | 2022 | R-{nnr:Nal}-R-R-{nnr:Nal}-{nnr:Nal}-R{cyc:N-C} | 18C | Free | Free | Cyclic | L | Nal = 3-(2-naphthyl)-L-alanine | 7 | Antibacterial | 50 % Hemolysis at 105 μM | Human | Synthetic Peptide | NA | NA | ||
| 34978443 | 2022 | R-R-{nnr:Nal}-{nnr:Nal}-R-R-{nnr:Nal}{cyc:N-C} | 19C | Free | Free | Cyclic | L | Nal = 3-(2-naphthyl)-L-alanine | 7 | Antibacterial | 50 % Hemolysis at 110 μM | Human | Synthetic Peptide | NA | NA | ||
| 36358242 | 2022 | WLLKWLKKL{ct:Amid} | WALK243.01 | Amidation | Free | Linear | L | None | 9 | Antibacterial | 5 % Hemolysis at 32 μg/mL | Human | Synthetic Walk Peptides | 10 mM sodium phosphate buffer = Disordered, 50% TFE or 10 mM SDS micelles = α-Helix | NA | ||
| 36358242 | 2022 | KWLLKWLLK{ct:Amid} | WALK243.02 | Amidation | Free | Linear | L | None | 9 | Antibacterial | 5 % Hemolysis at 64 μg/mL | Human | Synthetic Walk Peptides | 10 mM sodium phosphate buffer = Disordered, 50% TFE or 10 mM SDS micelles = α-Helix | Low hemolytic | ||
| 36358242 | 2022 | LKWLLKWLK{ct:Amid} | WALK243.03 | Amidation | Free | Linear | L | None | 9 | Antibacterial, Anti-inflammatory | 5 % Hemolysis at 32 μg/mL | Human | Synthetic Walk Peptides | 10 mM sodium phosphate buffer = Disordered, 50% TFE or 10 mM SDS micelles = α-Helix | NA | ||
| 36358242 | 2022 | LLKWLKKWL{ct:Amid} | WALK243.04 | Amidation | Free | Linear | L | None | 9 | Antibacterial, Anti-inflammatory | 5 % Hemolysis at 64 μg/mL | Human | Synthetic Walk Peptides | 10 mM sodium phosphate buffer = Disordered, 50% TFE or 10 mM SDS micelles = α-Helix | Low hemolytic | ||
| 36358242 | 2022 | KLLKWLLKW{ct:Amid} | WALK243.05 | Amidation | Free | Linear | L | None | 9 | Antibacterial | 5 % Hemolysis at 64 μg/mL | Human | Synthetic Walk Peptides | 10 mM sodium phosphate buffer = Disordered, 50% TFE or 10 mM SDS micelles = α-Helix | Low hemolytic | ||
| 36358242 | 2022 | LKWLKWLLK{ct:Amid} | WALK243.06 | Amidation | Free | Linear | L | None | 9 | Antibacterial | 5 % Hemolysis at 32 μg/mL | Human | Synthetic Walk Peptides | 10 mM sodium phosphate buffer = Disordered, 50% TFE or 10 mM SDS micelles = α-Helix | NA | ||
| 36358242 | 2022 | LKKWLKWLL{ct:Amid} | WALK243.07 | Amidation | Free | Linear | L | None | 9 | Antibacterial | 5 % Hemolysis at 16 μg/mL | Human | Synthetic Walk Peptides | 10 mM sodium phosphate buffer = Disordered, 50% TFE or 10 mM SDS micelles = α-Helix | NA | ||
| 36358242 | 2022 | WLKKLLKWL{ct:Amid} | WALK243.08 | Amidation | Free | Linear | L | None | 9 | Antibacterial | 5 % Hemolysis at 8 μg/mL | Human | Synthetic Walk Peptides | 10 mM sodium phosphate buffer = Disordered, 50% TFE or 10 mM SDS micelles = α-Helix | NA | ||
| 36358242 | 2022 | KWLLKLLKW{ct:Amid} | WALK243.09 | Amidation | Free | Linear | L | None | 9 | Antibacterial | 5 % Hemolysis at 64 μg/mL | Human | Synthetic Walk Peptides | 10 mM sodium phosphate buffer = Disordered, 50% TFE or 10 mM SDS micelles = α-Helix | Low hemolytic | ||
| 36704429 | 2022 | {conj:2-(6-Methoxy-2-naphthyl)propionic acid}RBRBR{ct:Amid} | naprolyginine | Amidation | 2-(6-Methoxy-2-naphthyl)propionic acid | Linear | L | 2-(6-Methoxy-2-naphthyl)propionic acid | 5 | Antibacterial | 0 % Hemolysis at 5 μM | Human | Synthetic Conjugated Ultrashort Antimicrobial Peptide | NA | Non-hemolytic | ||
| 36704429 | 2022 | {conj:2-(6-Methoxy-2-naphthyl)propionic acid}RBRBR{ct:Amid} | naprolyginine | Amidation | 2-(6-Methoxy-2-naphthyl)propionic acid | Linear | L | 2-(6-Methoxy-2-naphthyl)propionic acid | 5 | Antibacterial | 0 % Hemolysis at 10 μM | Human | Synthetic Conjugated Ultrashort Antimicrobial Peptide | NA | Non-hemolytic | ||
| 36704429 | 2022 | {conj:2-(6-Methoxy-2-naphthyl)propionic acid}RBRBR{ct:Amid} | naprolyginine | Amidation | 2-(6-Methoxy-2-naphthyl)propionic acid | Linear | L | 2-(6-Methoxy-2-naphthyl)propionic acid | 5 | Antibacterial | 0 % Hemolysis at 20 μM | Human | Synthetic Conjugated Ultrashort Antimicrobial Peptide | NA | Non-hemolytic | ||
| 36704429 | 2022 | {conj:2-(6-Methoxy-2-naphthyl)propionic acid}RBRBR{ct:Amid} | naprolyginine | Amidation | 2-(6-Methoxy-2-naphthyl)propionic acid | Linear | L | 2-(6-Methoxy-2-naphthyl)propionic acid | 5 | Antibacterial | 0 % Hemolysis at 40 μM | Human | Synthetic Conjugated Ultrashort Antimicrobial Peptide | NA | Non-hemolytic | ||
| 36704429 | 2022 | {conj:2-(6-Methoxy-2-naphthyl)propionic acid}RBRBR{ct:Amid} | naprolyginine | Amidation | 2-(6-Methoxy-2-naphthyl)propionic acid | Linear | L | 2-(6-Methoxy-2-naphthyl)propionic acid | 5 | Antibacterial | 0 % Hemolysis at 60 μM | Human | Synthetic Conjugated Ultrashort Antimicrobial Peptide | NA | Non-hemolytic | ||
| 36704429 | 2022 | {conj:2-(6-Methoxy-2-naphthyl)propionic acid}RBRBR{ct:Amid} | naprolyginine | Amidation | 2-(6-Methoxy-2-naphthyl)propionic acid | Linear | L | 2-(6-Methoxy-2-naphthyl)propionic acid | 5 | Antibacterial | 0 % Hemolysis at 80 μM | Human | Synthetic Conjugated Ultrashort Antimicrobial Peptide | NA | Non-hemolytic | ||
| 36704429 | 2022 | {conj:2-(6-Methoxy-2-naphthyl)propionic acid}RBRBR{ct:Amid} | naprolyginine | Amidation | 2-(6-Methoxy-2-naphthyl)propionic acid | Linear | L | 2-(6-Methoxy-2-naphthyl)propionic acid | 5 | Antibacterial | 1 % Hemolysis at 100 μM | Human | Synthetic Conjugated Ultrashort Antimicrobial Peptide | NA | Non-hemolytic | ||
| 36442155 | 2022 | RRRRWWWW{cyc:N-C} | 1 | Free | Free | Cyclic | L | None | 8 | Antibacterial | 50 % Hemolysis at 175 μg/mL | Human | Synthetic Cyclic Peptide | NA | NA | ||
| 36442155 | 2022 | RRWWW{cyc:N-C} | 2a | Free | Free | Cyclic | L | None | 5 | Antibacterial | 50 % Hemolysis at 120 μg/mL | Human | Synthetic Cyclic Peptide | NA | NA | ||
| 36442155 | 2022 | RRWWWW{cyc:N-C} | 2b | Free | Free | Cyclic | L | None | 6 | Antibacterial | 50 % Hemolysis at 85 μg/mL | Human | Synthetic Cyclic Peptide | NA | NA | ||
| 36442155 | 2022 | RRRWWW{cyc:N-C} | 3a | Free | Free | Cyclic | L | None | 6 | Antibacterial | 50 % Hemolysis at 155 μg/mL | Human | Synthetic Cyclic Peptide | NA | NA | ||
| 36442155 | 2022 | RRRWWWW{cyc:N-C} | 3b | Free | Free | Cyclic | L | None | 7 | Antibacterial | 50 % Hemolysis at 105 μg/mL | Human | Synthetic Cyclic Peptide | NA | NA | ||
| 36442155 | 2022 | RRRWWWWW{cyc:N-C} | 3c | Free | Free | Cyclic | L | None | 8 | Antibacterial | 50 % Hemolysis at 80 μg/mL | Human | Synthetic Cyclic Peptide | NA | NA | ||
| 36442155 | 2022 | RRRWWWWWW{cyc:N-C} | 3d | Free | Free | Cyclic | L | None | 9 | Antibacterial | 50 % Hemolysis at 65 μg/mL | Human | Synthetic Cyclic Peptide | NA | NA | ||
| 36442155 | 2022 | R{d}R{d}R{d}R{d}WWWW{cyc:N-C} | 4a | Free | Free | Cyclic | Mix | r = D-Arginine | 8 | Antibacterial | 50 % Hemolysis at 110 μg/mL | Human | Synthetic Cyclic Peptide | NA | NA | ||
| 36442155 | 2022 | RRRRWWWWW{cyc:N-C} | 4b | Free | Free | Cyclic | L | None | 9 | Antibacterial | 50 % Hemolysis at 100 μg/mL | Human | Synthetic Cyclic Peptide | NA | NA | ||
| 36442155 | 2022 | RRRRRWWWW{cyc:N-C} | 5a | Free | Free | Cyclic | L | None | 9 | Antibacterial | 50 % Hemolysis at 340 μg/mL | Human | Synthetic Cyclic Peptide | NA | Low hemolytic | ||
| 36508333 | 2022 | FPWIIS{ct:Amid} | BmT-2 | Amidation | Free | Linear | L | None | 6 | Antioxidant | 0 % Hemolysis at 400 µg/mL | Human | Crude Venom Of Bothrops Moojeni | NA | Non-hemolytic | ||
| 36279986 | 2022 | {nnr:β2,2-Ac6c}-{nnr:Gpn}-{nnr:β2,2-Ac6c}-{nnr:Gpn}-{nnr:β2,2-Ac6c}-{nnr:Gpn}{nt:H}{ct:OMe} | BG6 | OMe | H | Linear | NA | β2,2-Ac6c = 1-aminomethylcyclohexane carboxylic acid, Gpn = 2-(1-(aminomethyl)cyclohexyl)acetic acid | 6 | Anticancer, Anti-migratory and Anti-invasive | 8.05 % Hemolysis at 30 µM/ml | Human | Short Hybrid Synthetic Peptide | NA | Low hemolytic | ||
| 35987005 | 2023 | MCNDCGA | MOp3 | Free | Free | Linear | L | None | 7 | Antimicrobial agent against S. aureus | 0 % Hemolysis at 4 mg/mL | Rabbit | Moringa Oleifera Seeds | β-Sheet | Non-hemolytic | ||
| 36737967 | 2023 | YPVEPF | YPVEPF | Free | Free | Linear | L | None | 6 | α-glucosidase inhibitory | 0 % Hemolysis at 1 mg/mL | mouse | Chinese Rubing Cheese Whey Protien Hypoglycemic Peptides | antiparallel (50.50 %) and Random coil (35.20 %) structures | Non-hemolytic | ||
| 36508953 | 2023 | PFKLSLHL{ct:Amid} | Jelleine-I | Amidation | Free | Linear | L | None | 8 | Antibacterial, Antibiofilm, Anti-Listeria monocytogenes | 26.25 % Hemolysis at 1000 μg/mL | Rabbit | Honeybees Royal Jelly | NA | Low hemolytic | ||
| 36736093 | 2023 | KF{nt:Fmoc = fluorenylmethyloxycarbonyl}{ct:Amid} | Fmoc-KF | Amidation | Fmoc = fluorenylmethyloxycarbonyl | Linear | L | None | 2 | Antibacterial | <5 % Hemolysis at 2.4 mM | Rabbit | Synthetic Peptide | NA | NA | ||
| 36736093 | 2023 | KKF{nt:Fmoc = fluorenylmethyloxycarbonyl}{ct:Amid} | Fmoc-KKF | Amidation | Fmoc = fluorenylmethyloxycarbonyl | Linear | L | None | 3 | Antibacterial | 0 % Hemolysis at 2.4 mM | Rabbit | Synthetic Peptide | NA | Non-hemolytic | ||
| 36736093 | 2023 | KKKF{nt:Fmoc = fluorenylmethyloxycarbonyl}{ct:Amid} | Fmoc-KKKF | Amidation | Fmoc = fluorenylmethyloxycarbonyl | Linear | L | None | 4 | Antibacterial | 0 % Hemolysis at 2.4 mM | Rabbit | Synthetic Peptide | NA | Non-hemolytic | ||
| 37167720 | 2023 | RRWQWR{ct:Amid} | LfcinB6 (Lf6) | Amidation | Free | Linear | L | None | 6 | Antibacterial | 10 % Hemolysis at >512 µM | Sheep | Lactoferrin Bovine Milk | NA | Low hemolytic | ||
| 35326879 | 2022 | RRRRWWWW{cyc:N-C} | [R4W4] | Free | Free | Cyclic | L | None | 8 | Antibacterial, Cytotoxic | 80 % Hemolysis at 500 µg/mL | Human | Synthetic | NA | NA | ||
| 35326879 | 2022 | RRRRWWWW | (R4W4) | Free | Free | Linear | L | None | 8 | Antibacterial, Cytotoxic | 38 % Hemolysis at 500 µg/mL | Human | Synthetic | NA | NA | ||
| 35326879 | 2022 | ({conj:Levo}-{conj:C10}-KRRRWWWW) | (Levo-C10-KR3W4) | Free | Free | Linear | L | Levo = Levofloxacin covalent conjugates, C10 = 10-hydroxy decanoic acid(linker) | 8 | Antibacterial, Cytotoxic | ∼9 % Hemolysis at 500 µg/mL | Human | Synthetic | NA | NA | ||
| 35326879 | 2022 | [{conj:Levo}-{conj:C10}-KRRRWWWW]{cyc:N-C} | [Levo-C10-KR3W4] | Free | Free | Cyclic | L | Levo = Levofloxacin covalent conjugates, C10 = 10-hydroxy decanoic acid(linker) | 8 | Antibacterial, Cytotoxic | ∼30 % Hemolysis at 500 µg/mL | Human | Synthetic | NA | NA | ||
| 35326879 | 2022 | {conj:Levo}+ (RRRRWWWW) | Levo + (R4W4) | Free | Free | Linear | L | Levo = Levofloxacin, physical mixture of Levofloxacin and peptides (500 µg/mL (1:1; w/w)) | 8 | Antibacterial, Cytotoxic | ∼10 % Hemolysis at 500 µg/mL | Human | Synthetic | NA | NA | ||
| 35326879 | 2022 | {conj:Levo}+ [RRRRWWWW]{cyc:N-C} | Levo + [R4W4] | Free | Free | Cyclic | L | Levo = Levofloxacin, physical mixture of Levofloxacin and peptides (500 µg/mL (1:1; w/w)) | 8 | Antibacterial, Cytotoxic | ∼22 % Hemolysis at 500 µg/mL | Human | Synthetic | NA | NA | ||
| 35638842 | 2022 | YGIHTH{ct:Amid} | PIP1 | Amidation | Free | Linear | L | None | 6 | Antimicrobial | 4 ± 0.8 % Hemolysis at 50 µM | Horse | Synthetic | NA | NA | ||
| 35638842 | 2022 | YGIHTH{ct:Amid} | PIP1 | Amidation | Free | Linear | L | None | 6 | Antimicrobial | 0.5 ± 0.3 % Hemolysis at 150 µM | Horse | Synthetic | NA | NA | ||
| 35638842 | 2022 | YGIHTH{ct:Amid} | PIP1 | Amidation | Free | Linear | L | None | 6 | Antimicrobial | 0 ± 2 % Hemolysis at 250 µM | Horse | Synthetic | NA | NA | ||
| 35638842 | 2022 | YGIHTH{ct:Amid} | PIP1 | Amidation | Free | Linear | L | None | 6 | Antimicrobial | 1 ± 0.1 % Hemolysis at 375 µM | Horse | Synthetic | NA | NA | ||
| 35246675 | 2022 | KETTTIVR | MoHpP-2 | Free | Free | Linear | L | None | 8 | α-glucosidase inhibitory peptide | 7.18 % Hemolysis at 4 mg/mL | Rabbit | Moringa Oleifera | α-Helix | Low hemolytic | ||
| 35246675 | 2022 | KETTTIVR | MoHpP-2 | Free | Free | Linear | L | None | 8 | α-glucosidase inhibitory peptide | 4.23 % Hemolysis at 2 mg/mL | Rabbit | Moringa Oleifera | α-Helix | Low hemolytic | ||
| 35700987 | 2022 | W-W-{nnr:Orn}-N-{nnr:Nva}-{nnr:Aib}-R-W-W{nt:Acet} | Ac-oLBF127 | Free | Acetylation | Linear | L | Tyr(OMe) = Tyrosine (O-Methylated), Orn = Ornithine, Nva = Norvaline, Dpr = Dap (2,3-Diaminopropionic acid), Aib = Alpha-Amino isobutyric acid | 9 | Antifungal | Hemolysis at 25 µM | mouse | Synthetic; Lbf127 Analog | NA | NA | ||
| 35700987 | 2022 | {nnr:Aib}-R-W-W-{nnr:Dpr}-N | LBF127-tr6 | Free | Free | Linear | L | Dpr = Dap (2,3-Diaminopropionic acid), Aib = Alpha-Amino isobutyric acid | 6 | Antifungal | Hemolysis at >200 µM | mouse | Synthetic | α-Helix | NA | ||
| 35700987 | 2022 | {nnr:Nva}-{nnr:Aib}-R-W-W-{nnr:Dpr}-N | LBF127-tr7 | Free | Free | Linear | L | Nva = Norvaline, Dpr = Dap (2,3-Diaminopropionic acid), Aib = Alpha-Amino isobutyric acid | 7 | Antifungal | Hemolysis at >200 µM | mouse | Synthetic | α-Helix | NA | ||
| 35700987 | 2022 | N-{nnr:Nva}-{nnr:Aib}-R-W-W-{nnr:Dpr}-N | LBF127-tr8 | Free | Free | Linear | L | Nva = Norvaline, Dpr = Dap (2,3-Diaminopropionic acid), Aib = Alpha-Amino isobutyric acid | 8 | Antifungal | Hemolysis at >200 µM | mouse | Synthetic | α-Helix | NA | ||
| 35700987 | 2022 | {nnr:Orn}-N-{nnr:Nva}-{nnr:Aib}-R-W-W-{nnr:Dpr}-N | LBF127-tr9 | Free | Free | Linear | L | Orn = Ornithine, Nva = Norvaline, Dpr = Dpr, Dap = 2,3-Diaminopropionic acid, Aib = Alpha-Amino isobutyric acid, Lower-case letters signify D-amino acids | 9 | Antifungal | Hemolysis at >200 µM | mouse | Synthetic | α-Helix | NA | ||
| 35700987 | 2022 | {nnr:Tyr(oMe)}-W-W-{nnr:Orn}-N-{nnr:Nva}-{nnr:Aib}-R-W | LBF127-ctr3 | Free | Free | Linear | L | Tyr(OMe) = Tyrosine (O-Methylated), Orn = Ornithine, Nva = Norvaline, Dpr = Dap (2,3-Diaminopropionic acid), Aib = Alpha-Amino isobutyric acid, Lower-case letters signify D-amino acids | 9 | Antifungal | Hemolysis at 48.5 µM | mouse | Synthetic | α-Helix | NA | ||
| 35576531 | 2022 | HVLDTPLL | MOp2 | Free | Free | Linear | L | None | 8 | Antimicrobial | 3.715 % Hemolysis at 4.408 mM | Rabbit | Moringa Oleifera | β-Sheet | Non-hemolytic | ||
| 35576531 | 2022 | HVLDTPLL | MOp2 | Free | Free | Linear | L | None | 8 | Antimicrobial | 3.578 % Hemolysis at 2.204 mM | Rabbit | Moringa Oleifera | β-Sheet | Non-hemolytic | ||
| 35576531 | 2022 | HVLDTPLL | MOp2 | Free | Free | Linear | L | None | 8 | Antimicrobial | 2.331 % Hemolysis at 1.102 mM | Rabbit | Moringa Oleifera | β-Sheet | Non-hemolytic | ||
| 35576531 | 2022 | HVLDTPLL | MOp2 | Free | Free | Linear | L | None | 8 | Antimicrobial | 0.15 % Hemolysis at 0.551 mM | Rabbit | Moringa Oleifera | β-Sheet | Non-hemolytic | ||
| 36009917 | 2022 | GLWNSIKIA{ct:Amid} | GL-9 | Amidation | Free | Linear | L | None | 9 | Antimicrobial | No Hemolysis detected | Horse | Synthetic | α-Helix | NA | ||
| 36009917 | 2022 | FVNVLDKIR{ct:Amid} | FV-9 | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 10 % Hemolysis at 504.21 μM | Horse | Synthetic | α-Helix | NA | ||
| 36009917 | 2022 | VNVLDKIR{ct:Amid} | VN-8 | Amidation | Free | Linear | L | None | 8 | Antimicrobial | No Hemolysis detected | Horse | Synthetic | α-Helix | NA | ||
| 36009917 | 2022 | FVNVLDKI{ct:Amid} | FV-8 | Amidation | Free | Linear | L | None | 8 | Antimicrobial | No Hemolysis detected | Horse | Synthetic | α-Helix | NA | ||
| 36009917 | 2022 | GLWNSIKIA{ct:Amid} | GL-9 | Amidation | Free | Linear | L | None | 9 | Antimicrobial | <5 % Hemolysis at 512 μM | Horse | Synthetic | α-Helix | NA | ||
| 36009917 | 2022 | FVNVLDKIR{ct:Amid} | FV-9 | Amidation | Free | Linear | L | None | 9 | Antimicrobial | <5 % Hemolysis at 512 μM | Horse | Synthetic | α-Helix | NA | ||
| 36009917 | 2022 | VNVLDKIR{ct:Amid} | VN-8 | Amidation | Free | Linear | L | None | 8 | Antimicrobial | No Hemolysis detected | Horse | Synthetic | α-Helix | NA | ||
| 36009917 | 2022 | FVNVLDKI{ct:Amid} | FV-8 | Amidation | Free | Linear | L | None | 8 | Antimicrobial | 10 % Hemolysis at 504.21 μM | Horse | Synthetic | α-Helix | NA | ||
| 36140173 | 2022 | KLKLKL{ct:Amid} | KL6 | Amidation | Free | Linear | L | None | 6 | Antimicrobial | 50 % Hemolysis at >256 μg/mL | Human | Synthetic | β-Sheets | Low hemolytic | ||
| 36140173 | 2022 | KLKLKLKL{ct:Amid} | KL8 | Amidation | Free | Linear | L | None | 8 | Antimicrobial | 50 % Hemolysis at >256 μg/mL | Human | Synthetic | β-Sheets | Low hemolytic | ||
| 36140173 | 2022 | KLKLKLKLK{ct:Amid} | KL9 | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 50 % Hemolysis at >256 μg/mL | Human | Synthetic | β-Sheets | Low hemolytic | ||
| 36140173 | 2022 | LKLKLKLKL{ct:Amid} | LK9 | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 50 % Hemolysis at 145 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKL{ct:Amid} | KL6 | Amidation | Free | Linear | L | None | 6 | Antimicrobial | 0 % Hemolysis at 1 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKL{ct:Amid} | KL8 | Amidation | Free | Linear | L | None | 8 | Antimicrobial | 0 % Hemolysis at 1 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKLK{ct:Amid} | KL9 | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 2 % Hemolysis at 1 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | LKLKLKLKL{ct:Amid} | LK9 | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 5 % Hemolysis at 1 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKL{ct:Amid} | KL6 | Amidation | Free | Linear | L | None | 6 | Antimicrobial | 1 % Hemolysis at 2 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKL{ct:Amid} | KL8 | Amidation | Free | Linear | L | None | 8 | Antimicrobial | 0 % Hemolysis at 2 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKLK{ct:Amid} | KL9 | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 5 % Hemolysis at 2 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | LKLKLKLKL{ct:Amid} | LK9 | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 6 % Hemolysis at 2 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKL{ct:Amid} | KL6 | Amidation | Free | Linear | L | None | 6 | Antimicrobial | 1 % Hemolysis at 4 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKL{ct:Amid} | KL8 | Amidation | Free | Linear | L | None | 8 | Antimicrobial | 0 % Hemolysis at 4 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKLK{ct:Amid} | KL9 | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 7 % Hemolysis at 4 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | LKLKLKLKL{ct:Amid} | LK9 | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 8 % Hemolysis at 4 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKL{ct:Amid} | KL6 | Amidation | Free | Linear | L | None | 6 | Antimicrobial | 3 % Hemolysis at 8 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKL{ct:Amid} | KL8 | Amidation | Free | Linear | L | None | 8 | Antimicrobial | 0 % Hemolysis at 8 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKLK{ct:Amid} | KL9 | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 9 % Hemolysis at 8 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | LKLKLKLKL{ct:Amid} | LK9 | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 9 % Hemolysis at 8 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKL{ct:Amid} | KL6 | Amidation | Free | Linear | L | None | 6 | Antimicrobial | 2 % Hemolysis at 16 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKL{ct:Amid} | KL8 | Amidation | Free | Linear | L | None | 8 | Antimicrobial | 0 % Hemolysis at 16 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKLK{ct:Amid} | KL9 | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 9 % Hemolysis at 16 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | LKLKLKLKL{ct:Amid} | LK9 | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 9 % Hemolysis at 16 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKL{ct:Amid} | KL6 | Amidation | Free | Linear | L | None | 6 | Antimicrobial | 2 % Hemolysis at 32 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKL{ct:Amid} | KL8 | Amidation | Free | Linear | L | None | 8 | Antimicrobial | 0 % Hemolysis at 32 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKLK{ct:Amid} | KL9 | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 10 % Hemolysis at 32 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | LKLKLKLKL{ct:Amid} | LK9 | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 11 % Hemolysis at 32 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKL{ct:Amid} | KL6 | Amidation | Free | Linear | L | None | 6 | Antimicrobial | 4 % Hemolysis at 64 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKL{ct:Amid} | KL8 | Amidation | Free | Linear | L | None | 8 | Antimicrobial | 0 % Hemolysis at 64 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKLK{ct:Amid} | KL9 | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 12 % Hemolysis at 64 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | LKLKLKLKL{ct:Amid} | LK9 | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 14 % Hemolysis at 64 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKL{ct:Amid} | KL6 | Amidation | Free | Linear | L | None | 6 | Antimicrobial | 6 % Hemolysis at 128 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKL{ct:Amid} | KL8 | Amidation | Free | Linear | L | None | 8 | Antimicrobial | 0 % Hemolysis at 128 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKLK{ct:Amid} | KL9 | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 16 % Hemolysis at 128 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | LKLKLKLKL{ct:Amid} | LK9 | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 18 % Hemolysis at 128 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKL{ct:Amid} | KL6 | Amidation | Free | Linear | L | None | 6 | Antimicrobial | 7 % Hemolysis at 256 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKL{ct:Amid} | KL8 | Amidation | Free | Linear | L | None | 8 | Antimicrobial | 0 % Hemolysis at 256 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKLK{ct:Amid} | KL9 | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 21 % Hemolysis at 256 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | LKLKLKLKL{ct:Amid} | LK9 | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 20 % Hemolysis at 256 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36297519 | 2022 | K{d}K{d}I{d}R{d}V{d}R{d}L{d}S{d}A{d} | M33D | Free | Free | Linear | D | None | 9 | Antimicrobial | NA | Human | Synthetic | NA | Non-hemolytic | ||
| 36297519 | 2022 | K{d}K{d}L{d}R{d}V{d}R{d}L{d}S{d}A{d} | M33i/l | Free | Free | Linear | D | None | 9 | Antimicrobial | NA | Human | Synthetic | NA | Non-hemolytic | ||
| 37812567 | 2023 | RRWWRWWL | W544 | Free | Free | Linear | L | None | 8 | Antibacterial, Hemolytic | 50 % Hemolytic at 80µM | Human | Human Cathelicidin Analog | NA | NA | ||
| 27915018 | 2017 | WWWLKRIW{ct:Amid} | TetraF2W-KR | Amidation | Free | Linear | L | None | 8 | Antibacterial, Antifungal, candidacidal, Anti-MRSA, Hemolytic | 50 % Hemolytic at 30µM | Human | Synthetic Peptide | Rich | NA | ||
| 27915018 | 2017 | WWWLKRIW{ct:Amid} | TetraF2W-KR | Amidation | Free | Linear | L | None | 8 | Antibacterial, Antifungal, candidacidal, Anti-MRSA, Hemolytic | 50 % Hemolytic at 50µM | Porcine | Synthetic Peptide | Rich | NA | ||
| 27915018 | 2017 | WWWLKRIW{ct:Amid} | TetraF2W-KR | Amidation | Free | Linear | L | None | 8 | Antibacterial, Antifungal, candidacidal, Anti-MRSA, Hemolytic | 50 % Hemolytic at 35µM | Chicken | Synthetic Peptide | Rich | NA | ||
| 27915018 | 2017 | WWWLRKIW{ct:Amid} | TetraF2W-RK | Amidation | Free | Linear | L | None | 8 | Antibacterial, Antifungal, candidacidal, Anti-MRSA, Hemolytic | 50 % Hemolytic at 30µM | Human | Synthetic Peptide | Helix | NA | ||
| 27915018 | 2017 | WWWLRKIW{ct:Amid} | TetraF2W-RK | Amidation | Free | Linear | L | None | 8 | Antibacterial, Antifungal, candidacidal, Anti-MRSA, Hemolytic | 50 % Hemolytic at 40µM | Porcine | Synthetic Peptide | Helix | NA | ||
| 27915018 | 2017 | WWWLRKIW{ct:Amid} | TetraF2W-RK | Amidation | Free | Linear | L | None | 8 | Antibacterial, Antifungal, candidacidal, Anti-MRSA, Hemolytic | 50 % Hemolytic at 35µM | Chicken | Synthetic Peptide | Helix | NA | ||
| 27915018 | 2017 | WWWLKKIW{ct:Amid} | TetraF2W-KK | Amidation | Free | Linear | L | None | 8 | Antibacterial, Antifungal, candidacidal, Anti-MRSA, Hemolytic | 50 % Hemolytic at 40µM | Human | Synthetic Peptide | Rich | NA | ||
| 27915018 | 2017 | WWWLKKIW{ct:Amid} | TetraF2W-KK | Amidation | Free | Linear | L | None | 8 | Antibacterial, Antifungal, candidacidal, Anti-MRSA, Hemolytic | 50 % Hemolytic at 55µM | Porcine | Synthetic Peptide | Rich | NA | ||
| 27915018 | 2017 | WWWLKKIW{ct:Amid} | TetraF2W-KK | Amidation | Free | Linear | L | None | 8 | Antibacterial, Antifungal, candidacidal, Anti-MRSA, Hemolytic | 50 % Hemolytic at 50µM | Chicken | Synthetic Peptide | Rich | NA | ||
| 32723829 | 2020 | RRRWWWWL | WW306 (Horine-L) | Free | Free | Linear | L | None | 8 | Antibacterial, Anti-MRSA, Hemolytic | 50 % Hemolytic at 60µM | Human | Synthetic Peptide | Rich | NA | ||
| 31209048 | 2019 | GLLSLGKLL{ct:Amid} | DFT525 | Amidation | Free | Linear | L | None | 9 | Antibacterial, Anti-MRSA, Hemolytic | HL50 % Hemolysis at >300µM | Human | Synthetic Peptide | NA | NA |